annual report gsk annual report contents strategic report corporate governance financial statements gsk glance chairmans governance statement directors statement chairmans statement board responsibilities ceos statement corporate executive team independent auditors report financial performance leadership effectiveness financial statements longterm priorities nominations committee report notes financial statements key performance indicators accountability financial statements industry trends audit risk committee report glaxosmithkline plc prepared stakeholder engagement relations stakeholders uk gaap business model science committee report investor information pharmaceuticals corporate responsibility vaccines committee report quarterly trend consumer healthcare fiveyear record remuneration report trust product development pipeline risk management chairmans annual statement product competition group financial review annual report remuneration intellectual property remuneration policy summary principal risks uncertainties share capital share price dividends financial calendar annual general meeting tax information shareholders shareholder services contacts us law regulation cautionary statement group companies see inside back cover document cautionary statement glossary terms regarding forwardlooking statements nonfinancial information statement following aligns nonfinancial reporting requirements contained sections ca cb companies act description business model human rights policy due diligence outcomes gsk glance human rights summary principal risks business model data engagement principal risks uncertainties social matters third parties viability statement anticorruption bribery audit risk committee report global health policies health security living values expectations affordability availability reporting investigating concerns public policies codes standards employees antibribery corruption available gskcom environmental matters employee engagement diversity carbon water waste wellbeing development gender pay gap living values expectations board diversity nonifrs measures use number adjusted nonifrs measures report performance business total reported results represent group 's overall performance ifrs adjusted results nonifrs measures may considered addition substitute superior information presented accordance ifrs adjusted results nonifrs measures defined pages reconciliations nearest ifrs measures pages believe adjusted results considered together total results provide investors analysts stakeholders helpful complementary information understand better financial performance position group period period allow group 's performance easily compared majority peer companies measures also used management planning reporting purposes may directly comparable similarly described measures used companies gsk annual report strategic report governance remuneration financial statements investor information gsk glance scienceled global healthcare company purpose help people feel better live longer three global businesses discover develop strategy bring differentiated highquality manufacture innovative pharmaceutical medicines needed healthcare products many people vaccines consumer healthcare products every day possible three global businesses scientific millions patients consumers across world use technical knowhow talented people products delivered around billion scienceled healthcare company packs medicine million vaccine doses invested billion rd announced new billion consumer healthcare products approach rd focusing science related turnover billion actual immune system human genetics advanced exchange rates aer constant exchange rates technologies cer us largest single commercial market three longterm priorities innovation performance representing revenue followed international trust designed create longterm value europe patients consumers shareholders values employees across world driven patient focus transparency respect integrity purpose goal become one expectations courage accountability worlds innovative bestperforming trusted development teamwork define culture healthcare companies pharmaceuticals vaccines consumer healthcare pharmaceuticals business leading vaccines company consumer healthcare business broad portfolio innovative world delivering million develops markets portfolio established medicines vaccine doses every day people globally recognised consumer leadership positions respiratory living countries portfolio preferred expertrecommended hiv strengthening pipeline help protect individuals brands oral health pain relief pipeline focus throughout lives respiratory skin health nutrition immunology human genetics recently introduced breakthrough digestive health categories advanced technologies help vaccines shingrix shingles categoryleading brands include us identify promising bexsero first vaccine sensodyne parodontax poligrip new medicines meningitis b voltaren panadol otrivin theraflu read read read turnover turnover turnover respiratory meningitis wellness hiv shingles oral health immunoinflammation influenza nutrition established pharmaceuticals established vaccines skin health total total total gsk annual report chairmans statement pleased report year good financial performance gsk improvements sales earnings particularly cash flow generation delivery operating targets excellent notably successful launches new products also year strategic shape gsk coming years redefined research development capital allocation success rd always fundamental shareholder returns improving gsks pipeline new medicines remains first priority renewed focus rd set emma walmsley investment also continue invest behind key products became ceo new plan improve pipeline new including increasing manufacturing capacity shingrix medicines launched dr hal barron new chief gsks successful new vaccine help prevent shingles scientific officer dividend payments form part groups capital allocation progress evident oncology promising assets framework board recognises importance dividends laboratories also acquired tesaro oncology shareholders total dividends p per share paid focused biotechnology company based boston first time several years cash flow covered marketed oncology product several pipeline assets dividend payments level dividend expected development potential even recently proposed cash generation remain key focus given marked alliance merck kgaa darmstadt germany develop increase net debt arose taking full control promising new oncology medicine consumer healthcare business board science committee directors continue financial reporting engage closely executives actions taken noted commercial structures reporting improve scientific innovation focus worldclass innovation requirements sometimes lead complexity reporting essential drive longterm value investors would like continue evolve financial reporting future direction course made changes give addition increasing investment pharmaceuticals also greater prominence total results represent groups took steps strengthen consumer healthcare business overall performance experienced shareholders company first step buyout put option held novartis committed continuous improvement area line respect minority stake gsk consumer healthcare evolving regulatory requirements best practice completed june second step announcement succession december create new consumer healthcare joint venture announced simon dingemans would step pfizer chief financial officer coming agm eight latter transaction offers opportunity create substantial years gsk would like thank service gsk value shareholders new worldleading consumer succeeding simon iain mackay formerly group finance director healthcare business significant bearing future hsbc welcomed board january shape group transaction would transform scale last annual report chairman following gsks consumer healthcare business therefore board decision start year step board stated gsk intends separate joint venture within gsk one worlds great businesses three years completion transaction sets enormous privilege serve chairman path gsk create two focused new companies separate listings appropriate capital structures business emmas leadership gsk made good progress well positioned deliver attractive returns shareholders announcement intended separation years benefits patients consumers time believe right moment step allow new chair oversee process conclusion board fully supports proposed transaction pfizer senior independent director vindi banga leading seeking approval shareholders general meeting search appoint successor held immediately coming annual general meeting separate circular recommending transaction made would like thank gsks employees partners available shareholders prior annual general meeting hard work throughout shareholders customers continued support philip hampton chairman gsk annual report strategic report governance remuneration financial statements investor information ceos statement gsk made significant progress longterm priorities innovation performance trust underpinned continuing shift culture delivered improved operating performance started strengthen expected proceeds disposal used reduce pharmaceuticals pipeline particularly oncology undertook debt increase investment flexibility several significant transactions support strategy reshape december also announced formation consumer groups portfolio focus sustained delivery healthcare jv pfizer completed would create progress particular continued development pipeline new global leader consumer healthcare proposed performance transaction also supports key priority strengthen group sales billion actual exchange rates pharmaceuticals business increasing cash flows aer constant exchange rates cer sales growth intention separate set clear direction driven new products standout continues shingrix group ultimate aim creating two exceptional ukbased vaccine shingles sales million global companies one pharmaceuticalsvaccines company remarkable launch year vaccine hiv medicines also rd approach focused science related immune continued grow sales billion dolutegravir system human genetics advanced technologies based products respiratory continued build new new worldleading consumer healthcare company portfolio sales billion including good performances building trust trelegy ellipta new threeinone medicine chronic trust third longterm priority set alongside innovation obstructive pulmonary disease copd nucala biologic performance vitally important employees medicine severe asthma gsk set new commitments build trust total group operating margin percentage points strong focus three principal areas using science aer percentage points cer adjusted group operating technology address health needs making products margin flat aer percentage points cer affordable available modern employer total earnings per share doubled p aer committed providing access medicines cer adjusted earnings per share aer vaccines across world pleased cer p topped access medicines index also delighted see remain focused controlling costs cash generation approval tafenoquine p vivax malaria encouraging pleased free cash flow significantly data published potential vaccine tuberculosis tb improved billion actual terms compared remains leading cause death infectious delivered expectation paying p per share disease worldwide dividend expect pay p per share also continue drive necessary shift culture towards strengthening pipeline one focused performance based living values consistently said key priority strengthen patient focus transparency respect integrity expectations pharmaceuticals pipeline develop next generation medicines courage accountability development teamwork employee patients demonstrated good progress engagement key progress making objective particularly oncology advancing key internal assets people encouraged share views ideas key topics well targeted business development oncology regular conversations hosted leaders including assets clinical development double number executive team start acquisition tesaro added major new product important year gsk continue strengthen portfolio zejula approved use ovarian cancer pharmaceuticals pipeline execute announced transactions see strong development prospects product sustain improved operating performance particularly assets acquired transaction pleased navigate introduction generic advair us adding portfolio proposed global alliance anticipated prepared remain vigilant merck kgaa darmstadt germany codevelop dynamic operating environment continue invest cocommercialise novel immunotherapy asset longterm priorities bring benefits patients expect major data readouts significant consumers serve newsflow several new medicines expect pivotal data finally want sincerely thank customers suppliers three oncology assets potential launched investors employees support hard work next two years also expect approval decision look forward continued partnership exciting us food drug administration fda dolutegravir lamivudine year ahead fda filings two new medicines hiv phase iii start new treatment rheumatoid arthritis results pivotal respiratory study support filing trelegy ellipta use asthma accelerating strategy reshaping business line capital allocation priorities emma walmsley undertook series transactions accelerate strategy chief executive officer reshape business june acquired full ownership consumer healthcare business buying novartis minority stake december reached agreement includes subject proposed alliance merck kgaa darmstadt unilever divest horlicks consumer nutrition products germany expected close q gsk annual report financial performance total results growth turnover turnover cer turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit net finance costs profit disposal interest associates share tax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p performed cost sales operating incomeexpense cost sales percentage turnover operating expense primarily reflected accounting charges percentage points aer percentage points cer arising remeasurements contingent consideration primarily reflected favourable comparison write liability related acquisition former shionogiviiv downs assets related decision withdraw healthcare joint venture consumer healthcare joint venture tanzeum together favourable product mix put option previously held novartis partly offset profit vaccines consumer healthcare number asset disposals selling general administration operating profit sga costs percentage turnover total operating profit million compared percentage points aer cer increase million increase primarily reflected favourable primarily reflected higher restructuring costs investment comparison charges arising impact us promotional product support particularly new launches tax reform valuations consumer healthcare hiv respiratory hiv vaccines businesses reduced asset impairments restructuring costs cost sales rd research development rd expenditure million turnover tax aer cer lower reduction reflected charge million represented effective tax rate lower restructuring costs primarily due comparison total results reflected different provision obligations result decision tax effects various adjusting items reduction withdraw tanzeum addition lower intangible effective tax rate driven primarily favourable comparison asset impairments favourable comparison impact impact us tax reform resulted number priority review voucher purchased utilised charges noncontrolling interests allocation earnings noncontrolling interests amounted million million reduction primarily due lower allocation consumer healthcare profits following buyout novartis interest earnings per share total earnings per share p compared p gsk annual report strategic report governance remuneration financial statements investor information total adjusted results total reported results represent groups overall performance gsk undertaken number major restructuring programmes recent years response significant changes groups gsk uses number adjusted nonifrs measures report trading environment overall strategy following material performance business adjusted results nonifrs acquisitions including novartis transaction costs measures may considered addition substitute cash noncash programmes provided superior information presented accordance ifrs individual elements approved meet accounting see fuller definition recognition criteria result charges may incurred gsk believes adjusted results considered together number years following initiation major restructuring total results provide investors analysts stakeholders programme helpful complementary information understand better financial gsk committed continuously improving financial reporting performance position group period period line evolving regulatory requirements best practice allow groups performance easily compared made number changes recent years line majority peer companies measures also used practice gsk expects continue review reporting management planning reporting purposes may framework including relevant use alternative directly comparable similarly described measures used performance measures companies gsk encourages investors analysts rely single financial measure review gsks annual reports including financial statements notes entirety divestments intangible intangible significant total asset asset major transaction legal adjusted adjusting items results amortisation impairment restructuring related items results turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit net finance costs profit disposal associates share tax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p adjusting items intangible asset amortisation impairment transactionrelated amortisation impairment intangible assets excludes computer transactionrelated accounting adjustments related software goodwill significant acquisitions major restructuring divestments significant legal items major restructuring costs include impairments tangible proceeds costs disposals associates products assets computer software specific boardapproved businesses significant legal charges net insurance recoveries programmes structural significant scale expenses settlement litigation government costs individual related projects exceed million investigations operating income royalty income including integration costs following material acquisitions items gsk annual report financial performance continued adjusted results growth turnover turnover cer turnover cost sales gross profit selling general administration research development royalty income operating profit net finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p performed cost sales tax cost sales percentage turnover tax adjusted profit million representing effective percentage points aer percentage points adjusted tax rate reduction cer increase primarily reflected continued adverse effective rate primarily driven reduction us federal pricing pressure pharmaceuticals established vaccines tax rate well increased input costs noncontrolling interests selling general administration allocation adjusted earnings noncontrolling interests sga costs percentage turnover amounted million million reduction percentage points aer percentage points cer primarily due lower allocation consumer healthcare decrease reflected impact sales growth partly offset profits following buyout novartis interest cost increase aer cer primarily resulting earnings per share increased investment promotional product support particularly adjusted eps p aer cer compared new launches respiratory hiv vaccines cer increase adjusted operating profit primarily research development result reduced noncontrolling interest allocation rd expenditure million turnover consumer healthcare profits lower adjusted tax rate aer cer primarily reflected favourable comparison impact priority review voucher purchased utilised benefit prioritisation initiatives started second half operating profit adjusted operating profit million aer cer turnover increase adjusted operating margin flat aer percentage points cer reflected benefit sales growth cer three businesses favourable mix primarily vaccines consumer healthcare reduced rd expenditure gsk annual report strategic report governance remuneration financial statements investor information longterm priorities deliver longterm priorities three sets objectives highlights progress businesses designed create longterm value patients key objectives detail provided consumers shareholders underpinned ambition relevant business sections build culture greater performance focus aligned values expectations longterm priorities apply three businesses innovation performance trust invest scientific technical deliver growth based performance responsible company excellence develop launch investing effectively commit use science pipeline new products meet business developing people technology address health needs needs patients payers executing competitively make products affordable consumers available modern employer objectives objectives objectives excellent execution key launches grow sales priority therapy areas focus supply service levels trelegy ellipta juluca shingrix categories markets define new global health approach strengthen pharmaceutical pipeline increase operating margins deliver competitive employee engagement greater focus improved medicines improved cash flow development business development strengthen top talent profile key roles progress progress progress delivered industryleading launches group sales billion aer established new set priorities public shingrix trelegy ellipta strong cer growth new respiratory commitments build trust start sales juluca product sales hiv continued simplify supply chain new rd approach focus science total group operating margin improve supply performance immune system human genetics percentage points aer received approval tafenoquine first advanced technologies percentage points cer adjusted new treatment p vivax malaria years strengthened pipeline strategic group operating margin flat aer candidate tb vaccine showed positive business development andme percentage points cer results phase iib trial tesaro terminated divested around net cash flow operations billion competitive employee engagement programmes focus investment billion free cash flow focus modern employer promising assets billion billion employees globally access significant progress reshaping announced transaction create preventive healthcare package pharmaceuticals rd portfolio worldleading consumer healthcare joint new medicines targeting modulation venture pfizer bought novartis immune system stake gsk consumer healthcare key leadership appointments place top leaders new role objectives objectives objectives deliver continued strong sales trelegy continue drive sales growth focus supply service levels execute ellipta nucala hiv twodrug regimen operational performance portfolio network simplification shingrix successful integration tesaro deliver progress trust commitments continue strengthen pipeline deliver restructuring benefits plan progress global health research tb execution new rd approach integration pfizers consumer hiv accelerating priority assets optimising healthcare business deliver modern employer programmes recent strategic business development accelerate capability build priority areas empower employees transactions including digital data analytics feel good keep growing gsk culture committed building new culture gsk accelerate delivery longterm priorities focus establish new set expectations courage accountability development teamwork alongside values patient focus transparency respect integrity introduce new approach performance reward aim continue embed organisational understanding values expectations support change culture leading improved culture scores embed new performance system principal risks principal risks patient safety product quality financial controls reporting antibribery corruption commercial practices privacy research practices third party oversight environment health safety sustainability information security supply continuity risk management framework designed support longterm priorities detailed information found pages includes subject proposed alliance merck kgaa darmstadt germany expected close q gsk annual report key performance indicators operating key performance indicators kpis track progress provide performance data operating kpis longterm priorities measure performing reporting externally due commercial sensitivities overall group level across three businesses planning publish data operating kpis reviewed regularly corporate executive team board use number adjusted nonifrs measures report employees updated progress every quarter performance business described pages launched new performance system align employees bonuses including adjusted results free cash flow cer growth rates relevant subset ten kpis remuneration policy used nonifrs measures may considered addition reward performance executives includes measures substitute superior information presented accordance linked kpis see pages ifrs innovation growth bn cer bn bn innovation sales r sales pharmaceuticals vaccines products launched last five years internal purposes also measure pipeline value progress performance growth bn cer bn bn group turnover r operating profit margin r total operating profit adjusted operating profit total margin adjusted margin free cash flow r b b internal purposes also measure market share top talent key roles trust employee engagement employee engagement scores global employee survey internal purposes also measure supply service levels corporate reputation r linked executive lti awards bonus see pages comparative information reflects sales products meet definition b revised include proceeds sale intangible assets gsk annual report strategic report governance remuneration financial statements investor information industry trends healthcare industry changing rapidly strong growth potential strategy longterm priorities underpinned culture designed put us best position able respond opportunities challenges presents global economic growth remained steady projected pricing access annual growth rate despite concerns pricing healthcare products continues attract significant international trade weaker economic performance attention governments public calls better countries notably europe asia geopolitical friction transparency prices set greater emphasis health europe lack clarity nature uks future outcomebased pricing specialty medicines continue receive relationship eu caused political economic particular attention pricing reflects therapeutic benefits uncertainty see small number patients covered targeted treatments global healthcare market continues grow despite signs government payer budgets remain subject increasing reviews economic slowdown countries worldwide pharmaceutical demand healthcare grows due demographic change sales totalled billion september push universal health coverage advances preventive care north america remains largest pharmaceutical market treatment despite innovative medicines clearly share global sales europe representing differentiated areas unmet medical need continue china second largest individual country pharmaceutical attract strong coverage funding developed markets sales representing global sales global vaccine sales us variability drugs funded reimbursed rose approximately billion across insurance programmes current administration global consumer healthcare sales estimated undergoing comprehensive review drug pricing approximately billion published drug pricing blue print effort lower prices pharmaceutical medicines patients across us blue print global trends opportunities challenges focuses improved competition better government negotiation incentives lower list prices lowering outofpocket costs positive demographics patients administration aims achieve number demographic change driving demand preventive mechanisms limiting rebates introducing international therapeutic healthcare products people living longer reference pricing compare domestic drug prices number yearolds due double countries valuebased pricing pilots reform medicare global population expanding worldwide headcount due grow billion europe emerging markets international reference pricing billion increasing affluence changing continues gain traction markets involved diets lifestyles longer lifespans contributing globally although many countries continue negotiate confidential rising demand healthcare especially areas cancer contracts manufacturers increasingly countries also respiratory disease cooperating pricing procurement health technology assessments htas assess clinical cost advances science technology effectiveness broader impacts healthcare treatments rapid advances science technology transforming new hta regulation proposed europe would healthcare increasing probability success rd centralise clinical assessments new medicines medical better understanding human biology genetics enabling devices going legislative process scientists identify develop novel targeted treatments china authorities accelerated progress towards bringing vaccines advances digital technology data analytics innovative treatments market included increasing meanwhile allow researchers explore interpret greater pace frequency reimbursement coverage especially volume data much faster insights gained oncology drugs accelerating improving development preventive therapeutic medicines vaccines enabling manufacturers japan government continues seek expedite purchasers healthcare products better measure expand drug development however significant reduction effectiveness technology also central way people price maintenance premium exempts certain innovative discover assess buy healthcare products us medicines annual price reductions eroded price stability research suggesting consumers surveyed consider plans introduce new hta system created technology plays important part managing uncertainty health imf world economic outlook update january volatility sterling exchange rate revised data collection methods research provider iqvia mean years global figure entirely comparable billion iqvia data internal data gsk annual report industry trends continued regulatory environment strategic response healthcare highly regulated industry reflecting public expectations products comply stringent levels quality strategy bring differentiated highquality needed safety efficacy governments increasingly extending healthcare products many people possible three regulatory remit support accelerated development global businesses scientific technical knowhow talented introduction new medicines example china japan people designed respond trends longterm us recently introducing regulatory approaches encourage priorities underpinned culture help us deliver strategy pharmaceutical innovation meanwhile work crossborder innovation invest scientific technical excellence harmonisation pharmaceutical regulation increasing develop launch pipeline new products meet needs supranational bodies international conference patients payers consumers drug regulatory authorities international council performance deliver growth based performance investing harmonisation context healthcare industry supports effectively business developing people executing close cooperation medicine regulation systems processes competitively uk eu brexit trust responsible company commit use science competition technology address health needs make products healthcare sector remains intensely competitive companies affordable available modern employer increasingly pursuing acquisitions collaborations strengthen pipelines portfolios notable activity making important progress longterm priorities included takedas billion acquisition shire pharmaceuticals see enabling us respond dynamic momentum continued early bristolmyers squibb environment operate harness advances science announcing intention buy celgene billion technology forming partnerships bring ground breaking products patients faster aim manage pricing intellectual property ip protection important continue pressure researching developing differentiated medicines incentivise innovation helps researchbased healthcare attract greatest coverage funding pricing companies ensure reasonable return investments medicines according value outcomes bring allows continue conduct research develop new patients providers payers committed building trust innovative medicines ip protection expires challenges addressing societal expectations operating responsibly patent upheld generic competitors rapidly capture transparently large share market vaccines biologics face exposure generic competition patent cliffs complex dependent technical manufacturing processes consumer healthcare overthecounter otc sector seen greatest consolidation fast moving consumer goods fmcg lower barriers entry fewer regulatory hurdles seen rise niche ecommerce based companies focusing successfully fastadapting consumer trends societal expectations public trust large institutions including media governments ngos businesses remains low historical standards particularly developed markets making important issue businesses face growing public scrutiny society increasingly expects companies earn trust demonstrating integrity fairness transparency making positive contribution wider community pharmaceutical sector still suffers trust deficit result past challenges relation sales marketing practices ethics compliance issues concern also rising safeguarding personal data europe new legislation tightened regulations companies use personal information loss inappropriate use data could major consequences individuals businesses continuing focus issues diversity ranging equal pay representation senior management environment particularly climate change ocean protection plastic waste issues increased public concern pressure action companies also increasing scrutiny tax affairs including contribution transparency successful companies must operate way meets expectations creates longterm value wide range stakeholders including shareholders employees customers suppliers gsk annual report strategic report governance remuneration financial statements investor information stakeholder engagement engaging stakeholders key success delivering sets key stakeholder groups strategy various mechanisms enable board important us ways engage management understand consider stakeholder views part oversight decisionmaking see patients consumers investors insights patient organisations consumers enable us maintain regular constructive dialogue investors develop products advocate policies better meet communicate strategy performance order promote needs investor confidence ensure continued access capital advisory boards patient advocacy leaders summits provide onetoone meetings board members senior executives patient insights institutional investors engaging supporting patient groups disclosed gskcom running investor roadshows attending conferences events supporting initiatives empower patients get involved annual general meeting medicine development market research consumer sensory labs help us understand consumer needs healthcare professionals medical experts rd partners academia work healthcare professionals hcps medical experts partner scientific institutions business partners understand patient needs ensure products academia advance scientific discovery development administered right way establishing joint ventures improve efficiency strengthen advisory boards gather insights related scientific research improve innovation disease management rd collaborations gene sequencing initiative collaboration clinical trials research andme uk biobank peertopeer scientific dialogue increase understanding working academic researchers accelerate discovery diseases develop effective prevention development new medicines governments regulators ngos multilateral organisations work governments regulators advocate policies work partners improve access healthcare services encourage innovation promote efficient management products advocate policy environment healthcare spending give patients support need successful engaging regulatory bodies drug development working nongovernmental organisations ngos partners engaging government health agencies demonstrate research develop products support global health value products partnering ngos generic manufacturers manufacture working governments build strong operating supply products developing countries environment life sciences working multilateral organisations drive progress key global health priority areas suppliers employees work thousands suppliers large small provide involve listen employees help us maintain strong goods services support us delivering highquality employee engagement retain talented people safe products patients consumers conducting twiceyearly global employee survey engaging suppliers third party oversight act employee feedback programme external platforms help monitor performance promoting informal dialogue collaboration new providing platform suppliers share best practices internal tech platform environmental performance supplier exchange lets talk events leaders members corporate online community executive team auditing suppliers quality processes ensure comply established boardlevel workforce engagement director relevant regulations dr vivienne cox see gsk annual report business model discover develop manufacture innovative pharmaceutical medicines vaccines consumer healthcare products operations span value chain identifying researching groundbreaking discoveries development testing regulatory approval manufacturing commercialisation resources create value value create talented employees purpose patients people help deliver consumers purpose improve help people feel better live longer scientific technical health patients knowhow consumers around expertise regulation world intellectual property innovative medicines commercialisation longterm priorities vaccines consumer see healthcare products see pages innovation performance trust partnerships investors business development helps deliver growth strengthen pipeline based performance three global businesses complement inhouse paid resources important improve health create financial value dividend p per relationships external share shareholders organisations suppliers invest scientific research see pages third parties see invested billion research development bring new medicines vaccines employees consumer healthcare products patients employ payers consumers people globally access capital offer broad range generate revenue profit cash equity debt benefits including generate revenue executing new product enables us invest preventative healthcare launches brilliantly sales business services existing portfolios long term see employees attract reinvest distribute returns retain motivate part capital allocation framework best people reinvest three businesses also provide support business returns shareholders form dividends see culture committed building culture greater performance focus underpinned values expectations values expectations patient focus transparency respect integrity courage accountability development teamwork gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals pharmaceuticals business broad portfolio innovative established medicines leadership positions respiratory hiv strengthening pipeline focus immunology human genetics advanced technologies help us identify promising new medicines progress longterm priorities innovation performance trust new rd approach focus total turnover billion approval tafenoquine first science related immune system flat aer cer new treatment p vivax malaria human genetics advanced years new respiratory product sales technologies billion aer cer partnering increase access strengthened pipeline hiv sales billion aer paediatric formulations hiv medicines development targeting cer medicines modulation immune system refined priority markets trained healthcare accelerated oncology pipeline target resources professionals across countries doubling number assets clinical accelerate growth appropriate use antibiotics development via advancing key internal simplified pharmaceuticals assets eg gsk targeted supply chain separating business development eg acquisition consumer healthcare improve tesaro proposed alliance competitiveness merck kgaa launched juluca first twodrug hiv regimen expanded indications trelegy ellipta nucala innovation strengthen pipeline deliver next generation hiv medicines see bringing greatest value patients longstanding commitment advancing treatment embedding new approach rd prevention cure hiv developing medicines suppress approach focuses science related immune system prevent virus new ways help reduce burden use human genetics advanced technologies driven treatment hiv business managed viiv healthcare multiplier effect science x technology x culture global specialist hiv company gsk controls majority help us accelerate pace develop deliver owner pfizer shionogi also shareholders broad transformational medicines prioritising molecules higher portfolio antiretroviral medicines offers wide range probability success terminating less promising programmes therapeutic options people living hiv include also enable us increase focus specialty medicines highly successful therapies tivicay triumeq based areas oncology dolutegravir worldleading core agent broad clinical pipeline including potential new marking new era hiv care juluca first twodrug regimen medicines development range diseases includes dr oncedaily singlepill treatment hiv oncology assets double number start launched us japan several european markets potential new medicines immunomodulators containing fewer drugs conventional hiv therapies reflecting scientific focus immunology area juluca potential drs pipeline reduces see greatest potential anticipate phase iii data patients exposure multiple medicines often readouts key areas including hiv oncology respiratory lifelong treatment us focus effectively ensure rapidly progress filed regulatory submissions us europe best assets culture encourages smart risktaking another singletablet dr dolutegravir lamivudine singlepoint accountable decision making dr hal barron chief followed phase iii gemini studies demonstrated scientific officer president rd instrumental similar efficacy dr compared traditional threedrug driving scientific innovation since joined gsk january regimens decisions regulatory approvals anticipated includes subject proposed alliance merck kgaa darmstadt germany expected close q gsk annual report pharmaceuticals continued made progress investigational oncemonthly clinical trials assess use zejula monotherapy longacting injectable dr cabotegravir rilpivirine new combinations significantly larger opportunity first line option patients avoids daily oral treatment latte maintenance treatment ovarian cancer way results study showed high rates virologic response longterm first studies prima expected late durability threeyear period flair atlas zejula also investigated possible treatment lung studies demonstrated similar efficacy triumeq breast prostate cancer monotherapy oncemonthly injection regulatory filing fda planned combination medicines addition zejula tesaro several oncology assets pipeline including pd inhibitor tsr dostarlimab currently studied research inspiring phase iiib study demonstrated endometrial cancer expect pivotal data could support efficacy safety dolutegravirbased treatment regimen regulatory filing dostarlimab second half hiv tuberculosis coinfected patients january announced proposed global strategic alliance phase iii study fostemsavir heavily treatmentexperienced merck kgaa darmstadt germany jointly develop patients hiv whose current antiretroviral medicines commercialise bintrafusp alfa investigational proving inadequate also delivered positive results application bifunctional fusion protein immunotherapy currently clinical regulatory approval fostemsavir expected filed development including potential registration studies multiple oncology difficulttotreat cancers includes phase ii trial investigate cancer one leading causes death developed world compared pembrolizumab first line treatment focused delivering transformational therapies people patients pdl expressing advanced nonsmall cell lung cancer living cancer pipeline focused immunooncology nsclc cell therapy cancer epigenetics made significant completed transition nyeso spear tcell progress doubling number oncology assets clinical therapy programme gsk adaptimmune early trial data development goal achieve sustainable flow suggests asset could transformational synovial sarcoma new treatments based diversified portfolio investigational first cell therapy show clinical response solid tumours medicines utilising modalities small molecules antibodies another recipient european prime fda breakthrough status antibody drug conjugates cells either alone combination another oncology therapies agonistic antibody antibody drug conjugate targeting bcma gsk inducible tcell costimulator icos first investigational potential target multiple myeloma granted antiicos agonist antibody enter human clinical trials phase european prime fda breakthrough status potentially enabling safety pharmacokinetic pharmacodynamic data therapy faster regulatory review also recognised orphan alone combination pembrolizumab show early positive drug despite advances treatment multiple myeloma last indications activity decade remains cure high unmet need extensive development plan exploring use fourth first line respiratory settings fourth line following encouraging efficacy data led way developing innovative medicines advance dreamm study initiated pivotal dreamm study management asthma copd nearly years fully recruited october data expected mid past five years launched six respiratory medicines giving us potential regulatory submissions year end second line broadest portfolio oncedaily inhaled respiratory medicines dreamm pilot study looking use combination standard industry care initiated results available launched trelegy ellipta countries inform future pivotal studies dreamm pilot study class leaders key markets including us uk france looking first line use relapsed refractory patients planned start following landmark impact trial trelegy ellipta demonstrated superiority two dual medicines multiple accelerated strengthening pipeline endpoints expanded indications approved us acquisition tesaro oncologyfocused biopharmaceutical europe enabling use across broader group copd patients company tesaros major marketed product zejula oral poly submitted regulatory filings trelegy ellipta japan adp ribose polymerase parp inhibitor approved us china first single inhaler triple therapy copd europe adults recurrent ovarian cancer parp inhibitors countries launches planned throughout results transforming treatment ovarian cancer demonstrating phase iii captain study exploring efficacy marked clinical benefit patients without germline safety trelegy ellipta asthma anticipated mutations brca gene believe also offer significant opportunities treating patients many cancer types ellipta portfolio strengthened expanded indication relvar ellipta asthma applications support label updates us europe anoro ellipta incruse ellipta includes subject proposed alliance merck kgaa darmstadt germany expected close q gsk annual report strategic report governance remuneration financial statements investor information firstinclass severe eosinophilic asthma biologic nucala advanced technologies gained approval europe first antiinterleukin il paediatric indication alongside earlier approval adults significant investment wide range advanced technologies also filed regulatory submissions paediatric licence central new rd approach developing core us eu us new formulation nucala capability artificial intelligence machine learning enhance could used subcutaneously allow patients caregivers ability interpret understand genetics genomic data administer treatment also invest functional genomics applying techniques gene modification crispr technology help discover continue innovate respiratory biologics investigational validate potential targets investments supplement programmes nucala nasal polyps hypereosinophilic existing strengths advanced technologies including syndrome leading position cell gene therapy continue immunoinflammation develop benlysta worlds first biologic medicine specifically partnerships key innovation formed approved treat systemic lupus erythematosus sle chronic exclusive collaboration andme worlds leading consumer incurable autoimmune disease building data four previous genetics research company combine scientific phase iii clinical trials presented results phase ii pluto medical knowledge andmes largescale genetic study exploring use paediatric patients childhoodonset sle resources unique data science skills improving probability addition pivotal phase iii bliss studies showed low rates rd success exciting collaboration builds existing organ damage progression sle patients treated benlysta partnerships altius institute pioneers new results phase iv embrace study black adult patients technologies approaches decoding gene control uk active autoantibodypositive sle expected also biobank generating anonymised genetic sequence data began new phase iii study investigating benlysta combination volunteers open targets consortium rituximab adult patients sle assessing whether supports open access search engine searches evaluates coadministration enhances benlystas treatment effect potentially integrates biologic genetic disease data provide sustained disease control possibility clinical remission headline results expected improving rd governance continuing research antigmcsf antibody established two new governance boards research patients rheumatoid arthritis expect progress phase iii review board rrb development review board drb rrb accountable future portfolio providing technical additional programmes review quality research earlystage programmes received approvals us australia krintafel drb reviews latestage programmes make sure studies kozenis tafenoquine first new treatment p vivax malaria robust innovative years see aligned changes created separate organisations japan announced positive phase iii results daprodustat research development enable rigorous disciplined oral hypoxiainducible factor prolyl hydroxylase inhibitor patients decisionmaking oversight across early late stage anaemia associated chronic kidney disease strategic portfolio due specialist nature kept distinct rd collaboration kyowa hakko kirin company future units oncology global health commercialisation addition two ongoing daprodustat support promising potential medicines portfolio phase iii studies anticipated report terminated divested around programmes terminations also continue develop gepotidacin first new class included danirixin miridesap dezamizumab also transferred antibiotics rare disease gene therapy portfolio orchard therapeutics become equity shareholder sold rights tapinarof dermavant sciences gsk annual report pharmaceuticals continued pharmaceuticals pipeline overview assets development immunomodulators focused oncology expect number pivotal readouts phase compound indication pivotalregistration benlysta rituxan sle cabotegravir la rilpivirine la hiv dolutegravir lamivudine hiv daprodustat hifphi anaemia fostemsavir hiv ai hiv nucala copdhesnasal polyps trelegy ellipta asthma dectova iv influenza bcma adc multiple myeloma zejula parp inhibitor firstline maintenance ovarian cancer dostarlimab pd antagonist endometrial cancer phase ii gmcsf inhibitor ra hbv aso hbv icos receptor agonist cancer ripk inhibitor psorauc ilr antagonist severe asthma nyeso tcr cancer rhace acute lung injurypah gepotidacin topoisomerase iv inhibitor antibacterial osm antagonist systemic sclerosis sarm copd muscle weakness tnfr antagonist acute lung injury ox agonist cancer bet inhibitor cancer ibat inhibitor cholestatic pruritus prmt inhibitor cancer gr oxytocin postpartum haemorrhage tsr tim antagonist cancer tgf trapanti pdl bispecific nsclc phase lag ulcerative colitis bet targeted inhibitor ra ccl antagonist oa pikb inhibitor cancer ripk inhibitor ibd leucyl trna inhibitor tb hiv maturation inhibitor hiv il la antagonist asthma pikd inhibitor respiratory diseases tlr agonist cancer broadly neutralizing antibody hiv nyeso immtac cancer hpgd inhibitor muscle repair ripk inhibitor pancreatic cancer prmt inhibitor cancer tsr lag cancer nemiralisib pikd inhibitor apds includes programmes pivotal phases development pivotal data reported regulatory submissions consideration review inlicence alliance relationship third party additional indications also investigation pending closure transaction merck kgaa darmstadt germany subject regulatory approval note oncology phase studies conducted patients shift phase phase ii defined expansion cohorts started gsk annual report strategic report governance remuneration financial statements investor information performance performance summary recent years significantly strengthened online resources inhouse medical capabilities provide bespoke pharmaceuticals turnover million flat product information healthcare professionals hcps aer cer driven primarily growth hiv sales updated policy working hcps following consistent us sales declined aer grew cer feedback value opportunity learn new products growth hiv portfolio benlysta offsetting declines peertopeer programmes expert practitioners established pharmaceuticals respiratory following patent direct experience medicines expiries europe sales grew aer cer growth new policy ensure prescribers access available respiratory portfolio offsetting continued impact information innovative products make fully generic competition epzicom avodart international informed decisions support better outcomes patients flat aer grew cer growth driven hiv new medicines significant new data allow new respiratory portfolio payment global experts speak scientific evidence respiratory sales declined aer grew cer diseases treat clinical experience change million growth ellipta portfolio nucala partly offset implemented us japan late depending lower sales seretideadvair market prepares entry effective implementation assessment risk generic sales new respiratory products comprising ellipta implemented major developed markets europe north products nucala grew aer cer million america asia onwards avoid perceived conflict interest strengthened commitment hiv sales increased aer cer million transparency new controls expanded disclosure reflecting share growth dolutegravir portfolio triumeq payments individual hcps tivicay juluca partly offset decline established portfolio particularly impact generic competition creating simpler competitive supply chain epzicomkivexa europe immunoinflammation sales aer cer reliable supply fundamental enabling growth key therapy primarily driven benlysta areas pharmaceuticals supply performance levels continued established pharmaceuticals portfolio includes mainly offpatent improve ontime infull supply customers medicines sales million aer cer rating new products launched time reflecting efforts maximise value portfolio also adopting simplified structure operating model geared benefit certain postdivestment contract manufacturing sales driving performance increased focus priority brands first instalment month relenza supply contract europe markets clearer accountabilities pace included pharmaceuticals operating margin percentage separating pharmaceuticals manufacturing supply points lower aer percentage points lower organisation consumer healthcare network cer basis primarily reflected increased investment new continued adapt manufacturing network support product support continued impact lower prices particularly growth improve competitiveness meet business patient respiratory broader transition respiratory portfolio needs opened million facility montrose scotland reduction royalty income partly offset benefits supply active pharmaceutical ingredients ellipta respiratory prioritisation within rd favourable comparison medicines million facility parma italy produce impact priority review voucher purchased fostemsavir investigational hiv treatment revised supply demand warehousing distribution focusing resources accelerate growth operations align commercial priorities announced manufacturing site closures mexico bangladesh following made significant changes way pharmaceuticals extensive review cephalosporins antibiotics assets organisation works accelerate growth deliver best results decided restructure supply chain manufacturing site stakeholders ulverston uk help us improve competitiveness refocused resources prioritising major markets support growth emerging markets continued simplify us china reducing investment lower priority supplier base product portfolio ahead schedule markets also prioritised resource behind brands reduce contract manufacturers therapies greatest growth potential generate pharmaceuticals manufacturing supply organisation highest revenue support ambitions oncology delivered good performance safety quality compliance therapies pipeline strengthened oncology commercial regulatory inspections resulting infrastructure recruiting experts oncology haematology satisfactory outcomes colocating rd commercial teams simplified commercial medical regulatory teams fewer complex structures systems processes clearer accountabilities enables greater speed efficiency frees local operating companies focus customerfacing activities insights savings released changes reinvested priority products markets gsk annual report vaccines leading vaccines company world delivering million vaccine doses every day people living countries portfolio pipeline help protect individuals throughout lives recently introduced breakthrough vaccines shingrix shingles bexsero first vaccine meningitis b progress longterm priorities innovation performance trust shingrix launched successfully total turnover billion million doses vaccines us canada aer cer delivered gavi vaccine alliance help prevent pneumococcal disease sales came recent grew ahead market rotavirus cervical cancer innovations driven shingrix strengthening position bexsero leading vaccines company value million doses oral polio vaccine delivered unicef global candidate vaccines across addition shingrix key polio eradication initiative rd phases contributions influenza hepatitis franchises bexsero positive results candidate tb capabilities science new vaccine phase iib trial technologies continues differentiator innovation vaccines business innovative candidate vaccines delivering bestinclass innovation balance focus robust pipeline active lifecycle management existing vaccines helping protect shingles people expanded indications geographies breakthrough shingles vaccine shingrix investment breakthrough vaccines technologies creates recognised successful biopharma launch past real point differentiation deliver benefits years north america june canadas national advisory future vaccines scientists working three committee immunization naci made strong recommendation global rd centres belgium italy us international shingrix offered people following similar spread equips us diversity skills culture helps attract opinion us march shingrix received licensing best talent opens doors external partnerships approval eu japan may launched germany proportion sales innovations introduced past december standing committee vaccination germany five years stiko recommended shingrix people immunecompromising condition severe expanding capabilities become stronger player underlying disease vaccine approved australia worlds largest vaccines markets us china achieve july line phased launch strategy goal simplifying complexity across business reducing detailed capacity plans place necessary deliver rd timelines developing dynamic culture september meaningful increase doses needed meet longterm roger connor became new president global vaccines global demand shingrix marks step change prevention shingles painful potentially serious condition affects one three people lifetimes designed specifically address challenge agerelated decline immunity first approved shingles vaccine combine nonlive antigen trigger targeted immune response specifically designed adjuvant generate strong sustained immune response clinical trials proven shingrix efficacy age groups studied source independent assessment iqvia gsk annual report strategic report governance remuneration financial statements investor information meningitis phase ii studies demonstrated candidate vaccine market leader vaccines meningococcal safe capable inducing immune response began meningitis complementary portfolio menveo phase iib proof concept study europe north america serogroups c w bexsero targeting serogroup b efficacy results expected mid continued consolidate leadership broadening influenza working universal supraseasonal vaccine age range vaccines cover us bexsero researchers mount sinai us also expanded licensed toyearolds vaccine received breakthrough indications existing flu vaccines european approval therapy designation fda children two paediatric indication fluarix tetra years old june european medicines agency approved new alternative dosing schedule bexsero infants new technologies addition existing schedule offering healthcare professionals options help protect infants invasive success innovation reflects unique combination meningococcal disease imd caused serogroup b advanced technologies scientific experts across three global potential fewer visits doctor families rd centres external collaborations broad range technologies includes adjuvant systems selfamplifying messenger continued support external research meningitis b rna sam bioconjugates generalised modules membrane including funding largestever study adolescent carriage antigens gmma chimpanzee adenovirus chad platform meningococcal bacteria study led university capabilities potential significantly reduce cost adelaide saw teenagers vaccinated time vaccine development help make radical advances bexsero early findings significant step forward address unmet medical needs scientific understanding show fall number meningitis b cases south australian adolescents external partnerships statistically significant reduction nasopharyngeal carriage bacteria causes disease preliminary results partnerships remain central innovation around underscore need direct vaccination vulnerable individuals external scientific collaborations candidate particularly infants adolescents best way protect vaccines developed partnership partnerships meningococcal b disease technologies also support work tuberculosis shigella advanced work new formulations meningitis vaccines instance part ongoing commitment developing fully liquid menveo candidate vaccine entering phase ii vaccines diseases developing world clinical trials phase iii results us menveo booster found collaborations enable vaccines scientists learn effectively safely extend protection four six years leading experts stay close emerging technologies primary course menacwy vaccine also remain new science committed challenging goal developing single vaccine cover five common meningitis serogroups b c w priority assets pursuing full portfolio vaccines respiratory vaccines pipeline syncytial virus rsv tailored different age groups risk infection virus currently prophylactic vaccine approved prevention respiratory disease caused phase indicationvaccine rsv spite significant medical need maternal phase iii shingrix immunocompromised vaccine designed increase antibodies mother bexsero infants us transfer baby help protect first months life rotarix pcvfree disease severe candidate paediatric vaccine mmr us given directly babies designed induce protection disease throughout childhood potentially recipients entire phase ii copd lives late began phase iii trial children hepatitis c commenced phase study maternal vaccine us malaria next gen fda given fast track designation rsv candidate menabcwy vaccines pregnant women older adults menveo liquid entered clinical development shigella copd predicted become worlds thirdleading tuberculosis cause death copd candidate vaccine marks move away traditional concept vaccine given healthy people rsv paediatric prevent specific disease towards development hiv diseasemodifying vaccine could reduce frequency phase iii rsv older adults copd exacerbations slow diseases progress flu universal combines two antigens bacteria commonly found acute rsv maternal copd exacerbations proprietary adjuvant system aso gsk annual report vaccines continued performance performance summary focusing growth markets vaccines turnover grew aer cer million strengthened position worlds leading primarily driven growth sales shingrix hepatitis vaccines vaccines company value sales grew ahead market also benefited competitor supply shortage higher increasing market share profitability sales influenza products established leadership europe emerging markets operating margin percentage points higher focusing increasing presence worlds aer percentage points higher cer basis largest vaccines markets us china protect people primarily driven enhanced operating leverage strong improve business performance us number one sales growth improved product mix including impact priority market performance us launch shingrix together restructuring integration particularly strong welcome chinese governments recent benefits partly offset comparison benefit steps fasttrack approval clinically urgently needed new settlement lost thirdparty supply volume recorded medicines vaccines reflecting commitment enabling increased supply chain costs increased sga investments faster entry new prevention treatment options look support new launches business growth forward responding need innovative vaccines years ahead shingrix recorded sales million primarily us canada driven demand share gains us sales benefited creating simpler competitive supply chain market growth new patient populations covered immunisation recommendations shingrix achieved manufacturing sites across countries market share first half alone shingrix international presence enables us produce vaccines performed twice strongly competitor vaccine flexibility demonstrated year leveraged whole secondary manufacturing network increase capacity shingrix meningitis sales aer cer delivered million doses globally since launch million bexsero sales grew aer cer driven working hard build capacity meet longterm demand share gains us together continued growth global demand continue target highteens millions doses private market sales international partly offset completion next two three years undertaking vaccination catchup cohorts certain markets europe multiple initiatives boost production across global menveo sales declined aer cer primarily reflecting manufacturing network us europe every stage supply constraints europe international well strong manufacturing process primary antigen production comparator unfavourable yearonyear cdc stockpile packaging initiatives ensure sustainable steady supply movements us partly offset demand share gains growth vaccine coming years us year continued simplify supply chain fluarixflulaval sales grew aer cer million discontinued several vaccines duplicate existing products driven strong sales execution us improved sales ongoing investment manufacturing network enabled europe partly offset increased price competition us growth filling volume maintained strong established vaccines sales aer flat cer focus safety high quality vaccines reflecting lower sales dtpacontaining vaccines infanrix pediarix boostrix due increased competitive pressures particularly europe unfavourable yearonyear cdc stockpile movements us together lower synflorix sales reflecting lower pricing demand emerging markets hepatitis vaccines sales grew aer cer million benefiting stronger demand us europe well competitor supply shortage us gsk annual report strategic report governance remuneration financial statements investor information consumer healthcare consumer healthcare business combines science consumer insights develop innovative everyday healthcare brands oral health pain relief respiratory skin health nutrition digestive health categories reached agreement pfizer combine consumer healthcare businesses new worldleading joint venture progress longterm priorities innovation performance trust worldwide rollout sensodyne total turnover billion supply chain service levels continued rapid relief voltaren mess aer cer improve achieving ontime parodontaxcorsodyl infull delivery performance bought novartis stake sciencebased innovations included consumer healthcare joint venture fiveyear partnership smile train theraflu powerpods polident billion launched help children access denture care range lifechanging cleft lip palate surgery agreement pfizer combine new digital innovation hub established consumer healthcare businesses continued partnership allied accelerate innovations selfcare new worldleading joint venture dengue india south east asia prevent outbreaks announced sale horlicks dengue fever consumer nutrition brands unilever employee engagement score increased innovation delivered first market launches across categories pain relief continued rollout voltaren mess roll outs new products proportion sales additional markets including russia uk australia italy innovations introduced past three years spain innovative mess cap designed address key consumer barrier using topical pain relief makes delivering bestinclass innovation product easier less messy apply digestive health launched two extensions tums brand use deep consumer insights scientific technical expertise tums gas relief offers consumers multisymptom relief deliver innovations across categories example heartburn well gas introduced chewy bites format oral health strengthened leadership denture care preferred format growing number younger delivery two innovations improve experience consumers entering category also introduced sugarfree denture wearers addressed consumer need easy version tums consumers looking reduce overall discreet denturecleaning solution launch polident clean daily sugar intake refresh wipes used anywhere without need water wipes combine unique patented combination building industryleading capabilities tearresistant tissue double mint solution offering consumers main categories supported dedicated global quick effective clean improved denture confidence innovation hub scientists work close partnership addition new denture adhesive polident max seal commercial teams means rd hubs innovative precision nozzle finer tip enables exactly sciencebased consumerled helps speed new innovations right amount fixative applied creating precise seal around market networks footprint europe us asia also edge denture comfortable eating experience enables us stay close relevant global trends successful rollout sensodyne rapid relief premium markets extension sensodyne brand continued launched consumer sensory labs enable us listen understand designed provide fast relief tooth sensitivity little meet needs consumers scientists commercial teams seconds introduced additional labs assess consumer reactions products markets including us italy argentina new zealand development process help improve existing products develop egypt bringing total number successful market launches new ones year brought capabilities sensory labs closer markets via labs us uk india respiratory consumer insight inspired packaging innovation understand consumer preferences different parts behind theraflu powerpods new extension theraflu world example developed otrivin unblock heal respiratory power brand theraflu powerpods launched response consumer need medicated spray relieves us contain cold flu relief medicine active ingredients within congestion nasal dryness accompany cold pod used singleserve coffee makers format also helps fight virus launched tripleaction spray much convenient us consumers rarely use kettles europe late gsk annual report consumer healthcare continued increasing use digital technology revolutionising way external partnerships consumers learn buy use healthcare products created new londonbased consumer healthcare combining insights expertise scientists digital innovation hub hub close partnership commercial breakthrough ideas developed externally develop deliver technology rd focused identifying accelerating strong competitive pipeline consumerled sciencebased innovations categories develop digitally driven brands innovation since percentage innovation sales coming products services consumers use monitor manage externally sourced product innovation increased fivefold improve health products external partnerships accounted innovation sales including otrivin unblock heal year emerging markets opportunities entered external rd partnerships aim make pipeline future onethird sales emerging markets increasing prosperity boosting proportion middleclass consumers turn demand consumer healthcare innovation hubs india china forefront efforts understand meet growing consumer need remain competitive important markets india entered high protein drink category launch horlicks protein plus blends quality fast slow release proteins high level amino acids enabling product develop stronger sciencebased claims competitors performance performance summary pain relief sales flat low singledigit growth voltaren supported rollout voltaren mess markets marketing innovation resources targeted doubledigit growth fenbid offset decline panadol brands deliver strongest growth highest returns sales due change routetomarket model south east seven global power brands including sensodyne voltaren asia discontinuation slowrelease panadol products panadol theraflu regional core brands nordic countries tums excedrin together brands drive performance nutrition sales declined aer grew cer million consumer healthcare reinforce global leadership nutrition business india performed strongly across product pain relief respiratory therapeutic oral health portfolio including new innovations horlicks protein plus consumer healthcare sales million aer impact divestments india gst implementation nutrition cer broadbased growth oral health category growth approximately eight percentage points wellness partly offset decline panadol lower sales skin health sales aer cer million smaller brands international markets performed strongly consumer healthcare operating margin particularly india brazil europe impacted percentage points higher percentage intensifying competitive pressure second half points higher cer basis primarily reflected improved aggregate impact generic competition transderm product mix manufacturing restructuring integration scop us divestment horlicks maxinutrition benefits well continued focus delivering improved return uk small nonstrategic brands implementation investment advertising promotional spend goods service tax gst india reduced overall sales growth approximately one percentage point strategic business development oral health sales grew aer cer million increased competitive pressures europe offset double made progress performance digit growth sensodyne number international markets priority deliver sales growth operating margin improvements including india turkey strong singledigit growth us attractive returns completing billion buyout novartis driven sensodyne rapid relief premium gum health brand stake gsk consumer healthcare june parodontaxcorsodyl became worlds fastest growing global conducting strategic review nutrition portfolio toothpaste outperforming market four fold driven continued december announced sale horlicks consumer momentum us since launch strategic brand nutrition brands unilever part transaction repositioning across countries denture care brands announced merge stake glaxosmithkline performed category supported innovations including polident consumer healthcare limited india hindustan unilever max seal polident clean refresh strengthening limited proposed merger includes distribution arrangement global leadership position allow hindustan unilever limited leverage scale wellness sales declined aer grew cer strong reach sell distribute otc oral health brands million respiratory sales grew low single digits led india transaction expected close end theraflu supported strong cold flu season earlier year otrivin grew mid single digits benefiting new variants flonase returned growth following weaker allergy season earlier year gsk annual report strategic report governance remuneration financial statements investor information recently reached agreement pfizer december winning shoppers customers experts combine consumer healthcare businesses create new worldleading joint venture combined sales expert endorsement builds trust brands drives shopper approximately billion brings together two highly purchase decisions sensodyne instance number one complementary portfolios trusted consumer healthcare brands dentistrecommended brand sensitivity markets including gsks sensodyne voltaren panadol pfizers compete otc brands sold pharmacies advil centrum caltrate new combined business continued prioritise relationships dentists leadership positions pain relief respiratory vitamins pharmacists invest information supports products minerals supplements addition number one position expert sales representatives called dentists therapeutic oral healthcare well positioned deliver markets share relevant sciencebased information strong sales cash flow earnings growth published approximately abstracts clinical trials science together moves provide confidence improve margin target midtohighs assuming close business partnering retailers key example top six transaction pfizer improvement expected achieved customers us account approximately sales part delivering billion total annual costs savings continue develop strong capabilities joint joint venture additionally delivery businesswide business planning category management distribution programme aimed freeing cash improve returns management ensure win retailers shareholders reinvest business drive growth shopper science labs uk us singapore use focused four pillars net revenue management maximise stateoftheart technology track shopper behaviour real time value brands shoppers customers cost cash provide us rich insights consumers shopping habits discipline enabled zerobased budgeting strategic resource around world satellite facilities located allocation focus investments right areas get headquarters major retail partners labs enable best returns increased efficiencies supply chain us adapt shopping experience meet consumers joining forces pfizer consumer healthcare need make decisions new products promotions transformational scale gsk consumer healthcare packaging really make difference lays foundations new jv separated gsk via demerger expected take place within three years creating simpler competitive supply chain closing transaction pfizer expect occur second half subject approvals details continued strengthen supply chain reduce risks associated transaction set complexity improve efficiency addition formally integrated within business previously central digital transformation resources processes shared consumer healthcare pharmaceuticals supply chains central unit putting digital technology heart business aim also reorganised supply chain regional basis deliver meaningful interactions consumers fuel brand closely reflecting commercial operations make growth achieve efficiency savings invested responsive agile strongly digital capabilities including hiring expert new talent sold two sites aiken us slough uk reflecting far higher return online media compared announced closure three ireland us traditional television advertising significantly increased philippines part commitment remove complexity across digital balance marketing streamline media buying network streamline operations overall since appointed one global media agency oversee digital removed four sites supply chain network offline paid media strategy planning around world also announced closure another five continued streamline boosted attractiveness ecommerce channels optimising number contract manufacturers cmos use findability products developing rich content retailer reduced number almost since continued portals securing highprofile ads customers ecommerce simplify portfolio reducing number different sites enrich peoples digital skills rolled new ways products packaged marketing iq development programme marketers manufacturing sites recorded strong ontime infull delivery digital impact aided innovative industry partnerships performance service levels continued improve reflecting collaboration google helps us deliver relevant content good performance supply chain successfully supported consumers partnership chinese marketing media growing power brands met business innovation targets organisation alimama enables us target shoppers appropriate full including firstmarket launches timely information partnership google driven continued drive deliver robust performance quality greater efficiency media targeting drove billion safety issues arising regulatory inspections viewable digital media impressions investment would generated representing increase also draw invaluable external insights digital advisory board dab made digital marketing data ecommerce experts members gsk consumer healthcare strategic leadership team attend dab meetings benefit mentorship dab member role dab challenge thinking help shape digital strategy gsk annual report trust operating responsibly deliver purpose ensure greatest possible longterm impact improving health around world trust one three longterm priorities essential external benchmarking deliver purpose society high expectations us atmi topped access medicines index led industry dynamic environment operate presents us antimicrobial resistance benchmark big challenges opportunities must respond djsi ranked nd djsi world europe indices placing order remain commercially successful uphold reputation us top sector build trust ftsegood member ftsegood index since ensure able identify respond expectations effectively need mechanisms place cdp received score b cdp carbon cdp water engage key stakeholders summarise key named cdp supplier engagement leader cdp 's supply trends industry highlight engage chain programme across different stakeholder groups corporate political engagement index ranked number one external expectations mind published transparency international uks corporate political new set commitments describing actions take engagement index help deliver societal value build trust ambitious approach reporting commitments drive progress three key areas underpinned reporting progress commitments fundamental commitments running business responsibly annual report reflect integration responsible using science technology address health needs business approach core business strategy performance making products affordable available data document also available online provide current previous years data replace annual publication modern employer responsible business supplement g skcom performance data summary commitments trust purpose help people feel better live longer using science technology making products affordable modern address health needs available employer new medical innovations pricing engaged people develop differentiated highquality improve health millions people achieve maintain competitive needed medicines vaccines year making products employee engagement score consumer healthcare products available responsible prices inclusion diversity improve health sustainable business accelerate progress inclusion global health product reach diversity aiming female improve global health impact use access strategies reach representation senior roles rd infectious diseases affect million underserved people recognition global lgbt indices children young people developing developing countries products countries focusing hiv malaria health wellbeing development tb healthcare access leading company support health security partner improve disease prevention employee health wellbeing personal help world better prepare awareness access healthcare development future disease outbreaks pandemic services million people potential tackle antimicrobial resistance responsible business reliable supply ethics values data engagement environment commit quality safety operate ethical values use data responsibly reduce environmental reliable supply products driven culture transparently improve patient impact one quarter patients consumers issues responded swiftly scientific engagement transparently gsk annual report strategic report governance remuneration financial statements investor information science technology using science technology address health needs continuing trial international aids vaccine achieved medical innovation also initiative longstanding gsk collaborator hiv vaccine responsibility impact global health particularly prevention development recently acquired aeras tb vaccine treatment infectious diseases worldleading clinical programme scientific expertise taken proactive approach gsk also number promising tb medicines development addressing biggest global health challenges including two preparation phase ii trials preventing child deaths infectious diseases tackling member several major publicprivate partnerships urgent public health threat growing resistance antibiotics programmes tb drug accelerator aim speed discovery development novel compounds new medical innovations disease currently three preclinical candidates strong discovery pipeline arising partnerships biggest impact scienceled global healthcare company successfully research develop malaria innovative products innovation aim develop received approval us fda australian differentiated highquality needed medicines vaccines therapeutic goods administration tafenoquine krintafel consumer healthcare products improve health read kozenis singledose radical cure p vivax malaria developed innovation within three businesses pages partnership medicines malaria venture mmv first new treatment type relapsing malaria global health years marks major contribution towards efforts eradicate disease together partners mmv path aim year malaria tb hivaids kill almost million people provide treatment affordable price malaria endemic vast majority developing countries remains huge need countries submitted regulatory filing tafenoquine innovation address new global health strategy aims brazil first submission malaria endemic country improve global health impact rd infectious diseases rtss vaccine aims protect children p falciparum affect children young people developing countries malaria common subsaharan africa focusing hiv malaria tb responsible malarial deaths worldwide ghana kenya biggest contribution make science malawi approved use rtss malaria part pilot greatest impact need strong collaboration others vaccination implementation programme coordinated ensure always clear path innovation end end clinical trials also way nextgeneration malaria vaccine lab patient learned malaria vaccine hiv chlorhexidine gel umbipro getting innovation patients developing new formulations hiv medications specifically developing countries extremely challenging traditional children disproportionately affected disease route market absent alone carry significant developing countries global priority viiv healthcare costs risks associated full clinical development registration progressing clinical development programmes paediatric manufacture market access new medicines vaccines formulations medicines partnership international dont commercial return without action secure right maternal paediatric adolescent aids clinical trials network procurement models partnerships risk potential impact paediatric european network treatment aids treatments undermined instead need new sustainable collaborative models risk costs shared tb leading cause death people living hiv across partners translate scientific discoveries benefit coinfection hard treat phase iv study viiv healthcares vulnerable patients tivicay dolutegravir combination antiretrovirals demonstrated positive results people receiving treatment well addressing disease burden developing countries hiv tb latest hiv treatment guidelines recommend investment global health also brings business benefits dolutegravirbased regimens preferred first secondline helps us ensure sustainable long term treatment innovative science platforms discovered global health rd applied commercially example adjuvant used developing world diseases rtss malaria vaccine pivotal success well main focus hiv tb malaria early discovery shingles vaccine shingrix used tb candidate work allows us pursue promising scientific leads vaccine number vaccines development areas within gsk tres cantos open lab discovery work infectious diseases also potential vaccines institute global health uncover insights relevant disease areas benefit pledged additional million funding portfolio long term tres cantos open lab foundation open lab furthers rd tuberculosis diseases developing world offering external researchers aiming develop worldleading portfolio firstinclass potential access gsks compound library screening tools medicines tb including candidate vaccine phase iib trial scientific expertise well supporting research tb working nonprofit scientific organisation aeras malaria projects include neglected tropical diseases develop vaccine support bill melinda gates chagas disease leishmaniasis sleeping sickness since foundation uks department international development established open lab approved projects others received positive interim results phase iib trained scientists global health drug discovery delivered study showed candidate vaccine reduced risk significant pipeline candidate medicines including novel developing pulmonary tb half adults latent tb infection tb drug candidate treatment shortening potential gsk annual report trust continued vaccines institute global health also around also committed researching developing new vaccines scientists working diseases shigella invasive infections reduce need antibiotics even nontyphoidal salmonella typhoid paratyphoid fever example currently developing vaccines group streptococcus rsv virus well shigellosis tb caused bacteria drivers current antibiotic use health security pharmaceuticals pipeline gepotidacin first new class antibiotics worked uk government using vaccines medicines scientific knowhow proposal develop test new payment model help world better prepare future disease outbreaks incentivise muchneeded rd new antibiotics pandemic potential tackle antimicrobial resistance amr pharmaceutical industry pleased uk prepare future public health emergencies continue first country world progress type model advance rapidresponse vaccine platform technologies submitted gepotidacin programme collaborating development universal influenza vaccine supported creation innovative medicines initiatives candidate amr accelerator launched call proposals amr one biggest health challenges world faces publicprivate partnership aim speed discovery playing leading role industrys response ranking development new medicines treat prevent resistant first among large pharmaceutical companies access bacterial infections collaboration capability building medicine foundations amr benchmark survey antibiotic resistance soar programme vaccines play critical role avoiding need antibiotics study analyse publish reports antibiotic resistance preventing bacterial viral infections vaccines local level share findings hcps public health diseases diphtheria meningitis pneumonia pertussis bodies inform development local antibiotic prescribing protected tens millions individuals bacterial infections guidelines trained hcps across major drivers direct antibiotic prescribing addition countries appropriate use antibiotics vaccines nonbacterial infections influenza rotavirus g skcom antimicrobial resistance malaria prevent development diseases trigger use antibiotics example treat secondary infections affordability availability making products affordable available people us pricing product launches including around world responsible pricing strategic access recent launches trelegy ellipta benlysta sc shingrix programmes partnerships juluca incorporate specific market dynamics unique drug well profile new medicine vaccine context gsk topped access medicines index sixth existing treatment options consecutive time assessment recognised us largest proportion rd pipeline dedicated priority diseases average net price products us fallen creation integrated global health rd unit around average per year past five years also stimulate collaboration offer various types patient assistance help ensure appropriate access medicines provided prescribed pricing medicines vaccines eligible uninsured patients patient assistance programme aim improve health millions people year europe engage governments payers work making products available responsible prices towards sustainable health systems support ongoing innovation sustainable business example pricing trelegy ellipta reflects economic value developing countries use innovative pricing structures demonstrating costeffectiveness innovation within part access strategies extend product reach see acceptable budget offering potential cost saving compared however recognise pricing pharmaceutical medicines alternatives vaccines also important issue developed countries file patents medicines least developed countries understand patient payer concerns affordability lowincome countries enforce historic patents setting price medicines developed markets countries allows generic companies apply valuebased approach balance reward innovation manufacture supply generic versions gsk medicines access affordability price medicines according countries value outcomes bring patients providers payers g skcom ip access developing countries sensitive market societal expectations price discounts rebates allowances gsk annual report strategic report governance remuneration financial statements investor information product reach healthcare access set new target use access strategies reach set new longterm target partner improve million underserved people developing countries disease prevention awareness access healthcare services products strategies include tiered pricing product million people reached million people donations voluntary licensing agreements extend access partnerships generic manufacturers products reached year invested million improving million people access strategies health infrastructure developing countries training frontline accordance tiered pricing principles reserve health workers partnership amref health africa care lowest vaccines prices organisations gavi vaccine international save children support tailored alliance supports countries gni per head less meet specific community needs align government health eight gavi countries using new fourdose priorities investment helped train vial presentation synflorix pneumococcal vaccine designed frontline health workers two million people directly address cold chain challenges hot countries rotarix reached health worker healthcare service health facility vaccine available gavi countries protect rotavirus well efforts combat malaria rd see distributed around two million doses vaccine partnered comic relief africa south east asia cervarix zimbabwe support multiage cohort vaccination support local projects improve awareness prevention programme protect girls human efforts get treatment people need together papillomavirus delivered million doses oral reached one million people including health polio vaccine unicef support global polio eradication workers vulnerable populations pregnant women initiative reaching million children young children umbipro innovative chlorhexidine gel prevent umbilical cord alongside local global partner organisations continue infections approved countries far already efforts remove stigma support hiv education prevention benefited newborns kenya created partnership atrisk communities around world viiv healthcares save children potentially lifesaving product available positive action programmes girls women adolescents access price profit loss collaboration children men sex men msm transgender usp usaid share manufacturing knowhow stimulate people example viiv awarded grants million local production wider access qualityassured chlorhexidine support organisations working prevent treat paediatric hiv developing countries million support social science research adolescent viiv healthcare extended voluntary licence agreements hiv positive action children programme reached dolutegravir unbacked medicines patent pool people interventions alleviate impact direct licensee aurobindo two countries mongolia hiv aids women childrens health tunisia enable generic manufacturers supply dolutegravir partnership save children aims combine two adults living hiv joint partnership clinton organisations global expertise skills energy help reduce health access initiative unitaid two generic manufacturers child mortality partnership reached also helping catalyse development manufacture supply children five million children since paediatric formulations dolutegravir interventions including widening immunisation coverage donated million albendazole tablets billion accelerating access treatments strengthening healthcare last two decades tackle neglected tropical systems extended partnership next five diseases helping deworm millions school children free years support shared ambition child five countries lymphatic filariasis lf tackling lf intestinal die preventable causes worms part commitment partners gsk consumer healthcares heritage specialist oral health help control eliminate neglected tropical diseases know importance healthy mouth year launched fiveyear partnership smile train provide funding expertise help children get access lifechanging partnership americares direct relief ihp uk surgery cleft lip palate reached children map international also donated units essential first year corporate donations employee fundraising medicines including antibiotics inhalers humanitarian emergency response countries guatemala south leader pain relief fever management gsks consumer sudan syria healthcare business also created allied dengue campaign india south east asia campaign created gskcom access medicines developing countries bring together key stakeholders partners prevent treat outbreaks dengue fever potentially fatal mosquitoborne disease trained healthcare workers reached people range programmes mobilise communities promote behaviour change contribution community health programmes amounted million includes support access partnerships comic relief save children inkind product donations albendazole made patient assistance programme volunteering time employees total excludes reach albendazole donations assessed gskcom access healthcare partnerships viivhealthcarecom positive action programmes health worker data estimated based reach partner programmes level funding final data available april gsk annual report trust continued modern employer modern employer want make sure everyone women management empowered feel good keep growing gsk believe help us attract retain motivate svpvp best people support business future director engaged people manager total employee engagement important barometer gauge people feel working gsk aim achieve maintain employees gender number competitive employee engagement score male female total survey employees twice year get regular board feedback longterm priorities management culture change first global employee survey year total april record high response rate results showed strong employee engagement management senior managers defined companies act strategic report directors report regulations includes persons second survey september saw onepoint drop responsible planning directing controlling activities company engagement remained high strategically significant part company board including directors undertakings included consolidated accounts part culture change encouraged people share views ideas key topics regular support development career progression highperforming conversations hosted leaders including lets talk sessions female managers accelerating difference programme executive team also introduced collaborative internal provided coaching support around women tech platform enable employees communicate collaborate also recruit support women early careers informally discuss topics matter share women representing half intake graduate knowledge perspectives support faster decisions across mba programmes apprentices organisation users active new published second gender pay gap report online tool gender pay gap permanent ukbased gsk employees mean outperforming national average inclusion diversity tolerate harassment unwelcome unreasonable offensive behaviour discrimination kind includes take progressive approach inclusion diversity form sexual harassment included module want everyone bring perspectives mandatory code conduct training reinforce zerotolerance business together unique perspectives wide approach emphasised importance bystander intervention variety personal experiences make business stronger empower employees intervene see harassment enhancing ability innovate respond diverse occurring needs patients consumers around world september nearly people locations took part want accelerate progress inclusion diversity activities raise awareness commitment inclusion aiming female representation senior roles diversity global inclusion week part launched recognition global lgbt indices new learning programmes focused unconscious bias women made senior roles svpvp resources help build leaders awareness inclusion diversity level maintained strong female global disability council global lgbt council representation management level january well inclusion diversity implementation groups addition signed club gender campaign focused created new global gender ethnicity councils achieving female representation senior management drive diversity agenda support employee within ftse companies gsk already exceeded resource groups achieved top listing lgbt target remains committed maintaining improving network group british lgbt awards early group named uks employee network group latest independent hamptonalexander review ftse year stonewall lgbt rights organisation companies found gsk sixth highest proportion pledged support un lgbti global business women board representation overall standards us gsk named best place work increased female senior executive population executive team lgbt equality third consecutive year human rights direct reports longrunning campaigns corporate equality index early programmes create strong female pipeline deliver results ranked th stonewalls uk workplace equality index gsk also one prominent healthcare life science committed removing barriers increasing understanding companies join healthcare businesswomens association ensuring disabilities opportunities gender parity collaborative us launched foster signed charter change uk governments measurable gender parity progress industry department international development global disability summit joining organisations common aim ensure rights freedoms dignity inclusion people disabilities gsk annual report strategic report governance remuneration financial statements investor information health wellbeing development development want people keep growing every stage career need resilient motivated people right skills thats development one four expectations company knowledge help us achieve objectives strong focus improving effectiveness aim leading company support employee health people managers employees development wellbeing personal development plans place support developing leaders health wellbeing managers also participated leadership development programmes year successfully rolled comprehensive preventive healthcare package employees eligible introduced one reviews nearly managers dependants every country operate partnership help improve based feedback teams prevention programme covers people short survey measures leadership effectiveness three key every country operate includes preventive areas knowing people delivering results maximising healthcare services little extra cost potential one part performance management system designed ensure managers role models provide programmes help people feel good taking values expectations well helping enhance control health managing energy levels adopting leadership skills know one scores employees healthier behaviours well giving flexibility manage feel supported managers development question lives lifefriendly policies manager provides highly effective coaching guidance people took part energy support development scored average resilience programmes personalised digital health platform responses encouraged aspirations piloted employees belgium said improve scores changed one health behaviours result gsk member club group companies continue roll technology platforms support committed hiring young people development programmes holistic approach health wellbeing least uk roles people joined graduate gsk named worlds active organisation virgin development programmes globally began apprenticeships pulse global challenge third year running uk canada ireland singapore belgium us employees collectively taking billion steps may year employees contributed volunteering hours participants reported increased productivity lower stress levels orange days employees went pulse mental wellbeing important physical wellbeing assignments nonprofit organisations countries raised awareness important issue world mental health share expertise learn new skills recent volunteer day encouraging people seek support hour assessment found completing assignment confidential employee assistance programme resources agreed brought new ideas fresh ways thinking preventing injuries illnesses work fundamental working gsk peoples health wellbeing reportable injury illness rate g skcom employee volunteering training development data continued decline per hours worked remains comparable leading companies sector reliable supply ensuring highquality safe reliable supply products conducted audits suppliers quality patients consumers priority three businesses processes audits clinical trials run behalf product shortages happen variety reasons including gsk assess quality safety supply disruptions unexpected demand since launching detecting monitoring understanding preventing side effects shingrix vaccine delivered million doses globally pharmacovigilance important evaluating safety unprecedented demand meant people pharmaceutical products work experienced supply shortages working hard build capacity partners enhance systems reporting meet longterm global demand committed transcelerate collaboration working others promote communicating transparently actions taking harmonised approaches procedures clinical development robust quality management system supports continuous safety evaluation drugs implement key regulations improvement helping us maintain high standards product counterfeit gsk products present risk patient safety quality safety comply relevant regulations including support efforts prevent manufacture distribution good manufacturing practice good pharmacovigilance counterfeit gsk products working closely government practice good clinical practice bodies international organisations world customs external regulatory inspections pharmaceutical organization customs authorities industry vaccines consumer healthcare manufacturing sites associations also conduct investigation found issues resulted minor observations enforcement activities tackle counterfeit gsk products address every issue however minor regulatory authorities commitment high standards product quality safety accepted proposed plans corrective actions across value chain helps ensure reliable supply important performance see sections report performance individual businesses data restated due incidents reported previous verification period g skcom pharmacovigilance anticounterfeiting based benchmarking data pharmaceutical safety group gsk annual report trust continued ethics values committed creating ethical valuesdriven culture reporting investigating concerns issues responded swiftly transparently expect everyone gsk live values expectations encourage people speak concerns speak concerns engage appropriately relating unethical conduct behaviour inconsistent stakeholders respect human rights also extend values simply want ask question ethical expectations third parties work apply code conduct living values expectations anyone within outside gsk raise concerns speak independent third party integrity lines confidentially together values patient focus integrity respect anonymously prefer take every reported concern transparency expectations courage accountability seriously review one understand whether formal development teamwork help us create culture investigation warranted investigations show employee want included code conduct breached policies take appropriate disciplinary action updated make simpler easier use employees accused misconduct every gsk employee complementary worker required reviewed cases initiated formal investigations complete mandatory training code conduct annually result employees disciplined policy violations employees complementary employees dismissed voluntarily left workers completed training covered topics safety organisation received documented warnings health wellbeing third party oversight data breach reporting instances action short documented warning taken sexual harassment antibribery corruption abac also introduced additional microlearning modules taken employees disciplined breakdown types throughout year keep values expectations top mind policy violation updated discussion guides leaders engage teams related topics indepth training mandatory training completion people used reallife examples dilemmas experienced gsk behaviour workplace help understand manage abac risks relevant good manufacturing distribution practices roles reinforce zerotolerance approach bribery marketing promotional activities corruption expenses assessed different parts business protection physical assets security values maturity matrix including interviewing approximately employees understand well values expectations embedded individual areas business using insights assessments put plans place political engagement enhance way values integrated ways working gsk local examples include increasing opportunities everyone working behalf gsk must follow engagement leadership teams improve trust code conduct interactions political stakeholders enhancing employee recognition encourage greater sense additionally selection process public policy groups includes accountability criteria ensure groups share values gsk topped transparency international uks corporate gskcom gsk code conduct political engagement index global companies operating uk based criteria political contributions responsible lobbying transparency reporting spent million federal lobbying activities us registered us federal lobbying register spend includes cost operating office washington dc cost travel consulting cost representing interests eu institutions published eu transparency register million also publish list memberships trade associations may lobby indirectly behalf gsk make corporate political contributions us employees may support individual candidates political groups financially political action committee contributed state federal candidates breakdown spend available online gskcom online eu transparency register us federal lobbying register trade association membership list criteria working public policy groups latest available figures figures available april submission eus transparency register gsk annual report strategic report governance remuneration financial statements investor information human rights working third parties gsk committed upholding universal declaration human third party oversight programme strengthens management rights core labour standards set international risk supply chain driving improvements network labour organization part commitment third parties including suppliers distributors implementing un guiding principles business human organisations transfer value ensure rights reassessed human rights risks ensure share values work ethical business focusing efforts business greatest potential standards expected gsk programme rolled impact people across areas business six priority areas identified access healthcare research risk assessments completed practices patient safety labour rights environment health third parties identified highrisk undergone safety privacy initial review found appropriate detailed independent assessments ecovadis measures place manage human rights risks related also conducted indepth audits health safety ethics areas identified need continue strengthen environment work third parties help approach managing thirdparty labour rights risks improve significant issues resolved may developing actions address continue build suspend terminate contract understanding management human rights risks taking account evolving external expectations best practice gskcom working third parties g skcom human rights modern slavery act statement data engagement committed using data responsibly transparently addition people key roles across organisation engaging patients healthcare providers help meet undergoing certification accredited external association patient needs includes treating data respect sharing increase expertise enable us make informed decisions results clinical trials integrating patient insights handling personal data product development providing healthcare professionals protection individuals data privacy high priority information want way want exclusive collaboration andme combines andmes genetic expertise advanced data science skills using data responsibly transparently gsks extensive scientific capabilities scale enhance discovery development entirely new medicines data becoming increasingly central business potential cures andme customers choose participate healthcare industry broadly digital data analytics research contribute information unique dynamic strategy harnesses power data technology strengthen database purpose advancing scientific research business make real difference patients around world participation voluntary customers required affirmatively believe help scientists develop innovative medicines consent data used research choose quickly higher probability success ever participate information aggregated individual enhance clinical trials improve interaction healthcare identifiable gsk providers customers consumers make processes efficient clinical trial transparency part longstanding commitment data transparency data privacy clinical trials published clinical study reports recognise people increasingly concerned summaries results positive negative protection inappropriate use personal data particularly trials clinical study register related health new eu regulations also increased requirements companies use personal data also share anonymised patientlevel data trials loss inappropriate use personal information could via wwwclinicalstudydatarequestcom launched five years serious impact individuals affected business ago facilitate innovative datadriven research used take responsibility data privacy seriously trial sponsors funders external researchers granted access based review scientific merit research developed comprehensive suite training drive proposal independent panel access gsk trial data culture everyone gsk takes personal responsibility approved proposals since correct handling personal data privacy principles ensure use personal information kept minimum necessary gskcom online gsk privacy notice gsk clinical study register fair transparent accurate secure trained employees complementary workers privacy principles help understand apply daily work raise awareness privacy matters handle personal data gsk annual report trust continued improve patient scientific engagement improve engagement patients involved clinical trials begun developing patient engagement plans key assets improve delivery groundbreaking new therapies get input development trial protocols improve strengthening focus patients needs seeking insights experience trial make sure informed across business began implementing new global results completed standards working supporting patients engagement hcps aim provide information also support several initiatives empowering patients products way best suits recent years get involved development medicines training significantly strengthened online resources tools dialogue including european patients academy inhouse medical capabilities provide bespoke product information paradigm patients active research dialogues hcps improved generation medicines patient focused medicines updated policy working hcps following development consistent feedback prefer learn new products held patient advocacy leaders summits japan portugal peertopeer programmes experts direct switzerland supported one us year build experience medicines update designed ensure relationships gsk employees patient advocates health continue operate responsibly improve help policy experts industry representatives patient organisations prescribers understand new data clinical experience also provide insights european health advisory board innovative products pharmaceuticals section report respiratory health board provides detail policy change g skcom patient engagement environment new goal reduce environmental impact globally around electricity came renewable sources one quarter cutting greenhouse gas emissions reducing water targeting interim target impact redirecting waste beneficial use underpinned reduce operational emissions five new environmental commitments latest available data scope emissions increased baseline less decreased per billion revenue reduce operational carbon emissions scope supply chain makes largest share value chain carbon footprint encourage suppliers share best reduce value chain carbon emissions scope practices gsk supplier exchange running kaizen per billion revenue events improve energy efficiency recognising achievements source electricity renewable sources supplier environmental sustainability awards reduce total water use highrisk site carbon emissions plus intensity ratios per regulations ensure waste repurposed beneficial uses tonnes coe scope emissions carbon scope emissions committed playing part address climate change scope emissions full data set new targets cut carbon footprint across available value chain intended challenging achievable next years report also conducted review reporting requirements task force climaterelated financial disclosures tcfd intensity ratios considering use guidelines better scope emissions understand report risks climate change presents sales revenue tonnes business early accredited science co em based targets initiative set scope targets line scope emissions level decarbonisation required keep global temperature fte tonnes co efte increase c scope emissionsbn full data overall value chain carbon footprint made scope revenue million tonnes available emissions operations scope emissions co ebn revenue next years supplier base logistics use report products scope emissions reduced ongoing efficiency measures investment onsite generation renewable energy reduction number sites india example saved tonnes co e emissions past four years investment solar installations combined heat power plant efficient lighting heating manufacturing figures available april carbon emissions calculated according greenhouse gas protocol corporate accounting reporting standard revised edition gsk annual report strategic report governance remuneration financial statements investor information emissions use products increased environmental stewardship since make medicines accessible committed moving towards deforestationfree sourcing people emissions come propellant gases used key commodities purchased directly gsk indirectly ventolin metered dose inhalers mdis last years behalf although recognise challenge due conducted detailed analysis explore requirements complex nature supply chains date focused developing new propellant mdis lower carbon footprint paper packaging palm oil palm oil derivatives findings show would extremely complex requiring developed supplier selection criteria well sourcing standards extensive rd significant changes manufacturing process conjunction rainforest alliance new clinical trials test efficacy safety patients packaging products plays important role delivering weighing challenges given incremental safe stable trusted medicines vaccines consumer healthcare benefits patients along need us allocate capital products however gsk recognises impact plastic investments developing promising new medicines improve packaging environment number initiatives health therefore decided instead focus investment place reduce plastic use increase use recycled plastic content new generation dry powder inhaler technologies encourage recycling plastic components example release greenhouse gas emissions entire new portfolio ensuring packaging larger volume weight thickness inhaled medicines delivered via dry powder ellipta inhaler needs fulfil function protecting product lifecycle carbon footprint around times lower took steps understand quantify amount propellantbased inhaler based assessment plastic packaging produce globally across business gsk carbon trusts best product carbon footprinting using information evaluate award addition support efforts promote low reduce impact plastic use environment carbon inhalers possible commitment made uk government increase inhaler recycling gskcom environmental policies recovery reuse hfa gas water climate change must tackled global level water challenges much localised used million cubic metres water across operations compared focusing reduction programmes areas biggest overall water impact pharmaceutical consumer healthcare manufacturing sites completed risk assessments ensure compliance water stewardship standard assessments identified highrisk sites based water scarcity local water quality health social risks regulatory reputational risks sites developing strategies reduce water impact goal reduce total water use highrisk site waste cut amount waste produce since generating total tonnes including tonnes hazardous waste reductions amount waste created complete elimination waste extremely challenging new goal waste repurposed beneficial uses avoids harmful environmental impacts landfill keeps materials solvents circulation use new products sites achieved zero waste landfill globally waste recycled incinerated energy recovery example million used inhalers recycled complete cycle programme uk since began one years treatment use propellantbased inhalers results carbon footprint kg coe compared carbon footprint kg coe using ellipta dry powder inhalers gsk annual report risk management risk management framework well embedded continually corporate executive team member performs review reviewed oversight board level audit risk key principal risks ensure controls place wherever committee assisted risk oversight compliance council gaps identified clear plans assigned address framework enables board identify evaluate manage year audit risk committee considered gsks principal risks designed support longterm priorities risks strategies address reviews provides businesses framework risk management undertaken annual business unit risk assurance upward escalation significant risks conjunction values update reports strategy papers significant expectations speak processes ensures risks risks annual risk review associated business activities actively effectively agreed mitigated provides reasonable assurance emphasised importance data privacy internal material misstatement loss businesses governed risk management perspective separating privacy new risk management compliance board promotes standalone enterprise risk information security enterprise tone top establishes culture regarding risk risk consequently report principal risks rather oversees internal controls annual confirmation exercise ensures risks listed assessment consistent risk management approach across gsk external macro environment risk exposure post mitigation reinforces leader accountability order significance risk assessment mitigation activities patient safety macro risk level increased global scale due expanding strict diverse regulatory environment going evolve exemplified china general macro gsk exposure macro environment established us european markets remains unchanged environment post mitigation patient safety good pharmacovigilance practices gvp remaining consistent plans place ensure gsks approach patient safety compromised brexit gsk risk exposure remains unchanged providing strong oversight mitigate risk implementation organisational improvements local central pharmacovigilance model product quality macro risk level remained unchanged continuing industrylevel regulatory scrutiny data integrity drug shortages caused manufacturing issues need timely macro gsk exposure communication issues authorities environment post mitigation overall gsk exposure level remains unchanged however improvements annual performance metrics reflect gsks ongoing investment improvement initiatives facilities operating systems training financial controls reporting macro level remains unchanged material increase financial reporting requirements macro gsk exposure environment post mitigation gsk exposure level reduced result successful completion us intercompany system migrations onto new erp platform antibribery corruption abac macro risk level remains unchanged continued strict abac laws scrutiny government regulators high standards expected corporations macro gsk exposure environment post mitigation gsk exposure level remains unchanged improved targeted training exposed bribery corruption risks roles revised simplified applicable written standards continued develop risk indicators intended provide meaningful useful data potential corruption eg financial crimes reduced exposure abac risk business model change highrisk markets continue embed changes sec doj investigations regarding third party advisers engaged gsk china ongoing commercial practices macro risk level increased due greater competitive pressure increased regulatory enforcement expansion digital engagement laws macro gsk exposure regulations still evolving environment post mitigation gsk exposure level remains unchanged continue enhance maintain control evolving commercial practices notably shift marketing sales practices utilising data analytics ecommerce channels october gsk announced changes way engage expert practitioners improve sharing new data innovative medicines vaccines limited time among healthcare practitioners new controls training implemented support changes ensuring appropriate oversight assurance across markets gsk annual report strategic report governance remuneration financial statements investor information arc report see principal risks uncertainties see viability statement see internal control framework see risk assessment mitigation activities privacy macro risk level increased due new stringent data privacy legislation multiple countries rise enforcement regulators macro gsk exposure environment post mitigation gsk exposure level remains unchanged following implementation new global privacy framework operating model european economic area resulted development critical privacy expertise compliance legal business roles along embedding privacy controls within third party oversight research practices macro risk level increasing primarily driven high rate change regulations external ethical standards increasing data use technological complexity macro gsk exposure environment post mitigation gsk exposure level remains unchanged continue establish appropriate controls culture continuous improvement overseen enterprise risk governance structure third party oversight tpo macro environment remains unchanged industry continues vigilant thirdparty risks global sourcing supply consumer investor macro gsk exposure expectations mature environment post mitigation gsk exposure level remains unchanged tpo programme fully deployed due diligence lowrisk engagements based embedded process controls relieving business owners tpo activity without significant change risk appetite highrisk engagements continue require engagement risk assessment prescribed next steps riskbased approach proposed means lowrisk issues may occur require reactive response environment health safety macro risk level increased due greater emphasis environment controls sustainability ehss regulators activists stakeholders particular focus areas include antimicrobial resistance related manufacturing releases wider issue pharmaceuticals macro gsk exposure environment pie increasing emerging market regulation external scrutiny environment post mitigation external supply chain active ingredients existing pipeline assets also increased significantly gsk exposure level remains unchanged risks associated restructuring site network proactively managed mitigation improvement plans established progressing implementation information security macro risk level continues increase threat pharmaceutical business industry generally become sophisticated targeted evidenced macro gsk exposure wannacry notpetya global incidents environment post mitigation despite gsk exposure level remains unchanged due development programme safeguard cyberattacks protect critical information systems ability balance demands regulation digital transformation involves increased data collection analysis supply continuity macro risk level remains unchanged ongoing stringent regulation continued us focus contract manufacturers outside ukeu brexit uncertainties macro gsk exposure environment post mitigation overall gsk risk exposure level unchanged improved risk management supplier portfolio reduced complexity internal external networks improved crisis continuity management framework however seen increase complexity introduction major serialisation change programme eu falsified medicines directive coinciding brexit preparations gsk annual report risk management continued risks associated proposed separation gsks consumer healthcare business separation consumer healthcare business may dependent number factors outside gsks control including required shareholder regulatory approvals favourable conditions public equity markets public private debt markets changes applicable law regulation therefore certainty separation completed proposed addition separation completed assurance either gsk consumer healthcare realise expected benefits separation separation adversely affect gsk consumer healthcare value liquidity respective shares approach brexit preparing uks exit eu brexit overriding brexit plans prepare us elements within control priority maintain continuity supply medicines significant experience maintaining resilient supply chains vaccines consumer healthcare products people uk used existing processes develop new supply eu model based uk leaving eu march minimise disruption patients also adjusted stock levels result taken riskbased approach planning uk eu uncertainty remains new operating mitigation allocating costs million implement environment result support efforts secure status relevant changes next one two years future quo operating period postbrexit uk eu preparations relationship uk eu negotiated made minimise potential disruption supply medicines patients good progress implementing brexit contingency plan activity included arranging retesting certifying anticipate subsequent ongoing costs arising brexit medicines europe submitting marketing authorisation holder could include customs duties include cost transfers updating packaging securing additional warehousing duplicate testing release products continue supporting employees obtaining settled status equivalent estimate potential costs approximately million per year uk europe uk technical guidance outlines details emerge business need change acceptance testing eu sites timelimited period brexit assumptions underlying forecasts could allowed us reduce potential duplication supply chain change consequent adjustments short term continue revise plans expected financial impact negotiations regulations develop longer term continue believe brexit material impact business ggsskk aannnnuuaall rreeppoorrtt strategic report governance remuneration financial statements investor information group financial review section cfos statement reporting framework approach tax viability statement total results adjusting items adjusted results cash generation conversion financial position resources treasury policies critical accounting policies gsk annual report cfos statement continued make progress delivering strategy financial goals set financial architecture pleased report groups results demonstrate operating profit continued operational execution key strategic objectives strong performances three businesses total operating profit million aer cer showed strong progression higher charges sales remeasurement contingent consideration liability related viiv healthcare offset stronger operating group turnover aer cer million performance lower restructuring costs lower asset impairment pharmaceuticals sales flat aer cer driven charges favourable comparison charges taken primarily growth hiv sales progress new related us tax reform billion respiratory products nucala ellipta portfolio partly offset lower sales seretideadvair established adjusted operating profit million aer cer pharmaceuticals overall respiratory sales declined aer driven margin growth vaccines consumer healthcare grew cer pharmaceuticals operating profit aer flat cer reflecting continued investment new products vaccines sales aer cer primarily driven weaker gross margin face ongoing pricing pressures sales shingrix us growth influenza hepatitis vaccines also benefited competitor supply shortage earnings per share partly offset declines established vaccines stronger operational performance helped deliver improved consumer healthcare sales declined aer grew cer earnings per share eps group total eps broadbased growth oral health wellness partly offset doubled pence adjusted eps pence aer increased competitive pressures europe divestments cer smaller brands including horlicks maxinutrition uk well impact implementation goods services total eps also benefited favourable comparison tax gst india charges arising impact us tax reform lower noncontrolling interest allocation consumer healthcare cost sales profits following acquisition novartis interest consumer healthcare business june cost sales percentage turnover percentage points aer percentage points cer factors partly offset higher transactionrelated primarily reflected favourable comparison writedowns charges arising increases valuation liabilities assets related decision withdraw tanzeum contingent consideration put options preferential dividends together favourable product mix vaccines adjusted eps growth cer well ahead consumer healthcare partly offset adverse pricing pressure cer increase adjusted operating profit primarily result pharmaceuticals particularly respiratory established reduced noncontrolling interest allocation consumer healthcare vaccines profits lower adjusted tax rate selling general administration cash generation sga costs percentage turnover continued drive strong focus greater cash discipline percentage points aer cer reflecting growth across group pleased report made significant aer cer increase primarily reflected higher progress year resulting net cash inflow restructuring costs investment promotional product support operations million million free particularly new launches respiratory hiv vaccines cash flow million million increase particularly driven progress working capital despite research development growth business especially inventory control stronger rd expenditure lower compared collections reductions capital expenditure lower legal costs million total basis million adjusted higher proceeds intangible divestments also contributed basis reflected favourable comparison impact cash conversion remains key focus priority review voucher purchased used accelerate net debt billion december compared registration first hiv twodrug regimen dolutegravir billion december comprising gross debt lamivudine well benefits recent rd billion cash liquid investments billion prioritisation initiatives including billion reported within assets held sale savings initiatives used build investments increase net debt last year primarily driven number mid latestage clinical development programmes decision buyin minority stake held novartis particularly oncology functional genomics consumer healthcare business billion adverse currency translation impact billion gsk annual report strategic report governance remuneration financial statements investor information capital allocation viability statement pursued disciplined approach capital allocation viability statement sets assessment prospects reflected investment choices made group next three years presented transactions initiated strengthen business improve outlook financial flexibility support gsks key strategic priorities culminated agreement announced december last year expect adjusted eps decline range establish new worldleading consumer healthcare joint venture cer guidance reflects expected impact intend separate group within three years tesaro acquisition significant investments making transaction closing give us unique value creating behind products pipeline also reflects completion opportunity establish two leading global companies recently announced transactions well approval appropriate balance sheets better able support respective substitutable generic competitor advair us future investment requirements continuing offer shareholders attractive distributions strong year operational performance good progress made commercial delivery new products given improvements cash conversion free cash flow together continued focus costs led improved generation across group last years remain operating margins business showing good momentum comfortable support future investment requirements together important strategic moves made however new pathway group gives us additional different transactions initiated confident confidence visibility ability invest behind first outlook prospects gsk priority strengthening rd pipeline finally last report shareholders cfo would like delivering cash returns shareholders dividends also thank many partners support time priority dividends paid shareholders billion company delivered expectations laid dividend p per share year expect maintain dividend level p simon dingemans chief financial officer capital allocation framework key priorities capital pharmaceuticals pipeline invest business vaccines capacity innovation improved p per share dividend expected cash shareholder returns performance focus rebuilding free cash flow time generation target x x cover returning dividend growth trust strict discipline returns transactions gsk annual report group financial review reporting framework total adjusted results costs ordinary course smaller scale restructuring legal charges expenses retained within total group financial review discusses operating financial adjusted results performance group cash flows financial position adjusted results include benefits major restructuring resources results year compared primarily programmes exclude significant costs significant results preceding year legal major restructuring transaction items total results regarded complete picture groups financial performance total reported results represent groups overall performance presented total results exclusion adjusting items may result adjusted earnings materially gsk also uses number adjusted nonifrs measures report higher lower total earnings particular significant performance business adjusted results non impairments restructuring charges legal costs excluded ifrs measures may considered addition adjusted earnings higher total earnings substitute superior information presented accordance ifrs adjusted results defined nonifrs gsk undertaken number major restructuring programmes measures defined recent years response significant changes groups trading environment overall strategy following material gsk believes adjusted results considered together acquisitions including novartis transaction costs total results provide investors analysts stakeholders cash noncash programmes provided helpful complementary information understand better financial individual elements approved meet accounting performance position group period period recognition criteria result charges may incurred allow groups performance easily compared number years following initiation major restructuring majority peer companies measures also used programme management planning reporting purposes may directly comparable similarly described measures used time time group divests noncore investments products companies businesses records profit loss disposal adjusting item notable divestment past five years gsk encourages investors analysts rely single disposal oncology business one element financial measure review gsks annual reports including threepart transaction novartis financial statements notes entirety significant legal charges expenses arising gsk committed continuously improving financial reporting settlement litigation government investigations line evolving regulatory requirements best practice normal course materially larger regularly occurring made number changes recent years line individual matters also include certain major legacy matters practice gsk expects continue review reporting framework including relevant use alternative reconciliations total adjusted results providing performance measures information key adjusting items set five years set pages adjusted results adjusted results exclude following items total results gsk provides earnings guidance investor community together tax effects items basis adjusted results line peer companies amortisation intangible assets excluding computer software expectations investor community supporting easier goodwill comparison groups performance peers gsk impairment intangible assets excluding computer software able give guidance total results reliably forecast goodwill certain material elements total results particularly future fair value movements contingent consideration put options major restructuring costs include impairments tangible given rise significant adjustments driven assets computer software specific board approved external factors currency movements capital programmes structural significant scale markets costs individual related projects exceed million including integration costs following material acquisitions transactionrelated accounting adjustments related significant acquisitions proceeds costs disposals associates products businesses significant legal charges net insurance recoveries expenses settlement litigation government investigations operating income royalty income items impact enactment us tax cuts jobs act gsk annual report strategic report governance remuneration financial statements investor information reporting framework continued historical record adjusting items reconcilations total adjusted operating profit last five years summarised follows total operating profit intangible asset amortisation intangible asset impairment major restructuring transactionrelated items divestments significant legal items us tax reform adjusted operating profit analysis impact transactionrelated items operating profit last five years follows novartis consumer healthcare joint venture put option contingent consideration former shionogiviiv healthcare jv including shionogi preferential dividends viiv healthcare put options pfizer preferential dividends contingent consideration former novartis vaccines business adjustments transactionrelated items full reconciliations total adjusted results set pages explanations adjusting items reported noncontrolling interests viiv healthcare acquisitionrelated arrangements consideration acquisition shionogis interest trading profit allocations former shionogiviiv healthcare joint venture shionogi viiv healthcare subsidiary group received equity stake viiv healthcare viiv healthcare operating results turnover operating profit profit tax also agreed pay additional future cash consideration shionogi included within group income statement portion contingent future sales performance products earnings allocated noncontrolling interests owned developed joint venture principally dolutegravir shareholders line respective equity ifrs business combinations gsk required provide shareholdings pfizer shionogi estimated fair value contingent consideration time shareholders including gsk also entitled preferential dividends acquisition required update liability latest determined performance certain products estimate fair value subsequent period end liability shareholder contributed relative performance contingent consideration recognised balance sheet products changes time proportion overall earnings date acquisition million subsequent remeasurements viiv healthcare allocated shareholder change reflected within operating incomeexpense within particular increasing sales dolutegravircontaining products adjusting items income statement period favourable impact proportion preferential december liability discounted dividends allocated gsk adjusting items allocated stood million posttax basis shareholders based equity interests gsk entitled cash payments settle contingent consideration made approximately total earnings adjusted shionogi viiv healthcare quarter based actual earnings viiv healthcare remeasurements sales performance relevant products previous quarter liabilities preferential dividends allocated pfizer payments reduce balance sheet liability hence shionogi included within operating income recorded income statement cash payments made shionogi viiv healthcare million liability required recorded fair value estimated future payments significant timing difference charges recorded total income statement reflect movements fair value liability actual cash payments made settle liability gsk annual report group financial review continued reporting framework continued cash payments reflected cash flow statement partly however q gsk notified shionogi operating cash flows partly within investing activities tax irrevocably given right accordingly recognised liability relief payments reflected groups adjusting items put option groups balance sheet q part tax charge part payment relating initial value million q shionogi irrevocably original estimate fair value contingent consideration agreed waive put option result gsk derecognised acquisition shionogiviiv healthcare joint venture liability put option groups balance sheet directly million reported within investing activities cash flow equity value liability million statement part payment relating increase derecognised liability since acquisition reported within operating cash flows gsk also call option shionogis shareholding viiv movements contingent consideration payable shionogi healthcare original agreements exercisable follows six month windows commencing gsk irrevocably agreed waive first two exercise windows last six month window remains call option contingent consideration beginning year fair value value accounting purposes remeasurement income statement cash payments operating cash flows free cash flow cash payments investing activities introduction new rd strategy gsk contingent consideration end year revised definition free cash flow nonifrs measure include proceeds sale intangible assets balances contingent consideration payable posttax basis expenditure purchases intangible assets shionogi december million december deducted calculating free cash flow makes treatment million expected paid within one year intangible assets consistent property plant equipment exit rights free cash flow defined net cash inflow operating pfizer may request ipo viiv healthcare time activities less capital expenditure property plant equipment either gsk consent ipo offering intangible assets contingent consideration payments net completed within nine months pfizer could require gsk acquire interest dividends paid noncontrolling interests plus shareholding original agreements gsk proceeds sale property plant equipment unconditional right long made subsequent distribution intangible assets dividends received joint ventures shareholders withhold consent exercise pfizer associates used management planning reporting put option result accordance ifrs gsk purposes discussions presentations investment recognise liability put option balance sheet however analysts rating agencies free cash flow growth calculated q gsk notified pfizer irrevocably given reported basis reconciliation net cash inflow operations right accordingly recognised liability put option free cash flow set groups balance sheet q initial value free cash flow conversion million consistent revised treatment end q gsk also recognised liabilities future preferential free cash flow conversion free cash flow percentage dividends anticipated become payable pfizer shionogi earnings groups balance sheet working capital conversion cycle closing balances liabilities related pfizers shareholding follows working capital conversion cycle calculated number days sales outstanding plus days inventory outstanding less days purchases outstanding pfizer put option cer aer growth pfizer preferential dividend order illustrate underlying performance groups practice original agreements shionogi could also requested discuss results terms constant exchange rate cer gsk acquire shareholding viiv healthcare six month growth represents growth calculated exchange rates windows commencing gsk used determine results overseas companies sterling unconditional right long made subsequent distribution remained unchanged used comparative period shareholders withhold consent exercise cer represents growth constant exchange rates aer shionogi put option result gsk recognise represents growth actual exchange rates liability put option balance sheet gsk annual report strategic report governance remuneration financial statements investor information approach tax understand responsibility pay appropriate amount groups total tax rate tax fully support efforts ensure companies lower adjusted tax rate total tax charge includes appropriately transparent tax affairs managed effect reduced estimate impact us tax reform tax important element economic contribution bring following additional guidance released irs countries operate engage artificial tax reassessment estimates uncertain tax positions following arrangements without business commercial substance settlement number open issues tax authorities seek avoid tax use tax havens transactions ongoing public focus tax affairs would fully disclose tax authority zero multinational companies well continued focus tax reform tolerance approach tax evasion facilitation tax evasion driven oecds base erosion profit shifting substantial business employment presence beps project european commission initiatives fiscal many countries around globe pay significant amount state aid investigations outputs oecd beps projects tax including corporation business taxes well clarified important principle tax paid profits tax associated employees time throughout supply chain profitmaking activity takes responsibility shareholders financially efficient place gsk subject taxation throughout supply chain deliver sustainable tax rate part approach look gsk supports beps proposals particular implementation align investment strategies countries already oecds recommendations country country reporting substantial economic activity government policies including exchange data tax authorities promote regimes attractive business investment data validated existing information held taxpayers rd activity transparent intent available support ability ensure multinational groups pay relevant tax payers examples include uk patent box appropriate amount tax research development expenditure credit detailed tax implications brexit dependent outcome tax risk managed robust internal policies processes negotiations uk eu therefore currently ensure alignment across business compliance unknown however continue work closely abpi tax legislation audit risk committee board bia analyse potential implications industry order responsible approving tax policies risk management highlight key focus areas government part brexit approach negotiations direct tax implications particular expected seek maintain open positive relationships governments limited gsk indirect tax implications may tax authorities worldwide welcome constructive debate significant including potential customs duty costs additional taxation policy transaction administrative costs associated managing import export obligations movement goods uk group corporate tax charge million eu approach brexit set million profits tax million million representing effective tax rate tax strategy set detail within public policy positions made cash tax payments million section website details corporate tax year million addition taxes pay charges year set profits pay duties levies transactional employment taxes adjusted tax rate subject material changes product mix material changes tax regulations laws countries operate reflecting ongoing impact us tax reform groups effective adjusted tax rate next several years expected around gsk annual report group financial review continued viability statement accordance provision c revision code gsk assessed prospects company longer following hypothetical downside scenarios period months required going concern evaluated provision directors confirm reasonable scenario business performance risks include key expectation gsk continue operate meets liabilities performance risks including lower sales new products fall due next three years directors assessment greater adverse impact generic competition made reference gsks current position competitive launches gsk products well prospects strategy boards risk appetite gsks possible supply manufacturing challenges principal risks managed detailed pages strategic report assessment made scenario external macroeconomic risks scenario assuming separation new consumer healthcare joint reflects incremental risks business driven outside venture threeyear period consideration factors intense competition increased pricing pressure us europe well potential board reviews internal controls risk management impact material negative changes macroeconomic policies approves governance structure code healthcare environment conduct also appraises approves major financing investment licensing decisions evaluates monitors performance scenario principal risks scenario includes severe prospects gsk whole focus largely improving assessment potential loss impact principal risks longterm financial performance delivery company related patient safety product quality supply chain continuity three business strategies aligned innovation performance well antibribery corruption consequent trust priorities regulatory actions fines could fundamentally threaten operations risks managed board reviews gsks strategy makes significant capital mitigating activities described pages investment decisions longterm time horizon based multiyear assessment return capital performance scenario put option exercise scenario evaluates company three business units market opportunity additional funding requirements assuming earliest potential pharmaceutical vaccines consumer sectors approach exercise outstanding put option held partner aligned gsks model achieving balanced growth investing hiv business high quality innovative products patients consumers healthcare providers however since many internal external parameters become increasingly unpredictable longer time threeyear review also makes certain assumptions horizons gsk focuses detailed bottomup plan threeyear normal level capital recycling likely occur considers whether cycle plan reviewed least annually directors additional financing facilities required respective level approve business forecasts showing expected financial impact funding flexibility headroom directors believe threeyear assessment period viability results stress testing show certain combinations statement appropriate aligns companys well hypothetical scenarios could increase funding demands established business planning processes balance longterm gsk require mitigating changes groups funding strategy nature investments pharmaceutical vaccines consumer however light liquidity available group based sectors assessment period analysis analysis directors reasonable expectation even nearterm business performance realistically visible severe stress tests company able plan stress tested series robust operational continue operation meet liabilities fall due principal risk downside scenarios part boards review threeyear period assessment risk include potential effects brexit expected material although may shortterm disruption downside scenarios consider gsks cash flows sustainability dividends funding strategy insurance provision recovery well key financial ratios period metrics subject sensitivity analysis involves flexing number main assumptions underlying forecasts individually combination along mitigating actions could realistically taken avoid reduce impact occurrence underlying risk gsk annual report strategic report governance remuneration financial statements investor information total results turnover bn group turnover bn aer growth cer growth growth growth cer pharmaceuticals vaccines consumer healthcare group turnover group turnover aer cer million pharmaceuticals sales flat aer cer driven primarily growth hiv sales new respiratory products nucala ellipta portfolio partly offset lower sales seretideadvair established pharmaceuticals total operating profit bn overall respiratory sales declined aer grew cer bn aer growth cer growth vaccines sales aer cer primarily driven sales shingrix us growth influenza hepatitis vaccines also benefited competitor supply shortage partly offset declines established vaccines consumer healthcare sales declined aer grew cer broadbased growth oral health wellness partly offset increased competitive pressures europe divestments smaller brands including horlicks maxinutrition uk well impact implementation gst india group turnover geographic region growth growth total results group set cer us growth europe international turnover turnover cer turnover cost sales us sales grew aer cer driven growth shingrix selling general hepatitis vaccines well strong performances hiv administration benlysta offset declines established pharmaceuticals research respiratory development royalty income europe sales flat aer declined cer declines operating established pharmaceuticals older hiv products meningitis incomeexpense vaccines consumer healthcare offset growth operating profit tivicay triumeq new respiratory products net finance costs international sales declined aer grew cer profit disposal reflecting strong growth tivicay triumeq respiratory interest associates portfolio sales emerging markets declined aer grew share tax cer profits associates joint ventures profit taxation taxation profit taxation year profit attributable shareholders earnings per share p earnings per ads us gsk annual report group financial review continued total results continued pharmaceuticals relvarbreo ellipta sales grew aer cer million primarily driven growth europe aer cer million international turnover bn aer cer million us breo ellipta sales declined aer cer volume growth reflecting bn continued market share growth offset combined impact aer growth cer growth prior period payer rebate adjustments increased competitive group turnover pricing pressure anoro ellipta sales grew aer cer million driven primarily share gains us ellipta products breo anoro incruse arnuity trelegy continued grow market share us year sales new respiratory products comprising ellipta products nucala grew aer cer million seretideadvair sales declined aer cer million sales advair us declined aer cer volume decline negative impact price primarily reflecting increased competitive pricing pressures europe seretide sales pharmaceuticals turnover aer cer million volume decline price decline reflected continued competition growth growth cer generic products transition respiratory portfolio respiratory newer products international sales seretide aer cer million volume decline positive hiv impact price declines markets generic competition immunoinflammation partly offset growth developing markets established pharmaceuticals hiv hiv sales increased aer cer million pharmaceuticals turnover year million flat aer year us aer cer europe aer cer driven primarily growth hiv sales cer international aer cer aer cer million reflecting share growth year dolutegravir portfolio triumeq tivicay growth driven increase market share juluca respiratory sales declined aer grew cer year dolutegravir products grew aer cer million growth ellipta portfolio nucala partly offset decline established portfolio partly offset lower sales seretideadvair sales established particularly impact generic competition epzicomkivexa pharmaceuticals aer cer europe triumeq tivicay juluca approved us november recorded sales million million us sales declined aer grew cer growth million respectively year epzicomkivexa sales hiv portfolio benlysta offsetting declines established declined aer cer million pharmaceuticals respiratory europe sales grew aer cer growth respiratory portfolio offsetting immunoinflammation continued impact generic competition epzicom avodart sales year aer cer primarily driven international flat aer grew cer growth driven benlysta grew aer cer million hiv new respiratory portfolio us benlysta grew aer cer million benefiting launch subcutaneous formulation third quarter respiratory total respiratory sales declined aer grew cer established pharmaceuticals us aer cer europe sales grew aer sales established pharmaceuticals million cer international grew aer cer growth aer cer reflecting efforts maximise value ellipta portfolio nucala partly offset lower sales portfolio also benefit certain postdivestment contract seretideadvair manufacturing sales first instalment month relenza sales nucala million year aer supply contract europe cer continuing benefit global rollout product us avodart franchise aer cer million sales nucala grew aer cer million despite primarily due loss exclusivity europe us impact increased competition benefiting continued market expansion broadly annualised coreg franchise sales declined aer sales ellipta products aer cer driven cer following generic coreg cr entrant us market q lamictal sales declined aer cer million continued growth regions us sales grew aer cer reflecting market share gains partly offset impact continued competitive pricing pressures particularly icslabas europe sales grew aer cer sales trelegy ellipta new oncedaily closed triple product contributed million total ellipta sales benefiting expanded label us gsk annual report strategic report governance remuneration financial statements investor information total results continued vaccines influenza fluarixflulaval sales grew aer cer million driven strong sales execution us improved sales aer growth cer growth turnover bn europe partly offset increased price competition us bn shingles shingrix recorded sales million primarily us canada driven demand share gains us sales benefited group turnover market growth new patient populations covered immunisation recommendations shingrix achieved market share established vaccines sales dtpacontaining vaccines infanrix pediarix boostrix aer cer infanrix pediarix sales aer cer million reflecting increased competitive pressures europe well unfavourable yearonyear cdc stockpile movements us partly offset stronger demand international boostrix sales declined aer cer vaccines turnover million primarily driven return market growth growth competitor europe lower demand international cer hepatitis vaccines grew aer cer million meningitis benefiting stronger demand us europe well influenza competitor supply shortage us shingles rotarix sales aer cer million established vaccines reflecting higher demand europe partly offset lower demand international vaccines turnover grew aer cer million synflorix sales declined aer cer million primarily driven growth sales shingrix hepatitis vaccines primarily impacted lower pricing demand emerging also benefited competitor supply shortage higher markets sales influenza products partly offset lower sales dtpacontaining vaccines infanrix pediarix boostrix due increased competitive pressures particularly europe unfavourable yearonyear cdc stockpile movements us together lower synflorix sales reflecting lower pricing demand emerging markets meningitis meningitis sales aer cer million bexsero sales grew aer cer driven demand share gains us together continued growth private market sales international partly offset completion vaccination catchup cohorts certain markets europe menveo sales declined aer cer primarily reflecting supply constraints europe international well strong comparator unfavourable yearonyear cdc stockpile movements us partly offset demand share gains us gsk annual report group financial review continued total results continued consumer healthcare wellness wellness sales declined aer grew cer million respiratory sales grew low single digits led theraflu turnover bn supported strong cold flu season earlier year well theraflu powerpods launch us second half bn year otrivin grew mid single digits benefiting new variants aer growth cer growth flonase returned growth following weaker allergy season group turnover earlier year pain relief sales flat low singledigit growth voltaren doubledigit growth fenbid offset decline panadol sales due change routetomarket model south east asia discontinuation slowrelease panadol products nordic countries oral health oral health sales grew aer cer million increased competitive pressures europe offset double digit growth sensodyne number international markets including india turkey strong singledigit growth us consumer healthcare turnover driven sensodyne rapid denture care grew high single digits growth growth launch corega max russia brazil gum cer health delivered doubledigit growth continued strong wellness parodontax performance us growth also partly oral health impacted destocking international nutrition nutrition skin health nutrition sales declined aer grew cer million nutrition business india performed strongly across product portfolio including new innovations horlicks growth growth protein launched earlier year impact cer divestments india gst implementation growth us approximately eight percentage points europe skin health international skin health sales aer cer million largely driven decline physiogel divestment several consumer healthcare sales year declined aer grew small nonstrategic brands us negative impact cer million broadbased growth oral health growth one percentage point wellness partly offset decline panadol lower sales smaller brands international markets performed strongly particularly india brazil whilst europe impacted intensifying competitive pressure second half aggregate impact generic competition transderm scop us divestment horlicks maxinutrition uk small nonstrategic brands implementation gst india reduce overall sales growth approximately one percentage point gsk annual report strategic report governance remuneration financial statements investor information total results continued cost sales decline discovery reflected transfer certain oncology cost sales percentage turnover assets development phase decline development percentage points aer percentage points cer terms primarily reflects comparison impact utilisation compared primarily reflected favourable priority review voucher benefit comparison million noncash restructuring costs prioritisation initiatives started second half writedowns assets related decision withdraw partly offset increased investment progression number tanzeum year also benefited favourable product mid latestage programmes particularly oncology mix vaccines consumer healthcare particularly launch provision costs payable third party relating use shingrix together contribution integration priority review voucher awarded growth technology restructuring savings partly offset continued adverse facilities functional support costs primarily reflected increased pricing pressure pharmaceuticals particularly respiratory investments data analytics established vaccines together increased input costs royalty income adverse comparison benefit settlement lost third party supply volume vaccines royalty income million million aer cer reduction primarily reflecting patent selling general administration expiry cialis partly offset increase gardasil royalty sga costs percentage turnover percentage points higher aer cer operating incomeexpense reflecting growth aer cer increase sga operating expense million million costs primarily reflected higher restructuring costs investment primarily reflected million million promotional product support particularly new launches accounting charges arising remeasurement respiratory hiv vaccines partly offset tight control contingent consideration liabilities related acquisitions ongoing costs particularly nonpromotional back office former shionogiviiv healthcare joint venture former spending across three businesses novartis vaccines business value attributable consumer healthcare joint venture put option previously held novartis research development liabilities pfizer put option pfizer shionogi rd expenditure million turnover aer preferential dividends viiv healthcare charges included cer lower reflected reduced restructuring impact us tax reform increased fair value costs primarily due comparison provision liabilities million partly offset profit obligations result decision withdraw tanzeum number asset disposals including tapinarof well gain lower intangible impairments favourable comparison arising increase value shares hindustan unilever impact priority review voucher purchased utilised limited received disposal horlicks h benefit rd prioritisation initiatives started consumer healthcare brands net disposal costs second half last year partly offset increased investment progression number mid latestage accounting charges driven primarily million programmes particularly oncology well provisions remeasurement contingent consideration liability due costs payable third party relating use priority review shionogi largely related regular updates exchange rate voucher awarded assumptions period end rates sales forecasts following number studies including gemini study completed q together million unwind discount revised growth addition net charge million reflected remeasurement cer valuation consumer healthcare put option reflect discovery price agreed novartis acquire shareholding together development movements exchange rates largely offset gains hedging facilities central support functions contracts total pharmaceuticals vaccines rd consumer healthcare rd items reconciling adjusted rd total rd research development gsk annual report group financial review continued total results continued operating profit share tax profits associates joint ventures total operating profit million compared share profits associates joint ventures million million increase operating profit primarily million primarily arising investment innoviva reflected favourable comparison charges million profit taxation arising impact us tax reform valuation consumer healthcare hiv businesses reduced taking account net finance costs profit disposal restructuring costs asset impairments addition associates share profits associates profit contribution sales growth favourable mix primarily taxation million compared million vaccines consumer healthcare benefits prioritisation taxation rd expenditure comparison impact priority review voucher utilised expensed alongside continued tight control ongoing costs partly offset increased impact accounting charges related remeasurement uk current year charge liabilities contingent consideration put options preferential rest world current year charge dividends continuing pricing pressure particularly respiratory charge respect prior periods increased input costs comparison benefit q total current taxation settlement lost thirdparty supply volume vaccines investments new product support particularly launches total deferred taxation respiratory hiv vaccines reduction royalty income taxation total profits contingent consideration cash payments made shionogi charge million represented effective tax rate companies reduce balance sheet liability hence total results reflected different recorded income statement total contingent consideration tax effects various adjusting items includes effect cash payments amounted million reduced estimate impact us tax reform million included cash milestone paid novartis million following additional guidance released irs million million well cash payments made shionogi reassessment estimates uncertain tax positions following million million settlement number open issues tax authorities reduction prior year effective tax rate total profits net finance costs driven primarily favourable comparison impact us tax reform resulted number charges q finance income interest income noncontrolling interests fair value movements allocation earnings noncontrolling interests amounted million million reduction primarily due lower allocation consumer healthcare profits million finance expense million following buyout novartis interest interest expense partly offset increased allocation viiv healthcare profits unwinding discounts liabilities higher net profits entities non controlling interests remeasurements fair value movements finance expense earnings per share total earnings per share p compared p increase earnings per share primarily reflected favourable net finance costs million compared million comparison charges arising impact us reflected higher debt levels following acquisition tax reform reduced restructuring costs asset impairments novartis stake consumer healthcare joint venture increased operating profits lower tax rate reduced non june well additional interest tax arising historic controlling interest allocation consumer healthcare profits partly tax settlement recorded q adverse comparison offset higher transactionrelated charges arising increases provision release million q reflected valuation liabilities contingent consideration put options finance expense partly offset benefit preferential dividends oneoff accounting adjustment amortisation longterm bond interest charges million q reported interest dividends expense benefit older bonds refinanced lower board declared four interim dividends resulting total dividend interest rates translation impact exchange rate movements year pence line dividend declared reported sterling costs foreign currency denominated see note financial statements dividends interestbearing instruments profit disposal associates profit disposal associates million million gsk annual report strategic report governance remuneration financial statements investor information adjusting items divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal adjusted results amortisation impairment restructuring related items results december turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit net finance costs profit disposal associates share tax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions divestments intangible intangible significant total asset asset major transaction legal us tax adjusted adjusted results reconciliation results amortisation impairment restructuring related items reform results december turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit net finance costs profit disposal associates share tax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p p weighted average number shares millions gsk annual report group financial review continued adjusting items continued intangible asset amortisation impairment analysis major restructuring charges business intangible asset amortisation million compared follows million intangible asset impairments related commercial pharmaceuticals rd development assets million million charge included pharmaceuticals impairments related withdrawal tanzeum number vaccines commercial pharmaceuticals rd development consumer healthcare assets charges noncash items major restructuring integration corporate central functions within pharmaceuticals sector highly regulated manufacturing total major restructuring charges operations supply chains long lifecycle business mean restructuring programmes particularly involve analysis major restructuring charges income statement line rationalisation closure manufacturing rd sites likely follows take several years complete major restructuring costs related specific board cost sales approved major restructuring programmes major restructuring selling general administration programmes including integration costs following material research development acquisitions structural significant scale costs individual related projects exceed operating incomeexpense million ordinary course smaller scale restructuring total major restructuring charges costs retained within total adjusted results combined restructuring integration programme delivered board approved new major restructuring programme july incremental annual cost savings year billion given designed significantly improve competitiveness relatively recent launch benefit delivery year efficiency cost base savings delivered primarily major restructuring programme material supply chain optimisation reductions administrative costs analysis incremental annual cost savings year income statement line follows total major restructuring charges incurred million million analysed follows bn bn cost sales non non selling general administration cash cash total cash cash total research development combined restructuring total cash charges combined restructuring integration integration programme expected approximately billion programme noncash charges billion programme major delivered approximately billion annual savings including restructuring estimated currency benefit billion programme programme expected deliver total annual savings billion constant currency basis including estimated benefit billion currency basis average exchange rates noncash charges arising existing combined restructuring integration programme primarily related writedown major restructuring programme expected cost assets part announced plans reduce manufacturing billion period cash costs billion network cash charges arose restructuring europe noncash costs billion expected deliver international pharmaceuticals commercial operations annual savings around million rates manufacturing sites noncash charges major savings fully reinvested help fund targeted restructuring programme primarily related announced plans increases rd commercial support new products restructure manufacturing network cash charges date major restructuring programme primarily related restructuring us pharmaceuticals commercial operation well manufacturing sites central functions total cash payments two programmes made year million million gsk annual report strategic report governance remuneration financial statements investor information adjusting items continued transactionrelated adjustments contingent consideration cash payments made transactionrelated adjustments resulted net charge shionogi companies reduce balance sheet liability million million primarily reflected million hence recorded income statement total contingent accounting charges remeasurement contingent consideration cash payments year amounted million consideration liabilities related acquisitions former million included cash milestone paid shionogiviiv healthcare joint venture former novartis novartis million million well cash payments vaccines business value attributable consumer made viiv healthcare shionogi relation contingent healthcare joint venture put option held novartis consideration liability including preferential dividends liabilities pfizer put option pfizer shionogi amounted million million preferential dividends viiv healthcare explanation accounting noncontrolling interests viiv healthcare set chargecredit divestments significant legal charges items consumer healthcare joint venture put option divestments items included profit number contingent consideration former shionogiviiv asset disposals including tapinarof gain arising increase healthcare joint venture including shionogi value shares hindustan unilever limited received preferential dividends disposal horlicks consumer healthcare brands viiv healthcare put options pfizer preferential expected complete end net disposal dividends costs well equity investment impairments certain contingent consideration former novartis adjusting items charge million million vaccines business significant legal matters included benefit settlement adjustments existing matters well provisions ongoing litigation total transactionrelated charges significant legal cash payments million net charge million relating consumer healthcare million joint venture represented remeasurement valuation consumer healthcare put option agreed valuation billion billion signing together increase due movements exchange rates largely offset gains hedging contracts million charge relating contingent consideration former shionogiviiv healthcare joint venture represented million increase valuation contingent consideration due shionogi primarily result updated exchange rate assumptions sales forecasts following gemini study completed q together million unwind discount adjustments included million charge reflecting release indemnity asset relating tax treatment inventory acquired part novartis vaccines acquisition corresponding offset tax well acquisition costs relating acquisition tesaro completed january announced agreement pfizer combine consumer healthcare businesses gsk annual report group financial review continued adjusted results adjusted operating profit bn research development bn aer growth cer growth growth turnover turnover cer research development rd expenditure million turnover aer cer lower primarily reflecting favourable comparison impact priority review voucher purchased utilised benefit prioritisation initiatives started second half partly offset increased investment progression number mid latestage programmes particularly oncology well gsk uses number adjusted nonifrs measures report provision costs payable third party relating use performance business adjusted results nonifrs priority review voucher awarded utilised measures may considered addition substitute superior information presented accordance ifrs revised growth adjusted results nonifrs measures defined cer pages discovery development cost sales facilities central support functions growth total pharmaceuticals vaccines rd turnover turnover cer consumer healthcare rd cost sales research development cost sales percentage turnover adjusted rd expenditure declined aer cer percentage points aer percentage points cer terms pharmaceuticals aer cer decline discovery compared primarily reflected continued adverse reflected transfer certain oncology assets development pricing pressure pharmaceuticals particularly respiratory phase decline development primarily reflects comparison established vaccines well increased input costs impact utilisation priority review voucher adverse comparison benefit settlement lost third benefit prioritisation initiatives started party supply volume vaccines partly offset second half partly offset increased investment favourable product mix vaccines consumer healthcare progression number mid latestage programmes particularly launch shingrix well particularly oncology provision costs payable third contribution integration restructuring savings three party relating use priority review voucher awarded businesses growth technology facilities functional support selling general administration costs primarily reflected increased investments data analytics royalty income growth royalty income million million turnover turnover cer reduction primarily reflecting patent expiry cialis partly offset selling general increase gardasil royalty administration adjusted operating profit sga costs percentage turnover percentage points lower aer percentage adjusted operating profit million higher aer points lower cer basis reflected increase aer compared higher cer turnover increase cer primarily resulting increased investment adjusted operating margin flat aer promotional product support particularly new launches compared percentage points higher cer respiratory hiv vaccines partly offset tight control basis reflected benefit sales growth cer ongoing costs particularly nonpromotional back office three businesses favourable mix primarily vaccines spending across three businesses consumer healthcare benefits prioritisation rd expenditure comparison impact priority review voucher utilised expensed well continued tight control ongoing costs across three businesses partly offset continuing pricing pressure particularly respiratory increased input costs comparison benefit q settlement lost thirdparty supply volume vaccines investments promotional product support particularly new launches respiratory hiv vaccines reduction royalty income gsk annual report strategic report governance remuneration financial statements investor information adjusted results continued adjusted operating profit business net finance costs growth margin margin finance income cer interest income pharmaceuticals fair value movements pharmaceuticals rd pharmaceuticals finance expense vaccines interest expense consumer unwinding discounts liabilities healthcare remeasurements fair value movements finance expense corporate unallocated costs adjusted operating net finance costs million compared million profit increase reflected higher debt levels following acquisition novartis stake consumer healthcare pharmaceuticals operating profit joint venture june well million increase interest tax arising settlement historic tax matter pharmaceuticals operating profit million aer adverse comparison provision release million flat cer turnover increase cer operating reflected finance expense partly offset margin percentage points lower aer benefit oneoff accounting adjustment amortisation percentage points lower cer basis primarily longterm bond interest charges million reported reflected continued impact lower prices particularly interest expense benefit older bonds facilities respiratory broader transition respiratory portfolio utilised fund acquisition novartis stake consumer increased investment new product support reduction healthcare joint venture refinanced lower interest rates royalty income partly offset benefits prioritisation fair value gains hedging instruments within rd favourable comparison impact priority review voucher purchased share tax profits associates vaccines operating profit joint ventures vaccines operating profit million aer cer share profits associates joint ventures million higher turnover increase cer million primarily arising investment innoviva operating margin percentage points higher aer taxation percentage points higher cer basis primarily driven enhanced operating leverage strong tax adjusted profit amounted million represented sales growth improved product mix including impact effective adjusted tax rate launch shingrix together restructuring integration reduction effective adjusted tax rate primarily benefits partly offset comparison benefit driven reduction us federal tax rate settlement lost thirdparty supply volume recorded increased supply chain costs increased sga investments noncontrolling interests support new launches business growth allocation adjusted earnings noncontrolling interests consumer healthcare operating profit amounted million million reduction primarily due lower allocation consumer healthcare profits consumer healthcare operating profit million million million following buyout novartis aer cer turnover increase cer operating interest partly offset increased allocation viiv margin percentage points higher healthcare profits million million percentage points higher cer basis primarily reflected changes proportions preferential dividends due improved product mix manufacturing restructuring shareholder based relative performance different products integration benefits well continued tight control promotional well increases allocation due higher net profits operating expenses groups entities noncontrolling interests adjusted earnings per share adjusted eps p aer cer compared cer increase adjusted operating profit primarily result reduced noncontrolling interest allocation consumer healthcare profits lower adjusted tax rate gsk annual report group financial review continued cash generation conversion summary consolidated cash flow statement set free cash flow free cash flow amount cash generated group meeting obligations contingent consideration interest tax net cash inflow operating activities dividends paid noncontrolling interests capital net cash outflow investing activities expenditure property plant equipment intangible assets net cash outflow financing activities increasedecrease cash bank overdrafts revised cash bank overdrafts beginning year free cash inflow increasedecrease cash bank overdrafts exchange adjustments free cash flow million year cash bank overdrafts end year million increase primarily reflected improved operating profits smaller increase working capital following reduction inventory cash bank overdrafts end year balances strong focus collections favourable timing comprise payments returns rebates reduced legal settlement costs cash cash equivalents restructuring payments lower capital expenditure including cash cash equivalents reported assets favourable comparison impact priority review voucher held sale increased disposals intangible assets million overdrafts million primarily relating disposal tapinarof reduced dividend payments noncontrolling interests partly offset negative currency impact operating profit net cash inflow operating activities year increased contingent consideration payments including million million increase primarily reflected million million milestone paid novartis year improved operating profits smaller increase working capital result reduction inventory balances strong focus reconciliation net cash inflow operating collections favourable timing payments returns rebates activities free cash flow reduced legal settlement restructuring payments partly offset negative currency impact operating profit reconciliation net cash inflow operating activities total cash payments shionogi relation viiv healthcare closest equivalent ifrs measure free cash flow shown contingent consideration liability year million million million recognised cash flows operating activities million recognised revised contingent consideration paid within investing cash flows net cash inflow operating activities payments deductible tax purposes purchase property plant equipment capital expenditure financial investment purchase intangible assets proceeds sale property plant equipment cash payments tangible intangible fixed assets amounted proceeds disposal intangible assets million million disposals realised million million cash payments acquire interest paid equity investments amounted million million interest received primarily relating andme sales equity investments dividends associates joint ventures realised million million contingent consideration paid reported investing activities contribution noncontrolling interests distributions noncontrolling interests free cash flow gsk annual report strategic report governance remuneration financial statements investor information cash generation conversion continued future cash flow working capital long term expect future cash generated operations sufficient fund operating debt servicing working capital percentage turnover costs normal levels capital expenditure obligations working capital conversion cycle days existing licensing agreements expenditure arising restructuring programmes routine outflows including tax pension increase days compared contributions dividends subject principal risks predominantly due adverse impact exchange uncertainties discussed pages may time approximately five days well reduced denominator due time additional demands finance acquisitions lower restructuring impairment costs excluding including potentially acquiring increased ownership interests factors significant improvements made working capital viiv healthcare business minority shareholders hold put relative growth business reduced inventory options access multiple sources liquidity short result tight control inventory levels stronger collections longterm capital markets financial institutions receivables needs addition cash flow operations investment appraisal capital allocation strong framework capital allocation including board govern allocation capital businesses utilise consistent cash return invested capital croic methodology prioritise investment across group whole effectively compare returns businesses allocate capital also consider impact eps credit profile relevant discount rate used perform financial analyses decided internally allow determination extent investments cover cost capital individual investments discount rate may adjusted take account specific country business project risk gsk annual report group financial review continued financial position resources property plant equipment assets business sciencebased technologyintensive highly noncurrent assets regulated governmental authorities allocate significant property plant equipment financial resources renewal maintenance property goodwill plant equipment minimise risks interruption production intangible assets ensure compliance regulatory standards number processes use hazardous materials investments associates joint ventures investments total cost property plant equipment december deferred tax assets million net book value million land buildings represented million plant derivative financial instruments equipment million assets construction million noncurrent assets invested million new property plant total noncurrent assets equipment mainly related large number projects renewal improvement expansion facilities various current assets worldwide sites support new product development launches inventories well improve efficiency existing supply chains current tax recoverable property mainly held freehold new investment financed trade receivables liquid resources december contractual derivative financial instruments commitments future capital expenditure million liquid investments operating lease commitments million believe cash cash equivalents property plant facilities adequate current needs assets held sale observe stringent procedures use specialist skills total current assets manage environmental risks activities environmental issues total assets sometimes dating operations modified discontinued reported environment note liabilities financial statements legal proceedings current liabilities goodwill shortterm borrowings contingent consideration liabilities goodwill increased million december trade payables million increase primarily reflected impact derivative financial instruments exchange movements partly offset transfer goodwill current tax payable assets held sale shortterm provisions intangible assets total current liabilities intangible assets include cost intangibles acquired noncurrent liabilities third parties computer software net book value longterm borrowings intangible assets december million corporation tax payable million decrease reflected impact deferred tax liabilities amortisation impairment existing intangibles million pensions postemployment benefits million respectively partly offset development provisions costs capitalised year million additions million impact exchange movements derivative financial instruments contingent consideration liabilities investments associates joint ventures noncurrent liabilities held investments associates joint ventures carrying total noncurrent liabilities value december million million total liabilities market value december million net assets million largest investments innoviva inc book value december equity million million market value december share capital million see note financial statements share premium account investments associates joint ventures retained earnings reserves shareholders equity noncontrolling interests total equity gsk annual report strategic report governance remuneration financial statements investor information financial position resources continued investments provisions held investments carrying value december carried deferred tax provisions shortterm million million highest value noncurrent provisions million december investments held december andme million provisions yearend included acquired year book value december million million related legal disputes million theravance biopharma inc million million related major restructuring book value december million programmes provision made legal disputes million investments included equity stakes companies indemnified disposal liabilities employee related liabilities research collaborations provide access costs restructuring programme extent balance biotechnology developments potential interest interests sheet date legal constructive obligation existed could companies arise business divestments reliably estimated derivative financial instruments assets pensions postemployment benefits current derivative financial assets held fair value account pension postemployment arrangements million million noncurrent derivative financial assets accordance ias deficits net surpluses held fair value million million million allowing deferred taxation million current derivative financial assets related derivative embedded million pension arrangements million agreement divest horlicks nutritional brands million unfunded postemployment liabilities decrease net unilever plc see note information majority deficit predominantly driven higher discount rates remainder financial instruments related foreign exchange used discount value liabilities partly offset reduction contracts designated designated accounting hedges uk asset values inventories noncurrent liabilities inventory million decreased million noncurrent liabilities amounted million decrease primarily reflected tight control inventory levels december million trade receivables contingent consideration liabilities trade receivables million increased contingent consideration amounted million december million primarily reflecting impact higher sales million million particularly vaccines partly offset better collections together million represented estimated present value amounts payable exchange movements shionogi relating viiv healthcare million million represented estimated present value contingent deferred tax assets consideration payable novartis related vaccines acquisition following milestone payment million made novartis deferred tax assets amounted million january million december liability due shionogi included million respect derivative financial instruments liabilities preferential dividends liability preferential dividends due pfizer december million million held current noncurrent derivative financial liabilities fair explanation accounting noncontrolling interests value million million primarily related viiv healthcare set foreign exchange contracts designated designated accounting hedges contingent consideration payable posttax basis december million million trade payables expected paid within one year consideration payable acquisition shionogiviiv healthcare joint venture december trade payables novartis vaccines business expected paid number million compared million december years result total estimated liabilities discounted decrease primarily reflected elimination consumer present values posttax basis using posttax discount healthcare joint venture put option following buyout novartis rates shionogiviiv healthcare contingent consideration liability interest consumer healthcare joint venture june discounted novartis vaccines contingent buyout primarily funded utilising proceeds bonds consideration liability discounted partly partly issued maturity dates two twelve years us europe raised billion billion respectively committed bank facilities financed remaining amount billion transaction gsk annual report group financial review continued financial position resources continued maturity profile longterm debt equivalent gbp bonds eur bonds usd bonds longterm debt net debt cash liquid investments billion billion held centrally december analysis cash gross debt effects hedging follows cash cash equivalents liquid investments cash cash equivalents reported assets held sale cash liquid investments borrowings repayable within one year gross debt fixed borrowings repayable one year floating net debt noninterest bearing december net debt billion compared net debt billion december comprising gross debt includes billion equivalent notes swapped floating fixed rates via interest billion cash liquid investments billion including rate swaps billion reported within assets held sale reflecting agreement divest horlicks consumer healthcare nutritional brands movements net debt unilever plc net debt increased due billion acquisition novartis remaining stake consumer healthcare joint venture june billion investment andme billion unfavourable exchange impacts translation net debt beginning year nonsterling denominated debt dividends paid shareholders increasedecrease cash bank overdrafts billion partly offset increased free cash flow billion increase liquid investments milestone payment novartis increase longterm loans december gsks cash liquid investments held net repayment shortterm loans follows exchange movements movements net debt end year bank balances deposits bank balances deposits reported assets held sale us treasury treasury repo money market funds liquidity funds cash cash equivalents liquid investments government securities gsk annual report strategic report governance remuneration financial statements investor information financial position resources continued total equity commitments contingent liabilities december total equity increased million financial commitments summarised note financial december million primarily reflected statements commitments contingent liabilities set impact total profit remeasurement gains defined note financial statements contingent liabilities benefit plans offset dividends paid unfavourable exchange contractual obligations commitments translation impact year summary movements equity set following table sets contractual obligations commitments december fall due payment total equity beginning year total yr yrs yrs yrs implementation ifrs loans implementation ifrs interest loans total equity beginning year adjusted finance lease obligations total comprehensive income year finance lease charges dividends shareholders operating lease ordinary shares issued commitments changes noncontrolling interests intangible assets derecognition liabilities noncontrolling property plant equipment interests investments shares acquired esop trusts purchase commitments sharebased incentive plans pensions tax sharebased incentive plans total contributions noncontrolling interests commitments respect loans future interest payable loans distributions noncontrolling interests disclosed taking account effect derivatives total equity end year entered number research collaborations develop share purchases new compounds pharmaceutical companies terms arrangements include upfront fees equity investments shares acquired employee share ownership plan loans commitments fund specified levels research esop trusts million shares held addition often agree make payments future trusts satisfy future exercises options awards milestones achieved group share option award schemes proportion shares agreements relate compounds early held trusts respect awards rules stages development potential obligation make milestone scheme require us satisfy exercises market purchases payments continue number years compounds move rather issue new shares shares held trusts successfully development process generally closer matched options awards granted product marketing approval greater probability december esop trusts held million success amounts shown within intangible assets million gsk shares future exercise represent maximum would paid milestones share options share awards carrying value million achieved include billion relates externalised million deducted reserves projects discovery portfolio reduction market value shares million million commitments due amendments made existing shares repurchased company agreements obligations ceased december gsk held million shares treasury reached revised agreement trustees shares million shares cost million uk pension schemes make additional contributions assist million deducted retained eliminating pension deficit identified part december earnings actuarial funding valuation table includes ordinary shares purchased period january commitment excludes normal ongoing annual funding march company expect make requirement uk approximately million funding ordinary share repurchases remainder commitment supersedes previous agreement made information pension obligations see note financial statements pensions postemployment benefits gsk annual report group financial review continued financial position resources continued contingent liabilities provide outcome tax legal disputes outflow resources considered probable reliable estimate following table sets contingent liabilities comprising outflow may made december discounted bills performance guarantees letters credit disputes provision made possible items arising normal course business make reliable estimate potential outflow funds might expected expire required settle disputes possibility outflow remote total yr yrs yrs yrs ultimate liability matters may vary significantly guarantees amounts provided dependent upon negotiations contingent liabilities relevant tax authorities outcome litigation proceedings relevant discussed principal risks total uncertainties pages note financial normal course business provided various statements legal proceedings indemnification guarantees respect business disposals viiv healthcare contingent consideration liability legal disputes subsequently arisen provision made outflow resources considered contingent consideration payable shionogi amounted probable reliable estimate made likely outcome million december million dispute included note financial discounted undiscounted value million statements provisions december treasury policies report sterling pay dividends sterling cash flows longterm credit rating standard poors role treasury monitor manage groups external negative outlook moodys investor services moodys internal funding requirements financial risks support negative outlook shortterm credit ratings strategic objectives gsk operates global basis primarily p standard poors moodys respectively subsidiary companies manage capital ensure liquidity risk management subsidiaries able operate going concerns optimise returns shareholders appropriate balance policy borrow centrally order meet anticipated funding debt equity treasury activities governed policies requirements cash flow forecasts funding requirements approved annually board directors recently monitored tmg regular basis strategy diversify october treasury management group tmg liquidity sources using range facilities maintain broad meeting chaired chief financial officer takes place access financial markets regular basis review treasury activities members receive management information relating activities day sweep cash number global subsidiaries central treasury accounts liquidity management purposes treasury operations interest rate risk management objective gsks treasury activities minimise posttax net cost financial operations reduce volatility order objective minimise effective net interest cost benefit earnings cash flows gsk uses variety financial balance mix debt fixed floating interest rates instruments finance operations derivative financial time policy interest rate risk management limits net instruments manage market risks operations amount floating rate debt specific cap reviewed agreed derivatives principally comprise foreign exchange forward contracts less annually board swaps used swap borrowings liquid assets foreign exchange risk management currencies required group purposes well interest rate swaps used manage exposure financial risks foreign currency transaction exposures arising external trade changes interest rates flows normally hedged foreign currency transaction derivatives used exclusively hedging purposes relation exposures arising internal trade flows selectively hedged underlying business activities trading speculative objective minimise exposure overseas operating instruments subsidiaries transaction risk matching local currency income local currency costs possible gsks internal trading capital management transactions matched centrally manage intercompany payment terms reduce foreign currency risk foreign currency financial strategy implemented groups financial cash flows hedged selectively management architecture supports gsks strategic priorities regularly treasury tmg include hedges foreign reviewed board manage capital structure exchange risk arising acquisitions disposals assets group appropriate mix debt equity continue possible manage cash surpluses borrowing manage financial policies credit profile particularly requirements subsidiary companies centrally using forward targets shortterm credit ratings p maintaining contracts hedge future repayments back originating single longterm ratings consistent targets currency gsk annual report strategic report governance remuneration financial statements investor information treasury policies continued order reduce foreign currency translation exposure seek counterparty risk management denominate borrowings currencies principal assets cash flows primarily denominated us dollars set global counterparty limits banking euros sterling borrowings swapped investment counterparties based longterm credit ratings currencies required moodys standard poors treasurys usage limits monitored daily corporate compliance officer cco borrowings denominated swapped foreign currencies operates independently treasury breach limits would match investments overseas group assets may treated reported cfo immediately hedge relevant assets forward contracts major currencies also used reduce exposure groups cco also monitors credit rating counterparties investment overseas group assets tmg reviews changes ratings occur notifies treasury changes ratio borrowings assets major currencies regularly made investment levels authority limits appropriate addition relationship banks credit ratings reviewed regularly report presented annually tmg approval critical accounting policies consolidated financial statements prepared accordance us medicaid programme stateadministered programme ifrs adopted use european union also providing assistance certain poor vulnerable patients ifrs issued iasb following accounting policies medicaid drug rebate program established approved board described note financial reduce state federal expenditure prescription drugs statements accounting principles policies patient protection affordable care act became law participate providing rebates states accruals required make estimates assumptions affect medicaid rebates calculated based specific terms amounts assets liabilities revenue expenses reported relevant regulations patient protection affordable financial statements actual amounts results could differ care act estimates cash discounts offered customers encourage prompt critical accounting policies relate following areas payment accrued time invoicing turnover adjusted subsequently reflect actual experience taxation note record accrual estimated sales returns applying legal disputes notes historical experience customer returns amounts invoiced together market related information stock levels intangible asset impairments note wholesalers anticipated price increases competitor activity business combinations note reconciliation gross turnover net turnover us pensions postemployment benefits note pharmaceuticals business follows information judgements estimates made areas given note financial statements key accounting judgements estimates margin revised margin revised margin turnover gross turnover respect turnover accounting policy largest business market driven us pharmaceuticals us market complex segments arrangements rebates discounts allowances following government briefly describes nature arrangements existence mandated state programs us pharmaceuticals business cash discounts arrangements certain indirect customers whereby customer returns customer able buy products wholesalers reduced prior year adjustments prices chargeback represents difference prior year items invoice price wholesaler indirect customers contractual discounted price accruals estimating chargebacks items calculated based terms agreement historical total deductions experience product growth rates net turnover customer rebates offered key managed care group marketdriven segments consist primarily managed care purchasing organisations direct indirect customers medicare plans negotiate contract pricing arrangements require customer achieve certain honoured via rebates chargebacks mandated segments performance targets relating value product purchased consist primarily medicaid federal government programmes formulary status predetermined market shares relative receive governmentmandated pricing via rebates competitors accrual customer rebates estimated based chargebacks specific terms agreement historical experience product growth rates gsk annual report group financial review continued critical accounting policies continued increased deductions market driven segments may become involved significant legal proceedings respect gross turnover net turnover reconciliation primarily reflected possible make reliable estimate expected higher rebates chargebacks respiratory products financial effect could result ultimate resolution advair particular advair accounted proceedings cases appropriate disclosure us pharmaceuticals turnover approximately cases would included annual report provision total deduction rebates returns respiratory would made portfolio whole accounted approximately position could change time therefore total deduction year advair continued suffer pricing assurance losses result outcome pressures sought transition respiratory legal proceedings exceed material amount amount portfolio newer products provisions reported groups financial statements balance sheet accruals rebates discounts allowances like many pharmaceutical companies faced various returns us pharmaceuticals vaccines businesses complex product liability antitrust patent litigation well managed combined basis december investigations operations conducted various governmental total accrual amounted million million regulatory agencies throughout year general counsel monthly process operated monitor inventory levels group head groups legal function senior wholesalers abnormal movements process uses vice president head global litigation group gross sales volumes prescription volumes based third party responsible litigation government investigations routinely data sources information received key wholesalers brief chief executive officer chief financial officer aim maintain inventories consistent level board directors significant litigation pending year year based pattern consumption group governmental investigations group basis us pharmaceuticals vaccines inventory levels meetings appropriate detail status significant wholesalers distribution channels december litigation government investigations review matters estimated amount approximately four weeks turnover number claims notified us information potential calculation uses third party information accuracy claims yet notified assessment validity claims totally verified believed sufficiently reliable progress made settling claims recent settlement levels purpose potential reimbursement insurers legal disputes meetings also include assessment whether sufficient information available us able make reliable respect accounting policy legal disputes estimate potential outcomes disputes often external following briefly describes process determine counsel assisting us various litigation matters investigations level provision necessary also assist briefing board senior management following discussions matters possible accordance requirements ias provisions make reliable estimate amount provision contingent liabilities contingent assets provide may required level provision legal disputes anticipated settlement costs outflow resources reviewed adjusted appropriate matters discussed considered probable reliable estimate may made note financial statements legal proceedings likely outcome dispute legal expenses arising claims group strategic report strategic report approved board directors march simon dingemans chief financial officer march ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn corporate governance section chairmans governance statement board corporate executive team leadership effectiveness nominations committee report accountability audit risk committee report relations stakeholders engagement activities science committee report corporate responsibility committee report directors report gsk annual report chairmans governance statement purpose values always source great pride board employees powerful force attracting retaining talented people individuals want part company contributes meaningfully society dear shareholder reforms came effect january seek drive pleased present corporate governance report number changes companies underlying corporate governance processes result board reviewed existing practices governance structure operates board across group identify line reforms implemented believe underpins ability deliver strategy enhancements appropriate report create longterm value benefit shareholders reforms next years annual report allow time embed stakeholders new practices corporate governance framework monitor confirm throughout company complied operation effectiveness requirements financial reporting councils frc uk however wish highlight report corporate governance code current code except dr vivienne significant implementation steps may interest cox unable attend companys agm investors wider stakeholders include early publication required attend board meeting another public company ceo pay ratio designation dr vivienne senior independent director nomination governance cox workforce engagement director discussed chair resulted partial noncompliance current code also strengthened reporting provision e stakeholder relationships agenda copy current code available wwwfrcorguk summarising approach mechanisms place following pages set details composition board promote stakeholder engagement corporate governance arrangements processes activities highlighting specific role corporate responsibility year together reports boards committee plays monitoring identifying addressing committees addition related statutory disclosures set evolving views expectations broad range shareholder information section pages stakeholders pages corporate governance reform describing respond expectations stakeholders remain commercially successful protect year companies miscellaneous reporting reputation build trust regulations published conjunction frcs new code reforms reforms seek raise bar existing using science technology reduce health needs corporate governance practices encourage companies making products affordable available demonstrate broader responsibility within society fulfilment governments aim build trust business core modern employer require boards report regard matters set section companies act including stakeholder impacts fulfilling directors duties introduce new requirements around employee consultation pay practices board culture composition diversity encourage companies report new codes principles applied year gsk annual report strategic report governance remuneration financial statements investor information purpose strategy culture succession process purpose help people feel better live longer closing informed board start year intention underpinned values patient focus integrity retire board successor appointed respect transparency purpose values always senior independent director vindi banga leading process source great pride board employees identify recruit successor lead board next powerful force attracting retaining talented people phase development update process desired individuals want part company contributes attributes sought new chairman set meaningfully society emma walmsley keen preserve privilege serve chairman gsk last four commitment purpose values team years observe positive impact company emma developed companys priorities around ipt supported made relatively short time ceo annual report evolving culture foster pace performance edge demonstrates clarity current strategy resulted board receives regular papers ceo head human improvement performance business however feel resources global businesses update progress right time hand reins new chair clear alignment strategy performance run overseeing eventual separation gsk two world valuesbased culture introduced start class businesses confident successor culture change complex global organisation gsk takes continue crucial role chair promoting supporting time sustained effort however seeing encouraging strategy longterm benefit shareholders patients signs new expectations taking effect supporting employees stakeholders strategy ultimately enable swifter progress getting commend report stakeholders new medicines vaccines consumer healthcare products patients consumers around world risk management philip hampton chairman board continues consider gsks enterprise risks march strategies address reviews risks undertaken throughout course year including whether key enterprise risks affecting respective businesses managed mitigated proportionate way managements commitment maintain strong controls culture also note recent decision serious fraud office uk close investigation concluded action required investigation focused commercial practices company subsidiaries associated persons companys findings led improvements control environment investigations us securities exchange commission department justice remain ongoing gsk annual report board board composition gender diversity composition board date publication board close agm may executive male male nonexecutive female female tenure nonexecutive executive executive years male male years female female years nonexecutive nonexecutive male male international experience female female global us europe emap philip hampton emma walmsley nonexecutive chairman n chief executive officer nationality nationality british british appointed appointed january deputy chairman april nonexecutive january chief executive officer april chairman may skills experience skills experience prior appointment gsks ceo emma ceo gsk prior joining gsk philip chaired major ftse companies including consumer healthcare leading creation joint venture royal bank scotland group plc j sainsbury plc also gsk novartis march solely owned gsk since june served group finance director lloyds tsb group plc bt group plc emma joined gsk loreal worked years bg group plc british gas plc british steel plc philip previously variety roles paris london new york shanghai executive director lazards nonexecutive director rmc emma holds classics modern languages oxford group plc belgacom sa chairman uk financial university investments limited manages uk governments shareholdings banks philip senior independent director anglo american plc external appointments served board since emma cochairs consumer retail life sciences council business advisory group uk government honorary fellow external appointments royal society chemistry philip chair hamptonalexander review ftse women leaders independent review improving gender balance ftse leadership simon dingemans announced january philip step nonexecutive chief financial officer chairman board started process identifying successor nationality british appointed january chief financial officer april skills experience prior joining gsk simon years experience investment banking sg warburg goldman sachs simon advised gsk decade appointment closely involved number gsks key strategic projects simon previously chairman group finance directors key external appointments simon trustee donmar warehouse committee chair simon step board conclusion agm n nominations may audit risk r remuneration science c corporate responsibility gsk annual report strategic report governance remuneration financial statements investor information iain mackay dr vivienne cox chief financial officer designate independent nonexecutive director workforce engagement director r c nationality british nationality appointed british january chief financial officer april appointed skills experience july prior joining gsk iain group finance director global bank skills experience hsbc holdings plc position held eight years chartered vivienne wide experience business gained energy natural accountant iain worked asia us europe hsbc resources publishing sectors also deep understanding general electric schlumberger dowell price waterhouse regulatory government relationships worked bp plc years external appointments britain continental europe posts including executive vice president iain trustee british heart foundation member court chief executive bps gas power renewable business university aberdeen alternative energy unit vivienne previously nonexecutive director bg group plc rio tinto plc lead independent director iain holds business studies accounting honorary uk governments department international development vivienne doctorate aberdeen university scotland appointed commander order british empire new year honours services uk economy sustainability dr hal barron external appointments chief scientific officer president rd vivienne senior independent director pearson plc nonexecutive nationality director stena ab chairman supervisory board vallourec american advisory board member african leadership institute chair rosalind franklin institute vice president energy institute appointed member advisory board montrose associates vivienne sits january global leadership council sad business school oxford skills experience patron hospice st francis prior joining gsk hal president rd calico llc california life company alphabetfunded company uses advanced technologies lynn elsenhans increase understanding lifespan biology prior joining calico hal independent nonexecutive director c n executive vice president head global product development chief medical officer roche responsible products combined nationality portfolio roche genentech genentech senior vice american president development chief medical officer hal non appointed executive director chair science technology committee july juno therapeutics inc march acquired skills experience celgene corporation lynn wealth experience running global business significant external appointments knowledge global markets gsk operates served hal associate adjunct professor epidemiology biostatistics university chair president chief executive officer sunoco inc california san francisco also nonexecutive board director prior joining sunoco president chief executive grail inc early cancer detection healthcare company member officer lynn worked royal dutch shell joined advisory board verily life sciences llc subsidiary held number senior roles including executive vice president alphabet inc global manufacturing lynn previously non executive director flowserve corporation first tee greater manvinder singh vindi banga houston trustee united way greater houston senior independent nonexecutive director n r external appointments nationality lynn nonexecutive director baker hughes ge company chair audit committee well board director saudi aramco british addition lynn director texas medical center appointed september senior independent nonexecutive director may skills experience prior joining gsk vindi spent years unilever plc last role amongst several senior positions president global foods home personal care businesses member unilever executive board vindi sat prime minister indias council trade industry board governors indian institute management iim ahmedabad vindi also recipient padma bhushan one indias highest civilian honours vindi nonexecutive director thomson reuters corp chairman supervisory board mauser group senior independent director marks spencer group plc external appointments vindi partner private equity investment firm clayton dubilier rice chairman kalle gmbh director high ridge brands co member holdingham international advisory board vindi nonexecutive director confederation british industry cbi sits governing board indian school business hyderabad global leadership council sad business school oxford member indo uk ceo forum vindi chair board trustees marie curie gsk annual report board continued dr laurie glimcher judy lewent independent nonexecutive director scientific medical expert independent nonexecutive director n r nationality nationality american american appointed appointed april september skills experience skills experience judy extensive knowledge global pharmaceutical industry addition number senior leadership positions held harvard corporate finance joined merck co served medical school harvard school public health laurie also served chief financial officer retired judy stephen suzanne weiss dean professor medicine weill served nonexecutive director dell inc quaker oats company cornell medical college attending physician new york motorola inc held nonexecutive directorships purdue pharma inc presbyterian hospitalweill cornell medical center laurie stepped napp pharmaceutical holdings limited certain mundipharma board bristolmyers squibb co bms serving international limited companies years board laurie brings scientific public health expertise board determined judy recent relevant financial boards deliberations wealth global publicly listed experience agreed appropriate qualifications pharmaceutical business experience background audit committee financial expert external appointments external appointments laurie currently professor medicine harvard medical school judy nonexecutive director thermo fisher scientific inc ceo president attending physician danafarber cancer motorola solutions inc also trustee rockefeller family trust institute life member massachusetts institute technology corporation laurie member us national academy sciences national member american academy arts sciences member academy medicine member scientific steering committee business advisory board twoxar parker institute cancer immunotherapy nonexecutive director waters corporation also serves corporate urs rohner governance committee addition laurie cofounder chair independent nonexecutive director r n scientific advisory board quentis therapeutics inc scientific advisory board member repare therapeutics inc abpro therapeutics nationality kaleido biosciences inc swiss appointed dr jesse goodman january independent nonexecutive director scientific medical expert skills experience c urs broad range business legal experience served chairman number boards recently credit suisse nationality worldleading financial services company prior joining credit suisse american urs served chairman executive board ceo prosieben appointed prosiebensat media ag followed number years private january practice major law firms switzerland us admitted skills experience bars canton zurich switzerland state jesse previously served senior leadership positions us food new york us drug administration fda including recently fdas external appointments chief scientist previously deputy commissioner science urs chairman board credit suisse group ag public health director center biologics evaluation chairmans governance committee also chairman member research cber board trustees credit suisse research institute credit jesse played leadership role developing fdas regulatory science suisse foundation urs appointed vicechairman governing medical countermeasures initiatives worked collaboratively board swiss bankers association industry academia government global public health regulatory partners prepare respond major public health threats including emerging infectious diseases disasters terrorism led fdas response west nile virus hn influenza pandemic served senior leadership team white house medical countermeasure review jesse brings scientific public health expertise boards deliberations external appointments jesse currently professor medicine georgetown university directs georgetown university center medical product access safety stewardship compass active clinician serves attending physician infectious diseases also serves president member board united states pharmacopeia usp member regulatory legal working group coalition epidemic preparedness innovations cepi us national academy medicine jesse member board intellia therapeutics cambridge gsk annual report strategic report governance remuneration financial statements investor information corporate executive team brian mcnamara karenann terrell emma walmsley ceo gsk consumer healthcare chief digital technology officer chief executive officer brian joined cet karenann joined gsk cet simon dingemans appointed ceo gsk consumer healthcare chief digital technology officer responsible chief financial officer joined gsk head europe technology digital data analytics strategy iain mackay americas gsk consumer healthcare previously worked walmart chief chief financial officer designate following creation joint venture information officer prior gsk novartis previously head baxter international chief dr hal barron novartis otc division brian began information officer daimler chief scientific officer career procter gamble chrysler corporation karenann began president rd brian board member world self career general motors medication industry association serving biographical details see pages karenann member board trustees chairman february march new york hall science board member consumer goods became nonexecutive director pluralsight forum earned undergraduate degree llc earned graduate postgraduate electrical engineering union college roger connor new york mba finance degrees electrical engineering kettering purdue universities respectively president global vaccines university cincinnati claire thomas roger joined cet appointed luke miels senior vice president human resources president gsk global vaccines president global pharmaceuticals addition leadership vaccines business claire appointed cet senior responsible gsks global procurement luke joined gsk cet september vice president human resources organisation previously president president global pharmaceuticals joined company senior global manufacturing supply responsible commercial portfolio manager human resources sales vice president office ceo medicines vaccines marketing group uk pharmaceuticals corporate strategy roger joined gsk previously worked astrazeneca executive becoming director human resources astrazeneca vice president european business uk pharmaceuticals appointed roger holds degree mechanical prior executive vice president senior vice president human resources manufacturing engineering queens global product portfolio strategy global pharmaceuticals europe senior university belfast masters manufacturing medical affairs corporate affairs vice president human resources leadership cambridge university held roles increasing seniority roche pharmaceuticals international chartered accountant sanofiaventis us europe asia prior gsk claire worked ford motor member board viiv healthcare james ford company holding various positions human luke holds bachelor science degree resources bachelor science senior vice president general counsel biology flinders university adelaide degree economics management industrial james joined cet mba macquarie university sydney relations university wales appointed senior vice president general david redfern phil thomson counsel joined gsk served chief strategy officer president global affairs general counsel consumer healthcare general counsel global pharmaceuticals david joined cet chief strategy officer phil joined cet appointed vice president corporate legal acting responsible corporate president global affairs head governance ethics compliance development strategic planning previously responsibility groups strategic approach prior gsk james solicitor clifford senior vice president northern europe reputation policy development stakeholder chance dla holds law degree responsibility gsks pharmaceutical engagement university east anglia diploma businesses region prior previously phil senior vice president competition law kings college senior vice president central communications government affairs qualified solicitor england wales eastern europe joined gsk attorney new york state bar david appointed chairman board phil chairman whitehall industry group board member chinabritain viiv healthcare limited nick hirons business council earned degree nonexecutive director aspen pharmacare senior vice president global ethics english history russian studies holdings limited board compliance durham university bachelor science degree bristol nick appointed cet senior university chartered accountant vice president global ethics compliance regis simard responsible compliance risk management president pharmaceuticals supply chain corporate security investigations regis joined cet became nick joined gsk international president pharmaceuticals supply chain auditor later head audit assurance responsible manufacturing combined five audit functions supply gsks pharmaceutical products independent team common riskbased also leads quality environment health methodology nick relocated china safety sustainability corporate level imon dingemans step establish governance model china cet march iain mackay business created consistent approach regis joined gsk site director take formal responsibility cfo compliance notre dame de bondeville rising become april senior vice president global pharmaceuticals nick fellow chartered institute manufacturing current role previously luc debruyne dan troy sir patrick management accountants held senior positions sony konica minolta vallance members cet tyco healthcare member leaving company december board viiv healthcare mechanical january march respectively engineer holds mba gsk annual report leadership effectiveness corporate governance framework board established corporate governance framework clearly defined responsibilities accountabilities framework designed safeguard enhance longterm shareholder value provide platform realise groups strategy gsks longterm priorities innovation performance trust consistent culture values expectations internal control risk management arrangements described pages integral part governance framework board operate effectively give full consideration key matters board committees established set board chief nominations audit risk remuneration science corporate executive committee committee committee committee responsibility officer committee corporate executive r ead r ead read read read team see gskcom terms reference board committee scheduled board committee attendance corporate board nominations audit risk remuneration science responsibility total number scheduled meetings members attended attended attended attended attended attended philip hampton emma walmsley simon dingemans dr hal barron vindi banga dr vivienne cox lynn elsenhans dr laurie glimcher dr jesse goodman judy lewent urs rohner sir patrick vallance stepped march professor sir roy anderson retired may number adhoc meetings directors served part year numbers brackets denote number meetings directors eligible attend see committee reports attendees committee meetings chairman ceo executive directors work committees year reports included later corporate governance report gsk annual report strategic report governance remuneration financial statements investor information board programme board responsible longterm success company authority accountable shareholders ensuring group appropriately managed achieves strategic objectives sets performance duties regard interests key stakeholders cognisant potential impact decisions makes board discharges responsibilities annual programme meetings year focused number specific areas outlined table line longterm ipt priorities underpinned continuing shift culture addition year ceo met nonexecutive directors discuss various matters including progress companys strategy succession planning continuing regulatory investigations areas focus longterm priorities link strategy boards oversight execution strategy included receiving discussing reports three principal businesses pharmaceuticals vaccines p c consumer healthcare receiving ipt transformation programme p c scrutinising approving new rd strategy p c holding joint board corporate executive team strategy day discuss ipt priorities external landscape p c changes business performance competitors governance arrangements scrutinising approving major consumer deals novartis pfizer unilever p c scrutinising approving oncology deal purchase tesaro p c receiving discussing reports pensions insurance tax treasury strategies p c performance boards focus performance included evaluating ceos performance setting objectives p c setting reviewing agreeing annual budget forward looking three year plan p c receiving reports ceo three principal businesses p c scrutinising groups financial performance p c approving major group restructuring plan p c reviewing digital data analytics capabilities opportunities p c governance boards approach discharging corporate governance duties included receiving reports board committees c approving annual report c reviewing agm preparation approving notice agm general meeting approve c transaction novartis considering observations agreeing actions independent external evaluation boards performance c receiving reports corporate governance regulatory developments c approving appointment new auditor c undertaking training gsks code conduct antibribery corruption c approving appointment new chief financial officer p c cultural head hr briefed board transformation aligning gsks culture values support strategy longterm priorities p c engagement boards regard stakeholder impacts included reviewing approving new trust framework set context external trends stakeholder c expectations receiving regular external stakeholder development reports c approving evolution approach changes medical engagement key external experts p c designating dr vivienne cox workforce engagement director gather views groups workforce p c link longterm priorities innovation performance p trust culture c gsk annual report leadership effectiveness continued key board roles responsibilities leadership independent oversight rigorous challenge chairman nonexecutive directors philip hampton provide strong independent element board leads manages business board constructively support challenge management provides direction focus scrutinise performance meeting agreed ensures clear structure effective operation deliverables board committees shape proposals strategy management sets board agenda ensures sufficient time letter appointment setting terms allocated promote effective debate support sound conditions directorship decision making devote time necessary proper ensures board receives precise timely clear performance duties information expected attend meetings required meets nonexecutive director annual independence statement basis discuss individual contributions performance together training development needs board considers nonexecutive directors shares peer feedback provided part board identified pages independent evaluation process demonstrate appropriate degree meets nonexecutive directors independently independence character judgement free executive directors business relationship could maintains dialogue shareholders governance materially interfere exercise judgement company independence commitment lynn elsenhans judy lewent served board chairmans role description available gskcom six years subjected rigorous review chief executive officer emma walmsley senior independent nonexecutive director vindi banga responsible management group three businesses acts sounding board chairman trusted develops groups strategic direction consideration intermediary directors approval board together nonexecutive directors leads implements agreed strategy annual review chairmans performance taking supported members corporate executive account views executive directors team discusses results chairmans effectiveness maintains continual active dialogue review chairman shareholders respect companys performance leads search appointment process recommendation board new chairman chief executive officers role description available gskcom acts additional point contact shareholders maintains understanding issues concerns major shareholders briefings investor relations team company secretary senior independent nonexecutive directors role description available gskcom company secretary secretary board board committees victoria whyte supports board committee chairs annual agenda planning ensures information made available board members timely fashion supports chairman designing delivering board inductions coordinates continuing business awareness training requirements nonexecutive directors undertakes internal board committee evaluations request chairman advises directors board practice procedures corporate governance matters chairs groups disclosure committee point contact shareholders corporate governance matters gsk annual report strategic report governance remuneration financial statements investor information board induction development company secretary assists chairman designing board business key stakeholder awareness facilitating individual induction programmes new directors designed purpose orientating familiarising ensure nonexecutive directors develop maintain new directors industry organisation governance greater insight understanding business key longterm ipt priorities stakeholders new cet members meet board members part invited attend internal management meetings including induction ensure board maintains connections meetings cet cet meet employees informally visits groups operations induction receptions held staff around board meetings receive monthly investor relations stakeholder reports new director receives general induction includes maintain awareness investor stakeholder views duties responsibilities director listed company competitors performance strategy companys corporate governance structure undertaking training gsks code conduct personalised induction measure progress implementing longterm ipt priorities devised individually tailored new directors evolving culture allemployee survey undertaken background education experience role every six months reports regular conversations cet directly workforce lets talk induction programme executive directors normally includes programme explanation role executive director appropriate building relationships chairman board cet training arranging fill capability gaps new director may chairman meets director annually onetoone chief financial officer designates induction programme basis discuss continuing training development tailored iain mackay highly experienced global cfo requirements board kept date legal regulatory commenced joined board january includes governance matters regular papers briefings following features company secretary presentations internal familiarisation industry gsk external advisers introduction finance organisation gsks financial board members undertook completed training structure gsks code conduct antibribery corruption introduction senior management cet members advisors company induction programme nonexecutive directors normally includes introductory meetings members cet senior executives explain companys business financial structure commercial regulatory environment operate competitors investors perspective visits business operations also feature nonexecutive executive directors induction programmes gsk annual report leadership effectiveness continued internal evaluation board board committees evaluation process conducted internally company secretary board carries evaluation performance interviewed director small number focused performance committees every year facilitated questions externally every third year progress board outcomes external evaluation drew responses together information gathered facilitated ms ffion hague independent board evaluation discussed outcomes recommendations disclosed chairman following discussion board whole identified areas focus improvement board set improvements areas focus board identified set board performance action points improvements areas focus succession planning board sid running search process next chairman supported global executive search firm attendance nominations committee process expanded include nonexecutive directors details set nominations committee also progressing search successor judy lewent chair audit risk committee oversight rd pipeline revival key business development board continue monitor performance rd pipeline transactions proposed consumer healthcare joint venture integration operation key business development transactions pfizer including tesaro andme merck kgaa darmstadt germany also reviewing overseeing arrangements proposed consumer healthcare joint venture pfizer building board relationships culture line ceos culture continuing evolution boards culture building relationships work across group membership changed important area focus especially impending chairman succession enhancing boards decisionmaking ways working opportunities enhance boards decisionmaking ways working continue considered ensure board operate effectively possible board performance progress conclusions board evaluation review set areas focus progressachievements review rd strategy following appointment new board reviewed approved dr hal barrons new approach rd chief scientific officer president rd announced companys q results new approach focused science relating immune system use genetics investments advanced technologies enhancing boards focus decision making agreeing board agreed clear priorities focus pleased clear priorities focus year achieved succession planning senior executive board level board reviewed executive nonexecutive director succession planning succession processes continuing replace audit risk committee chair following chairmans decision step board sid leading succession process chairman collaboration nonexecutive directors details chairman succession set building board relationships culture line ceos board especially busy continues build relationships culture work across group evolve culture membership changes gsk annual report strategic report governance remuneration financial statements investor information nominations committee report dear shareholder philip hampton last years committee thoughtful approach refreshing board replacing retiring directors nominations committee chair recently committee supported emma walmsley since appointment ceo refreshment senior role leadership team drive delivery ipt priorities longterm benefit shareholders patients key committee reviews recommends board stakeholders structure size composition board appointment directors members board executive management succession committees cet committee report last year shared insights recruitment succession board cet several key senior executive appointments included dr hal barron joined board chief scientific officer president rd january bring fresh approach membership rd business process continued year reflects committee members committee member since positively strong pipeline top talent organisation philip hampton chair january january also ability attract highquality external hires bring new vindi banga january perspectives approaches outside business lynn elsenhans january iain mackay joined board hsbc next chief judy lewent may financial officer simon dingemans current cfo steps urs rohner january board planned may cfo succession professor sir roy anderson october process described detail may simon informed board intention leave details committee members skills experience given company committee engaged egon zehnder specialises biographies board pages see recruitment highcalibre executives carry targeted committee member attendance levels internal external search successor committee company secretary secretary committee compiled role profile next cfo set desired attends meetings attendees committee skills meetings may include committees view potential successor simon would require strong technical grasp reporting internal controls regular attends attendees attendee required cost capital discipline heshe would familiar chief executive officer international long cycle businesses execution though essential understanding manufacturing rd finally head human resources successor effective business partner ceo appropriate external advisers proven communicator shareholders possess strong set personal values advisory services egon zehnder initiated thorough global search agreed year egon zehnder provided recruitment profile yielded pool candidates reduced consultancy services committee addition shortlist several potential internal external candidates recruitment hr services provide shortlisted candidates met subsequently interviewed company committee supports engagement companys audit risk committee chair ceo executive search firms egon zehnder remuneration committee chair feedback signed voluntary code conduct gender candidate compiled committee also received ceos diversity best practice egon zehnder also one analysis candidates head hr process executive search firms accredited culminated committee meeting agree recommendation enhanced code conduct meeting exacting performance board mr iain mackay appointed next cfo criteria best practice standards genderbalanced recommendation received unanimous board approval august selection ftse boards announced iain would join board executive director effect january board pleased welcome iain gsk proven cfo complex regulated global bank eight years group finance director hsbc brings tremendous finance experience different sectors time hsbc general electric schlumberger dowell price waterhouse trained strong leader track record driving cost cash capital allocation discipline deliver strategy addition new cfo committee also reviewed following internal senior executive appointments cet gsk annual report leadership effectiveness continued nominations committee report continued james ford appointed svp general counsel august progress towards female board representation combined succeeding dan troy performed role gsk executive committee direct reports targets least years james previously svp general counsel published ftse women leaders report global pharma year career gsk reproduced gained wideranging legal experience including investigations female representation june complex corporate transactions litigation senior roles across combined executive us asia uk report female committee direct representation metrics board reports roger connor appointed president vaccines september ftse target succeeding luc debruyne last five years gsk year career gsk president vaccines roger cet since president global manufacturing ftse average supply led strategic transformation gsks supply chain ftse highest support improved quality supply performance date report women board proven track record leading complex global organisation women corporate executive team developing organisational capability driving cultural transformation female board representation return simon regis simard appointed president pharmaceutical supply dingemans steps board may chain september regis previously svp global pharma manufacturing joined gsk site director closing gap board cet gender representation france past worked electronics medical increasing pipeline female direct reports devices pharmaceutical industries cet achieve target particular area attention pleased good progress made diana conrad appointed succeed claire thomas stage almost line target combined svp hr april lead hr function executive committee direct reports representation board composition diversity women management positions gsk illustrated part gender diversity gsks global workforce board sought balance composition line parker reports recommendation committees refresh progressively time benefit experience longer serving directors decided step board sid vindi banga fresh external perspectives insights newer recent leading process identify successor details appointees given nonexecutive directors drawn wide range industries chairman succession search process next chairman backgrounds including pharmaceuticals industry rd underway supported global executive search firm next vaccines consumer products healthcare medical research chairman oversee delivery next phase companys academia insurance financial services wealth strategy continuing strengthen pharmaceutical business experience complex organisations global reach many whilst demerging consumer business formed board members experience longcycle industries integration pfizer business gsk specification assistance understanding industry operate agreed covering key skills experience personal committed diversity boardroom gsk characteristics deemed desirable role also committed equal opportunities employees levels engaging shareholders gather views selection organisation board management seek encourage committee process expanded include diverse inclusive culture throughout gsk nonexecutive directors key requirement effective board comprises vindi banga range balance skills experience knowledge gender senior independent director independence individuals prepared challenge work team needs backed diversity committee evaluation personal attributes including character intellect sound judgement honesty courage committees annual evaluation exercise internally facilitated committee responsible developing measurable objectives company secretary interviewed committee members support implementation boards diversity policy behalf committee chair concluded committee including gender monitoring progress towards achievement continued operate effectively terms enhancements objectives diversity policy line measurable committee would seek augment appointment process targets set appointment scientific financial experts coopting subject matter experts advise committee hamptonalexander review increase number women senior leadership positions ftse companies philip hampton parker review commissions report beyond one nominations committee chair increase ethnic diversity appointments boards ftse companies march gsk annual report strategic report governance remuneration financial statements investor information accountability audit risk committee report dear shareholder judy lewent following pages report aim share insights audit risk committee chair activities undertaken overseen committee year committee worked largely recurring structured programme activities devise programme company role secretary agree content management external committee reviews responsible auditor start year adapted appropriate year progresses financial internal reporting processes financial reporting integrity financial statements including annual report quarterly results announcements integrity financial statements including annual report system internal controls quarterly results announcements key focus committee includes committees assessment identification management risks external effectiveness internal controls financial reporting internal audit processes committee reviewed least quarterly companys significant initiating audit tenders selection appointment accounting matters including contingent consideration liabilities external auditor setting remuneration exercising revenue recognition accruals returns rebates oversight work restructuring tax accounting significant transactions well impact changes accounting standards membership committees position always aim clear transparent financial disclosure gsks financial reporting committee members committee member since support proactive approach step ahead judy lewent chair january april guidance requirements regulators line prior years vindi banga january committee continued review compliance latest lynn elsenhans january guidance endorsed management proposals improve dr laurie glimcher september disclosures particularly around use alternative performance measures gsks preliminary results annual report details committee members financial accounting scientific experience expertise given biographies board external auditor pages see committee member attendance levels competitive tender exercise deloitte llp appointed company secretary secretary committee companys new auditor agm replacing attends meetings entire board invited attend pricewaterhousecoopers llp smooth transition exercise committee meetings attendees include minimal disruption business maintained strong working relationship new audit partner throughout regular attends attendee attendee required transition audit process management general counsel deloitte also worked closely together deloitte could develop deep understanding gsks business could bring group financial controller bear group audit welcomed new head audit assurance perspectives challenge deloitte brought audit head global ethics compliance also pleased observed improvements audit chief medical officer quality efficiencies resulted deloittes deployment chief product quality officer data analytics external auditor accordance financial reporting councils uk corporate governance code board determined judy lewent recent relevant financial experience board also agreed appropriate qualifications background audit committee financial expert defined sarbanesoxley act determined independent within meaning securities exchange act amended committee whole competence relevant sector company operates gsk annual report accountability continued audit risk committee report continued internal framework control risk enterprise risk framework strategies year management developments committee considered gsks enterprise risks strategies address reviews undertaken another core area focus committee annual business unit risk assurance update reports following developments global ethics compliance gec enterprise risk strategy papers significant business units across enterprise continued strengthen risks controls culture compliance risk management technology user access controls part committees annual risk reviews contained risk management internal control report presented head gec role assessing effectiveness internal controls financial reporting certain technology systems associated part review committee assesses whether key infrastructure identified focus consideration enterprise risks affecting unit managed mitigated committee especially around user access management proportionate way committee examines whether satisfied throughout year committee closely monitored groups control environment operation effectiveness plans address control findings identified addition whether refinements management propose ensure programme implemented completed identify environment remains fit purpose appropriate also assesses validate additional layers controls group established commitment business units leadership maintain strong mitigate risk area well enhancements controls culture controls business reported key internal control framework icf enterprise risk management enhancements committee improvements simplification activities improve also overseen launch new enterprise risk management manage risks summarised erm cycle provides endtoend approach planning pharmaceuticals overall pharmaceuticals leadership team mitigation reporting key enterprise risks risk management compliance board rmcb established introducing enterprise risk plans erp business providing improved governance structure better aligned global support function set risk appetite organisation strengthening connections regional tolerance expected controls mitigation actions country rmcbs addition distributor control framework monitoring risk oversight compliance council approves designed implemented export markets simplifying committee reviews executive summaries erps management monitoring enabling thirdparty audits focus high risk distributors general manager confirmation process controlled process adaptions erps established continued key focus targeted discussions rmcbs achieve appropriate balance managing enterprise better understanding global mitigation actions accountability risks consistent basis providing measure risk local control efforts addition site director confirmation based flexibility various parts organisation justified run first time end end supply chain review making enterprise risk reports datafocused generate vaccines comprehensive risk reviews carried key informed discussion risk exposure mitigation assets shingrix bexsero gec independent committee agreed separate information protection business monitoring team also conducted first review vaccines two separate enterprise risks information security privacy focusing high risk areas primarily within commercial medical privacy year privacy centre excellence delivered external rd confirmation controls working change programme improve sustainably manage gsks intended monitoring sites corporate environment data privacy compliance whilst ensuring compliance health safety sustainability ehss assurance group also general data protection regulation became law may established rd mapping exercise performed included evaluate need ibm key business activities gaps identified next verification exercise planned implementation new control framework consumer health key risk themes monitoring audit remediation certain existing business activities including findings reviewed identify high risk areas enhanced risk adopting privacy controls privacy contract terms written management low risk areas clearer guidance policy records processing activities data protection impact simplification improved management monitoring toolkit assessments developed well new tool assessing country risk incorporating comprehensive training programme drive greater expertise culture commercial qualitative criteria awareness accountability managing personal information across entire organisation details approach data privacy issues given gsk annual report strategic report governance remuneration financial statements investor information audit risk committee report continued emerging risks number years committee aa team conducted values assurance reviews vars considering emerging risks scheduled meeting year test well values expectations discussions enhanced results audit embedded organisation identified follow assurance aa teams political economic social technological action areas including creating environment people legal environmental pestle external analysis emerging comfortable speak continuing develop managers leadership risks committee also examining leveraging new capabilities addressing perceptions complexity continuing technology risk scanning services better support identification drive simplification efforts raising awareness gsks emerging risks expectations mean context employees roles written standards review gsks important global written standards undertaken simplify gec continued focus people development building harmonise written standards controls make easier capabilities including access understand ethics compliance academy virtual academy run monitoring compliance activities quarterly basis antibribery corruption abac abac training strategy monitoring key element icf provides continuous evolved provide tailored targeted modules based source insights inform improvements control environment employees roles responsibilities particular emphasis significant focus businesses enhancing skills conduct high risk area included consolidated streamlined business business activities behalf company monitoring improved coordination enterprise risk owners businesses monitoring groups addition new travel privacy certification privacy function offered globally expenses system implemented control enhancements recognized professional privacy certification international utilising artificial intelligence enhanced data analytics association privacy professionals gec introduced early case assessment phase code conduct annual mandatory training code investigation process empowers investigator quickly conduct delivered two parts focused living determine appropriate action improve quality values expectations abac supplemented investigation ensure productive use resources introduction microlearning modules taken time investigations team sought increase trust speak channel arrangements updating processes committee evaluation promote better quality decision making improved monitoring lead indicators addition investigations training committees annual evaluation internally facilitated education programme improved investigation company secretary interviewed committee members work performed inhouse resulted significant reduction behalf committee chair concluded committee cost external support hr compliance continued operate effectively terms enhancements legal based employees trained investigative agreed continue interviewing techniques good progress made ensuring committee gsk values expectations papers concise accessible facilitate productive discussion high priority committee year range work nominations committee succession planning employee resources introduced promote awareness committee chair board committee members help facilitate discussions bring values expectations life financial experience employees resources included living values expectations discussion guides expectations descriptors lets talk channels april gec updated gsks code conduct make shorter simpler easier use judy lewent audit risk committee chair march gsk annual report accountability continued committee areas committee focus items discussed frequency financial reviewed integrity draft financial statements appropriateness accounting policies going concern reporting assumptions considered approval process confirming recommending board annual report fair balanced understandable reviewed recommended board approval annual report form f reviewed approved directors expenses reviewed recommended approval quarterly preliminary results announcements dividends q earnings guidance reviewed significant issues relation quarterly preliminary results q reviewed recommended inclusion viability statement annual report reviewed financial reporting framework disclosure arrangements reviewed major restructuring reports q reviewed accounting developments impacts well key accounting issues p external canvassed observations outgoing audit partner company committee finance organisations auditor reviewed approved auditnonaudit expenditure incurred considered auditors report annual results performed evidencebased assessment external auditor effectiveness external audit considered qualifications expertise independence external auditor recommended board appointment deloitte committee agree auditors remuneration approved audit plan fee proposal set performance expectations auditor year considered nonaudit services fees audit budget considered initial results external audit p considered internal control financial reporting global internal reviewed assurance reports global pharmaceuticals including rd viiv healthcare vaccines control consumer healthcare well global support functions compliance reviewed gsks internal control framework controls financial reporting reviewed technology access controls closely monitored plans address control findings identified p programme validate mitigation confirmed compliance sarbanesoxley act received independent external evaluation outcomes audit assurance p reviewed audit assurance work approved planned work reviewed us corporate integrity agreement p reviewed implementation enhancements healthcare professional engagement policy p reviewed general data protection regulation readiness compliance p received litigation reports updates received reports continuing investigations antibribery corruption abac issues risk reviewed risk management framework compliance reviewed risk elements group treasury pensions risk insurance tax policies agreed new approach enterprise risk management p received status reports companys enterprise risks risks disclosed pages p received fraud site security cyber security risk assessment update p received updates implications planning brexit p received risk oversight compliance council rocc meeting updates considered emerging risks governance confirmed compliance uk corporate governance code matters reviewed committees terms reference confirmed adhered received corporate governance updates p reviewed committees performance effectiveness reviewed approved groups modern slavery act statement p reviewed companys gender pay gap disclosures met privately separately heads global ethics compliance audit assurance general counsel p met privately external auditor end meeting appropriate committee activity key annually q quarterly p periodically standing gsk annual report strategic report governance remuneration financial statements investor information significant issues relating financial statements considering quarterly financial results announcements financial results contained annual report committee reviewed significant issues judgements made management determining results committee reviewed papers prepared management setting key areas risk actions undertaken quantify effects relevant issues judgements made management appropriate accounting required address issues financial statements significant issues considered relation financial statements year ended december set following table together summary financial outcomes appropriate addition committee external auditor discussed significant issues addressed committee year areas particular audit focus described independent auditors report pages significant issues considered committee relation financial statements issue addressed committee going concern basis preparation committee considered outcome managements halfyearly reviews current forecast net financial statements debt positions various financing facilities options available group following review risk potential impact unforeseen events committee confirmed application going concern basis preparation financial statements continued appropriate revenue recognition including returns committee reviewed managements approach timing recognition revenue accruals rebates rar accruals customer returns rebates us pharmaceuticals vaccines accrual returns rebates billion december committee reviewed basis accrual made concurred managements judgements amounts involved fuller description process operated us pharmaceuticals vaccines business determining level accrual necessary set critical accounting policies provisions legal matters including committee received detailed reports actual potential litigation internal external investigations groups legal counsel together number detailed updates investigations groups commercial commercial practices practices management outlined levels provision corresponding disclosure considered necessary respect potential adverse litigation outcomes also areas yet possible determine provision necessary amount december provision legal matters billion set note financial statements provisions provisions uncertain tax positions committee considered current tax disputes areas potential risk concurred managements judgement levels tax contingencies required december tax payable liability billion including provisions uncertain tax positions recognised groups balance sheet impairments intangible assets committee reviewed managements process reviewing testing goodwill intangible assets potential impairment committee accepted managements judgements intangible assets required writing resulting impairment charge million see note financial statements intangible assets details valuation contingent consideration committee considered managements judgement following improved sales relation viiv healthcare performance tivicay triumeq necessary increase liability pay contingent consideration acquisition former shionogiviiv healthcare joint venture december groups balance sheet included contingent consideration liability billion relation viiv healthcare see note financial statements contingent consideration liabilities details viiv healthcare put option committee reviewed agreed accounting pfizer put option concurred managements judgement valuation put option billion december gsk annual report accountability continued auditors appointment external auditor finally committee considered feedback external audit survey sought views financial following audit tender process conducted committee management team corporate business unit level covered concluded december deloittes appointment effectiveness challenge auditor integrity auditor company group approved transparency reporting management shareholders gsk agm may committee contractual similar obligations restricting groups choice external auditor clarity communication auditor ways working deloitte observed pricewaterhousecoopers pwc work alignment audit groups investment sap gsks previous statutory auditor year end auditing quality audit teams leadership process full report transition process pwc deloitte included pages gsks skills experience audit team annual report reviewed feedback noted areas committee considers company improvement implemented respect team complied mandatory audit processes audit committee audit committee responsibility provisions competition markets authority satisfied effectiveness auditor external statutory audit services order audit process effectiveness quality external audit process satisfied auditors independence qualifications objectivity expertise resources committee committed ensuring ongoing basis committee therefore recommended board gsk receives high quality effective audit external appointment deloitte forthcoming agm auditor evaluating deloittes performance prior making recommendation reappointment early committee reviewed effectiveness performance criteria agreed conjunction management beginning criteria set undertaking review committee considered overall quality audit independence deloitte whether exhibited appropriate level challenge scepticism work deloitte recently appointed gsks auditor length tenure taken account assessing independence objectivity gsk annual report strategic report governance remuneration financial statements investor information auditors appointment continued detailed criteria committee used judging effectiveness deloitte external auditor overriding responsibility deliver smoothrunning thorough efficiently executed audit set performance expectations gsks external auditor audit approach leverage centrally controlled audit approach ensuring gsks group joint ventures local statutory entities audited strategy refine consistent technologyled audit enhanced risk assessment analytical procedures providing insights combine data trend analysis process cycle pathways identification audit risks ensuring wellinformed efficient audit deliver focused consistent audit approach globally reflects local risks materiality high quality adhere independence policies gsks frcs revised ethical standard applicable sec standards independent audit maintain relentless focus audit quality deloittes internal quality control procedures provide timely clarity assessments accounting treatments ensure consistency advice levels maintain forwardthinking approach raising potential issues concerns soon identified provide timely uptodate knowledge technical governance issues including evolving market practice viability statement requirements esmasec guidelines new ifrss ie ifrs serve industry resource communicating best practice trends reporting integrated reporting provide high quality succession planning key staff members deloitte ensure technical skillsets continuously enhanced effective deliver smooth running thorough efficiently executed audit partnership discussing approach areas focus advance early engagement understanding implications new operating model ensuring sox scope additional procedures discussed endorsed corporate management communicated timely basis within gsk deloitte avoiding surprises timely reporting issues levels within group early engagement provision impact assessments key judgements ensuring clarity roles responsibilities local deloitte finance services responding issues raised corporate management timely basis meeting agreed deadlines providing sufficient time management consider draft auditor reports respond requests queries consistent timely communication engagement local central audit teams across gsk stakeholder groups liaise audit assurance avoid duplication work global ethics compliance ensure common understanding audit outcomes adopting collaborative approach solving issues ultimately provide highquality service board scrupulous scrutiny group act utmost integrity auditor ensure seamless effective efficient auditor transition pwc deloitte maximising use relevant information provided transition pwc respect audits company subsidiaries relation audit groups consolidated accounts value work closely management agree scope changes overruns efficiencies set clear milestones continuous monitoring money provide transparency audit time cost incurred analysis budget identifying areas enable reduction audit hours without compromising audit quality commensurately reducing audit fees gsk annual report accountability continued nonaudit services possible accounting firms engaged undertake preapproval categorywide preapproval process reflects nonaudit services restrictions frcs guidance audit committees nonaudit services external auditor permitted provide nonaudit services auditrelated tax services accordance preapproved committee chairman gsks policy contained gsks finance manual committee cfo delegated committee ensures auditor objectivity independence safeguarded preapproved requiring preapproval committee group financial controller following core policy guidelines engaging external auditor approved designate group provide nonaudit services observed financial controller process ensuring nonaudit services put fees paid companys auditor associates set competitive tender financial service providers details given note financial statements external auditor line groups procurement operating profit process unless skills experience external auditor make suitable supplier nonaudit service consideration auditnonaudit services three year comparison graph safeguards ensuring adequate safeguards place objectivity independence group audit threatened compromised deloitte fee cap ensuring total fee levels exceed annual audit fee except special circumstances would clear advantage companys auditor undertaking additional work p w c companys current policy complies financial reporting councils frc revised ethical standard eu audit regulation sarbanesoxley act policy contains following three guidelines pwc fee cap gsks policy cap annual audit fee cap stringent frcs fees cap set average fees preceding threeyear period audit assurance services prohibitions gsks policy includes black list prohibited services including tax regulatory compliance treasuryrelated services nonaudit services fair balanced understandable assessment one key compliance requirements groups financial code conduct reporting lines statements annual report fair balanced also number wellestablished policies including understandable coordination review groupwide code conduct available governance section contributions annual report follows wellestablished website together details confidential speak documented process performed parallel reporting lines reporting investigation unlawful formal process undertaken external auditor conduct updated version code conduct last published april committee received summary approach taken management preparation gsks annual report ensure met requirements frcs uk corporate governance code enabled committee board confirm gsks annual report taken whole fair balanced understandable provides information necessary shareholders assess companys position performance business model strategy gsk annual report strategic report governance remuneration financial statements investor information internal control framework board recognises obligation present fair balanced fit purpose framework conjunction corporate diligent assessment gsks current position prospects values expectations speak processes ensures risks board accountable evaluating approving associated business activities actively effectively effectiveness internal controls including financial operational controlled line agreed risk appetite believe compliance controls risk management processes operated framework provides reasonable absolute assurance gsk material misstatement loss internal control framework framework comprehensive groups risk oversight compliance council rocc enterprisewide risk management model means team senior leaders mandated board assist gsk ensures reliability financial reporting compliance committee overseeing risk management internal control laws regulations framework supports continuous activities also provides business framework risk process boards identification evaluation management management upward escalation significant risks groups principal risks required financial reporting business unit risk board structure reports rocc councils frcs uk corporate governance code code business unit risk management compliance boards designed manage risk achieving business objectives rmcbs responsible promoting local tone top risk culture well ensuring effective oversight internal controls risk management processes principal risk assigned risk owner member framework senior management risk owner accountable management hisher respective principal risk including enterprise oversight setting risk mitigation plans implementation reporting risk management approach progress rocc independent assurance committee every year rocc rmcbs assisted independent business monitoring b ady vg anlo cb ina gl e rit sh kic ms aa nn ad g c emom enp tl aa cn rc oe sg ec e n w teh rpic rh es ns dp fo r thib el e development working practices riskbased ethically disc ep nl fi rce ea mn ed nt b r ui ss ssk e nsm een st w cori ntt te ron ls standards v pao l rul lu um vn e ie dd e g sb ne ie ndr sc ds ut eo ra pa fc c entt oh nciv dee epol nalr ygp wa ar ao n sitm shs u ia n rtt ap e lo nips nn c l ee ect w ah obi ic l hp sea e e l lr nab na w ie ot aeh rg mi rnv en ao ed ncu arcr e gas g et r sh ud mur la eo rn nu ic n tg e n c ah e nw e dpin h l ta h b el ui n rg p ro ble mer ssp n ding activities training b thho eia ir r ad os vo en u rs rt ih gne hc te e af f h ne e dc l p aiv de vsn ie se n os rs r rm ef sr ai ps nk oa ngm sea im bn ia e litg n iee sm n ie ndn f ut ha lfiec l lr b ino gs tr ht dh e e g g ror eo ueu ptp mom na toa rg ine gment communication ot tr fa fikt cee ehg roi c ald e db r sj te h c eat cv ae os mh mn sd ta tb e eu u il ad li n reg p oru rts int gw li nh e p ia nt ti oe n thts e cn hd eo ft h fe inr ncial committee receives regular reports business units principal risk owners gec aa areas significant risk group related internal controls reports provide assessment internal control environment within gsk values expectations principal risk area including enhancements strengthen control environment following consideration reports committee concludes effectiveness internal control environment reports board annually accordance frcs code provisions board authority delegated committee conducted robust assessment groups principal risks includes consideration nature extent risk willing take achieving groups strategic objectives board committee maintained oversight ensure effectiveness internal control environment risk management processes operation across group whole year date approval annual report gsk annual report internal control framework continued boards review focuses company subsidiaries review groups risk management approach extend material associated undertakings joint ventures discussed risk management section strategic report investments although considers risk companys pages management principal risk participation activities established procedures explained principal risks uncertainties pages controls place identify entities whose results must groups viability discussed group financial review consolidated groups results believe process section strategic report followed board committee reviewing regularly system internal controls risk management processes accordance guidance risk management internal control related financial business reporting issued frc governance structure risk management gnirotinom rof ytilibatnuocca responsibility implementing accountability continued board directors responsible system corporate governance strategy risk management financial performance responsible reviewing approving audit risk committee adequacy effectiveness risk management internal controls corporate executive team supports ceo managing business activities authorised board assist audit risk oversight risk committee overseeing risk compliance council management internal control activities group responsible system corporate business units governance strategy risk management financial performance ensure appropriate internal controls risk management effective risk management implemented compliance boards complemented country executive risk boards ensure consistent approach risk management across local territories gsk annual report strategic report governance remuneration financial statements investor information relations stakeholders engagement activities performance legal duty promote success emma simon maintain continual active dialogue company board regard number factors including institutional shareholders performance plans objectives listening considering views shareholders key programme regular meetings year held stakeholders cognisant potential impacts decisions total individual meetings major shareholders makes stakeholders environment communities hosted total group meetings major shareholders operate potential major shareholders principal board committees delegated powers enable philip hampton also meets major shareholders hear indepth assessment impacts companys wider views discuss issues mutual importance engagement stakeholders also provides means communicates views rest board year identifying emerging stakeholderrelated issues brought held six individual meetings major shareholders range attention board turn enables us issues senior independent nonexecutive director sid invest activities build trust reputation operating nonexecutive directors available meet responsibly deliver purpose major shareholders engagement companys main stakeholder groups including normally hold governance event end year patients shareholders consumers customers employees institutional shareholders key investment industry bodies levels organisation across enterprise summarised influential proxy advisory firms chairman sid boards interactions two companys main committee chairs discuss particular areas focus stakeholder groups shareholders people set associated corporate governance corporate responsibility detail remuneration arrangements governance event cancelled company possession inside information shareholders ahead announcement proposed joint venture pfizers consumer healthcare business try engage shareholders several ways includes regular communications agm investor relations continuing basis investor relations department activities announce results quarterly basis offices london philadelphia acts focal point annual results included annual report shareholders communication institutional investors company secretary receive annual summary advises annual acts focal point communications corporate governance report notice annual general meeting available matters also small central corporate responsibility cr team coordinates strategy policy development reporting major shareholders specifically respect cr team communicates socially responsible investors stakeholders year publication quarterly results ceo emma walmsley cfo simon dingemans gave presentations retail shareholders institutional investors analysts media webcast teleconference july emma dr hal barron held rd update company secretary acts focal point retail investors event announced new approach rd manages key relationships companys registrars equiniti designed capitalise assets companys promising uk bank new york mellon administer adr earlystage pipeline build next wave growth gsk programme us benefit patients shareholders update major shareholders concluded qa session gsk annual report relations stakeholders continued engagement activities continued annual general meeting stakeholder engagement modern employer shareholders invited attend annual general meeting see see years agm held may sofitel london heathrow trust see shareholder information hotel see agm good level attendance engagement shareholders proposed resolutions approved shareholders level support ranged agm provides opportunity put questions board workforce engagement director chairs board committees formal agm proceedings providing shareholders chance underscore boards commitment strengthen meet informally board directors make engagement people gather views available meeting designated one independent nonexecutive directors dr vivienne cox companys workforce engagement people director december board fully supportive groups commitment board firmly believes formal model engagement progressive modern employer attract retain motivate likely best connect preexisting employee best talent drive high levels employee engagement engagement activity employee voice channels key transformation priority ceo evolve culture boardroom decisionmaking promote meaningful company enhance business performance strategic engagement success relies ability engage employees behind delivery companys longterm ipt priorities underpinned provides regular platform independent element continuing shift culture therefore employee engagement board direct conversations workforce key barometer measuring people feel working gsk individually group settings gain insights tools use measure peoples views discussed experiences concerns perspectives better understand whether cultural change already underway embedding organisation support longterm ipt priorities therefore model likely add immediate value programme activities compiled ensure vivienne accessible workforce gather feedback consideration board looking forward sharing insights experiences gained workforce engagement director next years annual report gsk annual report strategic report governance remuneration financial statements investor information science committee report oversight rd projects portfolio governance dr jesse goodman rds culture talent capabilities incentive arrangements science committee chair particular committee reviewed key features dr barrons new approach rd focuses science role related immune system use human genetics committee advanced technologies help identify next generation transformational medicines patients undertakes periodic reviews rd strategy progress committee reviewed several assets currently clinical assesses overall performance including relevant development notes significant progress made strengthen financial metrics effectiveness competitiveness rd pharmaceuticals pipeline particularly area oncology helps identify critical emerging trends science company currently assets development medicine potential impact company immunomodulators focused oncology addition committee considered scientific perspective undertakes periodic reviews companys scientific pleased recommend board following key capability talent business development transactions reviews scientific opportunity specific large scale tesaro strengthening pharmaceuticals pipeline investments business transactions acquisition oncologyfocused biopharmaceutical company reviews output groups science advisory boards major marketed project zejula oral poly adp ribose polymerase parp inhibitor approved us europe adults recurring ovarian cancer believe parp inhibitors membership also offer significant opportunities treating patients many committee members committee member since cancer types several promising oncology assets dr jesse goodman chair january january also acquired part transaction including pd inhibitor dostarlimab currently studied endometrial cancer dr laurie glimcher september judy lewent january andme forming exclusive collaboration worlds professor sir roy anderson january leading consumer genetics research company may combine scientific medical knowledge largescale genetic resources unique data science skills improving details committee members skills experience given probability rd success biographies board pages see committee member attendance levels merck agreeing proposed global strategic alliance merck company secretary secretary committee kgaa darmstadt germany jointly develop commercialise attends meetings attendees committee investigational bifunctional fusion protein meetings may include immunotherapy currently clinical development including potential registration studies multiple difficulttotreat cancers regular attends includes phase ii trial investigate compared attendee attendee required pembrolizumab first line treatment patients pdl company chairman expressing advanced nonsmall cell lung cancer chief executive officer committee evaluation chief scientific officer president rd president global vaccines second annual evaluation committee internally independent senior external scientific advisers facilitated company secretary interviewed committee chief financial officer members behalf committee chair terms company executives enhancements committee settles role consideration would given refines work focus exercise effective oversight embedding new rd strategy next steps dear shareholder pleased present second report science committee continue review new approach committees activities committee rd progressing culture change underway rd committee sought evolve ways expects see major data readouts news flow several new working oversight rd support board dr hal barron medicines finally would like thank professor sir roy considering science pipeline rd strategy priorities anderson stood committee retired board may significant contribution helping committee developed annual programme activities shape role focus committee support core role rd oversight help discharge responsibilities items consideration committee include receiving dr jesse goodman regular updates pharmaceuticals vaccines priority assets science committee chair regular rd strategy updates march gsk annual report corporate responsibility committee report dear shareholder lynn elsenhans chair corporate responsibility committee committee corporate responsibility committee chair pleased present committees report committee forms important part boards oversight companys responsible business agenda ensuring management role working deliver longterm value shareholders committee reviews society committee rolling agenda receives reports external issues potential serious impact members cet senior managers ensure upon gsks business reputation progress meeting responsible business commitments reviewed regular basis oversight views interests internal external stakeholders committee membership consideration gsks trust priority annual governance committee members bring wide range sector experience oversight progress gsks commitments insight stakeholder perspectives help provide oversight reflect important issues responsible topics helps monitor companys work engage sustainable growth effectively key stakeholders assess company membership operating way seeks meet high external expectations membership committee appointment dates gsk global healthcare company set year professor sir roy anderson stood committee retired board may committee members committee member since greatly appreciated insights brought work lynn elsenhans chair may october committee tenure including development dr vivienne cox july new commitments support delivery gsks trust priority dr jesse goodman may pleased invite regis simard president pharma supply professor sir roy anderson may may chain attend committee regular basis regis details committee members skills experience given responsibility product quality environment health safety biographies board pages see sustainability ehss vital areas companys operations committee member attendance levels committee exercises oversight company secretary secretary committee areas focus attends meetings attendees committee meetings may include committee focused topics material regular attends companys purpose strategy values expectations attendee attendee required committee plays integral role oversight gsks chief executive officer responsible business commitments year work company chairman committee included continued oversight development chief scientific officer president rd new set focused commitments support companys trust priority new commitments build strong performance general counsel responsible business many years set context president global affairs external trends stakeholder expectations framework president pharma supply chain surrounding commitments subject review key president global pharmaceuticals stakeholders feedback incorporated president global vaccines strengthen design operation board pleased ceo gsk consumer healthcare support committees recommendations head human resources new framework identifies commitments across three focus svp corporate affairs areas company maximise social impact using vp trust global health science technology address health needs making products executives affordable available modern employer focus areas supported commitments across fundamentals independent external corporate responsibility adviser responsible healthcare company reliable supply ethics values data engagement environment gsk annual report strategic report governance remuneration financial statements investor information corporate responsibility committee report continued year management presented committee independent external corporate responsibility advisor number topics across breadth trust priority ms sophia tickell serves independent external advisor using science technology address health needs committee ms tickell extensive experience committee reviewed proposals management new pharmaceuticals industry improving health systems productivity global health strategy designed align companys ipt sustainability energy supply distribution climate change strategy new approach focused achieve maximum policy shorttermism financial markets social impact support strategic theme fighting infectious diseases impacting children young people developing cofounder director meteos directs countries committee discussed importance endtoend pharma futures series aims better align societal planning global health assets partnering others shareholder value holds several board advisory roles rd manufacturing ensure sustainability ms tickell attended meetings committee provided longterm independent advice guidance corporate responsibility making products affordable available year matters committee chair ceo president also considered access affordability companys global affairs commitment making products available prices committee evaluation responsible sustainable business reviewed global pricing strategies pharmaceuticals business committees annual evaluation exercise internally facilitated particular focus us environment companys company secretary interviewed committee members current largest single market operating context behalf committee chair concluded committee continues evolve continued operate effectively terms enhancements modern employer committee also oversight committee would continue review opportunities develop companys new commitments modern employer remit support companys cr agenda goals centre three main elements engaged people inclusion part process would consider best practice similar diversity health wellbeing development committees examine current responsibilities relation committee discussed results global employee survey remit gsks board committees managements plans responding lower scoring areas committee aims responsible business year committee reviewed progress made gsks commitments fundamentals next year continue understand gsks responsible business included oversight progress material responsible business topics seek understand made reduce companys environmental impacts across management responding expectations external carbon water waste setting new targets stakeholders committee well positioned support updates business conduct engagement healthcare delivery new commitments support trust one professionals also discussed committee gsks longterm business priorities committee also reviewed approved companys reporting progress made companys responsible business lynn elsenhans commitments corporate responsibility committee chair march stakeholder engagement insights committee pays close attention evolving views expectations companys broad range key stakeholders regular report stakeholder insights reviewed discussed area responsibility items addressed meeting ensure committee considers issues external issues health safety update may bearing companys reputation delivery potential serious impact upon regular reputational emerging responsible business agenda committee also received gsks business reputation issues update update gsks reputation research understand relevant insights oversight corporate reputation strategy employee insights discussed relation research kpi companys modern employer agenda results global oversight stakeholder views stakeholder insights update employee survey engagement employee survey year continued enjoy positive engagement investors responsible business approach performance annual governance oversight responsible business supplement meet directly shareholders time time understand progress gsks approval issues concerns may committee responsible business oversight new commitments commitments support trust members also meet informally shareholders agm global health strategy committee pleased see company maintain first sustainable access affordability position access medicines index second position business conduct dow jones sustainability index industry two investor supported external benchmarks modern employer environmental targets gsk annual report directors directors powers determined uk legislation change control essential contracts articles association contain rules appointment contracts arrangements individually replacement directors provide directors may fundamental ability business operate effectively appointed ordinary resolution members company party material agreements would take resolution board provided appointed effect altered terminate upon change control following board director retires agm following appointment takeover bid agreements director would provide compensation loss office employment articles also provide directors required seek resulting takeover except provisions companys reelection annually agm accordance uk share plans may cause options awards granted corporate governance code plans vest takeover details termination provisions director cease director executive directors service contracts given full version becomes bankrupt companys remuneration policy available ceases director virtue companies act articles wwwgskcom investors section suffers mental physical ill health board resolves directors report shall cease director purposes uk companies act directors missed directors meetings continuous period six report glaxosmithkline plc year ended december months without permission board resolves comprises pages corporate governance shall cease director report directors statements responsibilities pages prohibited director law pages investor information strategic resigns offers resign board accepts offer report sets matters required disclosed required resign board directors report considered strategic directors conflicts interest importance directors duty companies act avoid risk management objectives policies pages situation could direct indirect conflict interest possible conflict company articles likely future developments company strategic report provide general power board authorise conflicts research development activities pages nominations committee authorised board inclusion diversity grant regularly review potential actual conflict provision information consultation employees authorisations recorded company secretary noted board directors counted quorum carbon emissions authorisation actual potential conflicts following information also incorporated directors report continuing basis directors responsible informing location annual report company secretary new actual potential conflicts interest capitalised financial statements may arise changes circumstances may notes affect authorisation previously given even provided publication unaudited financial information group financial review authorisation director absolved statutory duty details longterm incentive schemes remuneration report promote success company actual conflict arises waiver emoluments director applicable postauthorisation board may choose exclude director receipt relevant information participation waiver future emoluments director applicable debate suspend director board last resort non preemptive issues equity cash applicable require director resign non preemptive issues equity cash applicable unlisted major subsidiary undertaking nominations committee reviewed register potential parent company participation placing applicable conflict authorisations january reported board listed subsidiary conflicts appropriately authorised provision services controlling applicable process authorisation continues operate effectively except shareholder described note financial statements related party transactions end financial year director shareholder waiver dividends financial statements notes person closely associated material interest contract significance group company shareholder waiver future dividends financial statements notes articles also prohibit director voting resolution agreements controlling shareholders applicable concerning appointment terms termination appointment directors report drawn presented accordance reliance upon english company law independent advice liabilities directors connection report shall company agreed procedure directors take subject limitations restrictions provided law independent legal andor financial advice companys expense deem necessary directors report approved board directors march signed behalf indemnification directors qualifying third party indemnity provisions defined companies act force benefit directors philip hampton former directors held office chairman signing annual report march ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn remuneration section chairmans annual statement annual report remuneration remuneration policy summary gsk annual report remuneration report chairmans annual statement dear shareholder three years december threshold target behalf remuneration committee committee tsr measure met maximum rd target pleased present remuneration report achieved reviewing adjusted free cash flow performance annual report remuneration annual statement target adjusted upwards reflect outperformance subject advisory vote agm may attributable timing impact loss advair exclusivity resulted overall vesting level details performance vesting outcome psp dabp matching awards provided overall year good progress gsk saw group sales growth cer driven growth across three remuneration policy implementation businesses strong commercial execution new product launches especially shingrix continued cost discipline better cash ceo remuneration generation also achieved earnings growth adjusted eps time ms walmsleys appointment role ceo significant year group strategically committee set remuneration level reflect fact launch new rd strategy focused immunology genetics first ceo role significantly previous incumbent new technologies together series transactions support market time annual report gsks strategy reshape groups portfolio remuneration report highlighted intention keep ms walmsleys package review remuneration outcomes coming years subject development performance role awards relation made accordance ms walmsley position nearly two years approved remuneration policy key decisions made boards view already delivered number significant committee follows achievements including developing deploying innovation performance trust strategic priorities driving culture change bonus outcomes executive directors determined across company strong financial delivery reference performance agreed financial measure well committees assessment individual levels looking ahead ms walmsley also set clear capital allocation performance conjunction assessment individual framework group part delivered consumer performance resulted bonus payments made healthcare business buyout novartis announced target committee adjusted adjusted group pbit proposal creation consumer healthcare joint venture target upwards reflect outperformance measure pfizer towards end year remains subject attributable timing impact loss advair exclusivity shareholder approval created clear pathway group committee believe bonus outcomes appropriately reflect deliver substantial value shareholders longer term overall underlying performance details given view board ms walmsley bonus outcomes year provided established successfully already demonstrating track vesting performance share plan psp awards record delivering strongly priorities business matching awards deferred annual bonus plan believe right time start reflecting development dabp based preagreed measures rd new performance remuneration consistent product performance adjusted free cash flow relative tsr review remuneration employees develop equal weighting performance measured progress roles glance total remuneration following shows breakdown total remuneration paid executive directors office december respect emma walmsley simon dingemans dr hal barron ceo cfo chief scientific officer president rd usm usm usm usm usm fixed pay salary benefits pension r hal barron appointed board performance pay annual bonus ltis earned respect january three year performance period end gsk annual report strategic report governance remuneration financial statements investor information following consultation major shareholders august announced appointment iain mackay committee considered address taken role chief financial officer april joined feedback shareholders account deciding implement cet board january iains remuneration package twostep salary increase ms walmsleys follows fully line remuneration policy approved shareholders base salary committee increase january results base felt appropriate reflect experience qualifications salary currently total compensation also validated within increase january subject continued competitive range seen among uk crossindustry comparator development sustained performance role would group result base salary looking ahead phased approach enable committee monitor sustained performance well market developments committee reviewed current practices revised incentive measures uk corporate governance code code published following careful consideration committee determined financial reporting council frc report changes lti measures made complied code psp awards granted subject line commitment made report performance conditions previous grants rd new product disclosed ceo pay ratio year ahead reporting performance adjusted free cash flow relative tsr requirement line methodology prescribed details implementation set secondary legislation published uk government however taking opportunity respond feedback given remuneration policy expire agm shareholders reduce threshold level vesting year committee undertaking review gsks tsr element psp remuneration arrangements taking consideration maximum accordingly performance measures future governance developments period since current awards vest maximum opportunity policy approved threshold performance plan continue regular dialogue shareholders new appointments board hold annual meeting gsks largest investors later year listen views feedback may simon dingemans announced would retire company voluntary leaver therefore receive agm severance payment leaves company agm finally would like thank shareholders ongoing input may engagement welcome shareholders feedback report simon continue receive base salary leaves look forward receiving support annual report gsk also eligible receive bonus based remuneration agm may combination business individual performance receive bonus portion urs rohner employed psp dabp matching awards remuneration committee chairman already vested prior departure lapse leaves march eligible receive lti award pay performance annual bonus financial performance lti outcome performance period ended december overall vesting maximum target relative rd new target tsr products rd rd threshold target adjusted group pbit maximum performance target lapsed performance achieved vested adjusted free cash flow rd gsk annual report annual report remuneration total remuneration audited vesting annual total salary benefits pension lti bonus remuneration awards fixed pay b pay performance total remuneration executive director set table dr hal barron emma walmsley simon dingemans chief scientific officer sir patrick vallance ceo cfo president rd former president rd janmar fixed pay salary see benefits see pension see total fixed pay b pay performance annual bonus see pages vesting lti awards dabp matching awards see psp see total pay performance ab total remuneration notes simon dingemans vested psp shares subject twoyear holding period ms walmsleys psp shares subject holding requirement grant awarded appointed executive director dr hal barron appointed board effect january sir patrick vallance resigned company board march salary reflects basic salary earned time worked january march plus payment lieu accrued holiday taken accordance gsks standard uk holiday pay policy details mandatory bonus deferrals deferred annual bonus plan dabp set matching awards longer granted dabp details respect vesting dabp matching awards performance share plan psp awards threeyear period december provided committee may specific circumstances line stated principles apply clawbackmalus determines appropriate following due consideration committee recovery sums paid clawback reduction outstanding awards vesting levels malus applied respect executive directors past directors payments past directors set psp dabp awards sir andrew witty dr moncef slaoui granted vested awards vested following oneyear anniversaries respective leaving dates accordance terms executive recoupment policy awards vested accordance standard vesting policy psp awards subject additional twoyear holding period february february respectively disclosed annual report left gsk mutual agreement neither received termination payments outstanding incentive awards treated accordance remuneration policy approved shareholders granted gsk annual report strategic report governance remuneration financial statements investor information total remuneration audited continued following sections provide details element total remuneration including committee implemented approved remuneration policy comparator groups pay tsr committee used two pay comparator groups roles considering executive pay primary group used executive director follows uk crossindustry comparator group global pharmaceutical comparator group emma walmsley astrazeneca reckitt benckiser dr hal barron france us simon dingemans bhp group rio tinto sanofi abbvie bp royal dutch shell switzerland amgen british american tobacco unilever novartis bristolmyers squibb diageo vodafone roche holdings eli lilly johnson johnson uk merck co astrazeneca pfizer bbvie amgen included remuneration benchmarking included tsr comparator group reviewing ceos remuneration committee also references pay group leading european companies whose selection based size complexity fixed pay audited salary benefits benefits table sets base salaries executive directors emma walmsley last two years disclosed last year salary increases employee benefits made aligned provided wider travel workforce details salary levels provided benefits base salary total change simon dingemans emma walmsley employee benefits simon dingemans travel dr hal barron na benefits sir patrick vallance total walmsleys salary ceo designate january march sir patrick vallance salary increased april employee benefits became ceo travel benefits benefits table opposite shows breakdown grossed cash value total benefits received executive directors dr hal barron included employee benefits employee benefits employee share plans healthcare travel home security car allowance personal financial advice life benefits assurancedeath service cover total travel expenses include travel costs executive director appropriate spousepartner associated r hal barron based san francisco travels business purposes treated tax perspective benefit therefore included table accompanying executive director gsk business grossed cash value dr barrons travel deemed taxable benefits director benefits includes grossed value uk accommodation benefits expenses incurred ordinary course business deemed taxable benefits individual gsk annual report annual report remuneration continued fixed pay audited continued pensions executive director member since pension arrangements emma walmsley base salary matching contributions first salary base salary lieu pension salary excess simon dingemans base salary lieu pension dr hal barron member us cash balance supplemental cash balance pension plans gsk makes annual contributions base salary line us senior executives members gsks corporate executive team dr barron also member k plan open us employees executive supplemental savings plan essp savings scheme open us executives accrue benefits k plan limits completed one years service january dr barron receives combined contribution rate k essp plans core contributions plus match total base salary bonus less bonus deferred dabp sir patrick vallance base salary lieu pension member defined contribution plan emma walmsley eligible receive matching award first salary accordance terms plan emma walmsley receives cash payment lieu pension base salary excess line gsks defined contribution pension plan rates simon dingemans sir patrick vallance received cash payments lieu pension base salary line gsks defined contribution pension plan rates following table shows breakdown pension values set emma walmsley simon dingemans dr hal barron sir patrick vallance janmar pension remuneration values uk defined contribution us defined benefit employer cash contributions total pension remuneration value pension remuneration figures calculated accordance methodology set large mediumsized companies group accounts reports amendment regulations remuneration regulations details regarding pension values dr hal barron set table accrued pension december december pension remuneration dr hal barron pension values value us unfunded total r hal barron joined gsk january pensions figures disclosed dr barron member us style defined benefit plans accordance paragraph eii schedule large mediumsized companies groups accounts reports regulations amended table shows accrued benefit ie annual pension accrued date pension remuneration calculated increase accrued benefit adjusted inflation multiplied reflect fact benefit received number years gsk annual report strategic report governance remuneration financial statements investor information pay performance audited annual bonus individual annual bonus adjusted group pbit objectives performance targets financial measures weightings follows weighting adjusted group pbit performance positioning performance measure executive directors target outcome target adjusted group pbit individual objectives threshold maximum performance targets set target respectively target increased million reduce level performance attributable original timing assumption loss advair exclusivity adjusted group pbit target outcome purposes annual bonus calculation differ adjusted group pbit disclosed elsewhere annual report primarily target outcome numbers calculated applying gsk budget exchange rates actual exchange rates following table shows actual bonuses earned compared bonus opportunity bonus opportunity bonus outcome financial individual total total target maximum performance objectives bonus bonus bonus salary salary base salary salary salary salary emma walmsley simon dingemans dr hal barron table provides detail delivery adjusted group pbit financial performance group turnover billion increase aer cer adjusted operating profit million higher aer basis higher cer adjusted operating margin flat aer basis compared higher cer reflected benefit sales growth across three businesses cer basis favourable mix primarily vaccines consumer healthcare margin also benefited prioritisation rd expenditure comparison impact priority review voucher utilised expensed well continued tight control ongoing costs across three business partly offset continued pricing pressure particularly respiratory increased input costs comparison benefit settlement lost third party supply volume vaccines investments promotional product support particularly new product launches reduction royalty income gsk annual report annual report remuneration continued pay performance audited continued following table summarises performance scorecard individual objectives agreed committee executive director individual objectives emma walmsley continued focus progress longterm innovation significant transactions undertaken support strategy performance trust priorities reshape business strong financial operational performance group successful agreement novartis acquire full ownership turnover billion total operating profit billion consumer healthcare business free cash flow billion divestment horlicks consumer healthcare strong launch execution evidenced shingrix sales nutrition brands unilever million new respiratory products million proposed consumer healthcare joint venture agreed juluca million pfizer new approach rd launched start strengthening new commercial operating model pharmaceuticals pipeline particularly oncology new rd senior leadership implemented support evolving portfolio team established outstanding new hires significant new year pharmaceuticals supply chain strategy implemented pipeline prioritisation new rd portfolio governance resulting savings improved productivity whilst maintaining process across rd commercial compliance significant progress made rd business development successful employee engagement increased visibility agreement acquire tesaro multiyear cet members key internal communication platforms collaboration andme continued successful development cet successful implementation portfoliobrand geographic three internal cet promotions prioritisation pharmaceuticals consumer healthcare new external chief financial officer appointment businesses key leadership appointments place top leaders new role successfully achieved diversity target women senior vice president vice president level dr hal barron new approach rd launched start strengthening good progress made reshaping building capabilities pipeline particularly oncology new rd senior leadership medicinal science technology organisations within rd team established outstanding new hires significant continued strong momentum delivery new approach pipeline prioritisation new rd portfolio governance rd including process across rd commercial ongoing rebuild pharmaceuticals pipeline majority significant progress made business development new medicines development targeting modulation agreement acquire tesaro multiyear collaboration immune system andme major progress made oncology pipeline reflecting organic progress agreement acquire tesaro simon dingemans delivered strong financial leadership group significant contribution successful execution improved cash flow generation free cash flow billion strategy total operating profit billion group turnover successful agreement novartis acquire full ownership billion consumer healthcare business divestment horlicks consumer healthcare nutrition brands unilever proposed consumer healthcare joint venture agreed pfizer malus clawback policy line disclosure guidelines neither committee recoupment committee exercised malus clawback details policy malusclawback please refer executive director remuneration policy summary policies january respect financial year committee details policies recruitment remuneration loss office decided disclose whether recoupment committee termination payments please refer remuneration exercised malus clawback policy report pages annual report disclosure made matter subject available wwwgskcom investors section public reports misconduct fully resolved legally permissible disclose made without unduly prejudicing company therefore shareholders gsk annual report strategic report governance remuneration financial statements investor information pay performance audited continued value earned longterm incentives ltis following tables set performance achieved management targets set companys lti plans also includes update performance outstanding awards line committees agreed principles measure applicable lti awards actual performance targets reviewed adjustments made appropriate ensure vesting outcome reflects genuine underlying business performance details adjustments made provided time vesting awards performance period ended december committee reviewed performance psp awards dabp matching awards granted executive directors targets set committee decided increase adjusted free cash flow afcf target associated vesting scale psp dabp matching awards reduce level outperformance attributable original timing assumption loss advair exclusivity changes targets set rd new product performance measure relative tsr performance measure psp awards dabp matching awards performance achieved three years december vesting levels set table outcome vesting level performance measures relative weighting performance targets outcome maximum award rd new product rd new product sales performance measures aggregate threeyear sales new bn performance products launched threeyear performance period preceding two years rd ie target vesting maximum bn bn bn threshold bn adjusted free line companys agreed principles afcf figures included adjustments bn cash flow number material distorting items including legal settlements exchange rate performance movements special pension contributions rd original revised target target vesting maximum bn bn bn bn bn bn threshold bn bn relative tsr ranked th tsr ranking within comparator group vesting performance maximum st nd rd rd th th threshold median th th sr comparator group astrazeneca bristolmyers squibb eli lilly gsk johnson johnson merck co novartis pfizer roche holdings sanofi vesting schedule based delivering vesting median performance comparator group ten companies median falls two companies total vesting respect awards gsk annual report annual report remuneration continued pay performance audited continued update performance ongoing lti awards committee also reviewed performance psp awards granted executive directors dabp matching awards granted executive directors following charts provide estimate vesting levels taking account performance december actual vesting levels determined based performance full threeyear performance periods indications therefore regarded predictions final vesting levels addition adjustments made target associated vesting scale psp awards dabp matching awards adjustments made afcf targets associated vesting scales awards follows target psp awards dabp matching awards decreased aggregate bn reflect reduction target due forecast impact tesaro acquisition major restructuring programme announced q results ii n increase target reduce level advair outperformance attributable delayed loss exclusivity overall net impact reduction target target psp award similarly adjusted factors applicable psp net overall impact decrease target bn bn reduction primarily driven impact restructuring programme tesaro acquisition adjustment delayed loss exclusivity results increase target changes targets set rd new product performance measure tsr performance measure awards award performance update award performance update ranked rd ranked rd bn threshold bn threshold maximum maximum commercially commercially median bn sensitive median bn sensitive threshold threshold tsr adjusted free rd new tsr adjusted free rd new rd cash flow product rd cash flow product rd rd rd rd estimated vesting level threshold performance award vest respect rd new product afcf measures tsr element tsr comparator group remains unchanged shown respect awards gsk annual report strategic report governance remuneration financial statements investor information pay performance audited continued historical vesting gsks ltis year grant performance measures total vesting level lapsed r r r r b r b r b performance measures key r rd new product adjusted free cash flow tsr b business diversification lapsed lti awards levels participation dabp respect bonus deferrals shown table table also shows psp award details dabp awards psp awards total bonus number face value award level number face value deferred shares award base salary shares award emma walmsley shares shares simon dingemans shares shares dr hal barron na ads sir patrick vallance shares face values dabp awards calculated based share price closing price february nilcost options performance conditions attached dabp awards reflect mandatory deferrals respect annual bonus earned face values psp awards calculated based share price ads price closing prices february conditional shares based three equally weighted measures rd new product performance ii adjusted free cash flow iii relative tsr first two performance measures vest threshold third performance measure threshold performance period psp awards january december dr hal barron appointed board january sir patrick vallances dabp award vest normal three years date granted allemployee share plans dilution limits uk executive directors may participate hmrc approved awards made plans incorporate dilution allemployee share plans ie share save share reward plans limits consistent guidelines published investment association limits rolling tenyear period participants share save plan may save month plans rolling tenyear period executive share three years end period option buy plans estimated dilution existing awards made last gsk shares discount share price start ten years december follows savings contract participants share reward plan contribute month purchase gsk shares company gsk employee share plans matches monthly saving share save share reward emma walmsley simon dingemans executive share plans actual limit gsk annual report annual report remuneration continued ceo pay comparison ceo total remuneration positioning light also provided supplemental ratios long term incentive compensation excluded believe provides additional view long term incentive forms uk substantial ceos total remuneration crossindustry highly variable dependent business performance group ceo single figure remuneration excluding long term incentive global compensation pharmaceutical group p lower p p upper financial year methodology quartile median quartile european option crossindustry group total single figure remuneration less longterm incentive plans historic ceo remuneration lower quartile median upper emma walmsleys emma walmsley sir andrew witty median quartile current position remuneration includes salary expected value incentives based committees agreed benchmarking methodology single figure ceo pay ratios remuneration annual p lower p p upper bonus financial year methodology quartile median quartile award option maximum pay ratios calculated using actual earnings vesting ceo uk employees ceo total single figure remuneration lti awards given report maximum total remuneration uk fulltime equivalent employees ms walmsleys single figure remuneration includes pay period january company december calculated line march became ceo single figure methodology reflects actual earnings bonuses include amounts paid operational efficiency bonus received excluding business expense used place years overall maximum bonus receivable still subject limit base salary produce percentile calculation option business expenses excluded reimbursed sir andrew received prorata payment lieu variable bonus opportunity accordance remuneration policy employees substantial value significantly impact psp dabp awards sir andrew granted vest april ratios accordance terms executive financial recoupment policy gsk chosen option robust performance graph statistically accurate way company calculate three ratios options available regulations following graph sets performance company set table base salary total pay relative ftse index pharmaceutical benefits percentiles performance comparator group tenyear period december indices selected comparison th percentile median th percentile purposes reflect primary index gsk p p p constituent industry operates salary total pay benefits committee believes median pay ratio consistent companys pay reward progression policies base salaries employees including executive directors set reference range factors including market practice experience performance role supplementaladditional ratios gsks ceo pay ratio likely vary potentially significantly time since driven largely ceo variable pay outcomes line reward principles ceo larger portion pay based performance individuals p p p means depending gsks performance ratio could increase decrease significantly committee believes gsk total return gsk pharma peers ftse senior executives significant proportion total return index total return index pay directly linked performance index comprises astrazeneca bristolmyers squibb eli lilly johnson johnson merck co novartis pfizer roche holdings sanofi gsk annual report strategic report governance remuneration financial statements investor information additional remuneration disclosures percentage change remuneration ceo shareholder votes remuneration matters table shows recent shareholder votes respect emma walmsley uk employees remuneration report remuneration policy change change votes salary total votes total votes total votes withheld agm cast billion million benefits remuneration report annual bonus agm wider uk employee population salary increase includes remuneration policy annual salary review well additional changes external appointments executive directors year eg promotion uk employee benefits unchanged previous year changes benefit board encourages executive directors hold one listed policies levels reflect changes level company external directorship equivalent benefits individual may received result change become established roles broaden experience role eg promotion uk population considered development may retain fees relevant comparison closely reflects economic appointments considered nominations committee environment encountered ceo board line companys policy external appointments relative importance spend pay ascertain nature scope appointments ensure would cause actual potential conflict interest table shows total employee pay groups dividends paid individual executive director continues meet existing shareholders commitments gsk companys policy remuneration earned appointments may kept individual board recognises importance ensuring dr hal barron total employee pay remains connected life sciences community therefore dividends approved appointment boards grail inc private figures table reflect payments made company juno therapeutics inc nasdaq listed company year impact movements exchange prior appointment grail dr barron director juno rates set pages however acquisition celgene corporation march dividends declared respect million million increase company position period fees earned juno therapeutics inc nonexecutive january march total employee pay based employees average nasdaq listed director number people employed grail inc nonexecutive august private company director service contracts table sets relevant dates executive directors service contracts available review companys registered office office hours gskcom executive directors service contract contains month notice period set remuneration policy date contract effective date expiry date emma walmsley simon dingemans dr hal barron iain mackay na gsk annual report annual report remuneration continued implementation remuneration policy salary long term incentive plans committee determined following salary increases taking deferred annual bonus plan dabp awards account average increase wider workforce table provides details mandatory deferral dabp annual bonus payments associated change awards granted shares awarded performance wider workforce conditions must held three years regardless emma walmsley continued employment simon dingemans total bonus dabp award iain mackay na deferred shares number shares number ads dr hal barron emma walmsley simon dingemans based average increase budget employees level cet uk referenced chairmans annual statement following shareholder consultation dr hal barron committee decided adjust ms walmsleys pay reflect development performance role performance share plan psp awards table provides details awards granted psp benefits psp award psp award significant changes provision benefits proposed salary number shares number ads full details policy relation benefits please emma walmsley refer details remuneration policy report pages iain mackay annual report available wwwgskcom dr hal barron investors section performance measures pension metrics psp awards remain unchanged awards continue based three equally weighted table provides overview pension arrangements measures ongoing executive director rd new product performance pension contribution adjusted free cash flow emma walmsley base salary matching contributions iain mackay first salary accordance terms relative tsr plan open employees base salary prior years targets rd new products commercially lieu pension salary excess sensitive time grant however committee intends dr hal barron base salary disclose targets full following end performance period addition january combined contribution rate k essp plans core addition committee continue provide shareholders contribution plus match total base salary interim performance updates element course bonus less bonus deferred dabp performance period annual bonus tsr continue measured global pharmaceutical peers achieving threshold performance award significant changes operation annual bonus plan continue vest respect rd new product performance accordance shareholder approved remuneration afcf performance measures relative tsr vesting policy proposed schedule awards revised follows target maximum vesting schedule vesting schedule emma walmsley ranking position awards awards iain mackay st nd rd dr hal barron th th financial measure adjusted group pbit represents median threshold vesting weighting annual bonus plan individual th performance measure represents remaining weighting inevitably targets linked directly financial strategic plan tsr comparator group remains unchanged shown commercially sensitive committee consider respect awards appropriate disclose annual bonus targets year adjusted free cash flow targets awards follows may result competitive harm however details performance targets disclosed retrospective basis target vesting annual report maximum bn bn bn threshold bn gsk annual report strategic report governance remuneration financial statements investor information implementation remuneration policy continued shareholdings versus share ownership requirement sor addition simon dingemans required align interests executive directors maintain shareholding equal share ownership requirement shareholders required build maintain significant least months leaving company holdings shares gsk time executive directors required remuneration arrangements cfo designate continue satisfy share ownership requirements iain mackay joined gsk chief financial officer designate minimum months leaving gsk january executive director summary share ownership vs sor multiples base salary remuneration set notes emma walmsley x x base salary comparator group pay cfo position uk crossindustry simon dingemans x x comparator group annual bonus ontarget bonus would dr hal barron x maximum outgoing cfo x x x x x award ltis assumes expected value sor december shareholding award performance shares dr hal barron appointed board january companys performance share point shareholding gsk ads plan x multiple base salary outgoing cfo payments loss office audited share ownership line gsks requirement base salary remuneration policy loss office payments made sor termination arrangements cfo pension base pension line gsks announced simon dingemans leave board salary remuneration policy matching may simon dingemans voluntary leaver contributions receive severance payment leaves company salary bonus outstanding incentive awards treated benefits benefits line gsks accordance shareholder approved remuneration policy remuneration policy full disclosure payments made upon cessation included buyout arrangements annual report remuneration remuneration element summary treatment annual bonus receive bonus psp dabp granted psp awards bonus deferred dabp outstanding psp awards vested prior simon dingemans dabp matching awards departure lapse leaves gsk dabp deferred awards bonuses deferred respect bonus awards prior years vest normal vesting dates payments past directors audited set annual report sir andrew witty dr moncef slaoui left board march mutual agreement accordance remuneration policy approved shareholders psp awards dabp awards vested following oneyear anniversary termination dates terms executive financial recoupment policy dr moncef slaoui sir andrew witty number vested ads price equating number vested share price equating ads awarded july shares awarded april psp psp dabp dabp benefits grossed cost post employment benefits grossed cost post employment financial planning provided following leaving company financial planning home security following leaving company gsk annual report annual report remuneration continued remuneration governance role committee company secretary secretary committee attends meetings attendees committee include role committee set companys remuneration committee attendees policy gsk able recruit retain motivate executives regular attends attendee attendee required remuneration policy regularly reviewed ensure ceo consistent companys scale scope operations cfo supports business strategy growth plans helps drive head human resources creation shareholder value head reward terms reference committee adviser pwc committees full terms reference available judy lewent vindi banga members audit risk companys website terms reference reviewed least remuneration committees provide input audit risk annually last revised january reflect best committees review groups performance oversight practice particularly respect new uk corporate risk factors relevant remuneration decisions governance code adviser committee governance company undertook full commercial tender process board considers members committee appointed pricewaterhousecoopers llp pwc independent nonexecutive directors accordance independent adviser committee effect september uk corporate governance code pwc replaced willis towers watson llp wtw served independent adviser first part pwc membership wtw members remuneration consultants group voluntarily operate code conduct relation members committee together appointment executive remuneration consulting uk code conduct dates set found wwwremunerationconsultantsgroupcom committee members committee member since pwc resigned groups statutory auditor gsks annual report signed march provided urs rohner january consulting assurance services time chair chair since may committees independent advisers wtw provided additional vindi banga january market data committee also provided hr consulting dr vivienne cox january services company prior pwcs appointment line protocols agreed set committee chair pwc judy lewent january wtw provided advice committee satisfied committee meetings usually include closed session advice objective independent members committee present individuals may respective tenures pwc wtw also invited attend committee meetings year provided independent commentary matters consideration executives committee attendees involved committee updates market practice legislative decisions present discussions regarding requirements pwcs wtws fees advice period remuneration charged time materials basis respectively committee satisfied details committee members skills experience compromise either firms independence given biographies board pages see committee member attendance levels committee evaluation committees annual evaluation facilitated company secretary interviewed committee members behalf committee chair concluded committee continued operate effectively terms enhancements committees work agreed committee examine philosophy underpinning remuneration policy framework reviewing policy approval agm gsk annual report strategic report governance remuneration financial statements investor information remuneration governance continued committee areas committee focus items discussed remuneration policy remuneration impact major group restructuring committee sets broad structure remuneration policy engagement shareholders determines remuneration executive directors employee consultation setting policy pay chairman corporate officers board approval salary review remuneration environment including wider employee trends committee periodically reviews considers remuneration executive director cet benchmarking competitiveness environment executive directors cet approving annual gsk comparator groups adjustments necessary executive director cet salary recommendations increases setting remuneration iain mackay annual bonus ceo executive director cet bonus recommendations committee responsible setting specific performance bonus objectives measures annual bonus lti plans lti performance outcomes vesting lti awards cet committee responsible approving lti plan rule changes grants assessments performance vesting lti awards lti grants cet executive directors cet governance areas focus committee evaluation process committee adheres robust remuneration governance remuneration report framework ensuring alignment internal actions remuneration considerations committee programme external reportingcompliance requirements agm remuneration report feedback external remuneration environment performance target disclosure incentive plans chairmans fees remuneration report disclosures including ceo pay ratio remuneration committee external adviser tender process gender pay gap reporting recruitment policy briefing gsk annual report annual report remuneration continued nonexecutive directors fees chairman nonexecutive directors nonexecutive directors fees applied set table company aims provide chairman nonexecutive per annum directors fees competitive paid standard annual fee companies equivalent size complexity subject limits contained gsks articles association supplemental fees chair audit risk committee chairmans fees senior independent director scientificmedical experts chairman philip hampton paid fee per annum chairs remuneration corporate elected take gsk shares chairmans responsibility science committees fees reviewed year changed nonexecutive director undertaking intercontinental per meeting travel meetings nonexecutive directors fees nonexecutive director fees reviewed year following last increase january decided make change time minimum fees continue delivered shares ads deferred nonexecutive director steps board audited table sets value fees benefits received nonexecutive directors form cash shares ads details nonexecutive directors share allocation plan set nonexecutive directors fees paid currency sterling converted using average exchange rate reviewed time time benefits comprise grossed cash value travel subsistence costs incurred normal course business relation attendance board committee meetings overseasbased directors includes travel meetings uk nonexecutive directors fixed fees fixed fees emoluments audited cash sharesads benefits total pay cash sharesads benefits total pay vindi banga dr vivienne cox lynn elsenhans dr laurie glimcher dr jesse goodman philip hampton judy lewent urs rohner former directors professor sir roy anderson sir deryck maughan dr daniel podolsky hans wijers lynn elsenhans elected receive nonexecutive director fees usd professor sir roy anderson retired board may dr daniel podolsky sir deryck maughan retired board may hans wijers retired board may gsk annual report strategic report governance remuneration financial statements investor information directors interests shares audited interests directors company office persons closely associated pca shown tables total share plan interests december date retirement total directors interests sharesads options december aunvested aunvested unvested unvested march date january subject subject subject subject vested exercised leaving performance performance performance performance exercised year executive directors shares emma walmsleyabcdef simon dingemansabcdef sir patrick vallanceabcdf ads dr hal barronace share allocation plan nonexecutive directors total directors interests number shares ads december january dividends dividends reinvested reinvested march date date year december allocated december leaving appointment end paid year elected nonexecutive directors sharesg professor sir roy andersonh vindi banga dr vivienne cox philip hampton urs rohner adsg lynn elsenhans dr laurie glimcher dr jesse goodman judy lewent u nvested options subject performance emma walmsley represent bonus deferrals share save options u nvested shares subject performance simon dingemans represent shares awarded end threeyear performance period psp grant together subsequent reinvested dividends shares subject twoyear holding period unvested options subject performance mr dingemans represent bonus deferrals share save options unvested options subject performance sir patrick vallance represent bonus deferrals b otal directors interests includes shares purchased glaxosmithkline share reward plan emma walmsley simon dingemans awarded shares plan total number shares held within plan follows share reward plan shares march december january emma walmsley simon dingemans sir patrick vallance dr hal barron us employee eligible participate share reward plan open uk employees gsk annual report annual report remuneration continued directors interests shares audited continued c otal directors interests includes options shares ads resulting deferral bonus subsequent reinvestment dividends dabp totals shown table include bonus deferrals exclude unvested matching awards subject ongoing performance criteria amounts represent gross share ads balances prior sale shares ads satisfy tax liabilities december deferred annual bonus plan bonus deferrals march date retirement january emma walmsley shares simon dingemans shares dr hal barron ads sir patrick vallance shares otal directors interests march includes shares ads vested due performance met elements dabp psp awards less sold satisfy tax liabilities vested amounts see pages details e share save plan emma walmsley simon dingemans unvested options subject performance include holdings respectively share save plan ms walmsley mr dingemans participate terms employees ms walmsley granted options plan november f following table sets details options nilcost options dabp exercised executive directors number shares date market price gain exercise type award date grant option exercise grant price exercise emma walmsley dabp deferral dabp matching simon dingemans dabp deferral dabp matching sir patrick vallance dabp deferral dabp matching respect nilcost options dabp bonus deferred director recorded remuneration annual bonus year relates gain recorded exercise nilcost option comprises remuneration total amounts received reinvested dividends prior vesting gains losses resulting movements share price dates grant exercise initial bonus amount deferred dates dividend reinvestment exercise reinvested dividends matching element dabp remuneration executive director recorded year performance period ends represents number vested shares multiplied price vesting gain recorded exercise nilcost option comprises total remuneration gain loss resulting movement share price vesting exercise gsk annual report strategic report governance remuneration financial statements investor information directors interests shares audited continued emma walmsley gain recorded following exercise nilcost options relating deferral bonus earned respect comprises remuneration recorded annual bonus net gain relating reinvestment dividends prior vesting movements share price grant dividend reinvestment dates exercise date gain recorded following exercise nilcost options relating dabp matching award comprises remuneration recorded relation dabp see table investment gain relating movement share price vesting exercise dates simon dingemans gain recorded following exercise nilcost options relating deferral bonus earned respect comprises remuneration recorded annual bonus net gain relating reinvestment dividends prior vesting movements share price grant dividend reinvestment dates exercise date gain recorded following exercise nilcost options relating dabp matching award comprises remuneration recorded relation dabp see investment gain relating movement share price vesting exercise dates sir patrick vallance gain recorded following exercise nilcost options relating deferral bonus earned respect comprises remuneration recorded annual bonus net gain relating reinvestment dividends prior vesting movements share price grant dividend reinvestment dates exercise date gain recorded following exercise nilcost options relating dabp matching award comprises remuneration recorded relation dabp see investment gain relating movement share price vesting exercise dates g f nonexecutive directors total interests include shares ads received part fees nonexecutive directors share allocation plan note dividends received shares ads plan january converted shares ads february h p rofessor sir roy anderson retired board may deferred annual bonus plan matching awards following tables provide details executive director office respect dabp matching awards market price grant vesting represent closing share prices business day prior dates performance period emma walmsley shares market price grant unvested december dividends reinvested vested lapsed unvested december dividends reinvested vested lapsed unvested march vested shares number shares market price vesting gain remuneration remuneration gsk annual report annual report remuneration continued directors interests shares audited continued deferred annual bonus plan matching awards continued performance period simon dingemans shares market price grant unvested december dividends reinvested vested lapsed unvested december dividends reinvested vested lapsed unvested march vested shares number shares market price vesting gain remuneration remuneration performance period sir patrick vallance shares market price grant unvested december dividends reinvested vested lapsed unvested december dividends reinvested vested lapsed unvested march vested shares number shares market price vesting gain remuneration remuneration gsk annual report strategic report governance remuneration financial statements investor information directors interests shares audited continued performance share plan awards following tables provide details executive director office respect psp awards market price grant vesting represent closing share prices dates performance period emma walmsley shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december dividends reinvested vested lapsed unvested march granted face value grant unvested march vested shares number shares market price vesting total gain remuneration remuneration performance period simon dingemans shares market price grant unvested december granted face value grant dividends reinvested vested lapsed unvested december granted face value grant dividends reinvested vested lapsed unvested march vested shares number shares market price vesting gain remuneration remuneration gsk annual report annual report remuneration continued directors interests shares audited continued performance share plan awards continued performance period sir patrick vallance shares market price grant unvested december granted dividends reinvested vested lapsed unvested december vested shares number shares market price vesting gain remuneration iain mackay appointed board january following table provides details psp awards granted march performance period iain mackay shares market price grant number shares face value grant unvested march performance period dr hal barron ads market price grant unvested december granted face value grant dividends reinvested unvested december dividends reinvested unvested march granted face value grant unvested march gsk annual report strategic report governance remuneration financial statements investor information directors senior management information provided compensation interests directors senior management group group purpose group defined nonexecutive executive directors members cet company secretary financial year following table sets aggregate remuneration group periods served capacity remuneration total compensation paid aggregate increase accrued pension benefits net inflation aggregate payments defined contribution schemes members group awarded shares ads companys various executive share plans set table align interests senior management shareholders directors senior management required build maintain significant holdings shares gsk time cet members required hold shares equivalent multiple two times base salary required continue satisfy share ownership requirements minimum months leaving gsk awards dividend reinvestment awards awarded shares ads shares ads deferred annual bonus plan performance share plan deferred investment awardsa b share value planb march group pcas following interests shares ads company interests awarded various executive share plans described note financial statements employee share schemes interests march shares ads owned unexercised options deferred annual bonus plan performance share plan deferred investment awardsa b share value planb notional shares ads b executive directors eligible receive deferred investment awards participate share value plan gsk annual report remuneration policy summary executive director remuneration policy following summary policy salary provide core reward role set level appropriate secure retain high calibre individuals needed deliver groups strategic priorities operation opportunity performance measures individuals role experience performance formal maximum limit ordinarily salary overall performance independently sourced data relevant comparator increases broadly line average increases individual key consideration groups considered determining salary levels wider gsk workforce determining salary increases however increases may higher reflect change scope individuals role responsibilities experience salary adjustments may also reflect wider market conditions geography individual operates details current salary levels set annual report remuneration pages benefits levels set recruit retain high calibre individuals execute business strategy operation opportunity performance measures executive directors generally eligible receive formal maximum limit benefits costs none benefits line policy employees fluctuate depending changes provider cost may vary location include travel individual circumstances allowances including spousepartner travel healthcare details current benefits costs set life assurancedeath service provided annual report remuneration part individuals pension arrangements personal financial advice contractual postretirement benefits pension pension arrangements provide competitive level retirement income operation opportunity performance measures pension arrangements structured accordance policy current executive directors new external none plans operated country recruits individual likely retire individual uk salary contribution defined chooses become member pension contribution plan matched plan cash lieu relevant pension contribution contributions subject relevant cap paid instead line implementation principles members plan new executive directors uk entitled salary cash payment lieu pension either join defined contribution pension plan contribution receive cash payment lieu pension us e ligible benefits us senior contribution individual member executives gsk legacy defined benefit plan defined c ash balance pension plan supplemental contribution plan alternative pension plan cash balance pension plan including executive arrangement subsequently appointed pension credit provide maximum contribution board may remain member base salary across pension plans plan g sk k plan formerly us retirement savings plan executive supplemental savings plan core contributions salary bonus matched contributions salary bonus annual incentivise recognise execution business strategy annual basis rewards achievement bonus stretching annual financial strategic business targets delivery personal objectives operation opportunity performance measures financial operational business targets maximum bonus opportunity executive directors based combination set start year committee salary threshold performance bonus financial targets individual bonus levels determined committee payout nil strategic performance based performance targets objectives majority target performance bonus payout bonus assessed individual objectives set start maximum opportunity financial measures year committee performance weighting different objectives assessed committee measures determined executive directors required defer year according bonus earned shares ads business priorities appropriate three years deferred shares vest end three years gsk annual report strategic report governance remuneration financial statements investor information executive director remuneration policy continued lti awards incentivise recognise delivery longer term business priorities financial growth increases shareholder value compared pharmaceutical companies provide alignment shareholder interests retention element encourage longterm shareholding discourage excessive risk taking psp operation opportunity performance measures conditional awards made annually vesting normal maximum award limits may granted based combination dependent achievement performance psp individual one year set financial share price related conditions three years subject table strategic performance additional twoyear holding period conditions aligned salary companys strategic committee may adjust formulaic vesting ceo plan awards outcome either ensure cfo vest threshold overall outcome reflects underlying business executive directors performance performance vesting period dabp current operation bonus payments onwards executive directors required defer bonus earned shares three years dabp legacy pre operation opportunity performance measures bonus payments executive directors deferred shares matched maximum outstanding matching required defer bonus earned shares subject achievement performance awards subject three years could also voluntarily defer conditions three years matching awards measures awards additional bonus earned conditional shares nilcost options eligible made psp dividend equivalents given year share ownership requirements sor align interests executive directors shareholders executive directors required continue satisfy requirements required build maintain significant holdings shares minimum months following retirement gsk gsk time sor requirement ceo salary sor requirement executive directors salary clawback malus event triggering event eg significant misconduct way respect financial year remuneration committee violation regulation law significant gsk policy code disclose whether recoupment committee exercised conduct company ability claw back three clawback malus disclosure made matter years annual deferred bonuses well vested unvested subject public reports misconduct fully resolved ltis addition participant new psp dabp legally permissible disclose made shareholders approved agm subject investigation without unduly prejudicing company therefore shareholders vesting awards may delayed outcome additionally continuity responsibility investigation initiation adverse event emergence problem adverse separate recoupment committee established investigate event taken account assessing annual bonus awards relevant claims misconduct recoupment committee exercises lti vesting levels year problem identified future authority wider employee base comprises senior executives periods remuneration committee recoupment committee may relevant oversight appropriate experience including senior make appropriate adjustments individual annual bonuses well vice president global ethics compliance senior vice grant vesting levels lti awards reflect president general counsel gsk annual report remuneration policy summary continued scenarios future total remuneration charts opposite provide illustrations future total remuneration executive directors respect emma walmsley ceo remuneration opportunity granted policy range potential outcomes provided executive director underlying assumptions set scenarios base salary used benefits pension figures used ceo cfo chief scientific officer president rd ie based actual amounts received respect ongoing policy cfo designate role benefits value role based value benefits cfo pension arrangements apply fixed expected maximum amounts shown value psp awards based relevant multiples include amounts respect dividends reinvested factor changes simon dingemans cfo share price vesting period fixed none pay performance annual bonus psp would payable expected annual bonus assumed target performance achieved psp awards threshold levels vesting assumed fixed expected maximum maximum assumed annual bonus would payable iain mackay cfo designate maximum level awards psp would vest full fixed expected maximum dr hal barron chief scientific officer president rd fixed expected maximum fixed pay annual bonus psp cfo leave gsk may eligible bonus psp award figures represent actual remuneration january may gsk annual report strategic report governance remuneration financial statements investor information nonexecutive director remuneration policy companys remuneration policy nonexecutive directors set approved may gsks annual general meeting chairmans provide inclusive flat rate fee competitive paid companies equivalent size complexity subject fees limits contained gsks articles association operation opportunity performance measures committee responsible evaluating making formal maximum however fees reviewed none recommendations board fees payable annually set reference review chairmans chairman chairman participate discussions performance independently sourced market data respect fees details current fees set annual report fees paid combination cash andor gsk remuneration shares ads via nonexecutive directors share allocation plan basic fees operation opportunity performance measures chairman ceo responsible evaluating chairman fees reviewed annually none making recommendations board fees payable set reference independently sourced data companys nonexecutive directors details current fees set annual report minimum delivered form gsk shares remuneration ads using nonexecutive directors share allocation plan delivers shares ads nonexecutive director following retirement board supplemental compensate nonexecutive directors chairman taking additional board responsibilities undertaking fees intercontinental travel operation opportunity performance measures additional fees committee chairmen senior details supplemental fees set none independent nonexecutive director science annual report remuneration medical experts intercontinental travel benefits facilitate execution responsibilities duties required role operation opportunity performance measures travel subsistence costs nonexecutive directors formal maximum limit benefit costs none incurred normal course business relation fluctuate depending changes provider costs meetings board committee matters individual circumstances gskhosted events overseasbased nonexecutive details current benefits costs set directors includes travel meetings uk annual report remuneration event necessary business purposes whilst normal practice nonexecutive directors may accompanied spouse partner meetings events costs associated met company instances deemed taxable therefore treated benefits nonexecutive director gsk annual report remuneration policy summary continued operation scope remuneration policy remuneration policy policy set pages ii policy came effect provided terms annual report intended policy gsks payment consistent shareholderapproved executive nonexecutive directors operate period remuneration policy force time agreed three years date approval companys annual iii time relevant individual director general meeting may company opinion committee payment committee wrote policy principally relation consideration individual becoming director remuneration arrangements executive directors whilst company purposes payments includes committee taking account possible recruitment replacement satisfying awards variable remuneration relation additional executive director operation policy award shares ads terms payment agreed committee intends policy operate period set time award granted entirety however may due consideration seek performance share plan deferred annual bonus plan awards change policy period believes subject terms relevant plan rules appropriate longterm success company award granted committee may adjust amend consultation shareholders sought shareholder awards accordance provisions plan rules approval general meeting includes making adjustments reflect oneoff corporate committee reserves right make remuneration events change companys capital structure payments andor payments loss office including exercising committee may also make minor amendments policy discretions available connection payments regulatory exchange control tax administrative purposes notwithstanding line policy take account change legislation without obtaining terms payment agreed shareholder approval amendments agm may date companys first shareholderapproved directors remuneration policy came statement consideration shareholder views effect committee engages regular dialogue shareholders holds annual meetings gsks largest investors discuss take feedback remuneration policy governance matters basis preparation annual report remuneration prepared annual report remuneration approved accordance companies act large board directors signed behalf mediumsized companies groups accounts reports amendment regulations regulations accordance regulations following parts annual report urs rohner remuneration subject audit total remuneration figures remuneration committee chairman executive directors including details element remuneration salary benefits pension annual bonus longterm march incentive awards nonexecutive directors fees emoluments received year directors interests shares including interests gsk share plans payments past directors payments loss office share ownership requirements holdings opinion thereon expressed remaining sections annual report remuneration subject audit pages referred within audited sections ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn financial statements section directors statement responsibilities independent auditors report financial statements notes financial statements financial statements glaxosmithkline plc prepared uk gaap gsk annual report directors statement responsibilities directors responsible preparing annual report financial statements year ended december remuneration report group parent company financial included annual report published printed form statements accordance applicable law regulations made available website directors responsible maintenance integrity annual report website uk company law requires directors prepare financial accordance uk legislation governing preparation statements financial year directors required dissemination financial statements access website prepare group financial statements accordance available outside uk comparable legislation may international financial reporting standards ifrs adopted different european union preparing group financial statements directors also elected comply ifrs issued current directors whose names functions listed international accounting standards board iasb directors corporate governance section annual report elected prepare parent company financial statements confirms best knowledge accordance united kingdom accounting standards group financial statements prepared applicable law united kingdom generally accepted accounting accordance ifrs adopted eu ifrs practice company law directors must approve issued iasb give true fair view assets financial statements unless satisfied give true liabilities financial position profit group fair view state affairs group profit loss period strategic report risk sections annual report represent management report include fair review preparing financial statements directors required development performance business position select suitable accounting policies apply company group taken whole together consistently description principal risks uncertainties faces make judgements accounting estimates disclosure information auditor reasonable prudent directors office date annual report state group financial statements comply ifrs confirmed adopted european union ifrs issued iasb subject material departures disclosed explained far aware relevant audit information group financial statements companys auditor unaware state regard parent company financial statements taken steps ought taken applicable uk accounting standards followed subject director make aware relevant audit material departures disclosed explained parent information establish companys auditor aware company financial statements information prepare financial statements going concern basis unless confirmation given interpreted accordance inappropriate presume group parent provisions section companies act company continue business going concern basis directors responsible keeping adequate accounting pages contain information performance records sufficient show explain companys group financial position cash flows net debt position transactions disclose reasonable accuracy time borrowing facilities information including treasury risk financial position group enable ensure management policies exposures market credit risk group financial statements remuneration report comply hedging activities given note financial statements companies act article ias regulation financial instruments related disclosures assessed also responsible safeguarding assets group principal risks matters considered connection hence taking reasonable steps prevention viability statement directors considered appropriate adopt detection fraud irregularities going concern basis accounting preparing financial group financial statements year ended december statements comprising principal statements supporting notes set financial statements pages report parent company financial statements year ended december comprising balance sheet year ended december supporting notes set pages responsibilities auditor relation financial statements set independent auditors report pages gsk annual report strategic report governance remuneration financial statements investor information directors statement responsibilities continued internal control board audit risk committee reviewed assessment risks internal control framework operates gsk considered effectiveness system internal control operation group year covered annual report date approval board directors uk corporate governance code board considers glaxosmithkline plc applies principles complies provisions uk corporate governance code maintained financial reporting council described corporate governance section pages board considers annual report taken whole fair balanced understandable provides information necessary shareholders assess groups position performance business model strategy required financial conduct authoritys listing rules auditor considered directors statement compliance relation points uk corporate governance code specified review annual report annual report year ended december comprising report directors remuneration report financial statements additional information investors approved board directors signed behalf philip hampton chairman march gsk annual report independent auditors report members glaxosmithkline plc report audit financial statements opinion confirm nonaudit services prohibited frcs ethical standard provided group parent company opinion believe audit evidence obtained sufficient financial statements glaxosmithkline plc parent appropriate provide basis opinion company subsidiaries group give true fair summary audit approach view state groups parent companys affairs december groups profit first year audit transaction year ended first year appointed auditors group undertook number transitional procedures group financial statements properly prepared prepare audit commenced audit accordance international financial reporting standards establish independence group involved ceasing ifrss adopted european union ifrss issued number commercial relationships used time prior international accounting standards board iasb commencing audit meet key members management parent company financial statements properly gain understanding business issues prepared accordance united kingdom generally accepted environment operates accounting practice including frs reduced disclosure became independent group commenced audit framework planning july date attended audit risk financial statements prepared accordance committee meetings initially observer capacity worked requirements companies act regards alongside former auditor reviewed working papers group financial statements article ias regulation gain understanding groups processes audit risk audited financial statements comprise assessment controls relied purposes issuing audit opinion well understanding evidence group obtained key complex significant judgements consolidated balance sheet december made consolidated income statement year ended september held two day meeting audit partners consolidated statement comprehensive income year senior staff would responsible undertaking audits ended significant locations group main purpose meeting outline central audit approach including consolidated statement changes equity year use data analytics tools discuss possible significant audit ended risks brief teams groups key processes systems consolidated cash flow statement year ended structure subsequent strategic planning meeting held september participants take account notes financial statements includes current period updates impacted audit approach accounting principles policies parent company meetings also heard directly group management changes impacting business inform balance sheet december audit planning risk assessment statement changes equity year ended key audit matters notes n financial statements includes key audit matters identified current year accounting principles policies valuation acquisitionrelated liabilities financial reporting framework applied valuation us returns rebates rar accruals preparation group financial statements applicable law ifrss adopted european union financial reporting valuation intangible assets framework applied preparation parent valuation uncertain tax positions including transfer pricing company financial statements applicable law united kingdom updates impacts us tax reform accounting standards including frs reduced disclosure systems impact financial reporting framework united kingdom generally accepted accounting practice key audit matters considered groups auditor prior year broadly aligned items identified also basis opinion included consideration litigations investigations groups commercial operations less significant conducted audit accordance international standards current year auditing uk isas uk applicable law responsibilities standards described auditors materiality responsibilities audit financial statements section materiality used group financial statements report million determined basis composite benchmarking approach approach considers independent group parent company profit tax adjusted profit tax revenue net cash accordance ethical requirements relevant flows operations audit financial statements uk including financial reporting councils frcs ethical standard applied risk assessment group level listed public interest entities fulfilled ethical applied topdown risk assessment methodology responsibilities accordance requirements considers enterprise industry financial risks context financial statements gsk annual report strategic report governance remuneration financial statements investor information report audit financial statements continued part process spent time understanding key coverage obtained strategy summarised follows financial business processes group profit total implemented across organisation used audit analytics benchmark revenue tax assets tools analyse client data flow business transactions covered market specific procedures inform factbased risk assessment covered review group level audit scope execution residual consists components legal entities structured approach audit reflect group annual revenue turnover less total group revenue organised well ensuring audit effective entities components nonsignificant components risk focused summarised following areas individually aggregate present reasonable enabled us obtain evidence required form opinion possibility risk material misstatement group parent company financial statements conclusions relating going concern principal risks risk assessment audit planning group level viability statement central control common systems throughout group enabled us structure audit centrally addition going concern appointing partners three businesses also reviewed directors statement notes partners coordinate component legal entity audits financial statements whether considered appropriate country global business partners met regularly adopt going concern basis accounting preparing relevant management understand strategy matters identification material uncertainties groups arose throughout year could impacted companys ability continue period least financial reporting regular meetings members months date approval financial statements internal audit internal legal counsel global considered part risk assessment nature group ethics compliance team allowed us understand work business model related risks including relevant review reports enhance risk assessment impact brexit requirements applicable financial reporting audit work performed global shared service centres framework system internal control evaluated significant amount groups operational processes directors assessment groups ability continue going cover financial reporting undertaken shared service centres concern including challenging underlying data key assumptions central team included senior individuals responsible used make assessment evaluated directors plans global processes coordinated audit work future actions relation going concern assessment shared service centres scope group audit ensure developed good understanding endtoend view required state whether anything material add key processes supported material account balances draw attention relation statement required listing classes transactions disclosures within group financial rule r report statement materially inconsistent statements evaluated effectiveness internal knowledge obtained audit controls financial reporting processes confirm nothing material report add considered implications remainder audit work draw attention respect matters audit work executed component individual principal risks viability statement legal entities based solely reading directors statements considering following components subject marketspecific audit whether consistent knowledge obtained procedures well assessment internal controls course audit including knowledge obtained evaluation financial reporting belgium canada france germany italy directors assessment groups companys ability japan spain switzerland united kingdom united states continue going concern required state whether group audit team active dialogue throughout year anything material add draw attention relation component audit teams responsible audit work direction supervision group audit team disclosures pages describe principal included determining whether work planned risks explain managed mitigated performed accordance overall group audit strategy directors confirmation carried requirements group audit instructions robust assessment principal risks facing group components part supervising work components including would threaten business model future group audit team visited component countries well performance solvency liquidity locations shared service centre audits directors explanation audit procedures undertaken group level assessed prospects group period parent company done consider period appropriate addition also performed audit work group statement whether reasonable expectation parent company financial statements including group able continue operation meet limited consolidation groups results preparation liabilities fall due period assessment financial statements certain disclosures within directors including related disclosures drawing attention remuneration report litigation provisions exposures addition necessary qualifications assumptions managements entity level oversight controls relevant also required report whether directors statement relating financial reporting also carried analytical procedures prospects group required listing rule r confirm conclusion significant risks materially inconsistent knowledge obtained audit material misstatement aggregated financial information remaining components subject marketspecific audit confirm nothing material report add procedures draw attention respect matters gsk annual report independent auditors report continued report audit financial statements continued key audit matters key audit matters matters professional judgement significance audit financial statements current period include significant assessed risks material misstatement whether due fraud identified matters included greatest effect overall audit strategy allocation resources audit directing efforts engagement team matters addressed context audit financial statements whole forming opinion thereon provide separate opinion matters key audit matter description scope audit responded key audit matter valuation acquisitionrelated liabilities audit procedures performed recent years group completed number significant performed following audit procedures relevant transactions resulted recognition material made enquiries key individuals senior leadership judgemental acquisitionrelated liabilities significant team commercial strategy team key personnel involved liabilities budgeting forecasting process discuss challenge viiv healthcare shionogi contingent consideration liability evaluate managements evidence support key inputs viiv ccl group completed acquisition assumptions remaining interest shionogiviiv healthcare joint challenged business assumptions applied management venture upon completion group recognised estimating sales forecasts including benchmarking sales contingent consideration liability fair value forecasts external data included analysis results expected future payments made shionogi demand studies conducted third parties new drug december liability valued million launches assessed results clinical studies million target medicine profile new drugs understand pfizer put option group granted pfizer put option relative position market assess sources enabling pfizer put noncontrolling interest contradictory evidence viiv healthcare back group future assessed historical accuracy managements forecasts december liability valued million including estimates probability success pipeline million products prior year acquisitionrelated liabilities also included benchmarked sales forecasts analyst expectations consumer healthcare joint venture put option liability assess estimations made management represented present value expected redemption price consideration contradictory evidence available put option novartis noncontrolling interest consumer healthcare joint venture may consumer assessed reasonableness valuationspecific assumptions healthcare joint venture put option derecognised following used management including exchange rates discount rate approval shareholders acquisition novartis valuation multiples whether assumptions noncontrolling interest consumer healthcare joint venture consistent wellinformed independent third party therefore liability exist year end would value liabilities valuations liabilities sensitive changes assessed appropriateness accounting acquisition exchange rates discount rates sales forecasts related liabilities based upon managements assessment probability evaluated disclosures respect liabilities included success pipeline products expected launch dates subsequent notes financial statements determine whether sales volumes pricing compliant requirements relevant key risks valuation acquisitionrelated liabilities accounting standards specifically sales forecast used value viiv ccl internal controls financial reporting particularly dolutegravirbased regimens view tested design implementation operating effectiveness give rise material source estimation uncertainty key controls identified valuation acquisitionrelated acquisition related liabilities disclosed key liabilities review approval longrange accounting judgement estimate note group forecast valuation models financial statement disclosures provided notes key observations communicated audit risk committee matter also discussed audit risk whilst significant commercial risks forecasts committee report within corporate governance section future sales dolutegravirbased regimens related products annual report satisfied valuations associated liabilities within acceptable range values approach valuing acquisitionrelated liabilities consistent prior periods satisfied valuations acquisitionrelated liabilities reasonable consistent ifrs gsk annual report strategic report governance remuneration financial statements investor information report audit financial statements continued key audit matter description scope audit responded key audit matter valuation us returns rebates rar accruals audit procedures performed us group sells customers various commercial performed following audit procedures government mandated contracts reimbursement assessed historical accuracy managements estimates arrangements include rebates chargebacks right actual outcomes evaluate impact inform return certain products revenue recognition reflects assessment current year accrual grosstonet sales adjustments involve significant estimation judgement adjustments known returns developed expectation accrual balance rebates rar accruals source estimation key channels based historical claims received adjusted uncertainty could material impact reported revenue reflect market changes period including assessment three significant payer channels within rar accrual time lag initial point sale claim receipt managed healthcare organisations medicaid medicare part used expectation consider appropriateness managements ending accrual position two main causes significant estimation uncertainty recalculated accrual recognised determine utilisation rates portion total sales made consistent assumptions determined payer channel estimated management recording managements process accruals utilisation assumption challenging key assumptions used derive accrual given substantively tested individual utilisation rates sample basis influenced market demand factors outside evaluated monitoring news events industry control group developments appropriateness period end adjustments time lag point sale point liability made part ongoing review estimated exact rebate amounts known group upon receipt accrual claim payer channels longest time lag result evaluated benchmarked methodology applied greater accrued period greater level management estimating accrual industry practice estimation uncertainty level estimation uncertainty also impacted significant monitored market significant events period giving shifts channel mix driven changes competitive particular focus potential generic competition respect landscape advair one groups significant products generic us pharmaceuticals business million advair competitor product approved us food rar deductions made gross revenue million drug administration fda end january resulting net revenue million balance sheet therefore additional risk associated market accrual december accrual combined events determining advair rar liability pharmaceuticals vaccines businesses amounted internal controls financial reporting million tested design implementation operating effectiveness returns rebates disclosed key accounting judgement key controls estimation rar accruals including review estimate note group financial statement forecasts monthly accruals disclosures provided note matter also discussed key observations communicated audit risk committee audit risk committee report within corporate governance based assessment accuracy historical estimates section annual report made management comparing actual rebates claimed determined estimates accurate past giving assurance strength managements process estimating liability reporting date satisfied appropriateness rar accruals period end managements estimated liability reasonable gsk annual report independent auditors report continued report audit financial statements continued key audit matter description scope audit responded key audit matter valuation intangible assets audit procedures performed december group held million assessed appropriateness carrying value intangible assets including licences patents trademarks intangible assets performing following audit procedures brand names excluding goodwill computer software assessed valuation methodology used management recoverable value intangible assets relies certain involvement valuation specialists tested assumptions estimates future trading performance mechanical accuracy impairment models impact valuation evaluated reasonableness valuation assumptions assumptions applied management determining discount rates used management reference recoverable value include discount rate future sales growth external market data rate impact expiry patents product potential product obsolescence changes assumptions reviewed analyst reports external sources could lead impairment carrying value intangible information identify contradictory evidence assets could indicate impairment required assets risk material impairment identified using challenged appropriateness business assumptions sensitivity analysis key assumptions review potential used management sales growth probability triggering events could indicative impairment success products development assessing externally carrying value associated assets available reference data look contradictory evidence evaluate past performances relevant assessing disclosures relating intangible assets included historical accuracy forecast produced management note group financial statements matter also discussed audit risk committee report within enquired challenged management commercial corporate governance section annual report strategy associated products ensure consistent assumptions used estimating future cash flows considered whether events transactions occurred balance sheet date reporting date affect conclusions reached carrying values assets associated disclosures internal controls financial reporting tested design implementation operating effectiveness key controls impairment review process including review approval forecasts review valuation models key observations communicated audit risk committee audit procedures identify additional impairments satisfied managements intangible impairments estimates reasonable accordance ifrs gsk annual report strategic report governance remuneration financial statements investor information report audit financial statements continued key audit matter description scope audit responded key audit matter valuation uncertain tax positions including transfer pricing audit procedures performed updates impacts us tax reform support tax specialists assessed group operates numerous jurisdictions appropriateness uncertain tax provisions performing open tax transfer pricing issues exposures uk following audit procedures overseas tax authorities give rise uncertain tax assessed challenged provisions uncertain tax positions positions range possible outcomes provisions focused work jurisdictions group contingencies wide management required make greatest potential exposure highest level certain judgements respect estimates tax exposures judgement required contingencies order assess adequacy tax provisions involved transfer pricing specialists review transfer december group recorded provisions pricing methodology group associated approach million respect uncertain tax positions provisioning million involved uk us international tax transfer specialists december us tax cuts jobs act challenge conclusions reached management enacted limited guidance provided us relation expected outcome financial impact treasury apply principles reform practice judgement required year end considered evidence actual results previous management continued monitor impact reform outturns recent current tax authority audits enquiries us business associated accounting records third party tax advice obtained tax specialists given complexity uncertainty relating us tax reform knowledge market practice relevant jurisdictions management required make judgements assumptions involved deloitte us tax specialists determine interpretations tax law following additional guidance reasonableness judgements respect us released internal revenue service tax reform group reduced estimate impact us tax reform million internal controls financial reporting tested design implementation operating effectiveness valuation uncertain tax positions disclosed key key controls preparation tax packs tax consolidation accounting judgement estimate note group financial statements disclosures included note key observations communicated audit risk committee matter also discussed audit risk committee satisfied managements judgements relation report within corporate governance section annual uncertain tax positions related disclosures report accordance ifrs work concluded managements judgements prudent consistent prior periods within acceptable range continue appropriately recorded gsk annual report independent auditors report continued report audit financial statements continued key audit matter description scope audit responded key audit matter systems impact financial reporting audit procedures performed systems audit plan set place significant level reliance performed following risk assessment audit procedures systems underpinned ability rely effective test controls scope systems controls systems within group form critical systems considered key financial reporting purposes component groups financial reporting activities identified risks system based impact account balances controls context understanding flows transactions environment scope financial audit primarily relate user access security change control purpose controls determined whether general control individually prevent inappropriate changes made systems combination controls appropriately designed relation application functionality transactional processing address associated risk direct changes underlying data gsk place significant reliance tested design implementation operating effectiveness systems associated controls relevant general controls control deficiencies noted around user access management certain scope systems associated infrastructure existence deficiencies year resulted heightened risk data reports automated system functionality eg calculations affected systems might reliable assessesed impact deficiencies noted around user access management account balances determine specific impact audit plan key observations communicated audit risk committee year group implemented remediation plan address user access deficiencies primarily involved removal inappropriate access together implementation appropriate privileged access management processes controls planned fully complete group layers business process controls many levels help mitigate risk additional programme identify validate controls well enhancement controls completed deficiencies reported audit risk committee throughout year disclosed audit risk committee section annual report matter also discussed audit risk committee report within corporate governance section annual report satisfied mitigating business process controls addressed risks material misstatement gsk annual report strategic report governance remuneration financial statements investor information report audit financial statements continued application materiality define materiality magnitude misstatement financial statements makes probable economic decisions reasonably knowledgeable person would changed influenced use materiality planning scope audit work evaluating results work based professional judgement determined materiality financial statements whole follows group financial statements parent company financial statements materiality million million basic determining benchmark materiality materiality determined using total assets determining considered metrics used investors benchmark materiality readers financial statements particular considered statutory profit tax adjusted profit materiality used former auditor audit tax revenue net cash flows prior years parent company financial statements operations however given importance million metrics concluded composite approach appropriate based range materiality determined using benchmarks listed using professional judgement determined preliminary materiality million apply conservatism determination given first year audit metric statutory profit tax adjusted profit tax revenue net cash inflow operating activities reconciliation statutory profit tax adjusted profit tax detailed adjusting items section strategic report materiality used former auditor audit prior years group financial statements million rationale calculated range relevant parent company holds groups investments benchmark benchmarks used ranges exercising profitoriented strength balance applied professional judgement determine materiality sheet key measure financial health chosen materiality million deemed important shareholders since primary concern appropriate taking account various metrics used parent company payment dividends using investors readers financial statements benchmark total assets therefore appropriate component materiality allocated inscope components ranged million million range materiality allocated across components former auditor audit prior years group financial statements million million agreed audit risk committee would report committee audit differences excess million million used previous auditor well differences threshold view warranted reporting qualitative grounds also report audit risk committee disclosure matters identified assessing overall presentation financial statements gsk annual report independent auditors report continued information directors responsible information information comprises information included annual report financial statements auditors report thereon opinion financial statements cover information except extent otherwise explicitly stated report express form assurance conclusion thereon connection audit financial statements responsibility read information consider whether information materially inconsistent financial statements knowledge obtained audit otherwise appears materially misstated identify material inconsistencies apparent material misstatements required determine whether material misstatement financial statements material misstatement information based work performed conclude material misstatement information required report fact nothing report respect matters summarise work relation areas information including areas upon specifically required report matters specifically required report responsibility reporting fair balanced understandable consider whether statement given directors consider consider directors statement materially annual report financial statements taken whole fair balanced consistent knowledge obtained audit understandable provides information necessary shareholders assess groups position performance business model strategy materially inconsistent knowledge obtained audit audit risk committee report consider whether deals appropriately matters reported matters reported appropriately covered audit risk committee audit risk committee report directors statement compliance uk corporate governance code code identify matters consider whether parts directors statement required listing rules relating parent companys compliance code containing provisions specified review auditor accordance listing rule r properly discloses departure relevant provision code viability statement review confirmation description light knowledge set section conclusions relating going gathered audit including making enquiries considering concern principal risks viability statement directors processes used support statements made nothing material report add draw attention respect matters consider statements aligned relevant provisions uk corporate governance code code directors remuneration report report whether part directors remuneration report audited set section opinions matters properly prepared disclosures specified companies act prescribed companies act opinion made part directors remuneration report audited prepared accordance companies act strategic report directors report report whether consistent audited financial statements set section opinions matters prepared accordance applicable legal requirements prescribed companies act opinion report identified material misstatements either report based work undertaken course audit light knowledge understanding group parent information reports consistent audited company environment obtained course audit financial statements prepared accordance applicable legal requirements gsk annual report strategic report governance remuneration financial statements investor information information continued reporting information responsibility reporting alternative performance measures apms apms measures defined generally accepted accounting based work undertaken course audit practice gaap therefore typically included financial opinion statement part annual report group use apms adjusted use calculation disclosure apms consistent profit free cash flow constant currency growth rates groups published definitions policies quarterly annual reporting financial performance use apms groups reporting results reviewed assessed managements calculation reporting consistent guidelines produced esma metrics assess consistency groups published definitions frc policies items appropriate balance use also considered assessed whether use apms statutory metrics apms together clear definitions groups reporting results consistent guidelines produced reconciliation apms used financial reporting regulators european securities markets authority esma guidelines use apms frc alternative performance measures thematic review published november also considered whether appropriate balance use statutory metrics apms addition whether clear definitions reconciliation apms used financial reporting approach brexit consider whether brexit risks appropriately reflected based work undertaken course audit opinion risks relation brexit groups approach brexit outlined strategic report appropriately reflected dividends distribution policy consider whether dividends policy transparent dividends paid based work undertaken course audit consistent policy opinion dividends policy appropriately disclosed dividends paid consistent policy gsk annual report independent auditors report continued responsibilities directors discussing among engagement team including significant component audit teams involving relevant internal specialists explained fully directors responsibilities statement including tax valuations pensions industry specialists directors responsible preparation financial regarding fraud might occur financial statements satisfied give true fair view statements potential indicators fraud internal control directors determine necessary enable preparation financial statements free obtaining understanding legal regulatory frameworks material misstatement whether due fraud error group operates focusing laws regulations direct effect financial statements preparing financial statements directors responsible provisions uk companies act pensions legislation tax assessing groups parent companys ability legislations fundamental effect operations continue going concern disclosing applicable matters group including good clinical practice fda related going concern using going concern basis regulations general data protection requirements antibribery accounting unless directors either intend liquidate group corruption policy foreign corrupt practices act parent company cease operations realistic audit response risks identified alternative procedures respond risks identified included following auditors responsibilities audit financial reviewing financial statement disclosures testing statements supporting documentation assess compliance relevant objectives obtain reasonable assurance whether laws regulations discussed financial statements whole free material enquiring management audit risk committee misstatement whether due fraud error issue auditors inhouse external legal counsel concerning actual report includes opinion reasonable assurance high level potential litigation claims assurance guarantee audit conducted performing analytical procedures identify unusual accordance isas uk always detect material unexpected relationships may indicate risks material misstatement exists misstatements arise fraud misstatement due fraud error considered material individually aggregate could reasonably expected influence economic reading minutes meetings charged governance decisions users taken basis financial statements reviewing internal audit reports details extent audit considered capable also considered risks noted addressing risk detecting irregularities including fraud set fraud management override controls description responsibilities audit testing appropriateness journal entries financial statements located frcs website wwwfrcorg adjustments ukauditorsresponsibilities description forms part assessing whether judgements made making accounting auditors report estimates indicative potential bias extent audit considered capable evaluating business rationale significant transactions detecting irregularities including fraud unusual outside normal course business identify assess risks material misstatement also communicated relevant identified laws regulations financial statements whether due fraud error design potential fraud risks engagement team members significant perform audit procedures responsive risks including component audit teams remained alert indications obtaining audit evidence sufficient appropriate provide fraud noncompliance laws regulations throughout basis opinion audit identifying assessing potential risks related report legal regulatory requirements irregularities opinions matters prescribed companies act identifying assessing risks material misstatement respect irregularities including fraud noncompliance laws regulations procedures included following opinion part directors remuneration report audited properly prepared accordance enquiring management internal audit audit risk companies act committee including obtaining reviewing supporting documentation concerning groups policies procedures opinion based work undertaken course relating audit identifying evaluating complying laws regulations information given strategic report directors whether aware instances non report financial year financial statements compliance prepared consistent financial statements detecting responding risks fraud whether strategic report directors report prepared knowledge actual suspected alleged fraud accordance applicable legal requirements internal controls established mitigate risks related fraud light knowledge understanding group noncompliance laws regulations parent company environment obtained course audit identified material misstatements strategic report directors report gsk annual report strategic report governance remuneration financial statements investor information matters required report exception adequacy explanations received accounting records companies act required report opinion received information explanations require audit adequate accounting records kept parent company returns adequate audit received branches visited us parent company financial statements agreement accounting records returns nothing report respect matters directors remuneration companies act also required report opinion certain disclosures directors remuneration made part directors remuneration report audited agreement accounting records returns nothing report respect matters matters auditor tenure following recommendation audit risk committee appointed company annual general meeting may audit financial statements glaxosmithkline plc year ending december subsequent financial periods period uninterrupted engagement including previous renewals reappointments firm accordingly one year consistency audit report additional report audit risk committee audit opinion consistent additional report audit risk committee required provide accordance isas uk use report report made solely companys members body accordance chapter part companies act audit work undertaken might state companys members matters required state auditors report purpose fullest extent permitted law accept assume responsibility anyone company companys members body audit work report opinions formed parent company passed resolution accordance section companies act senior statutory auditors name stated deloitte llp statutory auditor london united kingdom march gsk annual report consolidated income statement year ended december notes turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit finance income finance expense profit disposal interest associates share tax profits associates joint ventures profit taxation taxation profit taxation year profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p consolidated statement comprehensive income year ended december profit year items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries fair value movements equity investments deferred tax fair value movements equity investments reclassification fair value movements equity investments deferred tax reversed reclassification equity investments fair value movements cash flow hedges deferred tax fair value movements cash flow hedges reclassification cash flow hedges income statement deferred tax reversed reclassification cash flow hedges items reclassified income statement exchange movements overseas net assets noncontrolling interests fair value movements equity investments deferred tax fair value movements equity investments remeasurement gainslosses defined benefit plans tax remeasurement defined benefit plans comprehensive income year total comprehensive income year total comprehensive income year attributable shareholders noncontrolling interests total comprehensive income year gsk annual report strategic report governance remuneration financial statements consolidated balance sheet investor information december notes noncurrent assets property plant equipment goodwill intangible assets investments associates joint ventures investments deferred tax assets derivative financial instruments noncurrent assets total noncurrent assets current assets inventories current tax recoverable trade receivables derivative financial instruments liquid investments cash cash equivalents assets held sale total current assets total assets current liabilities shortterm borrowings contingent consideration liabilities trade payables derivative financial instruments current tax payable shortterm provisions total current liabilities noncurrent liabilities longterm borrowings corporation tax payable deferred tax liabilities pensions postemployment benefits provisions derivative financial instruments contingent consideration liabilities noncurrent liabilities total noncurrent liabilities total liabilities net assets equity share capital share premium account retained earnings reserves shareholders equity noncontrolling interests total equity financial statements pages approved board march signed behalf philip hampton chairman gsk annual report consolidated statement changes equity year ended december shareholders equity share share retained noncontrolling total capital premium earnings reserves total interests equity january profit year comprehensive income year total comprehensive income year distributions noncontrolling interests dividends shareholders recognition liabilities noncontrolling interests derecognition liabilities noncontrolling interests changes noncontrolling interests shares issued shares acquired esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december profit year comprehensive income year total comprehensive income year distributions noncontrolling interests contribution noncontrolling interests dividends shareholders changes noncontrolling interests shares issued shares acquired esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december implementation ifrs implementation ifrs december adjusted profit year comprehensive income year total comprehensive income year distributions noncontrolling interests contribution noncontrolling interests derecognition noncontrolling interests consumer healthcare joint venture dividends shareholders realised profits disposal equity investments share associates joint ventures realised profits disposal equity investments shares issued writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december gsk annual report strategic report governance remuneration financial statements consolidated cash flow statement investor information year ended december notes cash flow operating activities profit taxation year adjustments reconciling profit tax operating cash flows cash generated operations taxation paid net cash inflow operating activities cash flow investing activities purchase property plant equipment proceeds sale property plant equipment purchase intangible assets proceeds sale intangible assets purchase equity investments proceeds sale equity investments contingent consideration paid purchase businesses net cash acquired disposal businesses investments associates joint ventures proceeds disposal interests associates decrease liquid investments interest received dividends associates joint ventures equity investments net cash outflow investing activities cash flow financing activities shares acquired esop trusts issue share capital purchase noncontrolling interests increase longterm loans repayment shortterm notes increase inrepayment shortterm loans net repayment obligations finance leases interest paid dividends paid shareholders distributions noncontrolling interests contributions noncontrolling interests financing cash flows net cash outflow financing activities increasedecrease cash bank overdrafts cash bank overdrafts beginning year exchange adjustments increasedecrease cash bank overdrafts cash bank overdrafts end year cash bank overdrafts end year comprise cash cash equivalents cash cash equivalents reported assets held sale overdrafts gsk annual report notes financial statements presentation financial statements description business implementation ifrs financial instruments gsk major global healthcare group engaged group applied ifrs financial instruments effect creation discovery development manufacture marketing january ifrs introduces new requirements pharmaceutical products vaccines overthecounter otc classification measurement financial assets financial medicines healthrelated consumer products gsks principal liabilities impairments financial assets general hedge pharmaceutical products include medicines following accounting therapeutic areas respiratory hiv immunoinflammation antivirals details new requirements well impact central nervous system cardiovascular urogenital metabolic groups consolidated financial statements described antibacterials dermatology group adopted ifrs retrospectively certain compliance applicable law ifrs permitted exceptions detailed classification measurement financial assets financial statements prepared accordance date initial application january group companies act article ias regulation applied requirements ifrs instruments international financial reporting standards ifrs related derecognised prior january restated prior interpretations adopted european union years difference previous carrying amount financial statements also compliance ifrs issued revised carrying amount january recognised international accounting standards board adjustment opening retained earnings january composition financial statements financial assets within scope ifrs required measured amortised cost fair value movements consolidated financial statements drawn sterling comprehensive income income statement basis functional currency glaxosmithkline plc accordance gsks business model managing financial assets ifrs accounting presentation financial statements contractual cash flow characteristics financial assets comprise ifrs following impact groups assets consolidated income statement group elected recognise movements fair value consolidated statement comprehensive income equity investments comprehensive income ifrs consolidated balance sheet investments equity instruments previously classified availableforsale financial assets measured fair value consolidated statement changes equity designated measured fair value comprehensive consolidated cash flow statement income fvtoci ifrs result fair value movements notes financial statements recorded comprehensive income along gains losses disposal investments composition group groups investments limited life funds included list subsidiaries associates opinion investments previously classified availableforsale directors principally affected amount profit net assets financial assets ias measured fair value group given note principal group companies classified measured fair value profit loss fvtpl ifrs contractual cash flows solely financial period payments principal interest principal amount financial statements cover financial year january outstanding december comparative figures financial years liquid investments classified availableforsale january december appropriate financial assets measured fair value ias january december classified measured amortised cost ifrs accounting principles policies held within business model objective collect contractual cash flows financial statements prepared using historical investments money market funds included cash cash cost convention modified revaluation certain items equivalents classified amortised cost financial assets stated accounting policies going concern basis ias classified fvtpl ifrs financial statements prepared accordance contractual cash flows solely payments principal groups accounting policies approved board interest principal amount outstanding described note accounting principles policies groups trade receivables classified financial information application accounting policies assets measured amortised cost ias ifrs including areas estimation judgement given note business model portfolio trade key accounting judgements estimates receivables held assessed group portfolios preparation financial statements conformity three business models ifrs collect generally accepted accounting principles requires management contractual cash flows measured amortised cost sell make estimates assumptions affect reported contractual cash flows measured fvtpl collect amounts assets liabilities disclosure contingent sell contractual cash flows measured fvtoci assets liabilities date financial statements reported amounts revenues expenses reporting period actual results could differ estimates gsk annual report strategic report governance remuneration financial statements investor information presentation financial statements continued amounts receivable insurance contracts included impact new standards financial noncurrent assets held fvtpl amortised cost statement line item ias ifrs contractual cash flows solely payments principal interest principal amount table shows amount adjustment financial outstanding amounts receivable classified measured statement line item affected application ifrs ifrs fvtpl january material changes carrying value financial assets previously ifrs ifrs result changes measurement basis reported adjustments adjustments restated impairment financial assets trade receivables ifrs requires expected credit loss ecl model applied liquid investments financial assets rather incurred credit loss model required payables returns ias expected credit loss model requires group rebates account expected losses result credit risk initial payables deferred recognition financial assets recognise changes income expected credit losses reporting date deferred tax assets month ecls applied financial assets measured fvtpl except net trade receivables measured total effect net assets reflecting lifetime ecls using simplified approach additional ecl allowance million trade receivables recognised fair value reserve transition ifrs transition adjustments arising change impairment basis retained earnings additional ecl allowance million january total effect equity recognised opening retained earnings together related deferred tax impact million million transfer retained earnings general hedge accounting fair value reserve resulted reclassification previous new general hedge accounting requirements retain three impairment losses equity investments designated types hedge accounting available ias measured fvtoci ifrs retained earnings fair value hedges cash flow hedges net investment hedges fair value reserve however effectiveness testing requirements application ifrs ifrs impact simplified consolidated cash flows group group applied ifrs hedge accounting requirements parent company financial statements prospectively date initial application january existing hedging relationships eligible continued financial statements parent company glaxosmithkline effective ifrs plc prepared accordance uk gaap uk accounting presentation company balance sheet presented implementation ifrs revenue contracts accounting policies given customers group applied ifrs revenue contracts customers effect january ifrs provides single principlesbased approach recognition revenue contracts customers focuses identification performance obligations contract requires revenue recognised performance obligations satisfied gsk adopted ifrs applying modified retrospective approach ifrs material impact amount timing recognition reported revenue january cumulative adjustment decrease retained earnings million recognised accordance requirements ifrs modified retrospective approach adopted prior year results restated gsk annual report notes financial statements continued accounting principles policies consolidation consideration transferred together noncontrolling interest exceeds fair value net assets liabilities consolidated financial statements include contingent liabilities acquired excess recorded goodwill assets liabilities results cash flows costs acquisition charged income statement company subsidiaries including esop trusts period incurred groups share results net assets associates goodwill capitalised separate item case subsidiaries joint ventures part cost investment case joint ventures associates goodwill denominated currency operation groups share assets liabilities revenue expenses acquired joint operations cost acquisition fair value net assets financial statements entities consolidated made acquired difference recognised directly income statement december year equity subsidiary acquired non entities group power direct relevant controlling interest recognised either fair value non activities affect returns group generally controlling interests share net assets subsidiary control financial operating policies accounted casebycase basis changes groups ownership percentage subsidiaries subsidiaries accounted within equity group ability exercise joint control foreign currency translation rights net assets entities entities accounted joint ventures group ability exercise joint foreign currency transactions booked functional currency control arrangement rights specified assets group company exchange rate ruling date obligations specified liabilities arrangement transaction foreign currency monetary assets liabilities arrangement accounted joint operation group retranslated functional currency rates exchange ruling ability exercise significant influence entities balance sheet date exchange differences included accounted associates results assets liabilities income statement associates joint ventures incorporated consolidated consolidation assets liabilities including related goodwill financial statements using equity method accounting overseas subsidiaries associates joint ventures translated groups rights assets liabilities revenue expenses joint sterling rates exchange ruling balance sheet date operations included consolidated financial statements results cash flows overseas subsidiaries associates joint accordance rights obligations ventures translated sterling using average rates exchange interests acquired entities consolidated date exchange adjustments arising opening net assets group acquires control interests sold deconsolidated profits year retained overseas subsidiaries associates date control ceases joint ventures translated sterling less exchange differences transactions balances subsidiaries eliminated arising related foreign currency borrowings hedge profit tax taken sales subsidiaries groups net investment operations taken separate products sold customers outside group relevant component equity proportion profits transactions joint ventures joint translating sterling assets liabilities results cash operations associates also deferred products flows overseas subsidiaries associates joint ventures sold third parties transactions noncontrolling interests reported currencies hyperinflationary economies recorded directly equity deferred tax relief unrealised intra adjustments made material reflect current price levels group profit accounted extent considered loss net monetary assets charged consolidated recoverable income statement business combinations revenue applicable january business combinations accounted using acquisition group receives revenue supply goods external accounting method identifiable assets liabilities contingent customers orders received majority contracts liabilities acquired measured fair value acquisition date gsk enters relate sales orders containing single performance consideration transferred measured fair value includes obligations delivery pharmaceutical vaccine consumer fair value contingent consideration healthcare products average duration sales order less fair value contingent consideration liabilities reassessed months balance sheet date changes recognised income product revenue recognised control goods passed statement payments contingent consideration reduce balance customer point control passes determined sheet liability result recorded income statement customer arrangement generally occurs delivery part payment relating original estimate fair customer value contingent consideration acquisition reported within product revenue represents net invoice value including fixed investing activities cash flow statement part variable consideration variable consideration arises sale payment relating increase liability since acquisition goods result discounts allowances given accruals date reported within operating cash flows estimated future returns rebates revenue recognised full highly probable significant reversal amount cumulative revenue recognised occur gsk annual report strategic report governance remuneration financial statements investor information accounting principles policies continued methodology assumptions used estimate rebates legal disputes returns monitored adjusted regularly light contractual provision made anticipated settlement costs legal legal obligations historical trends past experience disputes group outflow resources projected market conditions uncertainty associated considered probable reliable estimate made likely returns rebates resolved revenue adjusted accordingly outcome addition provision made legal expenses gsk enters development marketing collaborations arising claims received disputes respect product outlicences groups compounds products parties liability claims related certain products sufficient history contracts give rise fixed variable consideration claims made settlements enable management make upfront payments development milestones salesbased milestones reliable estimate provision required cover unasserted claims royalties certain cases incurred reported ibnr actuarial income dependent achievement development milestone technique used determine estimate recognised highly probable significant reversal group may become involved legal proceedings respect amount cumulative revenue recognised occur possible make reliable estimate expected usually related event occurs salesbased milestone financial effect could result ultimate resolution income recognised highly probable sales proceedings threshold reached cases appropriate disclosure cases would salesbased royalties licence intellectual property included provision would made costs associated recognised relevant product sale occurs claims made group third parties charged time recognition revenue payment income statement incurred customer expected one year impact pensions postemployment benefits material amount consideration discounted using appropriate discount rates costs providing pensions defined benefit schemes calculated using projected unit credit method spread value added tax sales taxes excluded revenue period benefit expected derived expenditure employees services consistent advice qualified actuaries pension obligations measured present value estimated expenditure recognised respect goods services received future cash flows discounted rates reflecting yields high supplied accordance contractual terms provision quality corporate bonds pension scheme assets measured made obligation exists future liability respect fair value balance sheet date past event amount obligation reliably estimated manufacturing startup costs validation costs postemployment liabilities calculated achievement normal production expensed incurred similar way defined benefit pension schemes spread advertising promotion expenditure charged income period benefit expected derived statement incurred shipment costs intercompany transfers employees services accordance advice qualified charged cost sales distribution costs sales customers actuaries included selling general administrative expenditure actuarial gains losses effect changes actuarial restructuring costs recognised provided assumptions recognised statement comprehensive appropriate respect direct expenditure business income year arise reorganisation plans sufficiently detailed well groups contributions defined contribution plans charged advanced appropriate communication affected income statement incurred undertaken employee share plans research development incentives form shares provided employees research development expenditure charged income share option share award schemes statement period incurred development fair values options awards calculated expenditure capitalised criteria recognising asset grant dates using blackscholes option pricing model charged met usually regulatory filing made major income statement relevant vesting periods market approval considered highly probable property plant equipment used research development capitalised group provides finance esop trusts purchase company depreciated accordance groups policy shares meet obligation provide shares employees exercise options awards costs running esop trusts environmental expenditure charged income statement shares held esop environmental expenditure related existing conditions resulting trusts deducted reserves transfer made past current operations current future reserves retained earnings vesting periods benefit discernible charged income statement group related share options awards reflect ultimate proceeds recognises liability sitebysite basis reliably receivable employees exercise estimated liability includes groups portion total costs also portion potentially responsible parties costs probable able satisfy respective shares cleanup obligation recoveries reimbursements recorded assets virtually certain gsk annual report notes financial statements continued accounting principles policies continued property plant equipment contingent milestone payments recognised point contingent event becomes probable development costs property plant equipment ppe stated cost incurred group associated acquired licences purchase construction less provisions depreciation patents knowhow marketing rights written income impairment financing costs capitalised within cost statement incurred unless criteria recognition qualifying assets construction internally generated intangible asset met usually depreciation calculated write cost less residual value regulatory filing made major market approval ppe excluding freehold land using straightline basis considered highly probable expected useful life residual values lives reviewed acquired brands valued independently part fair value appropriate adjusted annually normal expected useful businesses acquired third parties brand value lives major categories ppe substantial long term brands either contractual legal nature sold separately rest freehold buildings years businesses acquired brands amortised leasehold land buildings lease term years estimated useful lives years except considered plant machinery years useful economic life indefinite equipment vehicles years costs acquiring developing computer software internal use internet sites external use capitalised intangible disposal ppe cost related accumulated depreciation fixed assets software site supports significant impairments removed financial statements business system expenditure leads creation net amount less proceeds taken income statement durable asset erp systems software amortised seven leases ten years computer software three five years leasing agreements transfer group substantially impairment noncurrent assets benefits risks ownership asset treated finance carrying values noncurrent assets reviewed leases asset purchased outright assets impairment either standalone basis part larger cash included ppe computer software capital elements generating unit indication assets might leasing commitments shown obligations finance impaired additionally goodwill intangible assets indefinite leases assets held finance leases depreciated basis useful lives intangible assets yet available use consistent similar owned assets lease term shorter tested impairment annually provision impairment interest element lease rental included income charged income statement year concerned statement leases operating leases rental costs charged income statement straightline basis impairments goodwill reversed impairment losses lease term noncurrent assets reversed change estimates used determine recoverable amounts goodwill extent revised recoverable amounts exceed goodwill stated cost less impairments goodwill deemed carrying values would existed net depreciation indefinite useful life tested impairment least amortisation impairments recognised annually investments associates joint ventures joint fair value interest acquired entitys assets operations liabilities contingent liabilities exceeds consideration paid excess recognised immediately gain income investments associates joint ventures carried statement consolidated balance sheet groups share net assets date acquisition postacquisition retained profits intangible assets losses together goodwill arising acquisition group recognises rights assets liabilities revenue intangible assets stated cost less provisions amortisation expenses joint operations impairments expected credit losses recognised income statement licences patents knowhow marketing rights separately financial assets measured amortised cost fair value acquired acquired part business combination comprehensive income apart equity investments amortised estimated useful lives generally exceeding years using straightline basis time available inventories use estimated useful lives determining amortisation charge take account patent lives applicable well inventories included financial statements lower value obtained periods nonexclusivity asset lives cost including raw materials direct labour direct costs reviewed appropriate adjusted annually related production overheads net realisable value cost generally determined first first basis prelaunch inventory held asset high probability regulatory approval product point provision made carrying value recoverable amount provision reversed point high probability regulatory approval determined gsk annual report strategic report governance remuneration financial statements investor information accounting principles policies continued financial instruments applicable january borrowings borrowings initially recorded amount proceeds financial assets received net transaction costs borrowings subsequently financial assets measured amortised cost fair value carried amortised cost difference proceeds comprehensive income fvtoci fair value profit net transaction costs amount due redemption loss fvtpl measurement basis determined reference recognised charge income statement period business model managing financial asset relevant borrowing contractual cash flow characteristics financial asset financial assets trade receivables month expected derivative financial instruments credit loss ecl allowance recorded initial recognition derivative financial instruments used manage exposure subsequent evidence significant increase credit risk market risks principal derivative instruments used gsk asset allowance increased reflect full lifetime ecl foreign currency swaps interest rate swaps foreign exchange realistic prospect recovery asset written forward contracts options group hold issue derivative financial instruments trading speculative purposes investments investments comprise equity investments investments derivative financial assets liabilities including derivatives limited life funds group elected designate equity embedded host contracts separated investments measured fvtoci initially recorded host contract classified heldfortrading measured fair value plus transaction costs remeasured subsequent fair value changes fair value derivative instruments reporting dates fair value unrealised gains losses qualify hedge accounting recognised immediately recognised comprehensive income income statement disposal equity investment gains losses hedge accounting deferred comprehensive income transferred directly derivatives designated hedging instruments classified retained earnings investments limited life funds measured inception cash flow hedges net investment hedges fair value fvtpl initially recorded fair value remeasured hedges subsequent reporting dates fair value unrealised gains changes fair value derivatives designated cash flow losses recognised income statement hedges recognised comprehensive income extent dividends equity investments distributions funds hedges effective ineffective portions recognised recognised income statement groups right profit loss immediately amounts deferred comprehensive receive payment established income reclassified income statement hedged item affects profit loss purchases sales investments accounted trade date net investment hedges accounted similar way cash flow hedges trade receivables trade receivables measured accordance business changes fair value derivatives designated fair value model portfolio trade receivables held hedges recorded income statement together group portfolios three business models ifrs changes fair value hedged asset liability collect contractual cash flows measured amortised cost taxation sell contractual cash flows measured fvtpl collect sell contractual cash flows measured fvtoci current tax provided amounts expected paid applying trade receivables measured amortised cost carried tax rates enacted substantively enacted original invoice amount less allowances expected credit losses balance sheet date expected credit losses calculated accordance simplified deferred tax provided full temporary differences arising approach permitted ifrs using provision matrix applying tax bases assets liabilities carrying lifetime historical credit loss experience trade receivables amounts financial statements deferred tax assets expected credit loss rate varies depending whether extent recognised extent probable future taxable profits settlement trade receivables overdue also available temporary differences adjusted appropriate reflect current economic conditions utilised deferred tax provided temporary differences arising estimates future conditions purpose determining credit investments subsidiaries associates joint ventures except loss rates customers classified groupings similar timing reversal temporary difference loss patterns key drivers loss rate nature controlled probable temporary difference business unit location type customer reverse foreseeable future deferred tax provided using rates tax enacted substantively enacted trade receivable determined reasonable balance sheet date expectation recovery written firstly expected credit loss allowance available income statement uncertain tax position identified management make judgement probable outcome subsequent recoveries amounts previously provided written assessed economic outflow probable arise provision credited income statement longterm receivables made best estimate liability estimating discounted effect material liability gsk applies riskbased approach takes account cash cash equivalents appropriate probability group would able obtain cash held deposit accounts measured amortised cost compensatory adjustments international tax treaties investments money market funds held fair value estimates take account specific circumstances profit loss dispute relevant external advice gsk annual report notes financial statements continued accounting principles policies continued discounting trade receivables trade receivables carried original invoice amount less time value money material balances discounted provisions doubtful debts provisions made current values using appropriate discount rates unwinding evidence risk nonpayment taking account ageing discounts recorded finance income finance expense previous experience general economic conditions trade revenue applicable december receivable determined uncollectable written firstly provision available income statement revenue recognised income statement goods subsequent recoveries amounts previously provided services supplied made available external customers credited income statement longterm receivables orders received title risk loss passed customer discounted effect material reliable estimates made relevant deductions relevant obligations fulfilled earnings process borrowings regarded complete borrowings initially recorded amount proceeds received net transaction costs borrowings subsequently turnover represents net invoice value deduction carried amortised cost difference proceeds discounts allowances given accruals estimated future net transaction costs amount due redemption rebates returns methodology assumptions used recognised charge income statement period estimate rebates returns monitored adjusted regularly relevant borrowing light contractual legal obligations historical trends past experience projected market conditions market conditions derivative financial instruments hedging evaluated using wholesaler thirdparty analyses market derivative financial instruments used manage exposure research data internally generated information value added tax market risks principal derivative instruments used gsk sales taxes excluded revenue foreign currency swaps interest rate swaps foreign exchange forward contracts options group hold issue group copromotes product counterparty derivative financial instruments trading speculative purposes records sale group records share revenue copromotion income within turnover nature copromotion derivative financial instruments classified heldfortrading activities group records costs sales carried balance sheet fair value derivatives designated addition initial eventbased milestone income excluding royalty hedging instruments classified inception cash flow income arising development marketing collaborations hedges net investment hedges fair value hedges groups compounds products parties recognised changes fair value derivatives designated cash flow turnover hedges recognised comprehensive income extent royalty income recognised accruals basis accordance hedges effective ineffective portions recognised terms relevant licensing agreements profit loss immediately amounts deferred comprehensive income reclassified income statement hedged financial instruments applicable december item affects profit loss availableforsale investments net investment hedges accounted similar way cash liquid investments investments classified available flow hedges forsale investments initially recorded fair value plus changes fair value derivatives designated fair value transaction costs remeasured subsequent reporting hedges recorded income statement together dates fair value unrealised gains losses availableforsale changes fair value hedged asset liability investments recognised directly comprehensive income impairments arising significant prolonged decline fair changes fair value derivative instruments value equity investment reduce carrying amount asset qualify hedge accounting recognised immediately directly charged income statement income statement disposal impairment investments gains losses deferred comprehensive income reclassified income statement dividends equity investments recognised income statement groups right receive payment established equity investments recorded noncurrent assets unless expected sold within one year purchases sales equity investments accounted trade date purchases sales availableforsale investments accounted settlement date gsk annual report strategic report governance remuneration financial statements investor information key accounting judgements estimates preparing financial statements management required estimates make judgements items recognised sufficient information available estimating potential tax financial statements estimates assumptions affect liability gsk applies riskbased approach takes account amounts assets liabilities revenue expenses reported appropriate probability group would able obtain financial statements actual amounts results could differ compensatory adjustments international tax treaties estimates following considered critical estimates take account specific circumstances accounting judgements key sources estimation uncertainty dispute relevant external advice inherently judgemental could change substantially time dispute progresses turnover new facts emerge reported group turnover million december group recognised provisions million million respect uncertain tax positions estimates million nature uncertain positions gross turnover reduced rebates discounts allowances practicable give meaningful sensitivity estimates product returns given expected given vary factors affecting tax charge future years set note product arrangements buying groups arrangements taxation gsk continues believe made adequate purchasing organisations dependent upon submission provision liabilities likely arise open assessments claims time initial recognition sale accruals open issues exist ultimate liability matters may made time sale estimated rebates discounts vary amounts provided dependent upon outcome allowances payable returns made based available market negotiations relevant tax authorities necessary information historical experience litigation proceedings amounts estimated may fully reflect legal disputes final outcome amounts subject change dependent upon amongst things types buying group product legal costs year million million sales mix december provisions legal disputes amounted million million level accrual rebates returns reviewed adjusted regularly light contractual legal obligations historical judgement trends past experience projected market conditions market management makes judgement whether sufficient conditions evaluated using wholesaler thirdparty information able make reliable estimate likely analyses market research data internally generated information outcome dispute legal expenses arising revenue recognised full highly probable claims group insufficient information available significant reversal amount cumulative revenue recognised provision made disclosure claim given occur amount turnover recognised year estimates performance obligations satisfied previous periods set estimated provisions take account specific note turnover segment information circumstances dispute relevant external advice future events could cause assumptions accruals inherently judgemental could change substantially time based change could affect future results dispute progresses new facts emerge details group status various uncertainties involved significant unresolved disputes set note legal proceedings taxation companys directors taken legal advice tax charge year million million established provisions taking account relevant facts december current tax payable million circumstances matter accordance million noncurrent corporation tax payable million accounting requirements respect product liability claims related million current tax recoverable million certain products sufficient history claims made million settlements enable management make reliable estimate judgement provision required cover unasserted claims group may group open tax issues number revenue authorities become involved legal proceedings respect management makes judgement whether sufficient possible make reliable estimate expected financial effect information able make reliable estimate outcome could result ultimate resolution proceedings dispute insufficient information available provision cases appropriate disclosure cases would made provided provision would made contingent liability quantified ultimate liability legal claims may vary amounts provided dependent upon outcome litigation proceedings investigations possible settlement negotiations position could change time therefore assurance losses result outcome legal proceedings exceed amount provisions reported groups financial statements material amount gsk annual report notes financial statements continued key accounting judgements estimates continued contingent consideration put option liabilities pensions postemployment benefits income statement charge contingent consideration judgement put option liabilities million million surplus defined benefit scheme arises potential surplus arise committed future contributions december liability contingent consideration rights trustees prevent group obtaining refund amounted million million amount surplus future considered determining whether million million related acquisition necessary restrict amount surplus recognised former shionogiviiv healthcare joint venture four uk schemes surplus combined surplus million million related acquisition million december million gsk made vaccines business novartis judgement amounts meet requirements estimates recoverability contingent consideration included consideration payable estimates business combination recorded fair value date costs providing pensions postemployment benefits acquisition fair values generally based riskadjusted assessed basis assumptions selected management future cash flows discounted using appropriate posttax discount assumptions include future earnings pension increases rates fair values reviewed regular basis least discount rates expected longterm rates return assets annually changes reflected income statement mortality rates disclosed note pensions see note contingent consideration liabilities postemployment benefits june gsk acquired novartis shareholding consumer discount rates derived aa rated corporate bond yields healthcare joint venture billion resulted net charge except countries deep market corporate period million remeasure consumer healthcare bonds government bond yields used sensitivity analysis joint venture put option agreed valuation provided note pensions postemployment pfizer may request ipo viiv healthcare time either benefits reduction discount rate would lead gsk consent ipo offering completed increase net pension deficit approximately million within nine months pfizer could require gsk acquire increase annual pension cost approximately million shareholding liability pfizer put option derived selection different assumptions could affect future results internal valuation viiv healthcare business utilising group discounted forecast future cash flow multiplesbased methodologies amounted million december million sensitivity analysis given note trade payables new accounting requirements following new amended accounting standards gsk implement ifrs applying modified retrospective issued iasb likely affect future annual reports approach larger leases right use asset january calculated based original lease inception date ifrs leases issued january smaller leases right use asset set equal lease implemented group january standard liability adjusted prepaid accrued lease payments onerous replace ias leases require lease liabilities right lease provisions business combination fair value adjustments use assets recognised balance sheet almost transition date january group expects leases expected result significant increase recognise right use assets billion lease liability assets liabilities recognised costs operating leases billion including existing finance leases implementation currently included within operating costs split expected reduce net assets total equity billion financing element charge reported within finance expense overall impact earnings expected material finance lease obligations december set note net debt undiscounted commitments noncancellable operating leases set note commitments gsk annual report strategic report governance remuneration financial statements investor information exchange rates group uses average exchange rates prevailing period translate results cash flows overseas subsidiaries joint ventures associates sterling period end rates translate net assets entities currencies influence translations relevant exchange rates average rates period end rates us us euro euro yen yen turnover segment information operating segments reported based financial information provided chief executive officer responsibilities corporate executive team cet gsk reports results four segments pharmaceuticals pharmaceuticals rd vaccines consumer healthcare individual members cet responsible segment groups management reporting process allocates intragroup profit product sale market sale recorded profit analyses presented basis corporate unallocated costs included costs corporate functions revenue recognised year performance obligations satisfied previous periods totalled million included million reported turnover arising changes prior year estimates rar accruals million royalty income turnover segment pharmaceuticals vaccines consumer healthcare pharmaceuticals turnover therapeutic area respiratory hiv immunoinflammation established pharmaceuticals vaccines turnover category meningitis influenza shingles established vaccines us operations pharmaceuticals vaccines businesses made sales three wholesalers approximately million million million million million million million million million respectively allocating finalcustomer discounts wholesalers consumer healthcare turnover category wellness oral care nutrition skin health gsk annual report notes financial statements continued turnover segment information continued segment profit pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment profit corporate unallocated costs reconciling items segment profit operating profit operating profit finance income finance costs profit disposal interest associates share tax profits associates joint ventures profit taxation taxation profit taxation year reconciling items segment profit operating profit comprise items specifically allocated segment profit include impairment amortisation intangible assets major restructuring costs include impairments tangible assets computer software transactionrelated adjustments related significant acquisitions proceeds costs disposals associates products businesses significant legal charges expenses settlement litigation government investigations operating income royalty income items pretax impact enactment us tax cuts jobs act depreciation amortisation segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment depreciation amortisation corporate unallocated depreciation amortisation reconciling items segment depreciation amortisation total depreciation amortisation total depreciation amortisation gsk annual report strategic report governance remuneration financial statements investor information turnover segment information continued ppe intangible asset goodwill impairment segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment impairment corporate unallocated impairment reconciling items segment impairment total impairment total impairment ppe intangible asset impairment reversals segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment impairment reversals corporate unallocated impairment reversals reconciling items segment impairment reversals total impairment reversals total impairment reversals net assets segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment net operating assets corporate unallocated net operating assets net operating assets net debt investments associates joint ventures derivative financial instruments current deferred taxation assets held sale excluding cash cash equivalents net assets pharmaceuticals segment includes shionogiviiv healthcare contingent consideration liability million million pfizer put option million million put option liability million related consumer healthcare segment extinguished gsk annual report notes financial statements continued turnover segment information continued geographical information uk regarded groups country domicile turnover location customer uk us rest world external turnover noncurrent assets location subsidiary uk us rest world noncurrent assets noncurrent assets location excludes amounts relating investments deferred tax assets derivative financial instruments pension assets amounts receivable insurance contracts certain noncurrent receivables operating incomeexpense fair value remeasurements equity investments ifrs disposal businesses assets fair value remeasurements contingent consideration recognised business combinations remeasurement viiv healthcare put option liabilities preferential dividends remeasurement consumer healthcare put option liability fair value adjustments derivative financial instruments expenseincome impairment availableforsale equity investments ias disposal availableforsale equity investments ias disposal businesses assets included profit million disposal tapinarof dermavant sciences profit million disposal consumer healthcare tail brands us gain arising increase value shares hindustan unilever limited received disposal horlicks consumer healthcare brands expected complete end net disposal costs fair value remeasurements contingent consideration recognised business combinations included million related acquisition former shionogiviiv healthcare joint venture million payable novartis related vaccines acquisition fair value movements derivatives hedging foreign exchange exposure gsk annual report strategic report governance remuneration financial statements investor information operating profit following items included operating profit employee costs note advertising distribution costs depreciation property plant equipment impairment property plant equipment net reversals amortisation intangible assets impairment intangible assets net reversals net foreign exchange losses inventories cost inventories included cost sales writedown inventories reversal prior year writedown inventories operating lease rentals minimum lease payments contingent rents sublease payments fees payable companys auditor associates relation group see reversals prior year writedowns inventories principally arise reassessment usage demand expectations prior inventory expiration net foreign exchange losses include net loss nil million nil exchange arising reclassification exchange liquidation disposal overseas subsidiaries included within operating profit major restructuring charges million million million see note major restructuring costs fees payable companys auditor associates audit parent company consolidated financial statements audit companys subsidiaries attestation sarbanesoxley act audit auditrelated services taxation compliance taxation advice assurance services services assurance services provided auditor relate agreed upon procedures assurance services outside statutory audit requirements services provided auditor primarily related advisory services year ended december addition fees paid respect gsk pension schemes audit services gsk annual report notes financial statements continued employee costs wages salaries social security costs pension postemployment costs including augmentations note cost sharebased incentive plans severance costs integration restructuring activities increase wages salaries included impact movements exchange rates group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance cost sharebased incentive plans analysed follows share value plan performance share plan share option plans cash settled plans average monthly number persons employed group including directors year number number number manufacturing selling general administration research development average monthly number group employees excludes temporary contract staff numbers group employees end financial year given financial record monthly average number persons employed glaxosmithkline plc nil nil compensation directors senior management members cet aggregate follows wages salaries social security costs pension postemployment costs cost sharebased incentive plans information remuneration directors given remuneration report pages major restructuring costs within pharmaceuticals sector highly regulated manufacturing operations supply chains long lifecycle business mean restructuring programmes particularly involve rationalisation closure manufacturing rd sites likely take several years complete major restructuring costs related specific board approved major restructuring programmes including integration costs following material acquisitions structural significant scale costs individual related projects exceed million existing combined restructuring integration programme incorporates previous major change programme pharmaceuticals restructuring programme restructuring integration programme following novartis transaction july board approved new major restructuring programme designed significantly improve competitiveness efficiency groups cost base savings delivered primarily supply chain optimisation reductions administrative costs gsk annual report strategic report governance remuneration financial statements investor information major restructuring costs continued total restructuring costs million incurred number areas including following restructuring commercial operating model including staff reductions us europe international pharmaceutical commercial operations us respiratory field sales force manufacturing site restructuring including gsk steriles manufacturing facility ulverston united kingdom vaccines transformation remediation restructuring pharmaceutical consumer healthcare supply chains leading simplification operating model improved resource allocation transformation central functions including gsk technology platforms interfaces deliver greater digital synergies simplification applications staff reductions analysis costs charged operating profit programmes follows increase provision major restructuring programmes see note amount provision reversed unused see note impairment losses recognised noncash charges cash costs asset impairments noncash charges principally comprise fixed asset writedowns across support function manufacturing research facilities accelerated depreciation asset lives rd manufacturing shortened result major restructuring programmes charges settled cash include termination leases site closure costs consultancy project management fees analysis major restructuring charges income statement line follows cost sales selling general administration research development operating incomeexpense finance income year december ifrs finance income arising financial assets measured amortised cost financial assets measured fair value profit loss net gains arising hedge ineffectiveness net investment hedges years december december ias interest income arising cash cash equivalents availableforsale investments loans receivables fair value adjustments derivatives fair value profit loss interest income arising financial assets measured amortised cost includes interest income arising assets would classified availableforsale investments loans receivables prior years ias also includes interest income arising certain cash cash equivalents interest income arising financial assets measured fair value profit loss includes interest income arising cash cash equivalents net gains arising hedge ineffectiveness net investment hedges recorded fair value adjustments derivatives fair value profit loss derivatives accounted fair value profit loss designated effective hedging instruments see note financial instruments related disclosures classified heldfortrading financial instruments gsk annual report notes financial statements continued finance expense finance expense arising financial liabilities amortised cost derivatives fair value profit loss net losses arising financial instruments mandatorily measured fair value profit loss reclassification hedges comprehensive income unwinding discounts provisions finance expense derivatives accounted fair value profit loss designated effective hedging instruments see note financial instruments related disclosures classified heldfortrading financial instruments interest expense arising derivatives fair value profit loss relates swap interest expense finance expense includes million charge million credit interest relating historical income tax settlements associates joint ventures groups share tax profits losses associates joint ventures set share tax profits associates share tax profitslosses joint ventures december group held one significant associate innoviva inc summarised income statement information respect innoviva set periods group accounted investment innoviva associate groups share tax profits associates comprehensive income includes profit million comprehensive income nil respect innoviva turnover profit taxation comprehensive income total comprehensive income results innoviva included summarised income statement information represent estimated earnings innoviva relevant periods based publicly available information innovivas turnover royalty income gsk relation relvarbreo ellipta anoro ellipta trelegy ellipta sales aggregated financial information respect gsks share associated undertakings joint ventures set share turnover share tax lossesprofits share comprehensive income share total comprehensive expenseincome groups sales associates joint ventures million million million gsk annual report strategic report governance remuneration financial statements investor information taxation groups tax charge sum total current deferred tax expense taxation charge based profits year uk current year charge rest world current year charge credit respect prior periods total current taxation total deferred taxation total tax gsk made payments million uk corporation tax hmrc amounts uk corporation tax include various business taxes borne uk gsk year deferred tax credit reflected origination current year tax losses offset taxable profits future periods probable well uplift tax carrying value certain consumer healthcare brands result acquisition novartis interest former consumer healthcare joint venture deferred tax credit reflected revaluation existing deferred tax liabilities reflect lower swiss tax rate applicable following swiss tax reform increase deferred tax assets related intragroup profit inventory impact items partly offset revaluation existing deferred tax assets reflect lower us tax rate applicable following enactment us tax reform net deferred tax credit impacted greater extent remeasurement contingent consideration relation former shionogiviiv healthcare joint venture following table reconciles tax charge calculated uk statutory rate group profit tax actual tax charge year reconciliation taxation group profits profit tax uk statutory rate taxation differences overseas taxation rates benefit intellectual property incentives rd credits fv remeasurement nontaxable put options tax losses benefit recognised permanent differences disposals acquisitions permanent differences reassessments prior year estimates us swiss tax reform tax chargetax rate gsk substantial business presence many countries around world impact differences overseas taxation rates arose profits earned countries tax rates higher uk statutory rate significant us belgium india japan adverse impact partly offset increased benefit intellectual property incentives uk patent box belgian patent income deduction regimes regimes provide reduced rate corporate income tax profits earned qualifying patents groups tax rate influenced reassessment open issues tax authorities various jurisdictions together million credit related reduced estimate impact us tax reform following additional guidance released us tax authorities transaction related charges arising groups put option liabilities viiv healthcare former consumer healthcare joint venture novartis future tax charges therefore groups effective tax rate may affected factors acquisitions disposals restructuring location research development activity tax regime reforms resolution open matters tax affairs brought date around world gsk annual report notes financial statements continued taxation continued tax items charged equity statement comprehensive income current taxation sharebased payments defined benefit plans deferred taxation sharebased payments defined benefit plans fair value movements cash flow hedges fair value movements equity investments total chargecredit equity statement comprehensive income items charged statement comprehensive income except tax sharebased payments issues relating taxation integrated nature groups worldwide operations involves significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets line current oecd guidelines gsk bases transfer pricing policy arms length principle however different tax authorities may seek attribute profit activities undertaken jurisdiction potentially resulting double taxation group also open items several jurisdictions concerning matters deductibility particular expenses tax treatment certain business transactions gsk applies riskbased approach determine transactions likely subject challenge probability group would able obtain compensatory adjustments international tax treaties calculation groups total tax charge therefore necessarily involves degree estimation judgement respect certain items whose tax treatment finally determined resolution reached relevant tax authority appropriate formal legal process december group recognised provisions million respect uncertain tax positions million decrease recognised provisions driven reassessment estimates utilisation provisions uncertain tax positions following settlement number open issues tax authorities various jurisdictions whilst ultimate liability matters may vary amounts provided dependent upon outcome agreements relevant tax authorities litigation appropriate group continues believe made appropriate provision periods open yet agreed tax authorities gsk currently anticipate material changes amounts provided transfer pricing tax contingencies next months provision deferred tax liabilities million december million made respect withholding taxation would payable remittance profits certain overseas subsidiaries whilst aggregate amount unremitted profits balance sheet date approximately billion billion majority unremitted profits would subject tax including withholding tax repatriation uk legislation relating company distributions provides exemption tax overseas profits subject certain exceptions deferred tax provided temporary differences million nil arising unremitted profits management ability control future reversal consider reversal probable gsk annual report strategic report governance remuneration financial statements investor information taxation continued movement deferred tax assets liabilities pensions share accelerated post option net capital intangible contingent intragroup employment tax award temporary allowances assets consideration profit benefits losses schemes differences total january exchange adjustments creditcharge income statement creditcharge income statement associated us tax reform credit income statement associated swiss tax reform chargecredit statement comprehensive income equity january exchange adjustments creditcharge income statement creditcharge statement comprehensive income equity reclassification disposal december net credit income statement million included million charge related rd incentives recognised within operating profit taxation charge income statement deferred tax liabilities provided relation intangible assets predominately relate temporary differences arising assets liabilities acquired part historic business combinations group continues recognise deferred tax assets future obligations respect contingent consideration amounts payable minority shareholders payments tax deductible point time payment made deferred tax asset recognised intragroup profits arising intercompany inventory eliminated within consolidated accounts intragroup profits eliminated individual entities tax returns temporary difference arises reverse point time inventory sold externally deferred tax asset recognised tax losses million million related trading losses net temporary differences included accrued expenses tax deduction available paid basis pensions deferred tax asset liabilities recognised balance sheet follows deferred tax assets deferred tax liabilities deferred tax assets recognised us foreign tax credits probable future taxable profits available net amount foreign tax credits deferred tax provided million december million unrecognised unrecognised deferred tax deferred tax tax losses asset tax losses asset unrecognised tax losses trading losses expiring within years years available indefinitely december capital losses expiring available indefinitely december deferred tax assets recognised probable future taxable profit available utilise losses gsk annual report notes financial statements continued earnings per share pence pence pence basic earnings per share diluted earnings per share basic earnings per share calculated dividing profit attributable shareholders weighted average number shares issue period deducting shares held esop trusts treasury shares trustees waived rights dividends shares held esop trusts diluted earnings per share calculated adjusting weighted average number shares used basic calculation assume conversion potentially dilutive shares potentially dilutive share forms part employee share schemes exercise price average market price gsk shares period performance conditions attaching scheme met balance sheet date numbers shares used calculating basic diluted earnings per share reconciled weighted average number shares issue millions millions millions basic dilution share options awards diluted dividends dividend total dividend total dividend total per share dividend per share dividend per share dividend paidpayable pence paid pence paid pence first interim july july july second interim october october october third interim january january january fourth interim april april april total ifrs interim dividends recognised financial statements paid declared gsk normally pays dividend two quarters quarter relates one quarter declared financial statements recognise dividends paid namely third fourth interim dividends first second interim dividends amounts recognised year follows dividends shareholders gsk annual report strategic report governance remuneration financial statements investor information property plant equipment plant land equipment assets buildings vehicles construction total cost january exchange adjustments additions capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost december exchange adjustments additions capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost december depreciation january exchange adjustments charge year disposals writeoffs transfer assets held sale depreciation december exchange adjustments charge year disposals writeoffs transfer assets held sale depreciation december impairment january exchange adjustments disposals writeoffs impairment losses reversal impairments transfer assets held sale impairment december exchange adjustments disposals writeoffs impairment losses reversal impairments transfer assets held sale impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december weighted average interest rate capitalised borrowing costs year disposals writeoffs year included number assets nil net book value longer use business gsk annual report notes financial statements continued property plant equipment continued net book value december groups land buildings included million million held finance leases addition net book value plant equipment vehicles held finance lease december million million impairment losses principally arose decisions rationalise facilities calculated based either fair value less costs disposal value use fair value less costs disposal valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy calculations determine net present value projected riskadjusted posttax cash flows relevant asset cash generating unit applying discount rate group posttax weighted average cost capital wacc adjusted appropriate specific segment country currency risk value use calculations impairment indicated pretax cash flow calculation expected give materially different result test would reperformed using pretax cash flows pretax discount rate group wacc equivalent pretax discount rate approximately net impairment losses charged cost sales million million rd million million sga million million included million million arising major restructuring programmes reversals impairment arose subsequent reviews impaired assets conditions gave rise original impairments deemed longer apply reversals credited cost sales carrying value december assets impairments charged reversed year million million million million computer software reclassified assets construction intangible assets becoming ready use goodwill cost january exchange adjustments transfer assets held sale cost december net book value january net book value december goodwill allocated groups segments follows pharmaceuticals vaccines consumer healthcare net book value december gsk annual report strategic report governance remuneration financial statements investor information goodwill continued recoverable amounts cash generating units assessed using fair value less costs disposal model fair value less costs disposal calculated using discounted cash flow approach posttax discount rate applied projected riskadjusted posttax cash flows terminal value discount rate used based group wacc cash generating units integrated operations across large parts group discount rate adjusted appropriate specific segment country currency risks valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy details relating discounted cash flow models used impairment tests pharmaceuticals vaccines consumer healthcare cash generating units follows valuation basis fair value less costs disposal key assumptions sales growth rates profit margins terminal growth rate discount rate taxation rate determination assumptions growth rates internal forecasts based internal external market information margins reflect past experience adjusted expected changes terminal growth rates based managements estimate future longterm average growth rates discount rates based group wacc adjusted appropriate taxation rates based appropriate rates region period specific projected cash flows five years terminal growth rate discount rate terminal growth rate discount rate pharmaceuticals pa vaccines pa consumer healthcare pa terminal growth rates exceed longterm projected growth rates relevant markets reflect impact future generic competition take account new product launches case valuations indicated sufficient headroom reasonably possible change key assumptions unlikely result impairment related goodwill goodwill monitored segmental level pharmaceuticals cash generating unit comprises collection smaller cash generating units including assets indefinite lives carrying value million million consumer healthcare cash generating unit also comprises collection smaller cash generating units including brands indefinite lives carrying value billion billion details indefinite life brands given note intangible assets gsk annual report notes financial statements continued intangible assets computer licences amortised indefinite life software patents etc brands brands total cost january exchange adjustments capitalised development costs capitalised borrowing costs additions disposals asset writeoffs transfer assets held sale reclassifications cost december exchange adjustments capitalised development costs capitalised borrowing costs additions disposals asset writeoffs transfer assets held sale reclassifications cost december amortisation january exchange adjustments charge year disposals asset writeoffs transfer assets held sale amortisation december exchange adjustments charge year disposals asset writeoffs transfer assets held sale amortisation december impairment january exchange adjustments impairment losses disposals asset writeoffs transfer assets held sale impairment december exchange adjustments impairment losses reversal impairments disposals asset writeoffs transfer assets held sale impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december weighted average interest rate capitalised borrowing costs year net book value computer software included million million internally generated costs carrying value december intangible assets impairments charged reversed year following impairments reversals million million patent expiry dates groups significant assets relevant set pages gsk annual report strategic report governance remuneration financial statements investor information intangible assets continued amortisation impairment losses net reversals charged income statement follows amortisation net impairment losses cost sales selling general administration research development licences patents etc includes large number acquired licences patents knowhow agreements marketing rights either marketed use still development note acquisitions disposals gives details additions business combinations year book values largest individual items follows meningitis portfolio dolutegravir benlysta fluarixflulaval hiv assets acquired bms selzentry okairos technology platform others meningitis portfolio includes menveo bexsero men abcwy menjugate indefinite life brands comprise portfolio consumer healthcare products primarily acquired acquisitions sterling winthrop inc block drug company inc cns inc novartis consumer healthcare business together number pharmaceutical brands acquisition stiefel laboratories inc book values major brands follows voltaren otrivin fenistil theraflu panadol sensodyne lamisil breathe right stiefel trade name excedrin physiogel polident others brands considered indefinite life given strength durability brand level marketing support brands relatively similar stable profitable market sectors similar risk profiles size diversification market shares mean risk marketrelated factors causing reduction lives brands considered relatively low group aware material legal regulatory contractual competitive economic factors could limit useful lives accordingly amortised brand tested annually impairment amortised intangible assets tested indicators impairment arise testing applies fair value less costs disposal methodology generally using posttax cash flow forecasts terminal value calculation discount rate equal group posttax wacc adjusted appropriate specific segment country currency risks valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy main assumptions include future sales price volume growth product contribution future expenditure required maintain products marketability registration relevant jurisdictions exchange rates assumptions based past experience reviewed part managements budgeting strategic planning cycle changes market conditions sales erosion competition terminal growth rates applied nil managements estimates future longterm average growth rates relevant markets case valuations indicate sufficient headroom reasonably possible change key assumptions unlikely result impairment intangible assets gsk annual report notes financial statements continued investments associates joint ventures joint joint ventures associates total ventures associates total january exchange adjustments additions disposals distributions received movements profitloss tax recognised consolidated income statement december group held one significant associate december innoviva inc december group owned million shares innoviva biopharmaceutical company listed nasdaq innoviva partnered gsk development long acting beta agonist vilanterol currently receives royalty income sales products contain component namely relvarbreo ellipta anoro ellipta also economic interest royalties paid gsk sales trelegy ellipta remaining economic interest royalties held theravance biopharma inc group holds common stock investment innoviva market value million december million summarised balance sheet information based published information respect innoviva set december december noncurrent assets current assets current liabilities noncurrent liabilities net assetsliabilities interest associated undertaking goodwill fair value adjustments carrying value december investments investments designated investments measured measured fvtoci fvtpl january exchange adjustments additions net fair value movements comprehensive income net fair value movements profit loss impairment losses disposals settlements transfers assets held sale december investments comprise noncurrent equity investments recorded fair value balance sheet date investments traded active market fair value determined reference relevant stock exchange quoted bid price investments fair value estimated management reference relevant available information including current market value similar instruments discounted cash flows underlying net assets investments include listed investments million million gsk annual report strategic report governance remuneration financial statements investor information investments continued gsk elected designate majority equity investments measured fair value comprehensive income fvtoci significant investments held december theravance biopharma inc group holds common stock orchard group holds andme group holds investments fair value december million million million million respectively investment individually material investments include equity stakes companies gsk research collaborations companies provide access biotechnology developments potential interest information dividends received investments measured fvtoci provided note operating incomeexpense disposal equity investments measured fvtoci accumulated fair value movements reclassified fair value reserve retained earnings investments fair value million disposed year cumulative gain investments tax million certain investments investments funds limited lives measured fair value profit loss fvtpl cumulative gainloss investments measured fvtpl disposed year nil fair value investments derecognition nil prior groups implementation ifrs cumulative fair value movements based average cost shares acquired different times investments disposed period reclassified fair value reserve income statement impairment losses recorded prior year recognised income statement within operating income together amounts reclassified fair value reserve recognition impairments impairments resulted prolonged significant declines fair value equity investments acquisition cost carrying value december investments impaired follows original cost cumulative impairments recognised income statement subsequent fair value increases carrying value december cumulative impairments investments designated measured fvtoci ifrs transferred retained earnings fair value reserve january adoption ifrs noncurrent assets amounts receivable insurance contracts pension schemes surplus receivables amounts receivable insurance contacts held fair value profit loss regards receivables million million classified financial assets million classified fair value profit loss remaining balance million expected credit loss allowance immaterial december inventories raw materials consumables work progress finished goods gsk annual report notes financial statements continued trade receivables trade receivables net loss allowance accrued income prepayments interest receivable employee loans advances receivables trade receivables included million million due associates joint ventures receivables included nil million due associates joint ventures loss allowance january implementation ifrs january adjusted exchange adjustments charge year subsequent recoveries amounts provided utilised december total trade receivables balance million considered credit impaired million expected credit loss allowance applied amount purchased originated credit impaired receivables million million classified financial assets million classified fair value profit loss remaining balance million expected credit loss allowance million recognised december charge reported profit loss year discussion credit risk practices please refer note cash cash equivalents cash bank hand shortterm deposits addition million cash cash equivalents reported assets held sale see note assets held sale cash cash equivalents included billion billion available general use due restrictions applying subsidiaries held restrictions include exchange controls taxes repatriation gsk annual report strategic report governance remuneration financial statements investor information assets held sale property plant equipment goodwill intangibles inventory cash cash equivalents noncurrent assets disposal groups transferred assets held sale expected carrying amounts recovered principally disposal sale considered highly probable held lower carrying amount fair value less costs sell assets held sale primarily reflect disposal group arising gsks agreement divest horlicks consumer healthcare nutritional brands unilever plc announced december expected complete end see note acquisitions disposals included within assets held sale assets written fair value less costs sell million million valuation methodology used significant inputs based observable market data therefore valuation classified level fair value hierarchy trade payables trade payables wages salaries social security consumer healthcare put option viiv healthcare put option payables deferred income customer return rebate accruals accruals trade payables included million million due associates joint ventures group provides limited supplier financing arrangements certain customers amounts involved december material revenue recognised year included deferred income january million remaining balance million related proceeds site disposal india expected complete expected complete customer return rebate accruals provided group point sale respect estimated rebates discounts allowances payable customers included million million respect us pharmaceuticals vaccines fully described group financial review accruals made time sale actual amounts paid based claims made time initial recognition sale amounts estimated may fully reflect final outcome subject change dependent upon amongst things types buying group product sales mix level accrual reviewed adjusted quarterly light historical experience actual amounts paid changes arrangements future events could cause assumptions accruals based change could affect future results group pfizers put option shareholding viiv healthcare currently exercisable amount liability recognised derived several valuation methodologies including reference market multiples comparable companies table shows indicative basis income statement balance sheet sensitivity pfizer put option reasonably possible changes key assumptions increasedecrease financial liability lossgain income statement increase sales forecasts decrease sales forecasts cent appreciation us dollar cent depreciation us dollar cent appreciation euro cent depreciation euro explanation accounting viiv healthcare set gsk annual report notes financial statements continued pensions postemployment benefits pension postemployment costs uk pension schemes us pension schemes overseas pension schemes unfunded postretirement healthcare schemes analysed funded defined benefithybrid pension schemes unfunded defined benefit pension schemes unfunded postretirement healthcare schemes defined benefit schemes defined contribution pension schemes costs defined benefit pension postretirement healthcare schemes charged income statement follows cost sales selling general administration research development gsk entities operate pension arrangements cover groups material obligations provide pensions retired employees arrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length service pension costs defined benefit schemes accounting purposes calculated using projected unit method certain countries pension benefits provided unfunded basis administered trustee companies formal independent actuarial valuations groups main plans undertaken regularly normally least every three years actuarial movements year recognised statement comprehensive income discount rates derived aa rated corporate bond yields except countries deep market corporate bonds government bond yields used discount rates selected reflect term expected benefit payments projected inflation rate pension increases longterm predictions based yield gap longterm indexlinked fixed interest gilts uk mortality rates determined adjusting saps standard mortality tables reflect recent scheme experience rates projected reflect improvements life expectancy line cmi projections longterm rate improvement per year males females us mortality rates calculated using rp white collar table adjusted reflect recent experience rates projected using mp allow future improvements life expectancy gsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits continued average life expectancy assumed individual age projected apply individual age follows uk us male female male female years years years years current projected assets funded schemes generally held separately administered trusts either specific assets proportion general fund insurance contracts assets invested different classes order maintain balance risk return investments diversified limit financial effect failure individual investment physical asset allocation strategy three four uk plans remains unchanged returnseeking assets liabilitymatching assets remaining plan materially derisked given relative higher maturity well improved funding position asset allocation us plans currently set returnseeking assets liabilitymatching assets pension plans exposed risk arises estimated market value plans assets might decline investment returns might reduce estimated value plans liabilities might increase line agreed mix returnseeking assets generate future returns liabilitymatching assets better match future pension obligations group defined overall longterm investment strategy plans investments across broad range assets main market risks within asset hedging portfolio credit risk interest rates longterm inflation equities property currency bank counterparty risk plan liabilities series future cash flows relatively long duration ias basis cash flows sensitive changes expected longterm inflation rate discount rate aa corporate bond yield curve increase longterm inflation corresponds increase liabilities increase discount rate corresponds decrease liabilities interest rate risk credit rate risk us partially hedged targets based accounting measure plan liabilities uk plans interest rate inflation hedging strategy place targets based economic measure plan liabilities furthermore plans also currently hedge portion equity exposure staggered maturity profile uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants subsequent uk employees entitled join defined contribution scheme addition group operates number postretirement healthcare schemes principal one us group applied following financial assumptions assessing defined benefit liabilities uk us rest world pa pa pa pa pa pa pa pa pa rate increase future earnings discount rate expected pension increases na na na cash balance creditconversion rate na na na inflation rate sensitivity analysis detailing effect changes assumptions provided analysis provided reflects assumption changes material impact results group gsk annual report notes financial statements continued pensions postemployment benefits continued amounts recorded income statement statement comprehensive income three years ended december relation defined benefit pension postretirement healthcare schemes follows postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service costcredit net interest incomecost gains settlements expenses remeasurement gainslosses recorded statement comprehensive income postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service costcredit net interest cost expenses remeasurement gainslosses recorded statement comprehensive income postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service cost net interest cost gains settlements expenses remeasurement losses recorded statement comprehensive income amounts included within past service costs uk include charge million relation estimated impact gmp equalisation million million million augmentation costs million arising major restructuring programmes see note provisions gsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits continued summarised balance sheet presentation group defined benefit pension schemes postretirement benefits set table recognised noncurrent assets pension schemes surplus recognised assets held sale postretirement benefits recognised pensions postemployment benefits pension schemes deficit postretirement benefits event plan windup gsk believes uk pension scheme rules provide company right refund surplus assets following full settlement plan liabilities result net surplus uk defined benefit pension schemes recognised full fair values assets liabilities uk us defined benefit pension schemes together aggregated data defined benefit pension schemes group follows uk us rest world group december equities listed unlisted multiasset funds property listed unlisted corporate bonds listed unlisted government bonds listed insurance contracts assets fair value assets present value scheme obligations net surplusobligation included noncurrent assets included pensions postemployment benefits actual return plan assets multiasset funds comprise investments pooled investment vehicles invested across range asset classes increasing diversification within growth portfolio assets category comprises cash mark market values derivative positions previous years indexlinked gilts held part uk repo programme included government bonds related loan included within assets value million december million programme cancelled gsk annual report notes financial statements continued pensions postemployment benefits continued uk us rest world group december equities listed unlisted multiasset funds property unlisted corporate bonds listed unlisted government bonds listed insurance contracts assets fair value assets present value scheme obligations net surplusobligation included noncurrent assets included pensions postemployment benefits actual return plan assets uk us rest world group december equities listed unlisted multiasset funds property unlisted corporate bonds listed unlisted government bonds listed insurance contracts assets fair value assets present value scheme obligations net obligation included noncurrent assets included pensions postemployment benefits actual return plan assets gsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits continued postretirement pensions benefits uk us rest world group group movements fair values assets assets january exchange adjustments interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december exchange adjustments interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december exchange adjustments interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december group made special funding contributions uk pension schemes million million million million nil us scheme gsk reached revised agreement trustees uk pension schemes make additional contributions eliminate pension deficits identified within schemes december actuarial funding valuation based funding agreements additional contributions eliminate pension deficit expected million payments agreed years included within note commitments funding commitment supersedes previous agreement made contributions based government bond yield curve approach selecting discount rate rate chosen included allowance expected investment returns reflected asset mix schemes employer contributions including special funding contributions estimated approximately million respect defined benefit pension schemes million respect postretirement benefits gsk annual report notes financial statements continued pensions postemployment benefits continued postretirement pensions benefits uk us rest world group group movements defined benefit obligations obligations january exchange adjustments service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december exchange adjustments service cost past service costcredit interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december exchange adjustments service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december defined benefit pension obligation analysed follows funded unfunded liability us postretirement healthcare scheme assessed using assumptions us pension scheme together assumption future medical inflation grading thereafter december us postretirement healthcare scheme obligation million million million postretirement benefits unfunded gsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits continued movement net defined benefit liability follows january exchange adjustments service cost past service cost interest cost settlements curtailments remeasurements return plan assets excluding amounts included interest gain change demographic assumptions gainloss change financial assumptions experience lossesgains employer contributions expenses december remeasurements included within postretirement benefits detailed gain change demographic assumptions gainloss change financial assumptions experience gains gsk annual report notes financial statements continued pensions postemployment benefits continued defined benefit pension obligation analysed membership category follows active retired deferred postretirement benefit obligation analysed membership category follows active retired deferred weighted average duration defined benefit obligation follows years years years pension benefits postretirement benefits sensitivity analysis effect changes assumptions used benefit obligations annual defined benefit pension postretirement costs detailed information determined taking account duration liabilities overall profile plan memberships decrease discount rate would following approximate effect increase annual pension cost decrease annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation oneyear increase life expectancy would following approximate effect increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation increase rate future healthcare inflation would following approximate effect increase annual postretirement benefits cost increase postretirement benefits obligation increase inflation would following approximate effect increase annual pension cost increase pension obligation gsk annual report strategic report governance remuneration financial statements investor information provisions legal major employee restructuring related disputes programmes provisions provisions total january exchange adjustments charge year reversed unused unwinding discount utilised reclassifications movements transfer pension obligations december settled within one year settled one year december legal disputes major restructuring programmes group involved substantial number legal group undertaking two major restructuring programmes disputes including notification possible claims set combined restructuring integration programme note legal proceedings provisions legal disputes major restructuring programme programmes focused include amounts relating product liability antitrust government primarily simplifying supply chain processes rationalising investigations contract terminations self insurance groups manufacturing network restructuring environmental cleanup pharmaceuticals commercial operations charge year million net reversals provisions staff severance payments made management estimated insurance recoveries primarily related provisions made formal decision eliminate certain positions product liability cases commercial disputes various communicated groups employees affected government investigations appropriate consultation procedures completed appropriate provision made staff severance payments made discount provisions increased million immediately increased million discount calculated using riskadjusted projected cash flows riskfree rates return pension augmentations arising staff redundancies million million charged respect product liability claims related certain products year transferred pension obligations provision sufficient history claims made settlements enable shown note pensions postemployment benefits management make reliable estimate provision required asset writedowns recognised impairments cover unasserted claims ultimate liability matters property plant equipment note property plant may vary amounts provided dependent upon equipment majority amounts provided expected outcome litigation proceedings investigations possible utilised next two years settlement negotiations employeerelated provisions nature groups business number employee related provisions include obligations certain medical matters may subject negotiation litigation benefits disabled employees spouses us many years litigation proceedings including various appeal december provision benefits amounted procedures often take many years reach resolution million million employee benefits reflect outofcourt settlement discussions also often protracted variety provisions severance costs jubilee awards indemnified disputes recognise provision charge longservice benefits given nature provisions corresponding receivable amounts likely settled many years group potential settlement discussions number provisions disputes amounts provided based included provisions insurance provisions million current assessment progress disputes million onerous property lease provisions estimates million amount provided december million million number provisions settled within one year december including vehicle insurance regulatory matters expected million nil provision made legal disputes reimbursed third parties discussion legal issues see note legal proceedings gsk annual report notes financial statements continued noncurrent liabilities accruals deferred income payables payables includes acquisition accounting market value lease adjustments number employeerelated liabilities net debt listing exchange current assets liquid investments cash cash equivalents cash cash equivalents reported assets held sale shortterm borrowings commercial paper bank loans overdrafts obligations finance leases drawn bank facility us us medium term note new york stock exchange european medium term note london stock exchange longterm borrowings european medium term note london stock exchange euribor european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange libor us us medium term note new york stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange us us medium term note new york stock exchange european medium term note london stock exchange obligations finance leases longterm borrowings net debt gsk annual report strategic report governance remuneration financial statements investor information net debt continued current assets liquid investments classified financial assets amortised cost previously availableforsale investments prior years december included us treasury notes government bonds effective interest rate liquid investments december approximately approximately liquid investment balances december earning interest floating rates amount million million liquid investment balances december earning interest fixed rates amount nil nil effective interest rate cash cash equivalents december approximately approximately cash cash equivalents december earning interest floating fixed rates amount million million respectively million million noninterest bearing holdings amount million gsks policy regarding credit quality cash cash equivalents referred note financial instruments related disclosures shortterm borrowings gsk billion billion us commercial paper programme billion billion issue december billion billion gsk billion fiveyear committed facility billion billion day committed facility fiveyear committed facility agreed september extended one year september day committed facility agreed september additional bank facilities agreed support transactions two remained active december june billion drawn support acquisition novartis remaining stake consumer healthcare joint venture addition billion bank facility agreed december support acquisition tesaro undrawn december liquid investments cash cash equivalents shown table weighted average interest rate commercial paper borrowings december weighted average interest rate current bank loans overdrafts december december shortterm loan rates argentina disproportionate effect weighted average interest rate excluding impact weighted average interest rate current bank loans overdrafts stands average effective preswap interest rate notes classified short term december material decrease rate largely reflects maturity coupon note may upcoming maturity coupon note december longterm borrowings yearend gsk longterm borrowings billion billion billion billion falls due five years average effective preswap interest rate notes issue december approximately approximately longterm borrowings repayable five years carry interest effective rates repayment dates ranging pledged assets group held pledged investments us treasury notes par value million million million million security irrevocable letters credit issued groups behalf respect groups selfinsurance activity provisions respect selfinsurance included within provisions legal disputes discussed note provisions addition million assets included note noncurrent assets form part net debt pledged collateral future rental payments operating lease arrangements previously entered human genome sciences inc prior acquisition group terminated finance lease obligations rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total future rental payments future finance charges total finance lease obligations gsk annual report notes financial statements continued contingent liabilities december contingent liabilities comprising guarantees discounted bills items arising normal course business amounted million million december nil million financial assets pledged collateral contingent liabilities provision made outcome tax legal disputes probable group suffer outflow funds possible make reliable estimate outflow december disputes provision made possible make reliable estimate potential outflow funds might required settle disputes possibility outflow remote descriptions significant legal disputes group party set note legal proceedings share capital share premium account share ordinary shares p premium number share capital authorised december december december share capital issued fully paid january issued employee share schemes ordinary shares acquired esop trusts december issued employee share schemes ordinary shares acquired esop trusts december issued employee share schemes december december december number shares issuable employee share schemes number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemes gsk annual report strategic report governance remuneration financial statements investor information movements equity retained losses reserves amounted million december million loss million loss million million million relates joint ventures associated undertakings cumulative translation exchange equity follows net translation exchange included non total retained fair value controlling translation earnings reserve interests exchange january exchange movements overseas net assets december exchange movements overseas net assets reclassification exchange liquidation disposal overseas subsidiaries december exchange movements overseas net assets december analysis comprehensive income equity category follows non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges fair value movements cash flow hedges reclassification cash flow hedges income expense deferred tax fair value movements cash flow hedges deferred tax reversed reclassification cash flow hedges items reclassified income statement exchange movements overseas net assets noncontrolling interests fair value movements equity investments deferred tax fair value movements equity investments remeasurement gains defined benefit plans tax remeasurement gains defined benefit plans comprehensive incomeexpense year non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange liquidation disposal overseas subsidiaries fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax fair value movements availableforsale investments deferred tax reversed reclassification availableforsale investments fair value movements cash flow hedges items reclassified income statement exchange movements overseas net assets noncontrolling interests remeasurement gains defined benefit plans tax remeasurement gains defined benefit plans comprehensive incomeexpense year gsk annual report notes financial statements continued movements equity continued non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges fair value movements availableforsale investments reclassification fair value movements availableforsale investments deferred tax reversed reclassification availableforsale investments reclassification cash flow hedges income statement fair value movements cash flow hedges deferred tax fair value movements cash flow hedges items reclassified income statement exchange movements overseas net assets noncontrolling interests remeasurement losses defined benefit plans tax remeasurement losses defined benefit plans comprehensive income year analysis reserves follows esop trust fair value cash flow shares reserve hedge reserve reserves total january exchange adjustments transferred income expense year disposals transferred income expense year impairments net fair value movement year ordinary shares acquired esop trusts writedown shares held esop trusts december exchange adjustments transferred income expense year disposals net fair value movement year ordinary shares acquired esop trusts writedown shares held esop trusts december implementation ifrs december adjusted exchange adjustments transferred retained earnings year disposal equity investments net fair value movement year writedown shares held esop trusts december reserves include various nondistributable merger premerger reserves amounting million december million million reserves also include capital redemption reserve created result share buyback programme amounting million december million million gsk annual report strategic report governance remuneration financial statements investor information related party transactions december gsk owned million shares innoviva inc biopharmaceutical company listed nasdaq gsk began recognising innoviva associate september royalties due gsk innoviva year million million december balance payable gsk innoviva million million december gsk held interest japan vaccine co ltd jvc subsidiary glaxosmithkline kk joint venture daiichi sankyo co ltd primarily responsible development marketing certain prophylactic vaccines japan gsk sold million million vaccine products joint venture december trading balance due gsk jvc million million balance payable gsk jvc nil nil loans million medicxi ventures lp million index ventures life vi jersey lp remained due gsk december gsk increased equity investment kurma biofund ii fcpr million apollo therapeutics llp million longwood founders fund lp million reduced liability qura therapeutics llc million december outstanding liability qura million aggregate compensation directors cet given note employee costs adjustments reconciling profit tax operating cash flows profit tax tax profits share tax profits associates joint ventures finance expense net finance income depreciation amortisation intangible assets impairment assets written profit sale businesses profit sale intangible assets profit sale investments associates profit sale equity investments gain consumer healthcare joint venture put hedging business acquisition costs changes working capital decreaseincrease inventories increase trade receivables increase trade payables decrease receivables contingent consideration paid see note noncash increase contingent consideration liabilities increase payables increasedecrease pension provisions sharebased incentive plans fair value adjustments cash generated operations gsk annual report notes financial statements continued reconciliation net cash flow movement net debt net debt beginning year increasedecrease cash bank overdrafts decrease liquid investments net increase longterm loans repayment shortterm notes increase inrepayment shortterm loans net repayment obligations finance leases exchange adjustments noncash movements movement net debt net debt end year january profit reclass december exchange loss ifications cash flow analysis changes net debt liquid investments cash cash equivalents cash cash equivalents ahfs overdrafts debt due within one year commercial paper europeanus medium term notes bank facilities debt due one year europeanus medium term notes bank facilities net debt analysis changes liabilities financing activities debt due within one year debt due one year hedge borrowings derivative financial instruments financing items interest payable total liabilities financing activities information significant changes net debt see note net debt gsk annual report strategic report governance remuneration financial statements investor information acquisitions disposals details acquisition disposal significant subsidiaries associates joint ventures businesses given business acquisitions business acquisitions business disposals gsk made number small business disposals year net cash consideration million cash flows associates associates joint joint business venture venture disposals investments disposals cash consideration net deferred consideration received cash cash equivalents divested cash inflow transactions signed yet completed december gsk agreed divest horlicks consumer healthcare nutrition brands unilever plc merge gsk consumer healthcare limited hindustan unilever limited total consideration valued approximately billion gsk consumer healthcare limited public company listed national stock exchange nse bombay stock exchange bse india gsk holds stake hindustan unilever limited public company listed nse bse following merger gsk approximately hindustan unilever limited transaction expected complete end subject fulfilment certain conditions including approval merger shareholders gsk consumer healthcare limited hindustan unilever limited group entered forward foreign exchange contracts designated cash flow hedge part foreign exchange exposure arising transaction addition exposure share price movements forward purchase shares hindustan unilever limited recognised embedded derivative embedded derivative asset position fair value million december december gsk agreed acquire tesaro inc oncologyfocused biopharmaceutical company billion billion cash transaction completed nd january exercise determine acquisition fair values assets liabilities yet complete initial transaction costs recognised december december gsk agreed form new consumer healthcare joint venture acquiring pfizers consumer health business allshare transaction pfizer hold combined business controlled gsk new consumer healthcare joint venture expected formed second half subject approvals initial transaction costs recognised december gsk annual report notes financial statements continued acquisitions disposals continued business acquisitions business acquisitions business disposals gsk made number small business disposals year net cash consideration million including contingent consideration receivable million profit disposal determined follows total consideration including currency forwards purchase adjustments net assets sold goodwill intangible assets property plant equipment inventory cash cash equivalents net assets transaction costs reclassification exchange comprehensive income profit disposal investment associates joint ventures year gsk made cash investments million associates joint ventures addition gsk sold holdings two associates million cash total cash consideration net book value shares reclassification exchange comprehensive income transaction costs profit disposal cash flows associates associates joint joint business venture venture disposals investments disposals cash consideration net deferred consideration received cash cash equivalents divested transaction costs paid cash inflow gsk annual report strategic report governance remuneration financial statements investor information acquisitions disposals continued business acquisitions gsk completed two small business acquisitions cash consideration million paid year acquire hiv rd preclinical discovery stage portfolio bristol myers squibb consideration contingent commercial milestones future sales performance may due initial estimate million recognised contingent consideration intangible assets acquired valued million goodwill million recognised gsk formed galvani bioelectronics limited year acquired intangible assets million cash cash equivalents million verily life sciences llc return shareholding galvani bioelectronics fair value shareholding million gsk also recognised credit million noncontrolling interests representing verilys share net assets contributed business disposals gsk also made number small business disposals year net cash consideration million addition deferred consideration receivable million recognised cash flows business business acquisitions disposals cash consideration paidreceived purchase adjustments cash cash equivalents acquired cash inflow addition gsk made cash investments million associates joint ventures gsk annual report notes financial statements continued contingent consideration liabilities consideration certain acquisitions includes amounts contingent future events development milestones sales performance group provided fair value contingent consideration follows shionogi viiv novartis healthcare vaccines total january additions business combinations remeasurement income statement cash payments operating cash flows cash payments investing activities movements december remeasurement income statement cash payments operating cash flows cash payments investing activities december remeasurement income statement cash payments operating cash flows cash payments investing activities december contingent consideration payable december million million expected paid within one year contingent consideration payable respect novartis vaccines business included sales milestone million settled january consideration payable acquisition shionogiviiv healthcare joint venture novartis vaccines business expected paid number years result total estimated liabilities discounted present values shown shionogiviiv healthcare contingent consideration liability discounted novartis vaccines contingent consideration liability discounted partly partly shionogiviiv healthcare novartis vaccines contingent consideration liabilities calculated principally based forecast sales performance specified products lives products table shows indicative basis income statement balance sheet sensitivity reasonably possible changes key inputs valuations contingent consideration liabilities shionogi novartis viiv healthcare vaccines increasedecrease financial liability lossgain income statement increase sales forecasts decrease sales forecasts increase discount rate decrease discount rate increase probability milestone success decrease probability milestone success cent appreciation us dollar cent depreciation us dollar cent appreciation euro cent depreciation euro explanation accounting viiv healthcare set gsk annual report strategic report governance remuneration financial statements investor information noncontrolling interests viiv healthcare viiv healthcare subgroup material noncontrolling interest summarised financial information respect viiv healthcare group follows turnover profitloss taxation comprehensive income total comprehensive incomeexpense noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net liabilities net cash inflow operating activities net cash outflow investing activities net cash outflow financing activities decreaseincrease cash bank overdrafts year financial information relates viiv healthcare group standalone basis impact grouprelated adjustments primarily related recognition preferential dividends profit taxation million profit taxation million loss taxation million stated charging preferential dividends payable gsk shionogi pfizer charge million million million remeasurement contingent consideration payable acquisition former shionogiviiv healthcare joint venture consideration expected paid number years following amounts attributable viiv healthcare group included gsks consolidated statement comprehensive income consolidated statement changes equity consolidated balance sheet total comprehensive incomeexpense year attributable noncontrolling interests dividends paid noncontrolling interests noncontrolling interests consolidated balance sheet gsk annual report notes financial statements continued noncontrolling interests continued consumer healthcare joint venture group acquired novartis interest consumer healthcare joint venture obtain ownership acquisition became unconditional may completed june summarised financial information respect consumer healthcare joint venture follows period ended may turnover profit taxation comprehensive expenseincome total comprehensive expenseincome noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets period ended may net cash inflow operating activities net cash inflowoutflow investing activities net cash outflow financing activities increasedecrease cash bank overdrafts year financial information relates consumer healthcare joint venture standalone basis impact grouprelated adjustments major restructuring charges following amounts attributable consumer healthcare joint venture included gsks consolidated statement comprehensive income consolidated statement changes equity consolidated balance sheet total comprehensive income year attributable noncontrolling interests dividends paid noncontrolling interests noncontrolling interests consolidated balance sheet gsk annual report strategic report governance remuneration financial statements investor information commitments contractual obligations commitments contracted provided financial statements intangible assets property plant equipment investments purchase commitments pensions commitments interest loans finance lease charges commitments related intangible assets include milestone payments dependent successful clinical development meeting specified sales targets represent maximum would paid milestones however unlikely achieved amounts riskadjusted discounted decrease intangible commitments mainly attributable reduction commitments third parties nkarta inc gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified december actuarial funding valuation payment million due payment million due table includes commitment excludes normal ongoing annual funding requirement uk approximately million group also commitments principally relate revenue payments made licences alliances commitments respect future interest payable loans disclosed taking account effect interest rate swaps commitments noncancellable operating leases disclosed million million provided commitments groups balance sheet commitments noncancellable operating leases rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total commitments noncancellable operating leases gsk annual report notes financial statements continued financial instruments related disclosures objective treasury activity minimise posttax addition billion bank facility agreed december net cost financial operations reduce volatility benefit support acquisition tesaro undrawn earnings cash flows gsk uses variety financial instruments december month facility includes two sixmonth finance operations derivative financial instruments extension options manage market risks operations derivatives principally gsk billion european medium term note programme comprise foreign exchange forward contracts swaps december billion notes issue used swap borrowings liquid assets currencies programme group also billion billion required group purposes well interest rate swaps notes issue december us shelf registration used manage exposure financial risks changes gsks borrowings mature dates interest rates financial instruments reduce uncertainty foreign currency transactions interest payments put option owned pfizer viiv healthcare exercisable reviewing liquidity requirements gsk considers sufficient derivatives used exclusively hedging purposes relation financing options available put option exercised underlying business activities trading speculative instruments market risk capital management interest rate risk management objective gsks treasury activity minimise effective gsks financial strategy supports groups strategic priorities net interest cost balance mix debt fixed floating regularly reviewed board gsk manages capital rates time structure group appropriate mix debt equity groups main interest rate risk arises borrowings capital structure group consists net debt investments floating rates refinancing maturing fixed rate billion see note net debt total equity including debt changes interest rates affect future cash flows items related noncontrolling interests billion see fair values financial instruments policy interest rate consolidated statement changes equity risk management limits net amount floating rate debt total capital including provided noncontrolling interests specific cap reviewed agreed less annually billion board group continues manage financial policies credit majority debt issued fixed interest rates changes profile particularly targets shortterm credit ratings floating rates interest significantly affect groups p maintaining single longterm ratings consistent net interest charge includes borrowings interest targets groups longterm credit rating standard rate swaps place removes impact associated poors negative outlook moodys investor services periodic repricing shortterm borrowings including bank facilities moodys negative outlook groups shortterm credit exposed risk future changes market interest rate ratings p standard poors moodys majority cash liquid investments respectively foreign exchange risk management liquidity risk management foreign currency transaction exposures arising external trade flows normally hedged foreign currency transaction gsks policy borrow centrally order meet anticipated exposures arising internal trade flows selectively hedged funding requirements strategy diversify liquidity sources groups objective minimise exposure overseas operating using range facilities maintain broad access financial subsidiaries transaction risk matching local currency income markets local currency costs possible gsks internal trading december gsk billion borrowings transactions matched centrally intercompany payment repayable within one year held billion cash cash terms managed reduce foreign currency risk foreign currency equivalents liquid investments billion cash flows hedged selectively including hedges held centrally gsk access shortterm finance foreign exchange risk arising acquisitions disposals billion billion us commercial paper programme assets possible gsk manages cash surpluses billion billion issue december borrowing requirements subsidiary companies centrally using billion gsk billion fiveyear committed forward contracts hedge future repayments back facility billion billion day committed facility originating currency fiveyear committed facility agreed september order reduce foreign currency translation exposure group extended one year september day seeks denominate borrowings currencies principal committed facility agreed september facilities assets cash flows primarily denominated us undrawn december gsk considers level dollars euros sterling borrowings swapped committed facilities adequate given current liquidity currencies required requirements borrowings denominated swapped foreign currencies additional bank facilities agreed support match investments overseas group assets may treated transactions two remain active december hedge relevant assets forward contracts major june billion drawn support acquisition currencies also used reduce exposure groups novartis remaining stake consumer healthcare joint investment overseas assets see net investment hedges venture facility due mature december section note details includes one extension option june gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued credit risk gsk actively manages exposure credit risk reducing surplus cash balances wherever possible part gsks strategy credit risk risk counterparty default regionalise cash management concentrate cash centrally contractual obligations resulting financial loss group much possible table sets credit exposure arises cash cash equivalents favourable derivative counterparties rating liquid investments cash cash financial instruments held banks financial institutions equivalents derivatives well credit exposures wholesale retail customers including outstanding receivables gross asset position derivative contract considered purpose table although isda agreements group considers maximum credit risk december amount risk net position counterparty table e million december million sets groups financial assets liabilities total groups financial assets exception offset basis investments comprising equity investments bear equity risk rather credit risk see details december million cash categorised held groups total financial assets december gsks unrated subinvestment grade rated counterparties lower greatest concentration credit risk billion citibank bbbbaa million cash transit remaining aa billion citibank aa billion exposure concentrated overseas banks used local cash one us wholesaler bbbbaa management investment purposes including million nigeria held united bank africa zenith bank stanbic ibtc bank change estimation techniques first bank nigeria million btv austria million significant assumptions made current reporting period nacion argentina bank million banco de la republica assessing loss allowance financial assets amortised cost uruguay million bank balances deposits held since adoption ifrs start current reporting bbbbaa rated counterparties million held bbb period baa rated counterparties including balances deposits treasuryrelated credit risk million hdfc bank india million state bank gsk sets global counterparty limits gsks banking india banks used local investment purposes investment counterparties based longterm credit ratings gsk measures expected credit losses cash cash moodys standard poors usage limits equivalents function individual counterparty credit ratings monitored daily associated month default rates expected credit losses cash cash equivalents thirdparty financial derivatives deemed immaterial loss experienced bbba aaaaaa aaaa aa bbbbaa unrated total bank balances deposits us treasury treasury repo money market funds liquidity funds government securities rd party financial derivatives total bbba aaaaaa aaaa aa bbbbaa unrated total bank balances deposits us treasury treasury repo money market funds liquidity funds government securities rd party financial derivatives total credit ratings assigned standard poors moodys respectively opinions two rating agencies differ gsk assigns lower rating two counterparty local rating agency fitch data source available ratings converted global ratings equivalent standard poors moodys using published conversion tables credit ratings form basis assessment expected credit loss treasury related balances held amortised cost bank balances deposits government securities gsk annual report notes financial statements continued financial instruments related disclosures continued gsks centrally managed cash reserves amounted billion credit enhancements december available within three months group uses credit enhancements including factoring includes billion cash managed group viiv credit insurance minimise credit risk trade receivables healthcare owned subsidiary group invested group new global insurance programme centrally managed liquid assets bank deposits aaaaaa rated launched order consolidate locally negotiated programmes us treasury treasury repo money market funds aaa expand use credit insurance new markets aaa rated liquidity funds december million gsk trade receivables insured protecting gsks account receivables balance loss wholesale retail credit risk due credit risks default insolvency bankruptcy outside us customer accounts groups trade receivables balance group entity assesses credit risk private customers determine credit insurance required us line pharmaceutical companies group sells products small number wholesalers addition factoring arrangements managed locally entities hospitals pharmacies physicians groups sales used mitigate risk arising large credit risk concentrations three largest wholesalers amounted approximately factoring arrangements nonrecourse sales us pharmaceuticals vaccines businesses fair value financial assets liabilities december group trade receivables due three wholesalers totalling million table pages presents carrying amounts million group exposed concentration credit risk fair values groups financial assets liabilities respect wholesalers one december december encounters financial difficulty could materially adversely fair values financial assets liabilities included affect groups financial results price would received sell asset paid transfer groups credit risk monitoring activities relating liability orderly transaction market participants wholesalers include review quarterly financial information measurement date standard poors credit ratings development gsk internal following methods assumptions used estimate risk ratings establishment periodic review credit limits fair values new customers subject credit vetting process cash cash equivalents approximates carrying amount existing customers subject review least annually vetting process subsequent reviews involves obtaining liquid investments approximates carrying amount information including customers status government investments equity investments traded active market private sector entity audited financial statements credit bureau determined reference relevant stock exchange quoted reports debt rating agency eg moodys standard poors bid price equity investments determined reference reports payment performance history trade references current market value similar instruments reference industry credit groups bank references discounted cash flows underlying net assets trade receivables consist large number customers spread shortterm loans overdrafts commercial paper across diverse industries geographical areas ongoing credit approximates carrying amount short maturity evaluation performed financial condition accounts instruments receivable appropriate credit insurance purchased factoring arrangements put place longterm loans based quoted market prices level fair value measurement case european us medium amount information obtained proportional level term notes approximates carrying amount case exposure considered information evaluated quantitatively fixed rate borrowings floating rate bank loans ie credit score qualitatively ie judgement conjunction customers credit requirements determine credit limit contingent consideration business acquisitions based present values expected future cash flows trade receivables grouped customer segments similar loss patterns assess credit risk receivables interest rate swaps foreign exchange forward contracts swaps financial assets assessed individually historical options based present value contractual cash forwardlooking information considered determine flows option valuation models using market sourced data appropriate expected credit loss allowance group believes exchange rates interest rates balance sheet date credit risk provision required excess receivables payables including put options approximates allowance expected credit losses see note trade carrying amount receivables companyowned life insurance policies based cash surrender value lease obligations approximates carrying amount gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued carrying fair value value notes financial assets measured fair value comprehensive income fvtoci investments designated fvtoci trade receivables ab financial assets measured amortised cost noncurrent assets b trade receivables b liquid investments cash cash equivalents items assets held sale b financial assets mandatorily measured fair value profit loss fvtpl investments noncurrent assets ab trade receiveables ab derivatives designated effective hedging instruments ade held trading derivatives designated effective hedging relationship ade cash cash equivalents total financial assets financial liabilities measured amortised cost borrowings excluding obligations finance leases bonds designated hedging relationship bonds bank loans overdrafts commercial paper borrowings total borrowings excluding obligations finance leases f obligations finance leases total borrowings trade payables c provisions c noncurrent liabilities c items assets held sale c financial liabilities mandatorily fair value profit loss fvtpl contingent consideration liabilities ac derivatives designated effective hedging instruments ade held trading derivatives designated effective hedging relationship ade total financial liabilities net financial assets financial liabilities valuation methodology used measure fair value table table described categorised trade receivables noncurrent assets trade payables provisions noncurrent liabilities contingent consideration liabilities items assets held sale reconciled relevant notes pages cash cash equivalents table include million reported assets held sale see note assets held sale gsk annual report notes financial statements continued financial instruments related disclosures continued carrying fair value value notes availableforsale investments liquid investments government bonds investments loans receivables cash cash equivalents trade receivables noncurrent assets scope ias b financial assets fair value profit loss trade receivables noncurrent assets scope ias ab derivatives designated fair value profit loss ade derivatives classified held trading ias ade total financial assets financial liabilities measured amortised cost borrowings excluding obligations finance leases bonds designated hedging relationship bonds bank loans overdrafts commercial paper borrowings total borrowings excluding obligations finance leases f obligations finance leases total borrowings trade payables provisions certain noncurrent liabilities scope ias c financial liabilities fair value profit loss contingent consideration liabilities ac derivatives designated fair value profit loss ade derivatives classified held trading ias ade total financial liabilities net financial assets financial liabilities fair value investments gsk shares december employee share ownership plan esop trusts held gsk shares carrying value million million market value million million based quoted market price shares held esop trusts satisfy future exercises options awards employee incentive schemes carrying value lower cost expected proceeds shares recognised deduction reserves december gsk held treasury shares cost million million deducted retained earnings gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued financial instruments held fair value following tables categorise groups financial assets liabilities held fair value valuation methodology applied determining fair value possible quoted prices active markets used level prices available asset liability classified level provided significant inputs valuation model used based observable market data one significant inputs valuation model based observable market data instrument classified level investments classified level tables comprise equity investments unlisted entities group entered research collaborations also investments emerging life science companies level level level total december financial assets fair value financial assets fair value comprehensive income fvtoci investments designated fvtoci trade receivables financial assets mandatorily measured fair value profit loss fvtpl investments noncurrent assets trade receivables derivatives designated effective hedging instruments held trading derivatives designated effective hedging relationship cash cash equivalents financial liabilities fair value financial liabilities mandatorily fair value profit loss fvtpl contingent consideration liabilities derivatives designated effective hedging instruments held trading derivatives designated effective hedging relationship level level level total december financial assets fair value availableforsale financial assets liquid investments investments noncurrent assets financial assets fair value profit loss noncurrent assets trade receivables derivatives designated fair value profit loss derivatives classified held trading ias financial liabilities fair value financial liabilities fair value profit loss contingent consideration liabilities derivatives designated fair value profit loss derivatives classified held trading ias gsk annual report notes financial statements continued financial instruments related disclosures continued movements year financial instruments measured using level valuation methods presented january net losses recognised income statement net gains recognised comprehensive income contingent consideration businesses divestedacquired year payment contingent consideration liabilities additions disposals settlements transfers level exchange adjustments december net losses million million attributable level financial instruments recognised income statement attributable financial instruments held end year losses million reported operating income million losses operating income million income finance income million million arose remeasurement contingent consideration payable acquisition former shionogiviiv healthcare joint venture million million arose remeasurement contingent consideration payable acquisition novartis vaccines business net gains million million attributable level financial instruments reported comprehensive income fair value movements equity investments included net gains million net losses million respect financial instruments held end year net gains million net losses million arose prior transfer level equity investments transferred level valuation methodology result listing recognised stock exchange year financial liabilities measured using level valuation methods december included million million respect contingent consideration payable acquisition former shionogiviiv healthcare joint venture consideration expected paid number years vary line future performance specified products movements certain foreign currencies also included million million respect contingent consideration acquisition novartis vaccines business consideration expected paid number years vary line future performance specified products achievement certain milestone targets movements certain foreign currencies sensitivity analysis balances provided note contingent consideration liabilities b trade receivables noncurrent assets items assets held sale scope ifrs ias following table reconciles financial instruments within trade receivables noncurrent assets items assets held sale fall within scope ifrs ias relevant balance sheet amounts financial assets predominantly noninterest earning financial instruments within noncurrent assets balance include companyowned life insurance policies nonfinancial instruments include tax receivables pension surplus balances prepayments outside scope ifrs ias non non amortised financial financial loans financial financial fvtpl fvtoci cost instruments instruments total fvtpl receivables instruments instruments total trade receivables note noncurrent assets note items assets held sale note group applied ifrs financial instruments effect january therefore accounts expected credit losses initial recognition financial assets following table shows ageing financial assets past due december provision bad doubtful debts made date ias past due days past due days past due days past due days past due days gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued c trade payables provisions noncurrent liabilities contingent consideration liabilities items assets held sale scope ifrs ias following table reconciles financial instruments within trade payables provisions noncurrent liabilities contingent consideration liabilities items assets held sale fall within scope ifrs ias relevant balance sheet amounts financial liabilities predominantly noninterest bearing accrued wages salaries included within financial liabilities nonfinancial instruments includes payments account tax social security payables provisions arise contractual obligations deliver cash another financial asset outside scope ifrs ias non non amortised financial financial amortised financial financial fvtpl cost instruments instruments total fvtpl cost instruments instruments total trade payables note provisions note noncurrent liabilities note contingent consideration liabilities note items assets held sale note derivative financial instruments hedging programmes derivatives used economic hedging purposes speculative investments classified held trading designated effective hedging instruments presented current assets liabilities expected settled within months end reporting period otherwise classified noncurrent group following derivative financial instruments fair value fair value assets liabilities assets liabilities noncurrent cash flow hedges interest rate swap contracts principal amount million nil net investment hedges cross currency swaps principal amount million nil current cash flow hedges foreign exchange contracts principal amount million million net investment hedges foreign exchange contracts principal amount million million derivatives designated effective hedging instruments noncurrent embedded derivatives current foreign exchange contracts principal amount million million embedded derivatives derivatives classified held trading total derivative instruments fair value hedges december group designated fair value hedges net investment hedges year certain foreign exchange contracts designated net investment hedges respect foreign currency translation risk arising consolidation groups net investment european euro foreign operations shown table carrying value bonds includes million million designated hedging instruments net investment hedges gsk annual report notes financial statements continued financial instruments related disclosures continued cash flow hedges group entered forward foreign exchange contracts designated cash flow hedges entered hedge foreign exchange exposure arising cash flows euro denominated coupon payments relating notes issued groups european medium term note programme buyout novartis noncontrolling interest consumer healthcare joint venture planned divestment horlicks nutrition brands group manages cash flow interest rate risk using floatingtofixed interest rate swaps addition group carries balance reserves arose prehedging fluctuations longterm interest rates pricing bonds issued prior years balance reclassified finance costs life bonds foreign exchange forward contracts swaps current year group designated certain foreign exchange forward contracts swaps cash flow net investment hedges following tables detail foreign exchange forward contracts swaps outstanding end reporting period well information related hedged items foreign exchange derivative financial assets liabilities presented line derivative financial instruments either assets liabilities consolidated balance sheet notional value foreign exchange forward contracts swaps absolute total outstanding positions balance sheet date hedge effectiveness determined inception hedge relationship periodic prospective effectiveness assessments ensure economic relationship exists hedged item hedging instrument group enters hedge relationships critical terms hedging instrument match exactly terms hedged item qualitative assessment effectiveness performed changes circumstances affect terms hedged item critical terms longer match exactly critical terms hedging instrument group uses hypothetical derivative method assess effectiveness main source hedge ineffectiveness hedging relationships effect counterparty groups credit risk fair value foreign exchange forward contracts swaps reflected fair value hedged item attributable changes foreign exchange rates sources ineffectiveness emerged hedging relationships consequently ineffectiveness recorded cash flow hedges net investments foreign entity hedges average foreign notional fair exchange rate currency value value hedging instruments cash flow hedges foreign exchange contracts buy foreign currency less months months euro months sell foreign currency less months months months indian rupee net investment hedges foreign exchange contracts sell foreign currency less months euro months months euro balance cash flow hedge reserveforeign currency change value calculating translation reserve hedge ineffectiveness continuing hedges hedged items cash flow hedges variability cash flows highly probable forecast transaction variability cash flows foreign exchange exposure arising euro denominated coupon payments relating debt issued net investment hedges investment european foreign operations balances cash flow hedge reserve arising hedging relationships hedge accounting longer applied gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued following table details effectiveness hedging relationships amounts reclassified hedging reserve profit loss amount reclassified profit loss line item hedged amount profit future cash line item hedging hedge loss flows gainslosses ineffectiveness hedge longer hedged reclassification recognised recognised ineffectiveness expected item affects adjustment reserves profit loss included occur profit loss included cash flow hedges variability cash flows highly probable forecast transaction operating operating income income expense expense variability cash flows foreign exchange exposure arising finance finance euro denominated coupon payments relating debt issued income income expense expense net investment hedges net investment european foreign operations finance finance income income expense expense interest rate swap contracts group manages cash flow interest rate risk using floatingtofixed interest rate swaps quarterly intervals difference fixed contract rates floating rate interest amounts calculated reference agreed notional principal amounts exchanged interest rate swap contracts exchanging floating rate interest fixed interest designated cash flow hedges hedge variability interest cash flows associated floating rate debt relating notes issued groups european medium term note programme interest rate swaps interest payments loan occur simultaneously amount accumulated equity reclassified profit loss period floating rate interest payments affect profit loss critical terms interest rate swap contracts corresponding hedged items qualitative assessment effectiveness performed expected value interest rate swap contracts value corresponding hedged items systematically change opposite directions response movements underlying interest rates main sources ineffectiveness hedge relationships effects currency basis risk counterpartys groups credit risk fair value interest rate swap contracts reflected fair value hedged item attributable change interest rates sources ineffectiveness emerged hedging relationships following tables provide information regarding interest rate swap contracts outstanding related hedged items december interest rate swap contract assets liabilities presented line derivative financial instruments either assets liabilities consolidated balance sheet change fair value average notional recognising fair value contracted fixed principal hedge assets rate value ineffectiveness liabilities hedging instruments less year years years years change value balance cash used flow hedge calculating reserve hedge continuing ineffectiveness hedges hedged items variable rate borrowings gsk annual report notes financial statements continued financial instruments related disclosures continued following table details effectiveness hedging relationships amounts reclassified hedging reserve profit loss amount reclassified profit loss line item hedged amount profit future cash line item hedging hedge loss flows gainslosses ineffectiveness hedge longer hedged reclassification recognised recognised ineffectiveness expected item affects adjustment reserves profit loss included occur profit loss included cash flow hedges variability cash flows finance finance income income expense expense prehedging longterm interest rates finance finance income income expense expense e offsetting financial assets liabilities financial assets liabilities offset net amount reported balance sheet legally enforceable right offset recognised amounts intention settle net basis realise asset settle liability simultaneously also arrangements meet criteria offsetting still allow related amounts offset certain circumstances bankruptcy termination contract following tables set financial assets liabilities offset subject enforceable master netting arrangements similar agreements offset december december column net amount shows impact groups balance sheet offset rights exercised gross financial financial liabilities net financial related assets assets assets amounts net liabilities offset liabilities offset amount december financial assets trade receivables derivative financial instruments financial liabilities trade payables derivative financial instruments gross financial financial liabilities net financial related assets assets assets amounts net liabilities offset liabilities offset balance december financial assets trade receivables derivative financial instruments financial liabilities trade payables derivative financial instruments amounts meet criteria offsetting balance sheet could settled net certain circumstances principally relate derivative transactions isda international swaps derivatives association agreements party option settle amounts net basis event default party presently legally enforceable right offset amounts offset balance sheet presented separately table gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued f debt interest rate repricing table following table sets exposure group interest rates debt including commercial paper maturity analysis fixed rate debt stated contractual maturity floating rate debt interest rate repricing dates purpose table debt defined classes borrowings obligations finance leases total debt total floating fixed rate debt less one year one two years two three years three four years four five years five ten years greater ten years total original issuance profile fixed rate interest floating rate interest total interest bearing noninterest bearing g sensitivity analysis tables illustrate estimated impact income statement equity result hypothetical market movements foreign exchange interest rates relation groups financial instruments range variables chosen sensitivity analysis reflects managements view changes reasonably possible oneyear period foreign exchange sensitivity group operates internationally primarily exposed foreign exchange risk relation sterling movements us dollar euro japanese yen foreign exchange risk arises translation financial assets liabilities functional currency entity holds based groups net financial assets liabilities december weakening strengthening sterling currencies variables held constant illustrated tables tables exclude financial instruments expose group foreign exchange risk risk fully hedged another financial instrument increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposures cent appreciation us dollar cent appreciation euro yen appreciation yen increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposures cent depreciation us dollar cent depreciation euro yen depreciation yen gsk annual report notes financial statements continued financial instruments related disclosures continued equity impact shown foreign exchange sensitivity relates derivative nonderivative financial instruments hedging groups net investments european euro foreign operations cash flow hedges foreign exchange exposure arising euro denominated coupon payments relating notes issued groups european medium term note programme increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposures cent appreciation us dollar cent appreciation euro increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposures cent depreciation us dollar cent depreciation euro tables present groups sensitivity weakening strengthening sterling relevant currency based composition net debt shown note adjusted effects foreign exchange derivatives part net debt affect future foreign currency cash flows increasedecrease increasedecrease net debt net debt impact foreign exchange movements net debt cent appreciation us dollar cent appreciation euro yen appreciation yen increasedecrease increasedecrease net debt net debt impact foreign exchange movements net debt cent depreciation us dollar cent depreciation euro yen depreciation yen interest rate sensitivity group exposed interest rate risk outstanding borrowings investments changes interest rates affect future cash flows fair values financial instruments majority debt issued fixed interest rates changes floating rates interest significantly affect groups net interest charge although majority cash liquid investments earn floating rates interest table hypothetically shows groups sensitivity changes interest rates relation sterling us dollar euro floating rate financial assets liabilities interest rates applicable floating rate financial assets liabilities increased basis points assuming variables remained constant estimated groups finance income would decreased approximately million million increase basis points movement interest rates deemed material effect equity increasedecrease increasedecrease income income income statement impact interest rate movements basis points increase sterling interest rates basis points increase us dollar interest rates basis points increase euro interest rates gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued h contractual cash flows nonderivative financial liabilities derivative instruments following tables provide analysis anticipated contractual cash flows including interest payable groups nonderivative financial liabilities undiscounted basis purpose table debt defined classes borrowings except obligations finance leases interest calculated based debt held december without taking account future issuance floating rate interest estimated using prevailing interest rate balance sheet date cash flows foreign currencies translated using spot rates december contractual cash flows respect operating lease vacant space provisions excluded table included commitments noncancellable operating leases table note commitments finance charge trade payables obligations obligations interest finance finance liabilities debt debt leases leases net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows finance charge trade payables obligations obligations interest finance finance liabilities debt debt leases leases net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows anticipated contractual cash flows repayment debt debt interest increased billion year due funding buyout novartis stake consumer healthcare joint venture increase issuance commercial paper unfavourable exchange impacts translation nonsterling denominated debt table provides analysis anticipated contractual cash flows groups derivative instruments excluding equity options give rise cash flows embedded derivatives material using undiscounted cash flows cash flows foreign currencies translated using spot rates december gross cash flows foreign exchange contracts presented purpose table although practice group uses standard settlement arrangements reduce liquidity requirements instruments receivables payables receivables payables foreign foreign foreign foreign exchange exchange exchange exchange forward forward forward forward interest contracts interest contracts interest contracts interest contracts rate swaps swaps rate swaps swaps rate swaps swaps rate swaps swaps due less one year one two years two three years gross contractual cash flows amounts receivable payable less one year increased compared december predominantly hedging buyout novartis stake consumer healthcare joint venture divestment horlicks nutrition brands unilever gsk annual report notes financial statements continued employee share schemes gsk operates several employee share schemes including share value plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost three year vesting period performance share plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost subject achievement group specified performance targets granting restricted share awards replaced granting options employees cost schemes readily equates potential gain made employee group also operates savings related share option schemes whereby options granted employees acquire shares glaxosmithkline plc discounted price grants restricted share awards normally exercisable end threeyear vesting performance period awards normally granted employees acquire shares ads glaxosmithkline plc circumstances may settled cash grants savingsrelated share option schemes normally exercisable three years saving accordance uk practice majority options savingsrelated share option schemes granted price market price ruling date grant options historical share option schemes granted market price ruling date grant total charge sharebased incentive plans million million million amount million million million arose share value plan see note employee costs details glaxosmithkline share award schemes share value plan share value plan share awards granted certain employees cost awards vest two half three years performance criteria attached fair value awards determined based closing share price day grant deducting expected future dividend yield duration award shares weighted ads weighted number shares ads issuable number fair value number fair value january awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december performance share plan performance share plan share awards granted directors senior executives cost percentage award vests based upon performance group defined measurement period dividends reinvested period awards granted performance conditions based three equally weighted measures threeyear performance period adjusted free cash flow tsr rd new product performance fair value awards determined based closing share price day grant tsr performance elements adjusted likelihood condition met assessed time grant awards made million shares weighted fair value million ads weighted fair value december outstanding awards million shares million ads gsk annual report strategic report governance remuneration financial statements investor information employee share schemes continued share options savingsrelated options purposes valuing savingsrelated options arrive sharebased payment charge blackscholes option pricing model used assumptions used model follows grant grant grant riskfree interest rate dividend yield volatility expected life years years years savingsrelated options grant price including discount share option share option savingsrelated options outstanding schemes shares schemes ads share option schemes weighted weighted weighted number exercise number exercise number exercise price price price december range exercise prices options outstanding year end weighted average market price exercise year weighted average remaining contractual life years years years options million shares granted year savingsrelated share option scheme weighted average fair value december million savingsrelated share options exercisable share options ads options currently exercisable expire exercised july change effective exercise price outstanding options year employee share ownership plan trusts group sponsors employee share ownership plan esop trusts acquire hold shares glaxosmithkline plc satisfy awards made employee incentive plans options granted employee share option schemes trustees esop trusts purchase shares finance provided group way loans contributions costs running esop trusts charged income statement shares held esop trusts deducted reserves amortised value proceeds receivable employees exercise transfer retained earnings trustees waived rights dividends shares held esop trusts shares held share award schemes number shares nominal value carrying value market value shares held share option schemes number shares nominal value carrying value market value gsk annual report notes financial statements continued principal group companies following represent principal subsidiaries countries incorporation group december equity share capital entities wholly owned group except percentage interest shown otherwise companies incorporated principal country operation except stated england us glaxo group limited block drug company inc glaxo operations uk limited corixa corporation glaxosmithkline capital plc glaxosmithkline capital inc glaxosmithkline consumer healthcare holdings limited glaxosmithkline consumer healthcare holdings us llc glaxosmithkline consumer healthcare uk trading limited glaxosmithkline consumer healthcare lp glaxosmithkline consumer trading services limited glaxosmithkline holdings americas inc glaxosmithkline export limited glaxosmithkline llc glaxosmithkline finance plc human genome sciences inc glaxosmithkline holdings limited gsk consumer health inc formerly novartis consumer health inc glaxosmithkline research development limited sr one limited glaxosmithkline services unlimited stiefel laboratories inc glaxosmithkline uk limited viiv healthcare company setfirst limited smithkline beecham limited viiv healthcare limited viiv healthcare uk limited europe others glaxosmithkline biologicals sa belgium glaxosmithkline argentina sa argentina glaxosmithkline pharmaceuticals sa belgium glaxosmithkline australia pty ltd australia glaxosmithkline biologicals sas france glaxosmithkline consumer healthcare australia pty ltd australia glaxosmithkline sante grand public sas france glaxosmithkline brasil limitada brazil laboratoire glaxosmithkline france glaxosmithkline consumer healthcare inc canada viiv healthcare sas france glaxosmithkline inc canada glaxosmithkline consumer healthcare gmbh co kg germany id biomedical corporation quebec canada glaxosmithkline gmbh co kg germany glaxosmithkline limited china hong kong gsk vaccines gmbh germany glaxosmithkline tianjin co ltd china glaxosmithkline consumer healthcare spa italy sinoamerican tianjin smith kline french laboratories ltd china glaxosmithkline spa italy glaxosmithkline consumer healthcare limited india gsk vaccines srl italy glaxosmithkline pharmaceuticals limited india glaxosmithkline bv netherlands glaxosmithkline consumer healthcare japan kk japan glaxosmithkline consumer healthcare spzoo poland glaxosmithkline kk japan gsk services sp z oo poland viiv healthcare kabushiki kaisha japan glaxosmithkline trading services limited republic ireland glaxosmithkline pakistan limited pakistan glaxosmithkline healthcare ao russia glaxo wellcome manufacturing pte ltd singapore glaxosmithkline sa spain glaxosmithkline korea limited republic korea laboratorios viiv healthcare sl spain glaxosmithkline llaclari sanayi ticaret turkey gsk consumer healthcare sa switzerland e xempt provisions section companies act ireland accordance exemptions noted section act subsidiaries disclosed pages exempt provisions also consolidated group financial statements directly held wholly owned subsidiary glaxosmithkline plc subsidiaries associates listed principally affect figures groups financial statements glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline llc whollyowned finance subsidiary company company fully unconditionally guaranteed securities issued glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline llc see pages complete list subsidiary undertakings associates joint ventures form part financial statements gsk annual report strategic report governance remuneration financial statements investor information legal proceedings group involved significant legal administrative dolutegravirtivicaytriumeq proceedings principally product liability intellectual property september october viiv healthcare received tax antitrust governmental investigations well related patent challenge letters hatchwaxman act cipla private litigation significant matters dr reddys labs apotex triumeq tivicay tax matters described group makes provision lupin mylan triumeq sandoz tivicay viiv proceedings regular basis summarised note healthcare lists two patents dolutegravir active ingredient accounting principles policies note provisions tivicay one active ingredients triumeq fda orange book one patent covering molecule dolutegravir group may become involved significant legal proceedings expires october second patent claiming certain respect possible make reliable estimate crystal forms dolutegravir expires december expected financial effect could result ultimate letters challenged patent crystal form generic resolution proceedings cases appropriate companies alleged crystal form patent valid others disclosures cases would included note challenged validity asserted proposed product would provision would made cases infringe crystal form patent respect legal proceedings described february viiv healthcare filed patent infringement suits provision made group generic companies us district court unable make reliable estimate expected financial effect district delaware additionally viiv healthcare also filed suit stage group believe information certain generic companies us district court amount sought plaintiffs known would meaningful district new jersey us district court district respect legal proceedings due number west virginia case mylan proceeding factors including limited stage proceedings northern district west virginia court set case entitlement parties appeal decision clarity theories mylan trial june cases defendants liability damages governing law proceeding district delaware district delaware legal expenses incurred provisions related legal claims yet set trial date cases charged selling general administration costs provisions february viiv healthcare filed patent infringement made taking appropriate legal specialist advice litigation gilead sciences inc gilead bictegravir outflow resources considered probable us district court district delaware us patent reliable estimate made likely outcome dispute canadian federal court canadian patent certain product liability claims group make provision viiv healthcare alleges gileads triple combination sufficient history claims made settlements hiv drug containing hiv integrase inhibitor bictegravir infringes enable management make reliable estimate provision viiv healthcares patent covering dolutegravir compounds required cover unasserted claims december include dolutegravirs unique chemical scaffold us groups aggregate provision legal disputes canada viiv healthcare seeks financial redress rather including tax matters described note taxation injunctive relief district delaware case set trial million however provision offset related million september canadian court set trial date receivable means net exposure group canadian action million ultimate liability legal claims may vary amounts provided dependent upon outcome litigation kivexa proceedings investigations possible settlement negotiations viiv healthcare reached confidential agreements doc generici farmoz kyowa pharmaceuticals settle groups position could change time therefore various challenges validity supplementary protection assurance losses result outcome certificate spc patent covering combination legal proceedings exceed material amount lamivudine abacavir kivexa certain counterclaims amount provisions reported groups financial brought viiv healthcare infringement spc statements happen could material adverse settlements brought end litigation arbitration proceedings impact results operations group reporting viiv healthcare doc generici italy viiv period judgements incurred settlements healthcare farmoz portugal viiv healthcare entered kyowa pharmaceuticals japan intellectual property june biogaran commenced proceedings france seeking intellectual property claims include challenges validity revocation french spc covering kivexa trial date enforceability groups patents various products set action processes well assertions noninfringement patents loss cases could result loss patent q viiv healthcare commenced proceedings protection product issue consequences sandoz switzerland sandoz countered challenging validity loss could significant decrease sales product patent relating kivexa trial date set could materially affect future results operations group action gsk annual report notes financial statements continued legal proceedings continued product liability cts violence preclinical clinical trials conducted development february six pending claims cases potential products determine safety efficacy concerning allegations patients took paroxetine paxil products use humans following approval regulatory bodies committed attempted commit suicide acts violence five claims cases us one case canada one notwithstanding efforts drugs vaccines us cases dolin involving suicide man allegedly took introduced marketplace unanticipated safety issues may generic paroxetine manufactured mylan resulted million become claimed evident group verdict plaintiff however august us court currently defendant number product liability lawsuits related appeals seventh circuit reversed jury verdict groups pharmaceutical vaccine consumer healthcare found favour group plaintiff filed petition writ products group able make reliable estimate certiorari asking us supreme court review case expected financial effect matters discussed remaining us cases largely dormant category included provision appropriate matters provision legal disputes matters one pending canadian action carmichael group filed group made provision also noted note motion summary judgement based statute limitations provisions iscontinuation avandia uk longpending group action alleges seroxat caused group named product liability lawsuits behalf severe discontinuation symptoms legal services individuals asserting personal injury claims arising use commission lsc withdrew public funding hundreds avandia economic loss actions also filed seeking claimants causing termination claims legal aid restitution penalties consumer protection laws agency formerly lsc discharged public funding certificate following recommendation special cases review february seven remaining us cases four panel cases poor prospects success personal injury actions subject settlement agreement dismissed settlement finalised two class however recently fortitude law engaged actions brought thirdparty payers asserting claims purpose resurrecting seroxat group action obtained racketeer influenced corrupt organizations act rico thirdparty funding experts remaining claimants state consumer protection laws appeal summary group asked court require thirdparty funder judgements granted favour group last seven provide security litigation costs event plaintiffs lose santa clara county california action summary judgement december high court ruled favour group granted favour group issues except application order claimants litigation funder civil penalty claims californias false advertising act give security costs sum excess total funding additionally class actions pending canada committed case trial action scheduled group reached agreement subject court approval commence april settle zofran seroxatpaxil paxil cr plaintiffs allege children suffered birth defects result group received numerous lawsuits claims alleging mothers ingestion zofran andor generic ondansetron use paxil paroxetine caused variety injuries pregnancyrelated nausea vomiting plaintiffs assert lawsuits contain one following allegations group sold zofran knowing unsafe pregnant women failed use paxil pregnancy caused congenital malformations warn risks illegally marketed zofran offlabel use persistent pulmonary hypertension autism ii paxil treatment pregnant women caused patients commit suicidal violent acts iii february group defendant personal injury group failed warn patients could experience certain lawsuits two lawsuits part multidistrict symptoms discontinuing paxil treatment litigation proceeding mdl us district court district p regnancy massachusetts group reached agreements settle majority mdl parties process completing case us claims relating use paxil pregnancy specific discovery selecting cases potential trials february lawsuits related use pregnancy court recently denied groups motion summary judgment still pending various courts us based federal preemption argument group continues singh action alberta canada proposed national class seek dismissal individual cases grounds action seeks certify class relating birth defects generally appropriate court hearing argument january plaintiffs gsk also defendant four proposed class actions canada class certification motion consideration significant activity four matters however another canadian class action jensen alleging claims paxil parties recently agreed schedule class certification ssri use autism filed saskatchewan proceedings matter pending ontario january however activity case since filing gsk annual report strategic report governance remuneration financial statements investor information legal proceedings continued sales marketing regulation average wholesale price groups marketing promotion pharmaceutical attorney general illinois filed suit group vaccine products subject certain governmental number pharmaceutical companies claiming damages investigations private lawsuits brought litigants various restitution due average wholesale price awp andor wholesale theories law group able make reliable estimate acquisition cost wac price reporting pharmaceutical products expected financial effect matters discussed covered states medicaid programmes case alleges category included provision matters group reported caused reported false awp wac provision legal disputes except noted prices turn allegedly caused state medicaid agency reimburse providers money covered medicines matters group made provision also noted agency intended state sought recovery behalf note provisions payer behalf instate patients consumers case sfo secdoj anticorruption enquiries ongoing trial date yet set group may uk serious fraud office sfo began cidra thirdparty payer litigation formal criminal investigation groups commercial operations july number major us healthcare insurers filed suit number countries including china sfo inquiry followed group philadelphia pennsylvania county court investigations initiated chinas ministry public security june common pleas seeking compensation reimbursements china investigations resulted ruling made medicines manufactured groups former cidra plant according chinese law gsk china investment co ltd puerto rico insurers claim group knowingly gskci offered money property nongovernment illegally marketed sold adulterated drugs manufactured personnel order obtain improper commercial gains conditions noncompliant cgmp current good manufacturing gskci found guilty bribing nongovernment personnel practices thirdparty insurers unlawfully september group reached global resolution induced pay suit alleges us federal various us securities exchange commission sec regarding state law causes action discovery complete group secs investigation us foreign corrupt practices act filed motion summary judgement likely heard fcpa groups commercial practices countries outside spring trial date yet set us including china part resolution group antitrustcompetition agreed pay civil penalty million us government certain governmental actions private lawsuits us department justice doj confirmed brought group alleging violation competition concluded investigation groups commercial practices antitrust laws group able make reliable estimate would take action group part resolution expected financial effect matters discussed sec group agreed certain undertakings including category included provision matters period selfmonitoring reporting groups obligations provision legal disputes except noted resolution continued september matters group made provision also noted concluded note provisions course inquiry sfo requested additional uk competition markets authority investigation information group regarding thirdparty advisers engaged february uk competition markets company course china investigations sec authority cma issued decision fining group two doj also investigating matters following groups pharmaceutical companies infringement competition act reporting sfos inquiries group cooperating cma imposed fine million group well responding requests february sfo fines totaling million companies relates announced would closing investigation confirmed agreements settle patent disputes group would taking action group potential suppliers generic paroxetine formulations entered sec doj investigations issues continue group terminated agreements group unable make reliable estimate expected issue group believes strong grounds financial effect investigations provisions appeal cmas finding competition appeal tribunal made cat order overturn fine substantially reduce us vaccines subpoena appeal concluded april cat delivered initial february group received subpoena us judgement appeal march referring principle attorneys office southern district new york requesting points issue court justice eu preliminary documents relating groups vaccines business group ruling matter return cat final judgement responded subpoena informed government provision made matter government would closing matter without action gsk annual report notes financial statements continued legal proceedings continued lamictal addition sec case one private matter martinolich purported classes direct indirect purchasers filed suit case remains also pending federal district court florida us district court district new jersey alleging stayed pending trial sec matter allegations group teva pharmaceuticals unlawfully conspired delay martinolich case largely track sec matter generic competition lamictal resulting overcharges plaintiff former stiefel employee alleges stiefel officers purchasers entering allegedly anticompetitive reverse directors violated us employee retirement income security payment settlement resolve patent infringement litigation act erisa federal state securities laws inducing stiefel separate count accuses group monopolising market employees sell shares employee stock plan back stiefel greatly undervalued price without disclosing june court appeals reversed trial courts employees stiefel sold group decision dismiss case remanded action back trial court may trial court denied indirect environmental matters purchaser class plaintiffs motion reconsideration courts group notified potential responsibility relating dismissal claims result indirect purchaser class past operations past waste disposal practices certain representatives agreed settlement exit case resolve sites primarily us matters subject remaining claims december trial judge litigation including proceedings initiated us federal state granted plaintiffs class certification motion certifying class governments waste disposal site remediation costs tort direct purchasers action group pursuing appeal actions brought private parties court appeals regarding class certification group advised may responsible party commercial corporate approximately sites nine appear national priority group defendant certain cases allege violation list created comprehensive environmental response us federal securities erisa laws group able compensation liability act superfund proceedings make reliable estimate expected financial effect seek require operators hazardous waste facilities matters discussed category included provision transporters waste sites generators hazardous matters provision legal disputes matters waste disposed sites clean sites reimburse group made provision also noted note us government cleanup costs instances provisions group involved alleged generator hazardous waste securitieserisa class actions stiefel although superfund provides defendants jointly december us securities exchange severally liable cleanup costs proceedings frequently commission sec filed formal complaint stiefel resolved basis nature quantity waste disposed laboratories inc charles stiefel us district court generator site groups proportionate liability district florida alleging stiefel principals violated cleanup costs substantially determined sites federal securities laws inducing stiefel employees sell referred shares employee stock plan back company greatly groups potential liability varies greatly site site cost undervalued price without disclosing employees investigation study remediation sites could time company sold group case stayed significant group made provision matters several private actions brought former stiefel employees noted note provisions proceeded courts returned active status early summer unclear case ultimately scheduled trial post balance sheet events agreement acquire tesaro inc billion cash january mylan nv announced us food signed december completed january drug administration approved therapeutically equivalent generic advair diskus certain patients asthma chronic obstructive pulmonary disease gsk annual report strategic report governance remuneration company balance sheet financial statements investor information uk gaap including frs reduced disclosure framework december notes fixed assets investments f current assets trade receivables g cash bank total current assets bank overdrafts short term borrowings h trade payables total current liabilities net current assets total assets less current liabilities provisions liabilities j noncurrent liabilities k net assets capital reserves share capital l share premium account l reserves retained earnings january lossprofit year changes retained earnings equity shareholders funds financial statements pages approved board march signed behalf philip hampton chairman glaxosmithkline plc registered number company statement changes equity year ended december share share premium retained total capital account reserves earnings equity january profit total comprehensive income attributable shareholders dividends shareholders shares issued employee share schemes treasury shares transferred esop trust december loss total comprehensive expense attributable shareholders dividends shareholders shares issued employee share schemes december gsk annual report notes company balance sheet uk gaap including frs reduced disclosure framework presentation financial statements b accounting policies description business foreign currency transactions glaxosmithkline plc parent company gsk major global foreign currency transactions recorded exchange rate healthcare group engaged creation discovery ruling date transaction foreign currency assets development manufacture marketing pharmaceutical liabilities translated rates exchange ruling balance products including vaccines overthecounter otc medicines sheet date healthrelated consumer products dividends paid received preparation financial statements dividends paid received included financial statements financial statements prepared using historical period related dividends actually paid cost convention modified include revaluation certain received financial instruments going concern basis prepared expenditure accordance financial reporting standard reduced disclosure framework uk accounting presentation expenditure recognised respect goods services received companies act december comparative supplied accordance contractual terms provision figures december made obligation exists future liability respect past event amount obligation reliably permitted section companies act estimated income statement company presented annual report investments subsidiary companies investments subsidiary companies held cost less company included group financial statements provision impairment also adjusted movements glaxosmithkline plc publicly available contingent consideration following exemptions requirements ifrs applied preparation financial statements impairment investments accordance frs carrying value investments reviewed impairment indication investment might impaired paragraphs b ifrs sharebased payment provision resulting impairment review charged ifrs financial instruments disclosures income statement year concerned paragraphs ifrs fair value measurement sharebased payments paragraph ias presentation financial statements issuance company subsidiaries grant comparative information requirements respect companys shares represents additional capital contributions paragraph iv ias company subsidiaries additional investment subsidiaries results corresponding increase shareholders paragraphs f b equity additional capital contribution based fair value ias presentation financial statements grant issued allocated underlying grants vesting period ias statement cash flows taxation paragraph ias accounting policies changes current tax provided amounts expected paid applying accounting estimates errors tax rates enacted substantively enacted paragraph ias related party disclosures balance sheet date requirement ias disclose related party transactions deferred tax provided full using liability method entered two members temporary differences arising tax bases assets group liabilities carrying amounts financial statements deferred tax assets recognised extent accounting convention standards considered recoverable future taxable profits balance sheet prepared using historical cost convention complies applicable uk accounting deferred tax measured average tax rates expected standards apply periods temporary differences expected realised settled deferred tax liabilities assets accounting principles policies discounted preparation balance sheet conformity generally accepted accounting principles requires management make financial guarantees estimates assumptions affect reported amounts liabilities relating guarantees issued company behalf assets liabilities disclosure contingent assets subsidiaries initially recognised fair value amortised liabilities date balance sheet actual amounts could life guarantee differ estimates balance sheet prepared accordance companys accounting policies approved board described note b policies consistently applied unless otherwise stated gsk annual report strategic report governance remuneration financial statements investor information c key accounting judgements estimates ultimate liability legal claims may vary amounts provided dependent upon outcome litigation legal disputes proceedings investigations possible settlement negotiations company provides anticipated settlement costs position could change time therefore management makes judgement outflow resources assurance losses result outcome legal probable reliable estimate made likely outcome proceedings exceed amount provisions reported dispute legal expenses arising claims companys financial statements material amount company estimated provisions take account specific circumstances dispute relevant external advice perating profit inherently judgemental could change substantially time dispute progresses new facts emerge fee relating audit company charged operating profit companys directors taken legal advice established provisions taking account relevant facts e dividends circumstances matter accordance accounting requirements december provisions legal directors declared four interim dividends resulting dividend disputes amounted million million year pence line dividend details see note group financial statements dividends f fixed assets investments shares glaxosmithkline services unlimited shares glaxosmithkline holdings one limited shares glaxosmithkline holdings limited shares glaxosmithkline mercury limited capital contribution relating sharebased payments contribution relating contingent consideration g trade receivables amounts due within one year uk corporation tax recoverable receivables amounts owed group undertakings amounts due one year amounts owed group undertakings h shortterm borrowings billion borrowing relates facility taken june part financing buyout noncontrolling interest consumer healthcare joint venture held novartis facility maturity date december trade payables amounts due within one year creditors contingent consideration payable amounts owed group undertakings company guaranteed debt issued subsidiary companies two receives fees aggregate company outstanding guarantees billion debt instruments billion amounts due subsidiary company relation guarantee fees recovered life bonds disclosed within trade receivables see note g gsk annual report notes company balance sheet uk gaap including frs reduced disclosure framework continued j provisions liabilities january exchange adjustments charge year utilised december provisions relate number legal disputes company currently involved k noncurrent liabilities contingent consideration payable contingent consideration relates amount payable acquisition novartis vaccines portfolio current year liability included within trade payables l share capital share premium account share premium ordinary shares p account number share capital authorised december december share capital issued fully paid january issued employee share schemes treasury shares transferred esop trust december issued employee share schemes december december december number shares issuable employee share schemes number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemes retained earnings loss glaxosmithkline plc year million million profit dividends million million gave retained loss million profit milion effect nil treasury shares transferred subsidiary company million retained earnings december stood million million million unrealised million n group companies see pages complete list subsidiaries associates joint ventures forms part financial statements ggsskk aannnnuuaall rreeppoorrtt ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn investor information section quarterly trend pharmaceuticals turnover vaccines turnover five year record product development pipeline products competition intellectual property principal risks uncertainties share capital share price dividends financial calendar annual general meeting tax information shareholders shareholder services contacts us law regulation group companies glossary terms gsk annual report financial record quarterly trend unaudited analysis group results provided quarter sterling financial year income statement total months q q q q reported reported reported reported reported cer cer cer cer cer turnover pharmaceuticals vaccines consumer healthcare total turnover cost sales selling general administration research development royalty income operating incomeexpense operating profit net finance costs profit disposal associates share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p p p diluted earnings per share pence p p p p p income statement adjusted total turnover cost sales selling general administration research development royalty income operating profit net finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders adjusted earnings per share pence p p p p p calculation adjusted results described gsk annual report strategic report governance remuneration financial statements investor information quarterly trend quarterly trend continued unaudited analysis group results provided quarter sterling financial year income statement total months q q q q reported reported reported reported reported cer cer cer cer cer turnover pharmaceuticals vaccines consumer healthcare total turnover cost sales selling general administration research development royalty income operating incomeexpense operating profit net finance costs profit disposal associates share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p p p diluted earnings per share pence p p p p p income statement adjusted total turnover cost sales selling general administration research development royalty income operating profit net finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders adjusted earnings per share pence p p p p p calculation adjusted results described gsk annual report financial record continued pharmaceutical turnover therapeutic area total us europe international growth growth growth growth therapeutic areamajor products cer cer cer cer respiratory seretideadvair ellipta products anoro ellipta arnuity ellipta incruse ellipta relvarbreo ellipta trelegy ellipta nucalamepolizumab avamysveramyst flixotideflovent ventolin hiv dolutegravir products tivicay triumeq juluca epzicomkivexa selzentry immunoinflammation benlysta established pharmaceuticals dermatology augmentin avodart coreg eperzantanzeum imigranimitrex lamictal requip serevent seroxatpaxil valtrex zeffix pharmaceuticals gsk annual report strategic report governance remuneration financial statements investor information pharmaceutical turnover therapeutic area total us europe international growth growth growth growth therapeutic areamajor products cer cer cer cer respiratory seretideadvair ellipta products anoro ellipta arnuity ellipta incruse ellipta relvarbreo ellipta trelegy ellipta nucalamepolizumab avamysveramyst flixotideflovent ventolin hiv dolutegravir products tivicay triumeq juluca epzicomkivexa selzentry immunoinflammation benlysta established pharmaceuticals dermatology augmentin avodart coreg eperzantanzeum imigranimitrex lamictal requip serevent seroxatpaxil valtrex zeffix pharmaceuticals gsk annual report financial record continued vaccines turnover total us europe international growth growth growth growth major products cer cer cer cer meningitis bexsero menveo influenza fluarix flulaval shingles shingrix established vaccines infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix vaccines represents growth actual exchange rates cer represents growth constant exchange rates vaccines turnover total us europe international growth growth growth growth major products cer cer cer cer meningitis bexsero menveo influenza fluarix flulaval shingles shingrix established vaccines infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix vaccines represents growth actual exchange rates cer represents growth constant exchange rates gsk annual report strategic report governance remuneration financial statements investor information five year record record financial performance provided analysed accordance current reporting practice information included five year record prepared accordance ifrs adopted european union also ifrs issued international accounting standards board group turnover geographic region us europe international group turnover segment pharmaceuticals vaccines consumer healthcare segment turnover corporate unallocated turnover pharmaceuticals turnover respiratory hiv immunoinflammation established pharmaceuticals vaccines turnover meningitis influenza shingles established vaccines consumer healthcare turnover wellness oral care nutrition skin health gsk annual report financial record continued five year record continued financial results total turnover operating profit profit taxation profit taxation pence pence pence pence pence basic earnings per share diluted earnings per share millions millions millions millions millions weighted average number shares issue basic diluted financial results adjusted turnover operating profit profit taxation profit taxation pence pence pence pence pence adjusted earnings per share return capital employed return capital employed calculated total profit taxation percentage average net assets year gsk annual report strategic report governance remuneration financial statements investor information five year record continued balance sheet noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets shareholders equity noncontrolling interests total equity number employees us europe international manufacturing selling administration research development geographic distribution employees table based location gsks subsidiary companies number employees number permanent employed staff end financial period excludes employees employed managed gsk contract basis exchange rates guide holders ads following tables set periods indicated information exchange rate us dollars sterling reported bank england pm buying rate average rate year calculated average pm buying rates day year average mar feb jan dec nov oct sep high low pm buying rate march us gsk annual report financial record continued five year record continued divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal adjusted results amortisation impairment restructuring related items results december turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit net finance costs profit disposal associates share tax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions divestments intangible intangible significant total asset asset major transaction legal us tax adjusted adjusted results reconciliation results amortisation impairment restructuring related items reform results december turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit net finance costs profit disposal associates share tax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p p weighted average number shares millions gsk annual report strategic report governance remuneration financial statements investor information five year record continued divestments intangible intangible significant total asset asset major transaction legal adjusted adjusted results reconciliation results amortisation impairment restructuring related items results december turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit net finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions divestments intangible intangible significant total asset asset major transaction legal adjusted adjusted results reconciliation results amortisation impairment restructuring related items results december turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit net finance costs profit disposal associates share tax profits associates joint ventures profit taxation taxation tax rate profit taxation lossprofit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions gsk annual report financial record continued five year record continued divestments intangible intangible significant total asset asset major transaction legal adjusted adjusted results reconciliation results amortisation impairment restructuring related items results december turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit net finance costs share tax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions gsk annual report strategic report governance remuneration financial statements investor information pipeline products competition pharmaceuticals vaccines product development pipeline key inlicence alliance relationship third party r receipt complete response letter v iiv healthcare global specialist hiv company bla biological licence application gsk pfizer inc shionogi limited shareholders maa marketing authorisation application europe responsible developing delivering hiv medicines nda new drug application us registrational phii phase e valuation clinical pharmacology usually conducted review volunteers optionbased alliance ionis pharmaceuticals inc phase ii etermination dose initial evaluation efficacy optionbased alliance immunocore ltd conducted small number patients p ending closure transaction merck kgaa phase iii l arge comparative study compound versus placebo darmstadt germany andor established treatment patients establish first submission clinical benefit safety f irst regulatory approval maa first eu approval letter maa ndabla regulatory review milestones shown table achieved future filing dates included list achieved regulatory review milestones compound type indication phase maa ndabla oncology zejula niraparib poly adpribose polymerase parp first line maintenance ovarian cancer iii inhibitor solid tumours dostarlimab antiprogrammed cell death protein receptor ovarian cancer iii pd antibody nonsmall cell lung cancer msih cancer ii incl endometrial bcell maturation antigen antibody drug conjugate multiple myeloma ii nyeso autologous engineered tcrt cells sarcoma solid heme malignancies ii engineered tcr induced tcell costimulator icos agonist nonsmall cell lung cancer solid tumours ii antibody molibresib bet family bromodomain inhibitor er breast cancer solid tumours ii haematological malignancies transforming growth factor beta tgf trap nonsmall cell lung cancer ii immune checkpoint pd inhibitor bispecific tsr antitcell immunoglobulin mucin domain nonsmall cell lung cancer ii tim antibody ox agonist monoclonal antibody solid tumours haematological malignancies ii protein arginine methyltransferase prmt solid tumours heme malignancies iii inhibitor tolllike receptor tlr agonist cancer phosphatidylinositol kinase pik beta inhibitor cancer protein arginine methyltransferase prmt cancer inhibitor rip kinase inhibitor pancreatic cancer selected solid tumors nyesotargeting bispecific cancer tsr antilymphocyte activation gene lag antibody cancer hiv infectious diseases dectova neuraminidase inhibitor iv influenza submitted nov zanamivir iv dolutegravir hiv integrase strand transfer inhibitor hiv infection submitted ssep soct lamivudine nucleoside reverse transcriptase inhibitor nrti fostemsavir hiv attachment inhibitor hiv infection iii cabotegravir hiv integrase strand transfer inhibitor hiv infection iii rilpivirine nonnucleoside reverse transcriptase inhibitor nnrti longacting regimen cabotegravir hiv integrase strand transfer inhibitor longacting hiv preexposure prophylaxis iii gepotidacin type topoisomerase inhibitor bacterial infections ii hbv antisense oligonucleotide hepatitis b ii hbv lica antisense oligonucleotide hepatitis b ii hiv maturation inhibitor hiv infection ii leucyl trna synthetase inhibitor tuberculosis hiv broadly neutralizing antibody hiv infection gsk annual report pipeline products competition continued pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound type indication phase maa ndabla immunoinflammation benlysta rituxan b lymphocyte stimulator monoclonal systemic lupus erythematosus iii antibody sc cluster differentiation sjogrens syndrome ii cd monoclonal antibody iv granulocyte macrophage colony rheumatoid arthritis ii stimulating factor monoclonal antibody receptorinteracting protein rip psoriasis rheumatoid arthritis ulcerative colitis ii kinase inhibitor oncostatin osm monoclonal systemic sclerosis ii antibody lymphocyte activation gene lag ulcerative colitis protein monoclonal antibody receptorinteracting protein rip inflammatory bowel diseases kinase inhibitor bet targeted inhibitor rheumatoid arthritis ccl inhibitor pain osteoarthritis respiratory mepolizumab interleukin il monoclonal antibody copd complete r sep response letter hypereosinophilic syndrome nasal polyposis iii fluticasone furoate glucocorticoid agonist longacting asthma iii vilanterol beta agonist muscarinic umeclidinium cetylcholine antagonist recombinant human angiotensin acute lung injury pulmonary arterial ii converting enzyme rhace hypertension tumour necrosis factor receptor acute lung injury ii tnfr domain antibody interleukin r ilr monoclonal asthma ii antibody selective androgen receptor modulator copd muscle weakness ii nemiralisib phosphatidylinositol kinase delta activated pik delta syndrome pik inhibitor phosphatidylinositol kinase delta respiratory diseases pik inhibitor interleukin il longacting asthma monoclonal antibody pharmaceuticals krintafel tafenoquine aminoquinoline plasmodium vivax malaria approved jul daprodustat prolyl hydroxylase inhibitor oral anaemia associated chronic renal disease iii oxytocin inhaled oxytocin postpartum hemorrhage ii linerixibat ileal bile acid transporter ibat inhibitor cholestatic pruritus ii hematopoietic prostaglandin muscle repair hpgd synthase inhibitor gsk annual report strategic report governance remuneration financial statements investor information pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound type indication phase maa ndabla vaccines shingrix recombinant herpes zoster prophylaxis approved amarch zoster vaccine herpes zoster prophylaxis immunocompromised iii bexsero recombinant meningococcal b disease prophylaxis infants iii us rotarix live attenuated pcv porcine circovirus rotavirus prophylaxis iii free mmr live attenuated measles mumps rubella prophylaxis iii us copd recombinant reduction frequency moderate severe ii acute exacerbations copd patients targeting nontypeable haemophilus influenzae moraxella catarrhalis hepatitis c heterologous recombinant viral hepatitis c virus prophylaxis prevention ii vectors establishment chronic infection malaria next recombinant malaria prophylaxis plasmodium falciparum ii generation men abcwy recombinant conjugated meningococcal abcw disease prophylaxis ii adolescents menveo liquid conjugated meningococcal acw disease prophylaxis ii adolescents shigella conjugated outer membrane shigella diarrhea prophylaxis ii tuberculosis recombinant tuberculosis prophylaxis ii rsv replicationdefective recombinant respiratory syncytial virus prophylaxis paediatric ii viral vector population respiratory syncytial virus prophylaxis older adult iii population respiratory syncytial virus prophylaxis maternal iii population hiv recombinant proteins hiv infection prophylaxis ii flu universal universal inactivated split influenza flu disease prophylaxis broad protection iii vaccine multiple seasons brand names appearing italics trade marks owned licensed gsk group companies gsk annual report pipeline products competition continued pharmaceutical products competition intellectual property major patent expiry dates products compounds indications competitor brands us eu respiratory anoro ellipta umeclidinium bromide copd stiolto respimat vilanterol trifenatate utibronultibro nce nce breezhaler duaklir genuair device device bevespi aerosphere formulation formulation arnuity ellipta fluticasone furoate asthma qvar pulmicort na asmanex alvesco nce device formulation avamysveramyst fluticasone furoate rhinitis nasonex flixotideflovent fluticasone propionate asthmacopd qvar singulair expired expired diskus device diskus device expired hfadevice hfadevice incruse ellipta umeclidinium bromide copd spiriva handihaler respimat eklira genuair nce nce seebri breezhaler device device formulation formulation nucala mepolizumab severe eosinophilic asthma egpa xolair cinqair fasenra dupixent relvarbreo ellipta fluticasone furoate asthmacopd symbicort foster vilanterol trifenatate flutiform dulera nce nce device device formulation formulation seretideadvair salmeterol xinafoate asthmacopd symbicort foster expired expired fluticasone propionate flutiform dulera diskus device diskus device expired hfadevice hfadevice trelegy ellipta fluticasone furoate copd trimbow vilanterol trifenatate nce nce umeclidinium bromide device device formulation formulation ventolin hfa albuterol sulphate asthmacopd generic companies expired hfadevice hfadevice antivirals valtrex valaciclovir genital herpes coldsores shingles famvir expired expired central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expired expired imigranimitrex sumatriptan migraine zomig maxalt relpax expired expired seroxatpaxil paroxetine depression various anxiety effexor cymbalta expired expired disorders lexapro cardiovascular urogenital avodart dutasteride benign prostatic hyperplasia proscar flomax expired expired finasteride antibacterials augmentin amoxicillinclavulanate common bacterial generic products na expired potassium infections rare diseases volibris ambrisentan pulmonary hypertension tracleer revatio na immunoinflammation benlysta benlysta sc belimumab systemic lupus erythematosus generic competition commenced includes supplementary protection certificates granted multiple countries eu patent term extensions granted us data exclusivity expires eu us gsk annual report strategic report governance remuneration financial statements investor information pharmaceutical products competition intellectual property continued major patent expiry dates products compounds indications competitor brands us eu hiv epzicomkivexa lamivudine abacavir hivaids truvada atripla expired descovy genvoya combination odefsey juluca dolutegravir rilpivirine hivaids genvoya odefsey descovy atripla nce nce selzentrycelsentri maraviroc hivaids isentress intelence prezista nce nce tivicay dolutegravir hivaids isentress prezista reyataz kaletra nce nce biktarvy triumeq dolutegravir lamivudine hivaids atripla descovy abacavir odefsey genvoya nce nce biktarvy vaccine products competition intellectual property major patent expiry dates products compounds indications competitor brands us eu bexsero meningococcal groupb meningitis group b prevention trumenba vaccine boostrix diphtheria tetanus acellular diphtheria tetanus acellular adacel expired expired pertussis pertussis booster vaccination infanrix hexapediarix diphtheria tetanus pertussis prophylaxis diphtheria pentacel pediacel expired expired polio hepatitis b haemophilus tetanus pertussis polio pentaxim pentavac influenzae type b eu hepatitis b haemophilus hexaxim hexyon influenzae type b eu vaxelis cervarix hpv virus like human papilloma virus gardasil silgard particles vlps type adjuvant mpl aluminium hydroxide fluarix tetra split inactivated influenza seasonal influenza prophylaxis intenza flumist qiv antigens virus subtypes vaxigrip qiv subtype b fluzone qiv fluzone high dose flulaval split inactivated influenza seasonal influenza prophylaxis vaxigrip mutagrip antigens virus subtypes fluzone influvac subtype b aggripal fluad intenza flumist menveo meningococcal group c w meningitis group c w nimenrix menactra conjugate vaccine prophylaxis prepandrix derived split inactivated pandemic hn influenza aflunov vepacel influenza virus antigen prophylaxis adjuvant priorix priorix tetraab live attenuated measles mumps measles mumps rubella mmr ii mmrvaxpro expired varilrixb rubella varicella vaccine chickenpox prophylaxis proquad varivax rotarix human rotavirus rix strain rotavirus prophylaxis rotateq synflorix conjugated pneumococcal prophylaxis invasive prevenar prevnar na polysaccharide disease pneumonia acute otitis media shingrix zoster vaccine herpes zoster zostavax recombinant adjuvanted shingles see note financial statements legal proceedings generic competition commenced many markets includes supplementary protection certificates granted multiple countries eu patent term extensions granted us refers priorix priorix tetra patents varilrix expired related compoundsindications measles mumps rubella vaccineprophylaxis b related compound varicella vaccine gsk annual report pipeline products competition continued consumer healthcare products competition brand products application markets competition wellness respiratory otrivin nasal spray nasal decongestant germany poland afrin merck russia sweden ukraine nasivin merck theraflu tablets syrups pods cold flu relief russia poland ukraine tylenol cold flu us johnson johnson mucinex reckitt benckiser lemsip reckitt benckiser flonase nasal spray allergy relief us claritin bayer nasacort sanofi flixonase piriton nasal spray tablets allergy relief uk ireland benadryl johnson johnson nicorette us lozenges gum treatment nicotine withdrawal global nicorette johnson johnson nicoderm transdermal patches aid smoking reduction niquitin perrigo nicotinell cessation ex australia pain relief panadol tablets caplets infant paracetamolbased treatment global except us advil pfizer panadol cold syrup drops headache joint pain fever aspirin bayer flu cold symptoms tylenol johnson johnson voltaren topical gel nonsteroidal diclofenac based global except us advil pfizer antiinflammatory aspirin bayer tylenol johnson johnson eno effervescent immediate relief antacid global except us estomazil hypermarca gelusil pfizer tums chewable tablets immediate relief antacid us alkaseltzer bayer gaviscon reckitt benckiser rolaids sanofi oral health sensodyne toothpastes toothbrushes relief dentinal hypersensitivity global colgate sensitive prorelief pronamel mouth rinse pronamel additionally protects colgatepalmolive acid erosion elmex colgatepalmolive oral b procter gamble parodontax toothpaste medicated helps stop prevent global colgate total gum health corsodyl mouthwash gel spray bleeding gums treats colgatepalmolive prevents gingivitis oral b gum enamel repair crest gum detoxify procter gamble polident denture adhesive denture improve retention comfort global fixodent kukident poligrip cleanser wipes dentures cleans dentures procter gamble corega steradent reckitt benckiser aquafresh toothpastes toothbrushes aids prevention dental cavities global colgate colgatepalmolive mouthwashes maintains healthy teeth gums crest procter gamble fresh breath oralb procter gamble skin health zovirax topical cream lip care treat prevent global compeed johnson johnson abreva nonmedicated patch onset cold sores carmex carma labs blistex blistex incorporated retail label nutrition horlicks malted drinks foods nutritional indian subcontinent bournvita mondelez beverages food united kingdom ireland complan heinz gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties principal risks discussed risks uncertainties rules regulations change governmental interpretation relevant business financial condition results operations evolves nature particular risk may change changes may affect performance ability achieve objectives certain regulatory regimes may substantial change risks believe could cause actual failure comply applicable law regulations could results differ materially expected historical results materially adversely affect financial results evolved cycle management risks similarly global business exposes us litigation government helps us identify manage report important risks investigations including limited product liability litigation proportionate consistent way patent antitrust litigation sales marketing litigation must adapt comply broad range laws litigation government investigations including related provisions regulations apply research development manufacturing may make unfavourable outcomes increases related testing approval distribution sales marketing pharmaceutical costs insurance premiums could materially adversely vaccine consumer healthcare products affect affect financial results cost product development also time required reach detail status various uncertainties involved market likelihood successfully significant unresolved disputes potential litigation set continuous basis note legal proceedings pages also improved consistency risk management uk regulations require discussion mitigating activities across organisation evolution enterprise risk company takes address principal risks uncertainties summary management reporting cycle activities group takes manage principal risks accompanies description principal risk principal risks uncertainties listed order significance patient safety risk definition mitigating activities failure appropriately collect review follow report human chief medical officer cmo also medical officer safety information hsi including adverse events potential pharmaceuticals responsible medical governance sources act relevant findings timely manner global policy policy safeguarding human subjects clinical trials patients take products paramount risk impact importance cmo authoritative role evaluating risk impact potential compromise ability addressing matters human safety conduct robust safety signal detection interpretation individual medical officers within pharmaceutical vaccines ensure appropriate decisions taken respect risk consumer healthcare businesses substantial safety benefit profile products including completeness pharmacovigilance organisation keep track adverse issues accuracy product labels pursuit additional studies reported products course clinical studies analyses appropriate could lead potential harm group product approved marketing extensive patients reputational damage product liability claims postmarketing surveillance signal detection system information litigation governmental investigation regulatory action possible side effects products received several sources fines penalties loss product authorisation including unsolicited reports healthcare professionals hcps context patients regulatory authorities medical scientific literature traditional media social media policy employees preclinical clinical trials conducted development required report immediately issues relating safety investigational pharmaceutical vaccine consumer healthcare quality products country managers responsible products determine safety efficacy products use monitoring exception tracking training helps assure humans notwithstanding efforts make determine collection safety information reporting information safety products appropriate preclinical clinical relevant central safety department accordance policy trials unanticipated side effects may become evident legal requirements products widely introduced marketplace questions information changes riskbenefit profile one safety products may raised products result certain actions characterise communicate ongoing safety surveillance postmarketing studies also minimise risk proposed actions discussed governmental agencies third parties may analyse publicly regulatory authorities include modifying prescribing available clinical trial results constant vigilance flexibility information communications physicians healthcare required order respond varied regulatory environment providers restrictions product prescribingavailability help continues evolve diverge globally assure safe use sometimes carrying clinical trials group currently defendant number product liability certain cases may appropriate stop clinical trials lawsuits including class actions involve significant claims withdraw medicine market damages related products litigation particularly us inherently unpredictable class actions seek sweep together persons take products increase potential liability claims pain suffering punitive damages frequently asserted product liability actions allowed represent potentially openended exposure thus could materially adversely affect groups financial results gsk annual report principal risks uncertainties continued patient safety continued global safety board gsb comprising senior physicians addition medical governance framework described representatives supporting functions integral component use several mechanisms foster early evaluation system gsb including subsidiary boards dedicated mitigation resolution disputes arise potential consumer healthcare products vaccines reviews safety claims even occur goal programmes investigational marketed products authority create culture early identification evaluation risks stop clinical trial continued conduct trial ethically claims actual potential remains strong organisational scientifically justified light information emerged since regulatory change order minimise liability litigation start trial product quality risk definition single external quality standard system governs detailed global regulatory expectations quality medicinal failure comply current good manufacturing practices products requirements often complex fragmented across cgmp inadequate controls governance quality national regional boundaries therefore adopted supply chain covering supplier standards manufacturing internationally recognised principles ich q distribution products pharmaceutical quality systems framework basis risk impact gsk quality management system industry standard incorporates quality concepts failure ensure product quality could far reaching throughout product lifecycle gsk quality management implications terms patient consumer safety resulting system augmented consolidation numerous regulatory product launch delays supply interruptions product recalls requirements defined markets across world assures would potential damage reputation meets external expectations product quality markets well result regulatory legal financial consequences supplied quality management system routinely updated context ensure keeps pace evolving external regulatory environment new scientific understanding products patients consumers hcps trust quality products processes part drive continually improve product quality may influenced many factors including operational deployment quality management system product process understanding consistency manufacturing making policies procedures simpler understand components compliance gmp accuracy labelling reliability implement well adopting innovative tools give external supply chain embodiment overarching userfriendly experience quality culture internal external environment continues evolve new products new legislation introduced provide corporate executive team risk oversight critically addressing impact brexit supply compliance council integrated assessment regulated chain management quality oversight uk quality gxp performance defined key performance indicators eu developing deploying appropriate contingency cover manufacturing practice clinical practice pharmacovigilance plans avoid interruption supply patients practice regulatory practice drug safety assessment animal welfare mitigating activities implemented riskbased approach assessing extensive global network quality compliance professionals managing third party suppliers provide materials used aligned business unit provide oversight assist finished products contract manufacturers making products delivery quality performance operational compliance expected comply gsk standards regularly site level senior management level management oversight audited provide assurance standards met activities accomplished hierarchy quality staff members regularly trained ensure cgmp standards councils independent chief product quality officer behaviours based values expectations followed global product quality office additionally advocacy communication programmes routinely developed implemented single quality management deployed ensure consistent messages conveyed across system defines quality standards systems organisation whether originate changes regulation businesses associated pharmaceuticals vaccines learnings inspections regulatory submissions consumer healthcare products clinical trial materials continued emphasis value quality performance metrics system broad scope applicable throughout facilitate improvement foster culture right first time product lifecycle rd mature commercial supply gsk annual report strategic report governance remuneration financial statements investor information financial controls reporting risk definition expect continued focus tax reform future years driven initiatives organisation economic failure comply current tax laws incurring significant losses cooperation development address taxation digital due treasury activities failure report accurate financial information economy european commission initiatives including use compliance accounting standards applicable legislation fiscal state aid investigations together domestic initiatives risk impact around world may result significant changes established tax principles increase tax authority disputes noncompliance existing new financial reporting regardless merit outcomes costly divert disclosure requirements changes recognition income management attention may adversely impact reputation expenses could expose us litigation regulatory action relationship key stakeholders could materially adversely affect financial results changes mitigating activities tax laws application respect matters transfer pricing foreign dividends controlled companies rd tax credits financial results reviewed approved regional management taxation intellectual property restriction tax relief allowed reviewed financial controller chief interest debt funding could impact effective tax rate financial officer cfo allows financial controller significant losses may arise inconsistent application treasury cfo assess evolution business time policies transactional settlement errors counterparty defaults evaluate performance plan significant judgments reviewed changes substance application governing tax confirmed senior management business reorganisations laws failure comply tax laws significant losses due newly acquired activities integrated risk assessments treasury activities could materially adversely affect appropriate controls reviews applied financial results counterparty exposure subject defined limits approved context board credit rating individual counterparties oversight treasurys role managing counterparty risk line agreed group required laws various jurisdictions disclose policy performed corporate compliance officer publicly financial results events could materially affect operates independently treasury details mitigation financial results group regulators routinely review treasury risks found pages note financial statements listed companies compliance new financial instruments related disclosures revised existing accounting regulatory requirements maintain control environment designed identify material group believes complies appropriate regulatory errors financial reporting disclosure design operating requirements concerning financial statements disclosure effectiveness key financial reporting controls regularly tested material information including transactions relating business management via independent business monitoring restructuring acquisitions divestitures however provides us assurance controls key financial subject investigation potential noncompliance reporting disclosure processes operated effectively accounting disclosure requirements may lead minimum standard control set implemented whereby restatements previously reported results significant penalties finance activities required apply ensure treasury group deals high value transactions mostly foreign monitored global finance risk management controls exchange cash management transactions daily basis centre excellence provides extra support large group transactions involve market volatility counterparty risk organisations undergoing transformation system deployment groups effective tax rate reflects rates tax jurisdictions significant business finance transformations also group operates higher lower added operational resources ensure processes controls uk rate takes account regimes encourage innovation maintained business transformation upgrade investment science providing tax incentives financial systems processes additional risk mitigation changed could affect groups tax rate addition worldwide introduced amending programme timelines nature operations means intellectual property rd system upgrades optimise delivery manufacturing operations centered number key disclosure committee reporting board reviews locations consequence crossborder supply groups quarterly results annual report determines routes necessary ensure supplies medicines numerous throughout year consultation legal advisors whether end markets complex result conflicting claims necessary disclose publicly information group tax authorities profits taxed individual countries stock exchange announcements treasury management tax legislation also complex differs across countries group meets regular basis seek ensure liquidity operate tax risk also arise due interest rate counterparty foreign currency transaction foreign differences interpretation legislation tax charge currency translation risks managed line conservative included financial statements best estimate tax liability approach detailed associated risk strategies policies pending audits tax authorities adopted board gsk annual report principal risks uncertainties continued financial controls reporting continued tax risk managed robust internal policies processes tax affairs managed global basis coordinated training compliance programmes ensure alignment team tax professionals led global head tax works across business meet tax obligations seek closely business tax professionals suitably qualified maintain open positive relationships governments tax roles perform support training needs authorities worldwide welcome constructive debate order continue able provide date technical taxation policy monitor government debate tax policy advice submit tax returns according statutory time limits key jurisdictions deal proactively potential future changes engage tax authorities seek ensure tax affairs tax law engage advisors legal counsel confirm current entering arrangements continuous audit implications business tax legislation recently programmes advance pricing agreements appropriate enacted us tax cuts jobs act appropriate agreements provide longterm certainty tax authorities active providing relevant business input tax policy makers us tax treatment business exceptional significant decisions submitted consideration tax cases matters settled agreement tax governance board meets quarterly comprises senior authorities may resolve disputes formal appeals personnel across gsks finance division proceedings keep uptodate latest developments financial reporting requirements working external auditor legal advisors antibribery corruption abac risk definition mitigating activities failure gsk employees consultants third parties comply programme governance provided enterprise risk antibribery corruption abac principles standards management overseen abac governance board well applicable legislation includes representation key functional areas business dedicated abac team responsible implementation risk impact evolution programme response developments failure mitigate risk could expose group associated internal external environment complemented persons governmental investigation regulatory action civil independent oversight assurance undertaken audit criminal liability may compromise groups ability assurance independent business monitoring teams supply products certain government contracts addition enterprisewide abac programme designed ensure legal financial penalties failure prevent bribery compliance abac policies mitigate risk bribery complying abac legislation regulations could corruption builds business standards values substantial implications reputation company expectations form comprehensive practical approach credibility senior leaders erosion investor confidence compliance flexible evolving nature business governance risk management code conduct values expectations commitment context zero tolerance integral mitigate risk light complexity geographic breadth risk constantly evolve exposed bribery corruption risk global oversight activities data reinforce workforce clear business operations markets government structure expectations regarding acceptable behaviours maintain regular rule law less developed bearing communications centre local markets bribery corruption risk exposure addition global nature business healthcare sector nature maintains abac programme built best class principles relationships government bodies highly competitive subject ongoing review development provides us subject regulation increases instances basis seek manage risk top exposed bribery corruption risk bottom example programme comprises toplevel commitment board directors leadership global risk group subject number abac inquiries assessment key risk indicators enable targeted intervention reached resolution us authorities regarding risk management activities programme underpinned abac inquiry following subject selfmonitoring global abac policy written standards address commercial arrangement selfmonitorship concluded september practices give rise abac risk ongoing government investigations regarding china business communications provide mandatory periodic abac training operations ongoing investigations discussed staff relevant third parties accordance roles note legal proceedings responsibilities risks face addition programme mandates enhanced controls interactions government officials business development transactions continually benchmark abac programme large multinational companies use external expertise internal insights drive improvements programme gsk annual report strategic report governance remuneration financial statements investor information commercial practices risk definition mitigating activities failure engage commercial activities consistent strategic objectives designed ensure achieve letter spirit law industry groups requirements mission helping people feel better live longer relating marketing communications medicines continue strive new product launches competitive associated therapeutic areas appropriate interactions resourced effectively also strive healthy proportion healthcare professionals hcps patients legitimate groups sales ratio attributable new product innovation transparent transfer value sales risk impact innovation helps us defray effect example downward price pressure major markets declining emerging market growth failure manage risks related commercial practices could negative foreign exchange impact establishing new products materially adversely affect ability grow diversified priced balance expectations patients consumers global business deliver products value patients hcps payers shareholders community enables us consumers failure comply applicable laws rules maintain strong global business remain relevant needs regulations may result governmental investigation regulatory action patients consumers values behaviours provide legal proceedings brought group governmental guide lead make decisions constantly strive private plaintiffs could result government sanctions right thing deliver quality products ensure supply criminal andor financial penalties failure provide accurate sustained meet customer needs demand requirements complete information related products may result seeking ensure actions reflect values behaviours incomplete awareness riskbenefit profile products mission company possibly suboptimal treatment patients consumers taken action enhance improve standards practices found misaligned values could procedures customer consumer engagement utilising also result reputational harm dilute trust established application data analytics ecommerce channels external stakeholders policies standards governing commercial activities undertaken context us behalf training implemented support evolution activities relevant employees operate global basis industry highly activities conduct worldwide must conform high ethical competitive highly regulated competitors may make regulatory industry standards local standards differ significant product innovations technical advances may global standards stringent two applies intensify price competition light competitive environment harmonised policies procedures guide abovecountry continued development commercially viable new products commercial practice processes well clarified applicable development additional uses existing products reflect standards operations various markets operate insights help ensure products address needs business adopted internal control framework patientsconsumers hcps payers critical achieve support assessment management risks commercial strategic objectives practices activities appropriate monitoring programmes oversight business unit risk management compliance pharmaceutical vaccine consumer companies boards country executive boards manage risks across face downward price pressure major markets declining emerging incountry business activities past fallen market growth negative foreign exchange impact regulatory industry standards developing new pharmaceutical vaccine consumer healthcare sought improve framework culture products costly lengthy uncertain process product compliance processes candidate may fail stage including significant economic promotional materials activities must reviewed human resources invested competitors approved according policies standards conducted products pricing strategies failure part develop accordance local laws regulations seek ensure commercially successful products develop additional uses materials activities fairly represent products services existing products could materially adversely affect ability group necessary disciplined achieve strategic objectives including termination employees engaged misconduct committed ethical responsible commercialisation broadened ability claw back remuneration products support mission improve quality senior management event misconduct human life enabling people feel better live longer eliminated rewards based individual sales market accomplish mission engage healthcare community share prescription products sales professionals various ways provide important information medicines managers interact hcps favour rewards based promotion approved products seeks ensure hcps globally quality individuals interactions hcps access information need patients consumers access information products need october announced changes allow fair market products prescribed recommended used manner value payments made gsk expert practitioners speak provides maximum healthcare benefit patients consumers innovative medicines vaccines limited number committed communicating information related countries restricted time period products lifecycle approved products responsible legal ethical manner new controls training implemented support changes ensuring appropriate oversight assurance across markets new policy expand reporting payments individual hcps part commitment transparency responsible disclosure gsk annual report principal risks uncertainties continued privacy risk definition mitigating activities failure collect secure use destroy personal information chief compliance officer also chairperson privacy pi accordance applicable data privacy laws governance board pgb oversees gsks overall data privacy programme business function appointed risk impact risk owner accountable oversight privacy risks noncompliance lead harm individuals eg financial associated business functional area supported loss distress prejudice gsk eg fines management time privacy leaders within business function additionally operational inefficiency pocket costs reputational countries data privacy laws require data protection officer damage also damage trust gsk individuals dpo appointed gsk appointed single dpo communities business partners government authorities european union represented supported specific countries country privacy advisors chief compliance general data protection regulation gdpr increased officer enterprise risk owner ero ero appointed enforcement powers eu supervisory authorities including delegate risk owner global privacy officer gpo allowing impose fines global revenue accountability daytoday basis designing implementing require suspension processing pi certain circumstances control framework gpo coleads crossfunctional gdpr also gives individuals right bring collective legal actions privacy centre excellence coe together global gsk failure comply data privacy laws privacy counsel supported privacy officers privacy context counsel region multiple country privacy advisors familiar local privacy regulations data privacy laws diverse limited harmonisation despite gsk emphasised importance data privacy internal europes adoption gdpr many countries gsk risk management perspective separating privacy new operates local data privacy laws govern gsk collect standalone enterprise risk information security enterprise use pi challenging multinationals standardise risk created privacy centre excellence global ethics approach compliance data privacy laws due highlevel compliance overseen implementation local variation governments enforcing compliance data control framework ii remediation certain existing business privacy laws rigorously increasing focus activities ensure compliance gdpr including adopting ethical use pi compliance data privacy laws privacy controls eg privacy contract terms written records individuals increasingly aware rights data processing activities data protection impact assessments iii privacy laws comprehensive training programme drive greater awareness accountability managing pi across entire organisation key roles privacy network gsk certified accredited international privacy association monitoring continuously improve processes issue identification reporting handling capabilities developing process detect assess new privacy regulations proactively prepare mitigate regulatory risk gsk research practices risk definition context failure adequately conduct ethical sound preclinical research relating animals raise ethical concerns clinical research addition failure engage scientific activities attempt address proactively animal studies remain vital part consistent letter spirit law industry research many cases method groups requirements failure secure adequate patent used investigate effects potential new medicine living protection gsks products body studied humans animal research provide critical information causes diseases risk impact develop nonetheless continually seeking ways impacts risk include harm human subjects reputational minimise use animals research whilst complying damage failure obtain necessary regulatory approvals regulatory requirements products governmental investigation legal proceedings brought clinical trials healthy volunteers patients used assess group governmental private plaintiffs product demonstrate investigational products efficacy safety liability suits claims damages loss revenue due evaluate product approved marketing inadequate patent protection inability supply gsk products also work human biological samples samples regulatory action fines penalties loss product fundamental discovery development safety monitoring authorisation consequences could materially products adversely affect financial results cause loss trust customers patients gsk annual report strategic report governance remuneration financial statements investor information research practices continued integrity data essential success stages chief medical officer oversees following enterprise medical research data lifecycle design generation recording governance boards management analysis reporting storage retrieval human subject research board place provide research data governed legislation regulatory requirements oversight human subject research sponsored research data supporting documents core components supported us ensure conforms ethical medical various stages pipeline progression decisionmaking form scientific standards content regulatory submissions publications patent filings poor data integrity compromise research efforts data disclosure board provides oversight disclosure negatively impact company reputation sponsored supported human subject research make information available clinical studies including summaries innate complexities interdependencies required results whether positive negative first regulatory filings particularly given global research company publish clinical study reports form basis development footprint continually changing increasingly submissions regulatory agencies publicly posted stringent submission requirements continue increase clinical study reports addition complexity worldwide product registration study result summaries scientific engagement se defined interaction exchange specific accountability authorisation se overseen information gsk external communities advance scientific engagement promotional practices board scientific medical understanding including appropriate board responsible oversight applicable policies development use products essential part seeking ensure highest level integrity continuous scientific discourse nonpromotional engagement development se external stakeholder groups vital gsks mission necessary scientific medical advance se activities essential global human biological samples management hbsm present legal regulatory reputational risk sharing data governance framework place oversee ethical lawful invited media coverage payments hcps perceived acquisition management human biological samples promotional intent hbsm enterprise risk management team champions hbsm activities provides experienced group support internal wide variety biological materials used gsk discovery sample custodians regarding best practice research development phases convention biological diversity cbd nagoya protocol international remains important priority enhance data integrity controls community established global framework regulating access data integrity committees place provide oversight data use genetic resources nonhuman origin research integrity quality assurance teams conduct assessments provide development rd support principles access independent business monitoring internal controls rd benefit sharing genetic resources outlined cbd activities nagoya protocol recognising importance appropriate regulatory governance board serves global regulatory effective proportionate implementation measures national risk management compliance board promoting compliance regional levels regulatory requirements procedures oversees groupwide patent rights play important role providing gsk written standards cross business regulatory processes competitive advantage market loss patent protection established access benefit sharing centre excellence market gsks products developed rd including oversee applicable requirements enforcement measures reducing availability scope patent rights could materially acquisition use genetic material nonhuman origin adversely affect financial results market absence scope nagoya protocol adequate patent data exclusivity protection could lead example competition manufacturers generic rd maintains controls prepublication procedures guard pharmaceutical products could limit opportunity rely public disclosure advance filing patent applications markets future sales growth products addition loss patent protection occur due lack could also materially adversely impact financial results data integrity preparing patent application data information following expiration certain intellectual property rights generic legal experts collaborate rd support review process manufacturer may lawfully produce generic version product new patent applications introduction generic products typically leads rapid research practices risk overseen enterprise framework dramatic loss sales reduces revenues margins seeks ensure strengthened governance across rd proprietary products businesses pharmaceuticals vaccines consumer healthcare leadership research practices enterprise risk mitigating activities owner management risk takes pragmatic approach established office animal welfare ethics information sharing streamlining risk identification escalation strategy oawes led chief animal welfare ethics ensuring ownership stays business strategy ensures humane responsible care animals increases knowledge application nonanimal alternatives oawes provides framework animal welfare governance promotes application rs replacement refinement reduction animals research conducts quality assessments develops deploys strategies animal model reproducibility translatability gsk annual report principal risks uncertainties continued third party oversight tpo risk definition mitigating activities failure maintain adequate governance oversight guide enforce global principles interactions third party relationships failure third parties meet third parties global policy framework applicable buying contractual regulatory confidentiality obligations goods services managing external spend paying working third parties policy framework applies risk impact employees complementary workers worldwide enterprise failure adequately manage third party relationships could result wide tpo programme takes enterprisewide view third party business disruption exposure risks ranging suboptimal related risks ensure compliance abac policies contractual terms conditions severe business legal additional risks labour rights health safety human sanctions andor significant reputational damage safety information forms comprehensive practical approach consequences could materially adversely affect business third party oversight flexible evolving nature operations financial results business type engagement managed programme managed global ethics compliance context organisation globally deployed strengthened risk assessment contractual terms due diligence efforts third third parties critical business delivery integral parties improved overall management third party risks part solution meeting business objectives rely lifecycle third party engagement third parties including suppliers advisors distributors individual contractors licensees pharmaceutical biotechnology programme governance provided enterprise risk collaboration partners discovery manufacture marketing management overseen tpo governance board products supporting important business processes includes representation key functional areas business dedicated tpo team responsible implementation business relationships present material risk example evolution programme response developments share critical sensitive information marketing plans internal external environment clinical data employee data specific third parties conducting relevant outsourced business activities inadequate business leadership team retains ultimate accountability protection misuse information third parties could managing third party interactions risks working third significant business impact similarly use distributors agents parties employees expected manage external interactions range activities promotion tendering commitments responsibly expectation embedded inherent risks inappropriate promotion corruption values code conduct responsibility activities insufficient internal compliance controls distributors carried behalf performed safely compliance could affect reputation risks increased applicable laws values expectations standards code complexities working large numbers third parties across conduct see abac report diverse geographical spread programme complemented independent oversight assurance undertaken audit assurance independent business monitoring teams review tpo programme large multinational companies use external expertise internal insights drive improvements programme environment health safety sustainability ehss risk definition context failure manage environment health safety sustainability subject health safety environmental laws various ehss risks line objectives policies jurisdictions laws impose duties protect people relevant laws regulations environment communities operate well potential obligations remediate contaminated sites risk impact also identified potentially responsible party failure manage ehss risks could lead significant harm us comprehensive environmental response compensation people environment communities operate fines liability act number sites remediation costs relating failure meet stakeholder expectations regulatory requirements use ownership sites us failure manage litigation regulatory action damage groups reputation environmental risks properly could result litigation regulatory could materially adversely affect financial results action additional remedial costs may materially adversely affect financial results see note financial statements legal proceedings discussion environmental related proceedings involved routinely accrue amounts related liabilities matters gsk annual report strategic report governance remuneration financial statements investor information environment health safety sustainability ehss continued mitigating activities riskbased proactive approach articulated global ehss standard supports ehss policy corporate executive team cet responsible ehss objective discover develop manufacture supply sell governance global policy policy cet seeks products without harming people environment addition ensure control framework place manage risks design provision safe facilities plant equipment impacts legal compliance issues relate ehss operate rigorous procedures help us eliminate hazards assigning responsibility senior managers providing practicable protect employees health wellbeing maintaining controls individual managers seek ensure ehss control framework effective well implemented continuing efforts improve environmental sustainability respective business area fully compliant reduced value chain carbon intensity per pack water applicable laws regulations adequately resourced maintained consumption waste generation actively manage communicated monitored additionally employee environmental remediation obligations seek ensure practices personally responsible ensuring applicable local standard environmentally sustainable compliant operating procedures followed expected take responsibility ehss matters information security risk definition mitigating activities risk gsk business activities information becomes disclosed global information protection policy accompanying authorised see information systems fail information technology standards processes supported available corrupted typically cybersecurity threats dedicated team programme activity information although accident malicious insideraction may contributory protection function provides strategy direction oversight causes including active monitoring cyber security enhancing global information security capabilities ongoing risk impact programme investment sixth year failure adequately protect critical sensitive systems assess changes information protection risk environment information may result loss commercial strategic advantage briefings government agencies subscription could materially affect ongoing business operations commercial threat intelligence services knowledge sharing scientific research clinical trials manufacturing supply pharmaceutical businesses crossindustry bodies chain activities changes regularly reviewed executive team context board suitable adjustments agreed aim apply industry best practices part information rely critical sensitive systems data corporate security policies processes technologies invest strategies strategic plans intellectual property manufacturing systems commensurate changing nature security threat trade secrets potential computer systems landscape include suitable levels cyberrisk insurance information may exposed misuse unauthorised disclosure cover future believe cyber security incidents experienced date resulted significant disruptions operations significant adverse effect results operations third parties however threats evolve provide assurance significant efforts protecting monitoring systems information always successful preventing compromise disruption future increasingly involve highlyresourced threat actors nationstates organised criminals combined size complexity systems supply chain partners including outsourced operations means systems information expected continue subject cyberattacks various types gsk annual report principal risks uncertainties continued supply continuity risk definition mitigating activities failure deliver continuous supply compliant finished product supply chain model designed ensure supply quality inability respond effectively crisis incident timely manner security products globally far possible recover sustain critical operations including key supply chains supply chain governance committees closely monitor inventory status delivery products aim ensuring risk impact customers pharmaceutical vaccines consumer recognise failure supply products adversely healthcare products need improved links commercial impact consumers patients rely material forecasting manufacturing made possible core interruption supply exclusion healthcare programmes commercial cycle time reduce risk associated could expose us litigation regulatory action financial demand fluctuations impact ability supply penalties could adversely affect groups financial results cost writeoffs products exceed expiry date groups international operations partners node supply chain periodically reviewed ensure adequate expose workforce facilities operations information safety stock balancing working capital endtoend technology potential disruption natural events eg storm supply chain particular attention placed mitigating supply earthquake manmade events eg civil unrest terrorism global risks associated medically critical highrevenue products emergencies eg ebola outbreak flu pandemic important routinely monitor compliance manufacturing external robust crisis management recovery plans place suppliers identify manage risks supply base manage events practical minimise dependence single sources supply context critical items alternative sourcing arrangements possible inventory strategy aims protect supply chain supply chain operations subject review approval unanticipated disruption various regulatory agencies effectively provide license continue implement anticounterfeit systems product operate failure manufacturing distribution facilities serialisation accordance emerging supply chain requirements suppliers key services materials could lead litigation eu falsified medicines regulation around world regulatory action product recalls seizures interruption supply delays approval new products suspension corporate policy requires business functional area manufacturing operations pending resolution manufacturing head ensure effective crisis management business continuity logistics issues plans place include authorised response recovery strategies key areas responsibility clear communication rely materials services provided third party suppliers routes business disruption occurs corporate security make products including active pharmaceutical ingredients supports business coordinating crisis management api antigens intermediates commodities components business continuity training facilitating simulation exercises manufacture packaging pharmaceutical vaccine assessing preparedness recovery capability providing consumer healthcare products third party services assurance oversight central repository plans supporting procured services provided contract manufacturing critical business processes clinical research organisations support development key products important ensure continuous operation business performs risk oversight assure adequate risk business mitigation including identifying new emerging threats coordinated approach evaluate manage implications although undertake risk mitigation recognise certain business arising brexit approach brexit set events could nevertheless still result delays service interruptions use effective crisis management business continuity planning provide health safety people activities help ensure appropriate level readiness minimise impact us maintaining functional operations following response capability maintained also develop maintain natural manmade disaster public health emergency partnerships external bodies like business continuity institute un international strategy disaster risk reduction helps improve business continuity initiatives disasterprone areas supports development community resilience disasters gsk annual report strategic report governance remuneration financial statements investor information shareholder information share capital control details issued share capital number shares held share buyback programme treasury december found note board authorised issue allot ordinary shares financial statements share capital share premium account article companys articles association power article authority company make purchases ordinary shares listed london stock exchange shares subject shareholder authorities also quoted new york stock exchange nyse sought annual basis annual general meeting agm form american depositary shares ads ads shares purchased company may cancelled held represents two ordinary shares details listed debt treasury shares used satisfying share options grants listed refer note financial statements group employee share plans net debt programme covers purchases shares cancellation holders ordinary shares ads entitled receive held treasury shares accordance authority dividends declared companys annual report attend renewed shareholders agm may speak general meetings company appoint proxies company authorised purchase maximum exercise voting rights million shares details shares purchased cancelled restrictions transfer limitations holding held treasury shares subsequently transferred ordinary shares ads requirements obtain approval treasury satisfy awards groups employee share prior transfers ordinary shares ads carry special plans disclosed note financial statements share rights regard control company capital share premium account restrictions voting rights major shareholders determining specific share repurchase levels company voting rights per share shareholders considers development free cash flow year known arrangements financial rights held shares purchased financial years ended person holder shares known agreements restrictions share transfers voting rights company confirms currently intend make shares acquired groups employee share plans rank market purchases company review equally shares issue special rights potential future share buybacks line usual annual trustees employee share ownership plan trusts cycle subject return ratings criteria waived rights dividends shares held trusts market capitalisation exchange controls limitations affecting security holders market capitalisation based shares issue excluding certain economic sanctions may force treasury shares gsk december billion time time currently applicable laws decrees date gsk fifth largest company market regulations force uk restricting import export capitalisation ftse index capital affecting remittance dividends payments holders companys shares nonresidents uk share price similarly certain economic sanctions may force time time limitations relating january nonresidents uk english law companys december articles association right holder vote decreaseincrease respect companys shares high year interests voting rights low year stated far aware table sets middle market closing prices persons significant direct indirect holdings company companys share price increased compares information provided company pursuant financial decrease ftse index year conduct authoritys fca disclosure guidance transparency share price march rules dtrs published regulatory information service companys website wwwgskcom uk us company received notifications accordance fcas dtrs following notifiable interests voting rights companys issued share capital december march percentage percentage issued issued shares capital shares capital blackrock inc p ercentage ordinary shares issue excluding treasury shares acquired disposed interests shares period review exception transferred treasury satisfy awards groups employee share plans uk share price uk us ads price us gsk annual report shareholder information continued share capital control continued nature trading market following tables set periods indicated high low middle market closing quotations pence shares london stock exchange high low closing prices us dollars ads nyse ordinary shares ads pence per share us dollars per share high low high low march february january december november october september quarter ended december quarter ended september quarter ended june quarter ended march quarter ended december quarter ended september quarter ended june quarter ended march year ended december year ended december year ended december year ended december year ended december year ended december march analysis shareholdings december number total total number accounts accounts shares shares holding shares held nominee companies investment trust companies insurance companies individuals corporate bodies bny nominees limited held treasury shares glaxosmithkline bank new york mellon depositary companys ads listed nyse ordinary shares representing companys ads programme managed depositary registered name bny nominees limited march bny nominees limited held ordinary shares representing issued share capital excluding treasury shares date march number holders ordinary shares us holdings ordinary shares number registered holders ads holdings ads certain ordinary shares ads held brokers nominees result number holders record registered holders us representative number beneficial holders residence beneficial holders gsk annual report strategic report governance remuneration financial statements investor information dividends company pays dividends quarterly continues return cash board intends maintain dividend current shareholders dividend policy dividends remain level p per share subject material change external essential component total shareholder return gsk recognises environment performance expectations time free cash importance dividends shareholders company aims flow strengthens intends build free cash flow cover distribute regular dividend payments determined primarily annual dividend target range x returning reference free cash flow generated business dividend growth details dividends declared amounts funding investment necessary support groups future payment dates given note financial growth statements dividends dividends per share dividend calendar table sets dividend per share per ads exdividend last five years dividend per ads translated us dollars quarter date record date payment date applicable exchange rates q february february april q may may july year dividend pence us q august august october q november november january q february february april special q interim ordinary dividend receivable ads holders calculated based exchange rate april annual fee per ads per ads per quarter charged depository cumulative dividend receivable ads holders q q q special dividend related return part net cash proceeds novartis transaction completed march paid fourth quarter ordinary dividend financial calendar results announcements event date quarter results announcement may results announcements issued london stock exchange annual general meeting may available news service also sent quarter results announcement july us securities exchange commission nyse issued quarter results announcement october media made available website preliminaryquarter results announcement february financial reports annual report publication februarymarch annual report distribution march company publishes annual report made available website date publication shareholders may information company including share price available elect receive annual report contacting registrar website wwwgskcom information made available alternatively shareholders may elect receive notification website constitute part annual report email publication financial reports registering wwwshareviewcouk copies previous financial reports available website printed copies obtained registrar uk see contact details gsk annual report shareholder information continued annual general meeting annual general meeting agm held pm ads holders wishing attend meeting contact bny uk time wednesday may sofitel london heathrow mellon depositary request proxy appointment terminal london heathrow airport tw gd enable attend vote business transacted ads holders may instruct bny mellon way agm companys principal forum communication shares represented ads voted completing private shareholders addition formal business returning voting card provided depositary presentation ceo performance group future development opportunity documents display questions asked board chairs boards committees take questions relating committees articles association company directors service investors holding shares nominee service arrange contracts applicable letters appointment nominee service appointed proxy respect directors company subsidiaries side shareholding order attend vote meeting letters relating severance terms pension arrangements available inspection companys registered office made available inspection agm tax information shareholders summary certain uk tax us federal income tax taxation capital gains consequences holders shares ads citizens uk us set complete analysis uk resident shareholders may liable uk tax gains possible tax consequences purchase ownership sale disposal shares ads securities intended general guide holders disposals individuals uk tax year taxable advised consult advisers respect tax capital gain accruing disposal shares ads taxed consequences purchase ownership sale shares basic rate taxpayers allowable ads consequences state local tax laws deductions individuals taxable income year exceeds us implications current ukus tax conventions basic rate income tax limit note following use us holders ads generally treated owners exceptions available individual taxpayer annual underlying shares purposes current usuk double exempt amount taxation conventions relating income gains income tax corporation taxpayers may entitled indexation allowance convention estate gift taxes estate gift tax convention applies reduce capital gains extent gains purposes internal revenue code arise due inflation indexation allowance may reduce chargeable amended code gain create allowable loss assets acquired january legislation finance act freezes uk shareholders level indexation allowance given calculating companys chargeable gains value would apply summary applies uk resident shareholder holds disposal asset december assets acquired shares capital assets january onwards legislation finance act taxation dividends removes indexation allowance disposal inheritance tax uk tax year uk resident individuals entitled dividend tax allowance first individual ukdomiciled otherwise shareholders may liable dividends received tax year free tax dividends uk inheritance tax transfer shares ads tax may excess allowance taxed basic rate charged amount value shareholders taxpayers higher rate taxpayers additional estate reduced result transfer way lifetime gift rate taxpayers disposal less full market value case bequest uk resident shareholders corporation taxpayers note death tax may charged value shares dividends payable ordinary shares generally entitled date shareholders death gift disposal exemption corporation tax subject uk inheritance tax us estate gift tax estate gift tax convention would generally provide tax paid us credited tax payable uk gsk annual report strategic report governance remuneration financial statements investor information tax information shareholders continued stamp duty stamp duty reserve tax dividends qualified subject taxation us federal graduated tax rates maximum rate uk stamp duty andor stamp duty reserve tax sdrt subject types dividends automatically excluded qualified certain exemptions payable transfer shares rate dividends even meet requirements include rounded nearest case stamp duty limited consideration transfer notwithstanding provided capital gains distributions instrument executed pursuance agreement gave rise charge sdrt instrument stamped within six dividends bank deposits years agreement including stamped exempt ividends held corporation employee stock sdrt charge cancelled sdrt already ownership plan esop paid repaid dividends paid taxexempt corporations us shareholders us state local tax rates qualified nonqualified dividends may vary would assessed addition federal tax rates summary applies shareholder citizen communicated resident us domestic corporation person otherwise subject us federal income tax net income basis taxation capital gains respect shares ads holds shares ads capital assets resident uk uk tax purposes generally us holders subject uk capital gains tax hold shares purposes trade profession vocation subject us tax capital gains realised sale carried uk branch agency disposal shares ads gains longterm capital summary also address tax treatment holders gains subject reduced rates taxation individual holders subject special tax rules banks taxexempt shares ads held one year date entities insurance companies dealers securities currencies shares vestedreleased shortterm capital gains persons hold shares ads part integrated investment subject taxation rates whereas longterm capital including straddle comprised share ads one gains may subject rates state local tax positions persons directly indirectly rates capital gains may also apply voting stock company address tax information reporting backup withholding treatment may applicable result international income tax treaties dividends payments proceeds sale shares taxation dividends ads paid within us certain usrelated financial intermediaries subject information reporting may gross amount dividends received treated foreign source subject backup withholding unless us holder corporation dividend income us tax purposes eligible dividend exempt recipient provides taxpayer identification number received deduction allowed us corporations dividends ads certifies loss exemption occurred nonus payable us dollars dividends ordinary shares payable holders generally subject information reporting backup sterling dividends paid sterling included income withholding may required provide certification us dollar amount calculated reference exchange rate nonus status connection payments received amounts day dividends received holder subject withheld allowed refund credit holders us certain exceptions shortterm hedged positions individual federal income tax liability provided required information eligible us holder subject us taxation maximum furnished internal revenue service federal rate plus applicable state local tax respect estate gift taxes qualified dividends qualified dividend defined us internal revenue service irs dividend meets following criteria estate gift tax convention us shareholder ust issued us corporation corporation incorporated generally subject uk inheritance tax however us capital us possession corporation eligible shareholder may subject us estate gift tax benefits comprehensive income tax treaty deemed satisfactory published irs stamp duty dividends listed irs dividends uk stamp duty andor sdrt subject certain exemptions qualify payable transfer shares ads custodian required dividend holding period met shares depository rate amount consideration must owned days provided transferred sale value transferred holding period defined day period consideration begins days exdividend date day however stamp duty sdrt payable transfer stock trades without dividend priced example agreement transfer ads stocks exdividend date october shares must held days period august november year order count qualified dividend gsk annual report statutory disclosures shareholder services contacts registrar companys registrar equiniti limited aspect house spencer road lancing bn da wwwshareviewcouk tel uk tel outside uk equiniti provides range services shareholders service offers participate dividend reinvestment plan alternative receiving cash dividends may choose drip election form downloaded drip reinvest dividends buy gsk shares wwwshareviewcouk requested contacting equiniti dividend payment direct bank account currently receive dividends cheque dividend bank mandate form bank mandate post instead paid directly bank downloaded wwwshareviewcouk building society account quicker secure requested contacting equiniti avoids risk cheque going astray dividend payment direct bank instead waiting sterling cheque arrive post details service costs account overseas shareholders equiniti convert dividend local currency involved please contact equiniti send direct local bank account service available countries worldwide electronic communications shareholders may elect receive electronic notifications register wwwshareviewcouk company communications including annual report dividend payments paid way bank mandate access dividend confirmations availability online voting general meetings time gsk mails hard copy shareholder documents receive email containing link document relevant website shareview portfolio service enables create free online portfolio view register wwwshareviewcouk share balance movements update address dividend payment instructions register votes agm deduplication publications mailings receive duplicate copies mailings may please contact equiniti one account please contact equiniti arrange accounts merged one convenience avoid waste unnecessary costs share dealing service shareholders may trade shares either held certificated form online transactions please log please note market trading hours held corporate sponsored nominee online wwwshareviewcoukdealing pm uk time telephone postal dealing service provided equiniti telephone transactions please call monday friday excluding public financial services limited uk holidays england wales outside uk postal transactions please call request dealing form corporate sponsored nominee account convenient way manage shares without application form requested requiring share certificate service provides facility wwwshareviewcouk hold shares nominee account sponsored contacting equiniti company continue receive dividend payments annual reports attend vote companys general meetings shareholders names appear publicly available share register service free join individual savings accounts isas company arranged equiniti financial services details available wwwshareviewcouk limited provide gsk corporate isa hold gsk requested telephoning equiniti ordinary shares lines open pm dealing pm enquiries monday friday excluding public holidays england wales uk lines open pm monday friday excluding public holidays england wales provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser gsk annual report strategic report governance remuneration financial statements investor information shareholders services contacts continued ads depositary contacts ads programme administered bank new york investor relations mellon investor relations may contacted follows bny mellon shareowner services uk po box great west road louisville ky brentford middlesex tw gs overnight correspondence sent tel bny mellon shareowner services us south th street suite louisville ky crescent drive philadelphia pa wwwmybnymdrcom tel us toll free tel us toll free tel outside us tel outside us email shrrelationscpushareownerservicescom gsk response center tel us toll free depositary also provides global buydirect direct ads purchasesale dividend reinvestment plan ads holders share scam alert details enrol please visit wwwmybnymdrcom receive unsolicited telephone call offering sell buy call helpline number obtain enrolment pack shares please take extra care caller may part highly organised financial scam glaxo wellcome smithkline beecham corporate peps uk shareholder please contact financial conduct authority information similar activities share centre limited wwwfcaorgukconsumers consumer helpline oxford house oxford road aylesbury bucks hp sz tel uk tel tel outside uk wwwsharecom lines open pm uk time monday friday except uk public donating shares save children holidays pm saturdays gsk embarked ambitious global partnership save children share expertise resources aim helping save lives one million children shareholders small number shares value makes uneconomical sell may wish consider donating save children donated shares aggregated sold save children use funds raised help reach goal obtain share donation form please contact registrar equiniti managing donation sale uk shares save children free charge provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser gsk annual report statutory disclosures continued us law regulation number provisions us law regulation apply responsible establishing maintaining disclosure company shares quoted new york stock controls procedures ensure material information exchange nyse form ads made known evaluated effectiveness controls procedures yearend results nyse rules evaluation contained annual report form f general nyse rules permit company follow uk responsible establishing maintaining internal corporate governance practices instead applied us control financial reporting provides reasonable assurance provided explain significant variations explanation regarding reliability financial reporting preparation contained form f accessed financial statements external purposes accordance securities exchange commissions sec edgar database generally accepted accounting principles via website nyse rules came effect require us file annual interim written affirmations concerning audit disclosed annual report form f risk committee arc statement significant differences changes internal controls financial reporting corporate governance period covered annual report form f materially affected reasonably likely affect materially sarbanesoxley act companys internal control financial reporting disclosed based recent evaluation internal control following number corporate accounting scandals us financial reporting external auditor arc congress passed sarbanesoxley act sarbanesoxley significant deficiencies material weaknesses design wideranging piece legislation concerned largely financial operation internal controls financial reporting reporting corporate governance reasonably likely affect adversely companys ability record recommended sec company established process summarise report financial information fraud disclosure committee committee reports ceo regardless materiality involving persons significant cfo arc chaired company secretary role companys internal control financial reporting members consist senior managers finance legal group carried evaluation supervision corporate communications investor relations participation management including ceo external legal counsel external auditors internal experts cfo effectiveness design operation groups invited attend disclosure committees meetings disclosure controls procedures december periodically committee responsibility considering inherent limitations effectiveness system materiality information timely basis determining disclosure controls procedures including possibility disclosure information responsibility timely filing human error circumvention overriding controls reports sec formal review annual report procedures accordingly even effective disclosure controls form f committee met times procedures provide reasonable assurance achieving sarbanesoxley requires annual report form f control objectives contain statement whether member arc audit ceo cfo expect complete certifications committee financial expert defined sarbanesoxley report conclusions effectiveness disclosure controls statement relevant member arc judy lewent procedures march following certifications included audit risk committee report filed sec part groups form f biography additional disclosure requirements arise section section sarbanesoxley respect section managements annual report internal control disclosure controls procedures internal control financial reporting financial reporting accordance requirements section sarbanes oxley following report provided management respect section corporate responsibility financial companys internal control financial reporting defined reports rules af df us securities exchange act amended exchange act sarbanesoxley also introduced requirement ceo management responsible establishing maintaining cfo complete formal certifications confirming adequate internal control financial reporting group reviewed annual report form f internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting based knowledge annual report form f preparation financial statements external purposes contains material misstatements omissions accordance ifrs based knowledge financial statements management conducted evaluation effectiveness financial information fairly present material respects internal control financial reporting based framework financial condition results operations cash flows internal control integrated framework issued dates periods presented annual report committee sponsoring organisations treadway form f commission coso changes groups internal control financial reporting materially affected reasonably likely affect materially groups internal control financial reporting gsk annual report strategic report governance remuneration financial statements investor information us law regulation continued management assessed effectiveness internal control group regularly receive information regarding financial reporting december identity distributors downstream customers conclusion filed part groups form f establish proportion gross revenue sales potentially attributable entities affiliated iranian government deloitte llp audited consolidated financial parties sanctioned disclosable activities result group statements group year ended december reporting entire gross revenues million net profits also assessed effectiveness groups internal control million groups sales iran financial reporting auditing standard public company accounting oversight board united states group also aware hospitals medical audit report filed groups form f facilities lebanon may affiliated controlled hezbollah designated united states terrorist organisation section r exchange act group deal directly facilities sells distributors group also unable identify section r exchange act section r requires issuers certainty degree nature affiliation end customers make specific disclosure annual reports certain types hezbollah group unable establish proportion dealings iran including transactions dealings gross revenue sales potentially attributable reportable governmentowned entities well dealings entities entities result group reporting entire gross revenues sanctioned activities related terrorism proliferation million net profits million groups sales weapons mass destruction even activities lebanon prohibited us law involve us persons group addition section r us law also generally restricts dealings exports certain pharmaceutical vaccine consumer products us persons persons subject us jurisdiction iran via sales nonus entities two privately held iranian certain countries territories subject comprehensive distributors sanctions group business via nonus entities believe groups direct dealings jurisdictions targeted sanctions laws including syria cuba iran require specific disclosure requirements north korea crimea believe group complies group regularly receive information regarding applicable us sanctions laws material respects identity distributors downstream customers iran laws complex continue evolve rapidly possible customers include entities governmentowned hospitals pharmacies owned controlled directly indirectly iranian government persons entities sanctioned connection terrorism proliferation activities donations political organisations political expenditure effect january ensure consistent approach result definitions may cover legitimate business activities political contributions across group introduced global ordinary sense considered political donations policy voluntarily stop corporate political contributions political expenditure designed support political party independent election candidate period january december group make political donations eu noneu organisations therefore notwithstanding policy intend make donations eu political parties organisations notwithstanding introduction policy accordance incur eu political expenditure annually seek shareholder federal election campaign act us continue support authorisation inadvertent expenditure employeeoperated political action committee pac facilitates voluntary political donations eligible gsk employees authority precautionary measure ensure company subsidiaries inadvertently breach legislation pac controlled gsk decisions amounts recipients contributions made participating employees authorisation process expenditure exercising legal right pool resources make political year dates back agm held may following contributions subject strict limitations total introduction political parties elections referendums act us us donated political authority since renewed annually organisations gsk employee pac english law requires prior shareholder approval political contributions eu political parties independent election candidates well eu political expenditure definitions political donations political expenditure political organisations used legislation however quite broad particular definition eu political organisations may extend bodies concerned policy review law reform representation business community special interest groups concerned environment company subsidiaries might wish support gsk annual report statutory disclosures continued group companies accordance section companies act full list subsidiaries associates joint ventures joint arrangements address registered office effective percentage equity owned december disclosed unless otherwise stated share capital disclosed comprises ordinary shares indirectly held glaxosmithkline plc percentage held class share stated less unless otherwise stated subsidiary companies registered office country incorporation subsidiary companies resident tax purposes country incorporation unless otherwise stated name security registered address wholly owned subsidiaries alberta ulc common nd street sw calgary ab tp j canada action potential venture capital limited ordinary great west road brentford middlesex tw gs england adechsa gmbh iv ordinary co prv provides treuhandgesellschaft ag dorfstrasse baar switzerland adriatic acquisition corporation common corporation service company little falls drive wilmington delaware united states affymax research institute common corporation service company gateway oaks drive suite n sacramento california united states alenfarma especialidades farmaceuticas limitada iv ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal allen hanburys limited iv ordinary great west road brentford middlesex tw gs england allen hanburys pharmaceutical nigeria limited ordinary abimbola way ilasamaja isolo lagos nigeria allen farmaceutica sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain allen pharmazeutika gesellschaft mbh ordinary wagenseilgasse euro plaza gebude stock vienna austria barrier therapeutics inc common corporation service company little falls drive wilmington delaware united states beecham group plc p shares p shares b great west road brentford middlesex tw gs england beecham pharmaceuticals pte limited ordinary quality road jurong industrial estate jurong singapore beecham pharmaceuticals sa iv vi nominative av de agosto n naciones unidas edificio electroectuatoriana piso quito ecuador beecham portuguesaprodutos farmaceuticos e quimicos lda ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal beecham sa iv ordinary parc de la noire epine rue fleming wavre belgium biovesta ilalari ltd sti iv nominative bykdere caddesi levent plaza b blok levent istanbul turkey block drug company inc common corporation service company princeton south corporate center suite charles ewing blvd ewing new jersey united states block drug corporation iv common corporation service company princeton south corporate center suite charles ewing blvd ewing new jersey united states burroughs wellcome co bangladesh limited ordinary fouzderhat industrial area dhaka trunk road north kattali chittagong bangladesh burroughs wellcome international limited ordinary great west road brentford middlesex tw gs england cascan gmbh co kg partnership capital industriestrasse bad oldesloe germany castleton investment ltd vi ordinary co dtos cybercity th floor standard chartered tower ebene mauritius cellzome gmbh ordinary meyerhofstrasse heidelberg germany cellzome limited ordinary great west road brentford middlesex tw gs england cellzome therapeutics inc iv common corporation service company little falls drive wilmington delaware united states cellzome inc common corporation service company little falls drive wilmington series preferred delaware united states series b preferred series c convertible preferred series c convertible preferred charles midgley limited iv ordinary cumulative preference great west road brentford middlesex tw gs england chiron behring vaccines private limited vi ordinary wing th floorfloral deck plaza opp rolta bhavan central midc road mumbai andheri e india clarges pharmaceuticals limited iv ordinary preference great west road brentford middlesex tw gs england colleen corporation common corporation service company little falls drive wilmington delaware united states corixa corporation common corporation service company little falls drive wilmington delaware united states coulter pharmaceutical inc iv common corporation service company little falls drive wilmington delaware united states gsk annual report strategic report governance remuneration financial statements investor information group companies continued name security registered address wholly owned subsidiaries continued de micln sro ordinary priemyselny park gena ul e sachsa levice slovakia dealcyber limited ordinary great west road brentford middlesex tw gs england desarrollo energia solar alternativa sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain domantis limited ordinary great west road brentford middlesex tw gs england duncan consumer healthcare philippines inc common chino roces avenue makati city philippines duncan flockhart australia pty limited iv vi ordinary mountain highway boronia vic australia duncan pharmaceuticals philippines inc common chino roces avenue city makati philippines edinburgh pharmaceutical industries limited ordinary preference shewalton road irvine ayrshire ka ap scotland eskaylab limited p ordinary great west road brentford middlesex tw gs england etex farmaceutica ltda social capital avenue andres bello piso las condes santiago cp chile exlax inc common prentice hall corporation system puerto rico inc co fast solutions llc citi tower ponce de leon avenue floor san juan puerto rico fipar thailand ltd liquidation ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand genelabs technologies inc common corporation service company gateway oaks drive suite n sacramento california ca united states glaxo iv vi ordinary drammensveien lysaker norway glaxo group limited ordinary great west road brentford middlesex tw gs england glaxo kabushiki kaisha iv ordinary akasaka minatoku tokyo japan glaxo laboratories nigeria limited iv ordinary marine road apapa lagos nigeria glaxo laboratories limited iv ordinary great west road brentford middlesex tw gs england glaxo new zealand pension plan trustee limited ordinary level zurich house queen street auckland new zealand glaxo operations uk limited ordinary great west road brentford middlesex tw gs england glaxo properties bv ordinary huis ter heideweg lz zeist netherlands glaxo verwaltungs gmbh ordinary industriestrasse bad oldesloe germany glaxo wellcome australia pty ltd iv vi ordinary mountain highway boronia vic australia glaxo wellcome farmaceutica limitada ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal glaxo wellcome international bv v ordinary huis ter heideweg lz zeist netherlands glaxo wellcome manufacturing pte ltd ordinary pioneer sector jurong industrial estate jurong singapore glaxo wellcome production sas ordinary rue franois jacob rueilmalmaison france glaxo wellcome uk limited ordinary great west road brentford middlesex tw gs england glaxo wellcome vidhyasom limited iv ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxo wellcome sa ordinary poligono industrial allendeduero avenida de extremadura aranda de duero burgos spain glaxo sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxoallenburys nigeria limited iv ordinary creek road apapa lagos pmb nigeria glaxochem uk unlimited ordinary great west road brentford middlesex tw gs england ordinary b ordinary c glaxochem pte ltd v ordinary rochester park singapore glaxosmithkline produtos farmaceuticos limitada ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal glaxosmithkline cambodia co ltd vi ordinary th floor dksh building preah monivong boulevard corner street sangkat phsar deum thakov khan chamkarmon phnom penh cambodia glaxosmithkline china investment co ltd ordinary room building ocean international center mid th east ring road bejing chaoyang district china glaxosmithkline china rd company limited equity building halei road zhang jiang hi tech park pudong new area shanghai china glaxosmithkline cyprus limited ordinary arch makariou iii capital center th floor nicosia pc cyprus glaxosmithkline gsk srl ordinary costache negri street opera center one th th floors zone district bucharest romania glaxosmithkline ireland limited ii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline israel ltd ordinary basel street po box petachtikva israel glaxosmithkline malta limited ordinary first floor de la cruz avenue qormi qrm malta glaxosmithkline private limited iv ordinary unit anthony road msasa harare zimbabwe gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued glaxosmithkline thailand limited ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline aebe ordinary kifissias avenue halandri athens greece glaxosmithkline ab ordinary hemvarnsg solna sweden glaxosmithkline ag ordinary talstrasse muenchenbuchsee switzerland glaxosmithkline angola unipessoal limitada vi quotas luanda bairro petrangol estrada de cacuaco n angola glaxosmithkline argentina sa ordinary tucumn piso buenos aires caaa argentina glaxosmithkline ordinary drammensveien lysaker norway glaxosmithkline asia pvt limited equity patiala road nabha dist patiala punjab india glaxosmithkline australia pty ltd ordinary mountain highway boronia vic australia glaxosmithkline bv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline beteiligungs gmbh ordinary prinzregentenplatz munchen germany glaxosmithkline biologicals shanghai ltd ordinary niudun road china shanghai pilot free trade zone glaxosmithkline biologicals kft ordinary gdll homoki nagy istvn utca hungary glaxosmithkline biologicals sas ordinary rue des aulnois saintamand les eaux france glaxosmithkline biologicals sa ordinary preference rue de l'institut b rixensart belgium glaxosmithkline brasil limitada quotas estrada dos banderiantes rio de janeiro brazil glaxosmithkline brasil produtos para consumo e saude ltda quotas bl vitor civita street barra tijuca rio de janeiro brazil glaxosmithkline capital inc common wilmington trust sp services inc north market street suite wilmington delaware united states glaxosmithkline capital plc ordinary great west road brentford middlesex tw gs england glaxosmithkline caribbean limited ordinary great west road brentford middlesex tw gs england glaxosmithkline chile farmaceutica limitada social capital avenue andres bello piso las condes santiago cp chile glaxosmithkline colombia sa ordinary avenida el dorado bpiso bogota colombia glaxosmithkline consumer healthcare china co ltd ordinary floor xizangzhong road huangpu district shanghai china glaxosmithkline consumer healthcare hong kong limited ordinary units f tower gateway canton road harbour city tsimshatsui kowloon hong kong glaxosmithkline consumer healthcare ireland limited ii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline consumer healthcare overseas limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare thailand limited ordinary th floor unit wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline consumer healthcare uk limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare uk ip limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare uk trading limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare us ip llc llc interests corporation service company little falls drive wilmington delaware united states glaxosmithkline consumer healthcare ordinary nykaer brondby dk denmark glaxosmithkline consumer healthcare ab vii ordinary nykaer dk brondby denmark glaxosmithkline consumer healthcare australia pty ltd ordinary hughes avenue ermington nsw australia glaxosmithkline consumer healthcare bv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline consumer healthcare colombia sas ordinary avenida el dorado bpiso bogota colombia glaxosmithkline consumer healthcare czech republic sro ordinary hvezdova c prague czech republic glaxosmithkline consumer healthcare finance limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare finance limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare finland oy ordinary piispansilta fin espoo finland glaxosmithkline consumer healthcare gmbh ordinary wagenseilgasse euro plaza gebude stock vienna austria glaxosmithkline consumer healthcare gmbh co kg partnership capital barthstr mnchen germany glaxosmithkline consumer healthcare greece societe ordinary kifissias avenue halandri athens greece anonyme glaxosmithkline consumer healthcare holdings us llc llc interests corporation service company little falls drive wilmington delaware united states glaxosmithkline consumer healthcare holdings limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare inc common mississauga road north mississagua ln l canada glaxosmithkline consumer healthcare investments ireland ordinary knockbrack dungarvan co waterford x ry ireland limited ii v glaxosmithkline consumer healthcare investments ireland ordinary knockbrack dungarvan co waterford x ry ireland unlimited company ii v glaxosmithkline consumer healthcare investments ireland ordinary cork airport business park kinsale road cork county cork limited ii v vi ireland gsk annual report strategic report governance remuneration financial statements investor information group companies continued name security registered address wholly owned subsidiaries continued glaxosmithkline consumer healthcare ireland ip limited ii v vi ordinary currabinny carrigaline county cork ireland glaxosmithkline consumer healthcare japan kk ordinary akasaka minatoku tokyo japan glaxosmithkline consumer healthcare korea co ltd ordinary f ls yongsan tower hangangdaero yongsangu seoul korea republic glaxosmithkline consumer healthcare llc llc interests corporation service company interstate drive suite harrisburg pennsylvania united states glaxosmithkline consumer healthcare mexico ordinary calzada mexicoxochimilco colonia san lorenzo huipulco de rl de cv delegacion tlalpan mexico df mexico glaxosmithkline consumer healthcare new zealand limited ordinary level zurich house queen street auckland new zealand glaxosmithkline consumer healthcare norway ordinary drammensveien lysaker norway glaxosmithkline consumer healthcare philippines inc common chino roces avenue makati city philippines glaxosmithkline consumer healthcare pte ltd ordinary rochester park singapore glaxosmithkline consumer healthcare sa ordinary site apollo avenue pascal wavre belgium glaxosmithkline consumer healthcare sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxosmithkline consumer healthcare spa ordinary via zambeletti sncbaranzate milan italy glaxosmithkline consumer healthcare saudi limited ordinary salamah tower th floor madinah road alsalamah district jeddah saudi arabia glaxosmithkline consumer healthcare sdn bhd ordinary lot jalan enggang ampangulu kelang industrial estate selangor malaysia glaxosmithkline consumer healthcare slovakia r ownership interest galvaniho bratislava slovakia glaxosmithkline consumer healthcare south africa pty ltd ordinary flushing meadows building campus sloane street bryanston south africa glaxosmithkline consumer healthcare spzoo ordinary ul grunwaldzka poznan poland glaxosmithkline consumer healthcare sri lanka holdings limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare srl ordinary costache negri street opera center one th floor zone district bucharest romania glaxosmithkline consumer healthcare vietnam company limited charter capital floor metropolitan dong khoi ben nghe ward district iv ho chi minh city viet nam glaxosmithkline consumer healthcare produtos para ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges saude e higiene lda portugal glaxosmithkline consumer holding bv iv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline consumer private limited equity patiala road nabha dist patiala punjab india glaxosmithkline consumer trading services limited ordinary great west road brentford middlesex tw gs england glaxosmithkline costa rica sa ordinary san jose este de la rotonda betania carretera sabanilla costa rica glaxosmithkline doo quotas zmja od bosne broj sarajevo bosnia herzegovina glaxosmithkline doo equity capital ulica damira tomljanovica gavrana zagreb croatia glaxosmithkline doo beograd ordinary omladinskih brigada new belgrade city belgrade serbia glaxosmithkline dungarvan limited ii ordinary knockbrack dungarvan co waterford x ry ireland glaxosmithkline ecuador sa ordinary av de agosto n naciones unidas edificio electroectuatoriana piso quito ecuador glaxosmithkline eesti ou ordinary ltsa tallinn estonia glaxosmithkline el salvador sa de cv ordinary avenida el boqueron calle izalco parque industrial el boqueron santa elen antiguo custatlan la libertad el salvador glaxosmithkline eood ordinary g tsarigradsko shose blvd floor mladost region sofia bulgaria glaxosmithkline export limited ordinary great west road brentford middlesex tw gs england glaxosmithkline export panama sa ordinary panama city republic panama panama glaxosmithkline far east bv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline finance plc ordinary great west road brentford middlesex tw gs england glaxosmithkline gmbh co kg partnership capital prinzregentenplatz munchen germany glaxosmithkline guatemala sa ordinary novena avenida zona guatemala city guatemala glaxosmithkline healthcare ao ordinary presnenskaya nab moscow russian federation glaxosmithkline healthcare gmbh ordinary barthstr mnchen germany glaxosmithkline healthcare ukraine ooo ownership interest pavla tychyny avenue v kiev ukraine glaxosmithkline holding ordinary drammensveien lysaker norway glaxosmithkline holdings americas inc common wilmington trust sp services inc north market street suite wilmington delaware united states glaxosmithkline holdings ireland limited ordinary deferred great west road brentford middlesex tw gs england gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued glaxosmithkline holdings one limited ordinary great west road brentford middlesex tw gs england glaxosmithkline holdings limited ordinary great west road brentford middlesex tw gs england glaxosmithkline holdings pty ltd ordinary mountain highway boronia vic australia glaxosmithkline honduras sa ordinary tegucigalpa mdc honduras glaxosmithkline ihc limited ordinary great west road brentford middlesex tw gs england glaxosmithkline ilaclari sanayi ticaret nominative bykdere caddesi levent plaza b blok levent istanbul turkey glaxosmithkline inc class common class c preference mississauga road north mississauga ln l canada glaxosmithkline insurance ltd ordinary parlaville road hamilton hm bermuda glaxosmithkline intellectual property limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property development limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property holdings limited ordinary b ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limited ordinary deferred great west road brentford middlesex tw gs england glaxosmithkline intellectual property management limited ordinary great west road brentford middlesex tw gs england glaxosmithkline international limited ordinary great west road brentford middlesex tw gs england glaxosmithkline investigacin desarrollo sl ordinary severo ochoa parque tecnolgico de madrid tres cantos madrid spain glaxosmithkline investment holdings limited ordinary great west road brentford middlesex tw gs england glaxosmithkline investment services limited ordinary great west road brentford middlesex tw gs england glaxosmithkline investments ireland limited ii v vi ordinary currabinny carrigaline county cork ireland glaxosmithkline investments pty ltd ordinary mountain highway boronia vic australia glaxosmithkline kk ordinary akasaka minatoku tokyo japan glaxosmithkline korea limited ordinary f ls yongsan tower hangangdaero yongsangu seoul republic korea glaxosmithkline latin america sa ordinary panama city republic panama panama glaxosmithkline latvia sia ordinary duntes iela riga latvia glaxosmithkline lietuva uab ordinary ukmerges st vilnius lt lithuania glaxosmithkline limited ordinary units f tower gateway canton road harbour city tsimshatsui kowloon hong kong glaxosmithkline limited ordinary likoni road po box nairobi kenya glaxosmithkline llc llc interests corporation service company little falls drive wilmington delaware united states glaxosmithkline manufacturing spa ordinary via alessandro fleming verona italy glaxosmithkline maroc sa ordinary angle bd rachidi et abou hamed el glaza casablanca morocco glaxosmithkline medical healthcare products limited ordinary h csorsz utca budapest hungary glaxosmithkline mercury limited ordinary great west road brentford middlesex tw gs england glaxosmithkline mexico sa de cv ordinary calzada mexicoxochimilco colonia san lorenzo huipulco ordinary b delegacion tlalpan mexico glaxosmithkline nz limited ordinary level zurich house queen street auckland new zealand glaxosmithkline oy ordinary piispansilta po box espoo fin finland glaxosmithkline panama sa ordinary urbanizacion industrial juan calles b republic panama panama glaxosmithkline paraguay sa ordinary oficial gilberto aranda planta alta casi salvador del mundo asuncion paraguay glaxosmithkline peru sa ordinary av javier prado oeste san isidro lima peru glaxosmithkline pharma ordinary nykaer brondby dk denmark glaxosmithkline pharma gmbh ordinary wagenseilgasse euro plaza gebude stock vienna austria glaxosmithkline pharmaceutical kenya limited ordinary lr th floor icea lion centre riverside park west wing chiromo road westlands po box nairobi kenya glaxosmithkline pharmaceutical nigeria limited ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline pharmaceutical sdn bhd ordinary level quill jalan semangat petaling jaya selangor darul ehsan malaysia glaxosmithkline pharmaceuticals pvt ltd ordinary galle road kaldemulla moratuwa sri lanka glaxosmithkline pharmaceuticals suzhou limited ordinary su hong xi road suzhou industrial park suzhou china glaxosmithkline pharmaceuticals costa rica sa ordinary metros al este de la rotonda de la betania mercedes de montes de oca sabanilla montes de oca san jose costa rica gsk annual report strategic report governance remuneration financial statements investor information group companies continued name security registered address wholly owned subsidiaries continued glaxosmithkline pharmaceuticals sa ordinary ul grunwaldzka poznan poland ordinary b ordinary c ordinary glaxosmithkline pharmaceuticals sa ordinary site apollo avenue pascal wavre belgium glaxosmithkline pharmaceuticals ukraine llc chartered capital pavla tychyny avenue v kiev ukraine glaxosmithkline philippines inc common chino roces avenue city makati philippines glaxosmithkline pte ltd ordinary rochester park singapore glaxosmithkline puerto rico inc common centro internacional de mercadeo road tower ii suite guaynabo puerto rico glaxosmithkline republica dominicana sa ordinary av lope de vega torre empresarial novocentro local ensanche naco santo domingo distrito nacional dominican republic glaxosmithkline research development limited ordinary great west road brentford middlesex tw gs england glaxosmithkline sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxosmithkline spa ordinary via alessandro fleming verona italy glaxosmithkline sro ordinary hvezdova c prague czech republic glaxosmithkline sante grand public sas ordinary rue franois jacob rueilmalmaison france glaxosmithkline services gmbh co kg partnership capital prinzregentenplatz munchen germany glaxosmithkline services inc iv common corporation service company little falls drive wilmington delaware united states glaxosmithkline services unlimited ordinary great west road brentford middlesex tw gs england glaxosmithkline sl holdings llc llc interests corporation service company little falls drive wilmington delaware united states glaxosmithkline sl llc llc interests corporation service company little falls drive wilmington delaware united states glaxosmithkline sl lp iv partnership great west road brentford middlesex tw gs england glaxosmithkline slovakia sro ordinary galvaniho bratislava slovakia glaxosmithkline south africa pty limited ordinary flushing meadows building campus sloane street bryanston south africa glaxosmithkline trading ordinary leningradskiy prospect bld moscow russian federation glaxosmithkline trading services limited ii v ordinary currabinny carrigaline county cork ireland glaxosmithkline tuketici sagligi anonim sirketi nominative bykdere caddesi levent plaza b blok levent istanbul turkey glaxosmithkline tunisia sarl ordinary immeuble les quatres r rue du lac lochness berges du lac tunis tunisia glaxosmithkline uk limited ordinary great west road brentford middlesex tw gs england glaxosmithkline uruguay sa registered shares provisory stock salto cp montevideo uruguay glaxosmithkline us trading limited ordinary great west road brentford middlesex tw gs england glaxosmithkline venezuela ca ordinary urbanizacion la trinidad calle luis de camoems edif apatado posta caracas venezuela glaxosmithkline vietnam limited liability company iv vi equity capital metropolitan dong khoi street district th floor unit ho chi minh city viet nam glaxosmithklineconsumer hungary limited liability company membership h csorsz utca budapest hungary glycovaxyn ag vi common preferred grabenstrasse schlieren switzerland preferred b preferred c groupe glaxosmithkline sas ordinary rue franois jacob rueilmalmaison france gsk australia nvd pty ltd iv vi ordinary mountain highway boronia vic australia gsk business service centre sdn bhd ordinary level quill jalan semangat petaling jaya selangor darul ehsan malaysia gsk capital kk ordinary akasaka minatoku tokyo japan gsk ch argentina sa nominative non endorseable ordinary shares tucumn piso buenos aires caaa argentina gsk ch kazakhstan llp charter capital manasa str bostandyk district almaty kazakhstan gsk commercial sp z oo ordinary ul rzymowskiego warsaw poland gsk consumer health inc common corporation service company little falls drive wilmington delaware united states gsk consumer healthcare israel ltd ordinary basel street petech tikva israel gsk consumer healthcare sa ordinary route de i'etraz prangins switzerland gsk consumer healthcare schweiz ag ordinary suurstoffi rotkreuz switzerland gsk consumer healthcare services inc common corporation service company little falls drive wilmington delaware united states gsk consumer healthcare singapore pte ltd ordinary rochester park singapore gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued gsk doo ljubljana ordinary amerika ulica ljubljana slovenia gsk finance limited ordinary great west road brentford middlesex tw gs england gsk kazakhstan llp partnership interest n nazarbayev ave almaty medau district kazakhstan gsk pharmaceutical trading sa iv vi ordinary poienelor street brasov romania gsk services sp z oo ordinary ul grunwaldzka poznan poland gsk vaccines bv ordinary hullenbergweg amsterdam cl netherlands gsk vaccines gmbh ordinary emilvonbehringstr marburg germany gsk vaccines institute global health srl quotas via fiorentina siena italy gsk vaccines srl quotas via fiorentina siena italy gsk vaccines vertriebs gmbh iv ordinary rudolfdieselring holzkirchen germany hgs france sarl iv vi ordinary avenue victor hugo boulognebillancourt france horlicks limited ordinary great west road brentford middlesex tw gs england human genome sciences inc common corporation service company little falls drive wilmington delaware united states id biomedical corporation quebec common du parc technologique qubec pq gp r canada id biomedical corporation washington iv common corporation service company little falls drive wilmington delaware united states instituto luso farmaco limitada iv ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal interpharma dienstleistungen gmbh quotas wagenseilgasse euro plaza gebude stock vienna austria iodosan spa ordinary via zambeletti sncbaranzate milan italy jj technologies lc iv llc interests corporation service company bank america th floor east main street richmond virginia united states kuhs gmbh ordinary barthstr mnchen germany laboratoire glaxosmithkline ordinary rue franois jacob rueilmalmaison france laboratoire pharmaceutique algrien lpa production spa ordinary zone industrielle est boudouaou boumerdes algeria laboratoire pharmaceutique algrien spa ordinary zone industrielle est boudouaou boumerdes algeria laboratoires paucourt iv ordianry rue franois jacob rueilmalmaison france laboratoires saintgermain iv ordianry rue franois jacob rueilmalmaison france laboratorios dermatologicos darier sa de cv ordinary calzada mexico xochimilco san lorenzo huipulco district federal ordinary b mexico mexico laboratorios farmaceuticos stiefel portugal ltda iv ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal laboratorios stiefel de venezuela sa ordinary calle luis de camoens edificio glaxosmithkline urb la trinidad caracas venezuela laboratorios stiefel ltda ordinary rua professor joao cavalheiro salem guarulhos sao paulo brazil laboratorios wellcome de portugal limitada iv ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal maxinutrition limited liquidation ordinary baker street london wu eu england mixis genetics limited vi ordinary ordinary euro great west road brentford middlesex tw gs england montrose fine chemical company ltd ordinary shewalton road irvine ayrshire ka ap scotland montrose pharma company limited iv vi ordinary quota h csorsz utca budapest hungary nch nutrition consumer health ltd iv ordinary hamephalsim st petach tikva israel okairos ag liquidation common preferred preferred b co obc suisse ag aeschenvorstadt basel switzerland pt sterling products indonesia shares b shares graha paramita building th f jalan denpasar raya blok jakarta indonesia panadol gmbh ordinary barthstr mnchen germany penn labs inc iv common corporation service company little falls drive wilmington delaware united states pt gsk consumer healthcare indonesia ordinary graha paramita th f jl denpasar raya blok kuningan jakarta indonesia pt bina dentalindo liquidation ordinary gedung graha ganesha lantai jl raya bekasi km jakarta timur indonesia sr one international bv ordinary huis ter heideweg lz zeist netherlands sr one limited units common corporation service company interstate drive suite harrisburg pennsylvania united states gsk annual report strategic report governance remuneration financial statements investor information group companies continued name security registered address wholly owned subsidiaries continued setfirst limited ordinary preference great west road brentford middlesex tw gs england smith kline french laboratories limited ordinary great west road brentford middlesex tw gs england smith kline french portuguesaprodutos farmaceuticos ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges lda iv portugal smithkline beecham bangladesh private limited iv ordinary topkhana road segunbagicha dhaka bangladesh smithkline beecham cork limited ii ordinary currabinny carrigaline county cork ireland smithkline beecham export limited ordinary great west road brentford middlesex tw gs england smithkline beecham h limited noncumulative nonredeemables ordinary great west road brentford middlesex tw gs england smithkline beecham investments limited ordinary great west road brentford middlesex tw gs england smithkline beecham manufacturing limited ii ordinary currabinny carrigaline county cork ireland smithkline beecham swg limited ordinary great west road brentford middlesex tw gs england smithkline beecham biologicals us partnership partnership interest corporation service company little falls drive wilmington delaware united states smithkline beecham egypt llc quotas amoun street el salam city cairo egypt smithkline beecham farma sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain smithkline beecham interamerican corporation iv common corporation service company little falls drive wilmington delaware united states smithkline beecham limited ordinary p great west road brentford middlesex tw gs england smithkline beecham marketing technical services limited ordinary great west road brentford middlesex tw gs england smithkline beecham nominees limited ordinary great west road brentford middlesex tw gs england smithkline beecham overseas limited ordinary great west road brentford middlesex tw gs england smithkline beecham pension plan trustee limited iv ordinary great west road brentford middlesex tw gs england smithkline beecham pension trustees limited iv ordinary great west road brentford middlesex tw gs england smithkline beecham pharma gmbh co kg partnership capital prinzregentenplatz munchen germany smithkline beecham pharma verwaltungs gmbh ordinary prinzregentenplatz munchen germany smithkline beecham pharmaceuticals pty limited iv vi ordinary flushing meadows building campus sloane street bryanston south africa smithkline beecham pharmaceuticals co common corporation service company little falls drive wilmington delaware united states smithkline beecham port louis limited vi ordinary co cim corporate services ltd les cascades building edith cavell street port louis mauritius smithkline beecham research limited ordinary great west road brentford middlesex tw gs england smithkline beecham sa ordinary ctra de ajalvir km alcala de henares madrid spain smithkline beecham senior executive pension plan trustee ordinary great west road brentford middlesex tw gs england limited iv staffordmiller ireland limited ii ordinary clocherane youghal road dungarvan co waterford ireland staffordmiller limited ordinary noncumulative non great west road brentford middlesex tw gs england redeemable preference sterling drug malaya sdn berhad ordinary lot jalan enggang ampangulu kelang industrial estate selangor malaysia sterling products international incorporated iv common corporation service company little falls drive wilmington delaware united states stiefel consumer healthcare uk limited ordinary great west road brentford middlesex tw gs england stiefel distributors ireland limited ii iv ordinary finisklin business park sligo ireland stiefel dominicana srl iv vi ordinary ave lope de vega torre novocentro local santo domingo dominican republic stiefel farma sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain stiefel gmbh co kg partnership capital industriestrasse bad oldesloe germany stiefel india private limited equity wing th floor floral deck plaza opp rolta bhavan central midc road mumbai andheri e india stiefel laboratories ireland limited ii ordinary finisklin business park county sligo ireland stiefel laboratories maidenhead ltd vi ordinary eurasia headquarters concorde road maidenhead berkshire sl england stiefel laboratories uk ltd ordinary eurasia headquarters concorde road maidenhead berkshire sl england stiefel laboratories legacy ireland limited ii ordinary finisklin business park sligo ireland stiefel laboratories limited iv ordinary eurasia headquarters concorde road maidenhead berkshire sl england stiefel laboratories pte limited iv ordinary gul circle singapore gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued stiefel laboratories inc common corporation service company little falls drive wilmington delaware united states stiefel maroc sarl iv vi ordinary boulevard zerktouni casablanca morocco stiefel research australia holdings pty ltd ordinary mountain highway boronia vic australia stiefel research australia pty ltd ordinary mountain highway boronia vic australia stiefel west coast llc llc interests corporation service company little falls drive wilmington delaware united states strebor inc common corporation service company little falls drive wilmington delaware united states tempero pharmaceuticals inc series preference series b preference corporation service company little falls drive wilmington common delaware united states sydney ross co iv common corporation service company princeton south corporate center suite charles ewing blvd ewing new jersey united states wellcome foundation limited ordinary great west road brentford middlesex tw gs england ucb pharma asia pacific sdn bhd iv ordinary level symphony house pusat dagangan dana jalan pju petaling jaya selangor darul ehsan malaysia vog au pty ltd iv ordinary redeemable preference hughes avenue ermington nsw australia wellcome consumer healthcare limited iv ordinary great west road brentford middlesex tw gs england wellcome consumer products limited iv ordinary great west road brentford middlesex tw gs england wellcome developments pty ltd iv vi ordinary mountain highway boronia vic australia wellcome limited ordinary great west road brentford middlesex tw gs england wellcome operations pty ltd iv vi ordinary mountain highway boronia vic australia effective name security ownership registered address subsidiaries effective interest less amoun pharmaceutical industries co sae new monetary shares el salam city po box cairo egypt beecham enterprises inc iv common corporation service company little falls drive wilmington delaware united states biddle sawyer limited equity dr annie besant road mumbai india british pharma group limited capital great west road brentford middlesex tw gs england galvani bioelectronics inc common corporation service company little falls drive wilmington delaware united states galvani bioelectronics limited ordinary great west road brentford middlesex tw gs england b ordinary glaxo saudi arabia limited ordinary po box area warehouse city first stage al khomrah jeddah saudi arabia glaxo wellcome ceylon limited ordinary galle road kaldemulla moratuwa sri lanka ordinary b glaxosmithkline tianjin co ltd ordinary fifth avenue tai feng industrial park tianjin economic technolog tianjin china glaxosmithkline algrie spa ordinary zone industrielle est boudouaou wilaya de boumerdes algeria glaxosmithkline bangladesh limited vi ordinary fouzderhat industrial area dhaka trunk road north kattali chittagong bangladesh glaxosmithkline consumer healthcare limited vi ordinary patiala road nabha dist patiala punjab india glaxosmithkline consumer healthcare pakistan limited ordinary sykes building dockyard road west wharf karachi pakistan glaxosmithkline consumer healthcare lp partnership capital corporation service company little falls drive wilmington delaware united states glaxosmithkline consumer nigeria plc iii ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline otc pvt limited ordinary sykes building dockyard road west wharf karachi pakistan glaxosmithkline pakistan limited ordinary dockyard road west wharf karachi pakistan glaxosmithkline pharmaceuticals limited equity dr annie besant road mumbai india glaxosmithkline sae ordinary boomerang office building land zone j st district town center th tagammoe new cairo city egypt gsk annual report strategic report governance remuneration financial statements investor information group companies continued effective name security ownership registered address subsidiaries effective interest less continued gskgebro consumer healthcare gmbh ordinary bahnhofbichl fieberbrunn kitzbhel austria laboratorios viiv healthcare sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain modern pharma trading company llc quotas amoun street po box el salam city cairo egypt pt smithkline beecham pharmaceuticals shares b shares jl pulobuaran raya kav iii dd kawasan industri pulogadung jakarta indonesia phivco jersey ii limited iv v vi ordinary castle street st helier je ut jersey phivco jersey limited iv v vi ordinary castle street st helier je ut jersey phivco uk ii limited ordinary great west road brentford middlesex tw gs england phivco uk limited ordinary great west road brentford middlesex tw gs england phivco llc llc interests corporation service company little falls drive wilmington delaware united states phivco llc llc interests corporation service company little falls drive wilmington delaware united states pt glaxo wellcome indonesia shares b shares jl pulobuaran raya kav iii dd kawasan industri pulogadung timur jakarta indonesia shionogiviiv healthcare llc iv common interests corporation service company little falls drive wilmington delaware united states sinoamerican tianjin smith kline french laboratories ltd ordinary cheng lin zhuang industrial zone dong li district tianjin china smithkline beecham private limited ordinary world trade center level west tower echelon square colombo sri lanka smithkline beechambiomed ooo participation interest leningradskiy prospect bld moscow russian federation stiefel egypt llc iv quota amoun street el salam city cairo egypt viiv healthcare south africa proprietary limited iv vi ordinary flushing meadows building campus sloane street bryanston south africa viiv healthcare bv ordinary huis ter heideweg lz zeist netherlands viiv healthcare company common corporation service company little falls drive wilmington delaware united states viiv healthcare finance limited vi ordinary great west road brentford middlesex tw gs england viiv healthcare finance limited ordinary great west road brentford middlesex tw gs england viiv healthcare finance limited ordinary redeemable great west road brentford middlesex tw gs england preference viiv healthcare gmbh ordinary prinzregentenplatz munchen germany viiv healthcare gmbh ordinary talstrasse muenchenbuchsee switzerland viiv healthcare hong kong limited iv ordinary f tower gateway canton road harbour city tsimshatsui kowloon hong kong viiv healthcare kabushiki kaisha ordinary akasaka minatoku tokyo japan viiv healthcare limited class shares deferred great west road brentford middlesex tw gs england class b shares class c shares class class class e cumulative preference viiv healthcare overseas limited ordinary great west road brentford middlesex tw gs england viiv healthcare pty ltd ordinary mountain highway boronia vic australia viiv healthcare puerto rico llc llc interests centro international de mercadeo carr torre suite guaynabo puerto rico viiv healthcare srl quota via alessandro fleming verona italy viiv healthcare sas ordinary rue franois jacob rueilmalmaison france viiv healthcare sprl ordinary site apollo avenue pascal wavre belgium viiv healthcare trading llc iv participation interest leningradskiy prospect bld moscow russian federation viiv healthcare trading services uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited v vi ordinary castle street st helier je ut jersey viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england gsk annual report statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less continued viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare ulc common nd street sw calgary ab tp j canada viiv healthcare venture llc llc interests corporation service company little falls drive wilmington delaware united states viivhiv healthcare unipessoal lda quota rua dr antonio loureiro borges arquiparque miraflores alges portugal winster pharmaceuticals limited iv ordinary association avenue ilupeju industrial estate lagos po box nigeria zhejiang tianyuan biopharmaceutical co ltd ordinary tian road yuhang economic development zone hangzhou zhejiang province china associates apollo therapeutics llp partnership interest gunnels wood road stevenage sg fx england calci medica inc series junior coast boulevard south suite la jolla ca preferred united states glaxosmithkline landholding company inc common chino roces avenue city makati philippines index ventures life vi jersey lp partnership interest burlington gardens london w ep england innoviva inc common sierra point parkway suite brisbane ca united states japan vaccine distribution co ltd ordinary yobancho chiyodaku tokyo japan kurma biofund ii fcpr partnership interest rue royale e tage paris france longwood founders fund lp partnership interest prudential tower boylston street suite boston united states medicxi ventures lp partnership interest great pulteney street soho london wf nd england joint ventures chiron panacea vaccines private limited vi equity shares th floor wing sagar tech plaza saki naka andheri east mumbai maharashtra india japan vaccine co ltd vi ordinary yonbancho chiyodaku tokyo japan japan vaccine distribution co ltd vi ordinary yonbancho chiyodaku tokyo japan qualivax pte limited ordinary robinson road singapore quell intellectual property corp llc iv membership interest corporation service company little falls drive wilmington delaware united states qura therapeutics llc units corporation service company little falls drive wilmington delaware united states key directly owned glaxosmithkline plc iv dormant company ii e xempt provisions section companies act v tax resident uk ireland accordance exemptions noted section act vi entity expected disposed removed iii c onsolidated subsidiary accordance section vii incorporated sweden companies act grounds dominant influence gsk annual report strategic report governance remuneration financial statements investor information glossary terms terms used annual report us equivalent brief description accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay charging payment tax equivalent tax depreciation american depositary receipt adr r eceipt evidencing title ads gsk adr represents two ordinary shares american depositary shares ads listed new york stock exchange represents two ordinary shares basic earnings per share basic income per share called share capital ordinary shares issued fully paid cer growth growth constant exchange rates company glaxosmithkline plc currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan pension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share employee share ownership plan trusts trusts established group satisfy sharebased employee incentive plans equity shareholders funds shareholders equity finance lease capital lease freehold ownership absolute rights perpetuity group glaxosmithkline plc subsidiary undertakings gsk glaxosmithkline plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements making offsetting commitments intangible fixed assets assets without physical substance computer software brands licences patents knowhow marketing rights purchased outside parties novartis transaction threepart interconditional transaction novartis ag involving consumer healthcare vaccines oncology businesses completed march ordinary share fully paid ordinary share capital company profit income profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid share option stock option share premium account additional paidup capital paidin surplus distributable shares issue number shares outstanding subsidiary entity gsk exercises control treasury share treasury stock turnover revenue uk corporate governance code required uk listing authority company disclosed annual report applied best practice corporate governance provisions financial reporting councils uk corporate governance code gsk annual report index accountability investor relations accounting principles policies key accounting judgements estimates acquisitions disposals key performance indicators adjustments reconciling profit tax operating leadership effectiveness cash flows legal proceedings affordability availability major restructuring costs annual general meeting modern employer approach brexit movements equity approach tax net debt assets held sale new accounting requirements associates joint ventures nominations committee report audit risk committee report noncontrolling interests business model noncontrolling interests viiv healthcare cash cash equivalents nonexecutive directors fees cash generation conversion nonfinancial information statement ifc ceos statement notes financial statements cfos statement operating profit chairmans statement intangible assets chairmans governance statement investments chairmans remuneration annual statement noncurrent assets commitments noncurrent liabilities consolidated balance sheet operating incomeexpense consolidated cash flow statement provisions consolidated income statement board consolidated statement changes equity longterm priorities consolidated statement comprehensive income pensions postemployment benefits consumer healthcare pharmaceuticals consumer healthcare products competition pharmaceutical products competition contingent consideration liabilities intellectual property contingent liabilities pipeline corporate executive team post balance sheet events corporate governance presentation financial statements corporate responsibility committee report principal group companies critical accounting policies principal risks uncertainties data engagement property plant equipment directors senior management quarterly trend directors interests shares reconciliation net cash flow movement net debt directors statement responsibilities registrar dividends related party transactions donations political organisations relations stakeholders political expenditure reliable supply earnings per share remuneration governance employee costs remuneration policy summary employee share schemes remuneration report environment reporting framework ethics values risk management exchange rates science technology executive director remuneration science committee report finance expense share capital control finance income share capital share premium account financial calendar shareholder information financial instruments related disclosures shareholder services contacts financial performance stakeholder engagement financial position resources taxation financial statements glaxosmithkline plc prepared tax information shareholders uk gaap trade payables five year record trade receivables glossary terms treasury policies goodwill trust group companies turnover segment information group financial review us law regulation independent auditors report vaccines industry trends vaccine products competition intellectual property inventories viability statement investments associates joint ventures gsk annual report gsk glaxosmithkline plc incorporated english brand names brand names appearing italics throughout report public limited company december trade marks either owned andor licensed gsk associated companies exception cialis owned formed merger glaxo wellcome plc eli lilly company gardasil owned merck sharp dohme corp rituxan owned biogen inc zofran smithkline beecham plc gsk acquired two owned novartis ag trumenba owned pfizer inc volibris owned gilead science english companies december part acknowledgements merger arrangements design friend wwwfriendstudiocom printing shares listed london stock exchange pureprint group iso fsc certified carbon neutral new york stock exchange paper annual report printed revive silk recycled paper full fsc certification read wwwgskcom pulps used made deinked paper waste elemental chlorine free manufacturing mill holds iso eu ecolabel certificates environmental management download pdfs annual report form f cautionary statement regarding information document constitute also assume proposed consumer healthcare forwardlooking statements offer sell invitation buy shares glaxosmithkline nutrition disposal closes end groups reports filed furnished us plc invitation inducement engage proposed consumer healthcare joint venture pfizer securities exchange commission sec including investment activities past performance relied closes h integration document written information released oral upon guide future performance nothing investment programmes following tesaro acquisition statements made public future behalf annual report construed profit forecast proposed consumer healthcare joint venture group may contain forwardlooking statements pfizer period delivered successfully f e md pt sxo ere lp ar cw ae n nt nc la nt yr bd ct g ot ei hi p ol l nho e ian e iso css veek eoo nsn rr ng e ia cf n e ts ce trt l ie tmma oo ic ot tr aee h ntn cm e e wt ut ss r n wr tbo ee ht oys xf n ap r f ttg du nh efi st yaev cu ce dr f tae n sch de c nte tv utt ee hg eh srn e na smr ito st u u nh p oa e w oe fns f w ldi fc l umou v tr r ue p lnr rse ro es rotn j st err ue cc cl taa h n e p r pn es ies pvo srs er ei uu kou n lm et id nm uli n p eesp sn aiit n og nai n w n dtn dh h rs ae ei fi cb sr ne tx r l u tp una ht ce ct ee tt tc ih h ugd ee l ra b rt nt hg oo eo ge u nrn po p es lu rt fio oh f p pc g r h ea r f r r ms e mm e ea c aa sd nn eu cdd r uc l tt rto e hh h ro er ee et nk dfi ti nv ei pfe f l oie v ry r e tee fr ona l tr io r cnh h ea ned p se tur th ai mta ta nle ol v e tnc e n cto k tib ua dm lt reds e ea c en nf io v cf ber oeli c bn apv afe r sf e e ie st c hm n ei et ne e tn p x b pt ti yn ih eo ae c n n e se ad w x ti ip p e ot n ohr c n e ut tlg l tu r odi eoc r oa ont g kt us al ia avp gu e td sin n rv c pe v oh en npe n e g rl c ia ni v en ee dd rn operating financial performance particular group specifically period gsk subject material changes product mix groups include statements relating future actions prospective expects declines sales seretideadvair mediumterm effective tax rate expected around products product approvals future performance introduction generic alternative advair us adjusted profits incorporates managements results current anticipated products sales efforts factored groups assessment future best estimates impact us tax reform group expenses outcome contingencies legal performance group assumes premature loss based information currently available proceedings financial results exclusivity key products period information detailed application us tax cuts accordance legal regulatory obligations jobs act becomes available assumptions including uk listing rules disclosure assumptions groups revenue earnings underlying estimates could change consequent transparency rules financial conduct dividend expectations assume material interruptions adjustments charges taken could material authority group undertakes obligation update supply groups products material mergers impact results group forwardlooking statements whether result acquisitions disposals except acquisition new information future events otherwise reader tesaro proposed divestment horlicks notice regarding limitations however consult additional disclosures consumer healthcare products unilever director liability english law group may make documents publishes proposed formation new consumer healthcare uk companies act safe harbour limits andor files sec readers wherever located joint venture pfizer announced december liability directors respect statements take note disclosures accordingly material litigation investigation costs company omissions directors report see assurance given particular expectation save already recognised strategic report remuneration report met shareholders cautioned place provisions made share repurchases english law directors would liable undue reliance forwardlooking statements company change groups shareholdings company third party one viiv healthcare assumptions also assume reports contained errors result recklessness forwardlooking statements subject assumptions material changes macroeconomic healthcare knowing misstatement dishonest concealment inherent risks uncertainties many relate environment guidance outlook material fact would otherwise liable pages factors beyond groups control precise factored divestments product exits since inclusive comprise estimate group cautions investors number including divestment exit directors report pages inclusive comprise important factors including document could noncore tail brands billion annual sales strategic report pages inclusive comprise cause actual results differ materially expressed announced july product divestments remuneration report drawn implied forwardlooking statement planned connection proposed consumer presented accordance reliance upon factors include limited discussed healthcare transaction pfizer english company law liabilities directors u n e f p thr ii sn c aip na nl u r ais l k rs e pn od rt u anc ne r ft oa ri wnt aie rds lon p kia ng ge ss e eo n ts gh ug pr u inp es g e rx ap tie oc nt nio dn rs e sa ts rs uu cm tue ri ns gu c pc lae ns ss f ou vl ed tl hiv ee r py e rif dh e c limon itn ae tic ot nio sn w ndit h sh te ris ce ti ore np pr rts vs ih da el dl b su ub cj c lat w made behalf group speak date including extension enhancement website anh nfe ny r u ar le r im ena p oae v rta iln ad b la er e b ta hs ee dd ru ep co ton r sh oe nk n tho ew dle ad teg e fa tn hd w h ee l jlc uao ls ym hb ein ne ed w p r mo ag jr oa rm rem se tr un cn tuo ru inn gc e pd la nn nn j uu nly c ed n g inn htk h ises gw nre nob uus api lt e rn ew ptw oww ri tt h tg oss gk nc sdo kim n sg g wti hv ee e bs r ea itfd eed r e nit n oio c nn e ea l wi fn tef ho emrm aa kt eio n number nonifrs measures used report information made available website constitutes performance business measures defined part annual report shall deemed pages reconciliation adjusted results incorporated reference herein total results set head office registered office glaxosmithkline plc great west road brentford middlesex tw gs united kingdom tel search us registered number wwwgskcom